<?xml version="1.0" encoding="UTF-8" standalone="yes"?>
<add>
 <doc>
  <field name="id"><![CDATA[6811743]]></field>
  <field name="articleCreationDate"><![CDATA[1982-12-02T00:00:00Z]]></field>
  <field name="articleYear"><![CDATA[1982]]></field>
  <field name="articleCompletionDate"><![CDATA[1982-12-02T00:00:00Z]]></field>
  <field name="articleRevisionDate"><![CDATA[2008-11-21T00:00:00Z]]></field>
  <field name="articlePubmodel"><![CDATA[Print]]></field>
  <field name="journalTitle"><![CDATA[Journal of medicinal chemistry]]></field>
  <field name="journalTitleAbrv"><![CDATA[J. Med. Chem.]]></field>
  <field name="articleTitle"><![CDATA[Monophenolic octahydrobenzo[f]quinolines: central dopamine- and serotonin-receptor stimulating activity.]]></field>
  <field name="articleAbstract"><![CDATA[Eight monophenolic cis- and trans-4-n-propyl-1,2,3,4,4a,5,6,10b-octahydrobenzo[f]quinolines have been synthesized and tested for central dopamine- and serotonin-receptor stimulating activity, using biochemical and behavioral tests in rats. The trans-7-, -8-, and -9-hydroxy isomers all elicited central pre- and postsynaptic dopaminergic receptor stimulation, while the trans-10-hydroxy isomer was devoid of dopaminergic activity but instead showed central serotoninergic activity. In all four isomeric pairs, the trans isomers were consistently much more potent than their corresponding cis analogues. The apparent presynaptic selectivity of the dopaminergic cis isomer cis-9-hydroxy-4-n-propyl-1,2,3,4,4a,5,6,10b-octahydrobenzo[f]quinoline could not be confirmed due to the toxic properties of this compound. Central dopamine receptors (autoreceptors and postsynaptic receptors) can accept dopaminergic compounds with one of possibly two N-substituents being larger than n-propyl, if this substituent is properly oriented in relation to the rest of the molecule.]]></field>
  <field name="author"><![CDATA[Wikström H]]></field>
  <field name="author"><![CDATA[Sanchez D]]></field>
  <field name="author"><![CDATA[Lindberg P]]></field>
  <field name="author"><![CDATA[Arvidsson L E]]></field>
  <field name="author"><![CDATA[Hacksell U]]></field>
  <field name="author"><![CDATA[Johansson A]]></field>
  <field name="author"><![CDATA[Nilsson J L]]></field>
  <field name="author"><![CDATA[Hjorth S]]></field>
  <field name="author"><![CDATA[Carlsson A]]></field>
  <field name="articleLang"><![CDATA[eng]]></field>
  <field name="publicationType"><![CDATA[In Vitro]]></field>
  <field name="publicationType"><![CDATA[Journal Article]]></field>
  <field name="substanceName"><![CDATA[Quinolines]]></field>
  <field name="substanceName"><![CDATA[Receptors, Dopamine]]></field>
  <field name="substanceName"><![CDATA[Receptors, Serotonin]]></field>
  <field name="substanceName"><![CDATA[5-Hydroxytryptophan]]></field>
  <field name="substanceName"><![CDATA[Dihydroxyphenylalanine]]></field>
  <field name="articleDescriptor"><![CDATA[5-Hydroxytryptophan]]></field>
  <field name="articleQualifier"><![CDATA[metabolism]]></field>
  <field name="articleDescriptor"><![CDATA[Animals]]></field>
  <field name="articleDescriptor"><![CDATA[Brain Chemistry]]></field>
  <field name="articleQualifier"><![CDATA[drug effects]]></field>
  <field name="articleDescriptor"><![CDATA[Chemical Phenomena]]></field>
  <field name="articleDescriptor"><![CDATA[Chemistry]]></field>
  <field name="articleDescriptor"><![CDATA[Dihydroxyphenylalanine]]></field>
  <field name="articleQualifier"><![CDATA[metabolism]]></field>
  <field name="articleDescriptor"><![CDATA[Motor Activity]]></field>
  <field name="articleQualifier"><![CDATA[drug effects]]></field>
  <field name="articleDescriptor"><![CDATA[Quinolines]]></field>
  <field name="articleQualifier"><![CDATA[chemical synthesis]]></field>
  <field name="articleQualifier"><![CDATA[pharmacology]]></field>
  <field name="articleDescriptor"><![CDATA[Rats]]></field>
  <field name="articleDescriptor"><![CDATA[Rats, Inbred Strains]]></field>
  <field name="articleDescriptor"><![CDATA[Receptors, Dopamine]]></field>
  <field name="articleQualifier"><![CDATA[drug effects]]></field>
  <field name="articleDescriptor"><![CDATA[Receptors, Serotonin]]></field>
  <field name="articleQualifier"><![CDATA[drug effects]]></field>
 </doc>
 <doc>
  <field name="id"><![CDATA[6811744]]></field>
  <field name="articleCreationDate"><![CDATA[1982-12-02T00:00:00Z]]></field>
  <field name="articleYear"><![CDATA[1982]]></field>
  <field name="articleCompletionDate"><![CDATA[1982-12-02T00:00:00Z]]></field>
  <field name="articleRevisionDate"><![CDATA[2008-11-21T00:00:00Z]]></field>
  <field name="articlePubmodel"><![CDATA[Print]]></field>
  <field name="journalTitle"><![CDATA[Journal of medicinal chemistry]]></field>
  <field name="journalTitleAbrv"><![CDATA[J. Med. Chem.]]></field>
  <field name="articleTitle"><![CDATA[Methotrexate analogues. 15. A methotrexate analogue designed for active-site-directed irreversible inactivation of dihydrofolate reductase.]]></field>
  <field name="articleAbstract"><![CDATA[N alpha-(4-Amino-4-deoxy-N10-methylpteroyl)-N epsilon-(iodoacetyl)-L-lysine (1) was synthesized as a potential active-site-directed irreversible inhibitor of dihydrofolate reductase (DHFR). In an ultraviolet spectrophotometric assay of dihydrofolate reduction of Lactobacillus casei DHFR, 1 and methotrexate (MTX, 4-amino-4-deoxy-N10-methylpteroyl-L-glutamic acid) had ID50 values of 4.5 and 6.2 nM. The corresponding ID50 values in a competitive radioligand binding assay against [3H]MTX were 31 and 16 nM. Thus, as reversible inhibitors of this enzyme over a short exposure time, 1 and MTX had comparable activity. On the other hand, when L. casei DHFR was incubated for up to 6 h with 0.1 or 1.0 microM 1, a progressive decrease in the ability of [3H]MTX to subsequently displace the drug was observed. When MTX itself was used at the same concentrations, the extent of displacement of [3H]MTX did not decrease with time. These results were consistent with rapid reversible binding of 1 to the enzyme, followed more slowly by covalent bond formation near the active site. The pH profile for this effect followed a curve with a sigmoidal shape. The apparent inflection point near pH 7.2 was consistent with alkylation of a histidine residue.]]></field>
  <field name="author"><![CDATA[Rosowsky A]]></field>
  <field name="author"><![CDATA[Wright J E]]></field>
  <field name="author"><![CDATA[Ginty C]]></field>
  <field name="author"><![CDATA[Uren J]]></field>
  <field name="articleLang"><![CDATA[eng]]></field>
  <field name="publicationType"><![CDATA[Journal Article]]></field>
  <field name="publicationType"><![CDATA[Research Support, U.S. Gov't, P.H.S.]]></field>
  <field name="substanceName"><![CDATA[Folic Acid Antagonists]]></field>
  <field name="substanceName"><![CDATA[Methotrexate]]></field>
  <field name="substanceName"><![CDATA[lysine-iodoacetylmethotrexate]]></field>
  <field name="articleDescriptor"><![CDATA[Binding Sites]]></field>
  <field name="articleQualifier"><![CDATA[drug effects]]></field>
  <field name="articleDescriptor"><![CDATA[Chemical Phenomena]]></field>
  <field name="articleDescriptor"><![CDATA[Chemistry]]></field>
  <field name="articleDescriptor"><![CDATA[Folic Acid Antagonists]]></field>
  <field name="articleDescriptor"><![CDATA[Hydrogen-Ion Concentration]]></field>
  <field name="articleDescriptor"><![CDATA[Lactobacillus casei]]></field>
  <field name="articleQualifier"><![CDATA[enzymology]]></field>
  <field name="articleDescriptor"><![CDATA[Methotrexate]]></field>
  <field name="articleQualifier"><![CDATA[analogs & derivatives]]></field>
  <field name="articleQualifier"><![CDATA[chemical synthesis]]></field>
  <field name="articleQualifier"><![CDATA[pharmacology]]></field>
  <field name="articleDescriptor"><![CDATA[Time Factors]]></field>
 </doc>
 <doc>
  <field name="id"><![CDATA[6214632]]></field>
  <field name="articleCreationDate"><![CDATA[1982-12-02T00:00:00Z]]></field>
  <field name="articleYear"><![CDATA[1982]]></field>
  <field name="articleCompletionDate"><![CDATA[1982-12-02T00:00:00Z]]></field>
  <field name="articleRevisionDate"><![CDATA[2009-11-18T00:00:00Z]]></field>
  <field name="articlePubmodel"><![CDATA[Print]]></field>
  <field name="journalTitle"><![CDATA[Journal of medical genetics]]></field>
  <field name="journalTitleAbrv"><![CDATA[J. Med. Genet.]]></field>
  <field name="articleTitle"><![CDATA[A genetic register for Huntington's chorea in South Wales.]]></field>
  <field name="articleAbstract"><![CDATA[A regional genetic register for Huntington's chorea in South Wales is described, based on previous family studies in this area, which is one of high prevalence for the disorder. The primary role of the register is to help in the efficient delivery of services, including genetic counselling, to affected subjects and relatives, and to monitor changes in the population at risk. The mode of operation of the register is described and the essential importance of strict confidentiality is stressed.]]></field>
  <field name="author"><![CDATA[Harper P S]]></field>
  <field name="author"><![CDATA[Tyler A]]></field>
  <field name="author"><![CDATA[Smith S]]></field>
  <field name="author"><![CDATA[Jones P]]></field>
  <field name="author"><![CDATA[Newcombe R G]]></field>
  <field name="author"><![CDATA[McBroom V]]></field>
  <field name="articleLang"><![CDATA[eng]]></field>
  <field name="publicationType"><![CDATA[Journal Article]]></field>
  <field name="articleDescriptor"><![CDATA[Computers]]></field>
  <field name="articleDescriptor"><![CDATA[Confidentiality]]></field>
  <field name="articleDescriptor"><![CDATA[Humans]]></field>
  <field name="articleDescriptor"><![CDATA[Huntington Disease]]></field>
  <field name="articleQualifier"><![CDATA[epidemiology]]></field>
  <field name="articleQualifier"><![CDATA[genetics]]></field>
  <field name="articleDescriptor"><![CDATA[Registries]]></field>
  <field name="articleDescriptor"><![CDATA[Wales]]></field>
 </doc>
 <doc>
  <field name="id"><![CDATA[7120312]]></field>
  <field name="articleCreationDate"><![CDATA[1982-12-02T00:00:00Z]]></field>
  <field name="articleYear"><![CDATA[1982]]></field>
  <field name="articleCompletionDate"><![CDATA[1982-12-02T00:00:00Z]]></field>
  <field name="articleRevisionDate"><![CDATA[2009-11-18T00:00:00Z]]></field>
  <field name="articlePubmodel"><![CDATA[Print]]></field>
  <field name="journalTitle"><![CDATA[Journal of medical genetics]]></field>
  <field name="journalTitleAbrv"><![CDATA[J. Med. Genet.]]></field>
  <field name="articleTitle"><![CDATA[A three generation family study of cleft lip with or without cleft palate.]]></field>
  <field name="articleAbstract"><![CDATA[A family study of cleft lip, with or without cleft palate, was based on those treated by operation at The Hospital for Sick Children, London, between 1920 and 1939 in order to give information on the proportion affected of children and grandchildren. The probands were those who had survived, were successfully traced, and found to have had at least one child. Care was taken to exclude patients who were traced through a child, whether normal or affected, and not through the usual tracing procedure. Patients with recognised syndromes were also excluded. Because the series was based on patients who had survived and reproduced it was biased in favour of those with milder degrees of the malformation, and against those with any severe associated malformation. The proportion affected of children of probands was 3.15% (+/- 0.56), of sibs 2.79% (+/- 0.52), and of parents 1.18% (+/- 0.37), respectively. The lower proportion of parents affected is attributed to reduced reproductive fitness of patients born two generations ago. The proportion affected of nephews and nieces, aunts and uncles, and grandchildren was 0.47% (+/- 0.18), 0.59% (+/- 0.13), and 0.8% (+/- 0.6) respectively. The proportion affected of first cousins was 0.27% (+/- 0.08). The birth frequency of cleft lip (+/- cleft palate) is estimated to be about 0.1% in England. There were two first cousin and one second cousin marriages among the marriages of the parents. There was no increase of cleft palate among the relatives of the probands. The proportion of sibs affected increased with increasing severity of the malformation in the proband, where the proband was female, and where the proband had an affected parent or already had one affected sib. It was not, however, increased where a more remote relative was affected. The proportion of children affected was not increased when the proband had an affected parent or sib, but few families provided information. The most economical hypothesis to explain the findings is the multifactorial threshold model. The birth frequency of the malformation and the family patterns found make it improbable that one single mutant gene makes a major contribution to the liability to develop the condition.]]></field>
  <field name="author"><![CDATA[Carter C O]]></field>
  <field name="author"><![CDATA[Evans K]]></field>
  <field name="author"><![CDATA[Coffey R]]></field>
  <field name="author"><![CDATA[Roberts J A]]></field>
  <field name="author"><![CDATA[Buck A]]></field>
  <field name="author"><![CDATA[Roberts M F]]></field>
  <field name="articleLang"><![CDATA[eng]]></field>
  <field name="publicationType"><![CDATA[Case Reports]]></field>
  <field name="publicationType"><![CDATA[Journal Article]]></field>
  <field name="articleDescriptor"><![CDATA[Adult]]></field>
  <field name="articleDescriptor"><![CDATA[Aged]]></field>
  <field name="articleDescriptor"><![CDATA[Cleft Lip]]></field>
  <field name="articleQualifier"><![CDATA[complications]]></field>
  <field name="articleQualifier"><![CDATA[genetics]]></field>
  <field name="articleDescriptor"><![CDATA[Cleft Palate]]></field>
  <field name="articleQualifier"><![CDATA[complications]]></field>
  <field name="articleQualifier"><![CDATA[genetics]]></field>
  <field name="articleDescriptor"><![CDATA[Female]]></field>
  <field name="articleDescriptor"><![CDATA[Humans]]></field>
  <field name="articleDescriptor"><![CDATA[Male]]></field>
  <field name="articleDescriptor"><![CDATA[Middle Aged]]></field>
  <field name="articleDescriptor"><![CDATA[Pedigree]]></field>
 </doc>
 <doc>
  <field name="id"><![CDATA[7120313]]></field>
  <field name="articleCreationDate"><![CDATA[1982-12-02T00:00:00Z]]></field>
  <field name="articleYear"><![CDATA[1982]]></field>
  <field name="articleCompletionDate"><![CDATA[1982-12-02T00:00:00Z]]></field>
  <field name="articleRevisionDate"><![CDATA[2011-11-17T00:00:00Z]]></field>
  <field name="articlePubmodel"><![CDATA[Print]]></field>
  <field name="journalTitle"><![CDATA[Journal of medical genetics]]></field>
  <field name="journalTitleAbrv"><![CDATA[J. Med. Genet.]]></field>
  <field name="articleTitle"><![CDATA[Measurement of erythrocyte membrane elasticity as a diagnostic aid in Duchenne muscular dystrophy.]]></field>
  <field name="articleAbstract"><![CDATA[Using a micropipette aspiration technique, erythrocyte membrane shear elastic modulus was determined for 23 patients with Duchenne muscular dystrophy, for 14 female carriers, and for three control groups (age matched boys and adult males and females). On average the elastic modulus was slightly greater than normal for both affected males and female carriers. However, there was overlap in the values from all groups. The decreased deformability of dystrophic membranes demonstrated by the test is not great enough to be used for carrier detection nor to make the possibility of prenatal diagnosis likely.]]></field>
  <field name="author"><![CDATA[Nash G B]]></field>
  <field name="author"><![CDATA[Wyard S J]]></field>
  <field name="articleLang"><![CDATA[eng]]></field>
  <field name="publicationType"><![CDATA[Journal Article]]></field>
  <field name="publicationType"><![CDATA[Research Support, Non-U.S. Gov't]]></field>
  <field name="substanceName"><![CDATA[Anticonvulsants]]></field>
  <field name="articleDescriptor"><![CDATA[Adult]]></field>
  <field name="articleDescriptor"><![CDATA[Anticonvulsants]]></field>
  <field name="articleQualifier"><![CDATA[therapeutic use]]></field>
  <field name="articleDescriptor"><![CDATA[Child]]></field>
  <field name="articleDescriptor"><![CDATA[Clinical Laboratory Techniques]]></field>
  <field name="articleDescriptor"><![CDATA[Elasticity]]></field>
  <field name="articleDescriptor"><![CDATA[Erythrocyte Membrane]]></field>
  <field name="articleQualifier"><![CDATA[ultrastructure]]></field>
  <field name="articleDescriptor"><![CDATA[Erythrocytes]]></field>
  <field name="articleQualifier"><![CDATA[ultrastructure]]></field>
  <field name="articleDescriptor"><![CDATA[Female]]></field>
  <field name="articleDescriptor"><![CDATA[Humans]]></field>
  <field name="articleDescriptor"><![CDATA[Male]]></field>
  <field name="articleDescriptor"><![CDATA[Muscular Dystrophies]]></field>
  <field name="articleQualifier"><![CDATA[blood]]></field>
  <field name="articleQualifier"><![CDATA[diagnosis]]></field>
  <field name="articleQualifier"><![CDATA[drug therapy]]></field>
  <field name="articleDescriptor"><![CDATA[Prenatal Diagnosis]]></field>
 </doc>
 <doc>
  <field name="id"><![CDATA[7120314]]></field>
  <field name="articleCreationDate"><![CDATA[1982-12-02T00:00:00Z]]></field>
  <field name="articleYear"><![CDATA[1982]]></field>
  <field name="articleCompletionDate"><![CDATA[1982-12-02T00:00:00Z]]></field>
  <field name="articleRevisionDate"><![CDATA[2010-11-18T00:00:00Z]]></field>
  <field name="articlePubmodel"><![CDATA[Print]]></field>
  <field name="journalTitle"><![CDATA[Journal of medical genetics]]></field>
  <field name="journalTitleAbrv"><![CDATA[J. Med. Genet.]]></field>
  <field name="articleTitle"><![CDATA[Linkage analysis of five pedigrees affected with typical autosomal dominant retinitis pigmentosa.]]></field>
  <field name="articleAbstract"><![CDATA[Five pedigrees (including an expanded version of a previously reported pedigree) exhibited typical autosomal dominant retinitis pigmentosa were analysed for linkage of RP to 29 genetic markers. No significant lod scores resulted. The largest lod score is +1.51 and suggests linkage between RP and Rh blood group at an estimated recombination fraction of 20% in males and 40% in females. Further studies are needed to confirm or refute this suggested linkage.]]></field>
  <field name="author"><![CDATA[Field L L]]></field>
  <field name="author"><![CDATA[Heckenlively J R]]></field>
  <field name="author"><![CDATA[Sparkes R S]]></field>
  <field name="author"><![CDATA[Garcia C A]]></field>
  <field name="author"><![CDATA[Farson C]]></field>
  <field name="author"><![CDATA[Zedalis D]]></field>
  <field name="author"><![CDATA[Sparkes M C]]></field>
  <field name="author"><![CDATA[Crist M]]></field>
  <field name="author"><![CDATA[Tideman S]]></field>
  <field name="author"><![CDATA[Spence M A]]></field>
  <field name="articleLang"><![CDATA[eng]]></field>
  <field name="publicationType"><![CDATA[Case Reports]]></field>
  <field name="publicationType"><![CDATA[Journal Article]]></field>
  <field name="publicationType"><![CDATA[Research Support, Non-U.S. Gov't]]></field>
  <field name="publicationType"><![CDATA[Research Support, U.S. Gov't, P.H.S.]]></field>
  <field name="articleDescriptor"><![CDATA[Adolescent]]></field>
  <field name="articleDescriptor"><![CDATA[Adult]]></field>
  <field name="articleDescriptor"><![CDATA[Aged]]></field>
  <field name="articleDescriptor"><![CDATA[Child]]></field>
  <field name="articleDescriptor"><![CDATA[Female]]></field>
  <field name="articleDescriptor"><![CDATA[Genes, Dominant]]></field>
  <field name="articleDescriptor"><![CDATA[Genetic Linkage]]></field>
  <field name="articleDescriptor"><![CDATA[Humans]]></field>
  <field name="articleDescriptor"><![CDATA[Male]]></field>
  <field name="articleDescriptor"><![CDATA[Middle Aged]]></field>
  <field name="articleDescriptor"><![CDATA[Pedigree]]></field>
  <field name="articleDescriptor"><![CDATA[Retinitis Pigmentosa]]></field>
  <field name="articleQualifier"><![CDATA[genetics]]></field>
 </doc>
 <doc>
  <field name="id"><![CDATA[7120315]]></field>
  <field name="articleCreationDate"><![CDATA[1982-12-02T00:00:00Z]]></field>
  <field name="articleYear"><![CDATA[1982]]></field>
  <field name="articleCompletionDate"><![CDATA[1982-12-02T00:00:00Z]]></field>
  <field name="articleRevisionDate"><![CDATA[2009-11-18T00:00:00Z]]></field>
  <field name="articlePubmodel"><![CDATA[Print]]></field>
  <field name="journalTitle"><![CDATA[Journal of medical genetics]]></field>
  <field name="journalTitleAbrv"><![CDATA[J. Med. Genet.]]></field>
  <field name="articleTitle"><![CDATA[Screening for latent acute intermittent porphyria: the value of measuring both leucocyte delta-aminolaevulinic acid synthase and erythrocyte uroporphyrinogen-1-synthase activities.]]></field>
  <field name="articleAbstract"><![CDATA[Acute intermittent porphyria (AIP) is an autosomal dominantly inherited disorder of haem biosynthesis characterised by reduced activity of the enzyme uroporphyrinogen-1-(URO) synthase and compensatory increased activity of the rate controlling enzyme delta-aminolaevulinic acid (ALA) synthase. Subjects with the disorder should be identified as they are at risk of developing severe porphyric attacks if exposed to a variety of drugs or chemicals. We have assessed the value of measuring the activities of ALA synthase and URO synthase in peripheral blood cells as a means of identifying latent cases in affected families. In AIP subjects, ALA synthase activity was increased and URO synthase decreased compared to controls, through there was considerable overlap between the two groups when either enzyme was examined alone. When both enzymes were examined together, all but one of the 19 AIP patients had both increased ALA synthase activity (greater than 250 nmol ALA/g protein/h) and reduced URO synthase activity (less than 25.1 nmol URO/l RBC/h), whereas none of the 62 controls showed this enzyme pattern. Examination of 35 asymptomatic first degree blood relatives of AIP patients showed that 17 (49%) had the porphyric enzyme pattern with no sex bias. The combined study of these two enzymes permits accurate detection of latent cases of AIP and confirms its autosomal dominant inheritance.]]></field>
  <field name="author"><![CDATA[McColl K E]]></field>
  <field name="author"><![CDATA[Moore M R]]></field>
  <field name="author"><![CDATA[Thompson G G]]></field>
  <field name="author"><![CDATA[Goldberg A]]></field>
  <field name="articleLang"><![CDATA[eng]]></field>
  <field name="publicationType"><![CDATA[Journal Article]]></field>
  <field name="substanceName"><![CDATA[Heme]]></field>
  <field name="substanceName"><![CDATA[5-Aminolevulinate Synthetase]]></field>
  <field name="substanceName"><![CDATA[Hydroxymethylbilane Synthase]]></field>
  <field name="substanceName"><![CDATA[Ammonia-Lyases]]></field>
  <field name="articleDescriptor"><![CDATA[5-Aminolevulinate Synthetase]]></field>
  <field name="articleQualifier"><![CDATA[blood]]></field>
  <field name="articleDescriptor"><![CDATA[Acute Disease]]></field>
  <field name="articleDescriptor"><![CDATA[Adolescent]]></field>
  <field name="articleDescriptor"><![CDATA[Adult]]></field>
  <field name="articleDescriptor"><![CDATA[Aged]]></field>
  <field name="articleDescriptor"><![CDATA[Ammonia-Lyases]]></field>
  <field name="articleQualifier"><![CDATA[blood]]></field>
  <field name="articleDescriptor"><![CDATA[Child]]></field>
  <field name="articleDescriptor"><![CDATA[Clinical Enzyme Tests]]></field>
  <field name="articleDescriptor"><![CDATA[Erythrocytes]]></field>
  <field name="articleQualifier"><![CDATA[enzymology]]></field>
  <field name="articleDescriptor"><![CDATA[Female]]></field>
  <field name="articleDescriptor"><![CDATA[Heme]]></field>
  <field name="articleQualifier"><![CDATA[biosynthesis]]></field>
  <field name="articleDescriptor"><![CDATA[Humans]]></field>
  <field name="articleDescriptor"><![CDATA[Hydroxymethylbilane Synthase]]></field>
  <field name="articleQualifier"><![CDATA[blood]]></field>
  <field name="articleDescriptor"><![CDATA[Leukocytes]]></field>
  <field name="articleQualifier"><![CDATA[enzymology]]></field>
  <field name="articleDescriptor"><![CDATA[Male]]></field>
  <field name="articleDescriptor"><![CDATA[Middle Aged]]></field>
  <field name="articleDescriptor"><![CDATA[Porphyrias]]></field>
  <field name="articleQualifier"><![CDATA[diagnosis]]></field>
  <field name="articleDescriptor"><![CDATA[Reference Values]]></field>
 </doc>
 <doc>
  <field name="id"><![CDATA[6214633]]></field>
  <field name="articleCreationDate"><![CDATA[1982-12-02T00:00:00Z]]></field>
  <field name="articleYear"><![CDATA[1982]]></field>
  <field name="articleCompletionDate"><![CDATA[1982-12-02T00:00:00Z]]></field>
  <field name="articleRevisionDate"><![CDATA[2012-05-09T00:00:00Z]]></field>
  <field name="articlePubmodel"><![CDATA[Print]]></field>
  <field name="journalTitle"><![CDATA[Journal of medical genetics]]></field>
  <field name="journalTitleAbrv"><![CDATA[J. Med. Genet.]]></field>
  <field name="articleTitle"><![CDATA[The incidence of Down's syndrome in Nigeria.]]></field>
  <field name="articleAbstract"><![CDATA[Studies of Down's syndrome covering a period of 9 years revealed an incidence of 1 in 865 livebirths in a Nigerian hospital. Cytogenetic analysis in 386 patients showed 369 (95.5%) cases to be the result of regular trisomy 21, and translocation trisomy 21 was found in nine (2.5%) patients. Six (1.5%) patients were mosaics and the remaining two (0.5%) cases were classified as miscellaneous. A high incidence of cases among young mothers was recorded, but a search for environmental factors contributory to non-disjunction in this relatively young age group was unrevealing. The study has shown that Down's syndrome occurs as commonly in Negroes as in other races. Epidemiological studies like this are necessary to heighten the awareness of health planners in communities that have for a long time considered haemoglobinopathies to be the major genetic disorder, in order to prepare the ground for preventive measures.]]></field>
  <field name="author"><![CDATA[Adeyokunnu A A]]></field>
  <field name="articleLang"><![CDATA[eng]]></field>
  <field name="publicationType"><![CDATA[Journal Article]]></field>
  <field name="articleDescriptor"><![CDATA[Adolescent]]></field>
  <field name="articleDescriptor"><![CDATA[Adult]]></field>
  <field name="articleDescriptor"><![CDATA[Chromosomes, Human, 21-22 and Y]]></field>
  <field name="articleDescriptor"><![CDATA[Down Syndrome]]></field>
  <field name="articleQualifier"><![CDATA[epidemiology]]></field>
  <field name="articleDescriptor"><![CDATA[Humans]]></field>
  <field name="articleDescriptor"><![CDATA[Infant, Newborn]]></field>
  <field name="articleDescriptor"><![CDATA[Nigeria]]></field>
  <field name="articleDescriptor"><![CDATA[Translocation, Genetic]]></field>
  <field name="articleDescriptor"><![CDATA[Trisomy]]></field>
 </doc>
 <doc>
  <field name="id"><![CDATA[7120316]]></field>
  <field name="articleCreationDate"><![CDATA[1982-12-02T00:00:00Z]]></field>
  <field name="articleYear"><![CDATA[1982]]></field>
  <field name="articleCompletionDate"><![CDATA[1982-12-02T00:00:00Z]]></field>
  <field name="articleRevisionDate"><![CDATA[2009-11-18T00:00:00Z]]></field>
  <field name="articlePubmodel"><![CDATA[Print]]></field>
  <field name="journalTitle"><![CDATA[Journal of medical genetics]]></field>
  <field name="journalTitleAbrv"><![CDATA[J. Med. Genet.]]></field>
  <field name="articleTitle"><![CDATA[A family study of craniosynostosis, with probable recognition of a distinct syndrome.]]></field>
  <field name="articleAbstract"><![CDATA[A family study was based on 184 consecutive patients who had undergone surgery for craniosynostosis at The Hospital for Sick Children, London, between 1953 and 1976. Of these, 127 were traced and visited and are the probands for this study. Crouzon syndrome was recognised in 16, Apert in 11, Saethre-Chotzen in nine, and Pfeiffer in two. In addition, two probands had Saethre-Chotzen-like facies and bilaterally broad big toes owing to partial or complete duplication of the distal phalanx. This syndrome is distinct from Pfeiffer syndrome, in which the facies more closely resembles that in Crouzon syndrome and in which it is the proximal phalanx of the big toe (and often of the thumb) which is abnormal. It is suggested that this newly recognised syndrome be called after Robinow and Sorauf, who appear to be the first to have described a family with the condition. One proband with coronal stenosis had a mother and brother affected, but no syndrome was recognised in them. Excluding this last case, no non-syndromic proband had an affected parent. The 58 probands with predominantly sagittal synostosis had 106 sibs, none of whom was affected. The 21 probands with predominantly coronal synostosis included one sib pair both affected; the remaining 17 sibs were unaffected. The four probands with predominantly metopic stenosis had 13 unaffected sibs and the four with multiple sutures involved had eight unaffected sibs. One sagittal proband had an unaffected monozygotic twin and another an unaffected dizygotic twin.]]></field>
  <field name="author"><![CDATA[Carter C O]]></field>
  <field name="author"><![CDATA[Till K]]></field>
  <field name="author"><![CDATA[Fraser V]]></field>
  <field name="author"><![CDATA[Coffey R]]></field>
  <field name="articleLang"><![CDATA[eng]]></field>
  <field name="publicationType"><![CDATA[Case Reports]]></field>
  <field name="publicationType"><![CDATA[Journal Article]]></field>
  <field name="articleDescriptor"><![CDATA[Craniosynostoses]]></field>
  <field name="articleQualifier"><![CDATA[genetics]]></field>
  <field name="articleQualifier"><![CDATA[surgery]]></field>
  <field name="articleDescriptor"><![CDATA[Female]]></field>
  <field name="articleDescriptor"><![CDATA[Genes, Dominant]]></field>
  <field name="articleDescriptor"><![CDATA[Humans]]></field>
  <field name="articleDescriptor"><![CDATA[Infant]]></field>
  <field name="articleDescriptor"><![CDATA[Male]]></field>
  <field name="articleDescriptor"><![CDATA[Sex Factors]]></field>
  <field name="articleDescriptor"><![CDATA[Skull]]></field>
  <field name="articleQualifier"><![CDATA[surgery]]></field>
  <field name="articleDescriptor"><![CDATA[Syndrome]]></field>
 </doc>
 <doc>
  <field name="id"><![CDATA[7120317]]></field>
  <field name="articleCreationDate"><![CDATA[1982-12-02T00:00:00Z]]></field>
  <field name="articleYear"><![CDATA[1982]]></field>
  <field name="articleCompletionDate"><![CDATA[1982-12-02T00:00:00Z]]></field>
  <field name="articleRevisionDate"><![CDATA[2009-11-18T00:00:00Z]]></field>
  <field name="articlePubmodel"><![CDATA[Print]]></field>
  <field name="journalTitle"><![CDATA[Journal of medical genetics]]></field>
  <field name="journalTitleAbrv"><![CDATA[J. Med. Genet.]]></field>
  <field name="articleTitle"><![CDATA[An unusual form of familial acrocephalosyndactyly.]]></field>
  <field name="articleAbstract"><![CDATA[A family is described in which at least six members have an unusual form of acrocephalosyndactyly showing autosomal dominant inheritance. The most characteristic feature in the more severely affected individuals is duplication of the distal phalanx of the hallux. Review of family photographs suggests that the cosmetic outcome in apparently affected infants may be much better than anticipated.]]></field>
  <field name="author"><![CDATA[Young I D]]></field>
  <field name="author"><![CDATA[Harper P S]]></field>
  <field name="articleLang"><![CDATA[eng]]></field>
  <field name="publicationType"><![CDATA[Case Reports]]></field>
  <field name="publicationType"><![CDATA[Journal Article]]></field>
  <field name="articleDescriptor"><![CDATA[Acrocephalosyndactylia]]></field>
  <field name="articleQualifier"><![CDATA[genetics]]></field>
  <field name="articleDescriptor"><![CDATA[Adolescent]]></field>
  <field name="articleDescriptor"><![CDATA[Child]]></field>
  <field name="articleDescriptor"><![CDATA[Chromosome Aberrations]]></field>
  <field name="articleDescriptor"><![CDATA[Chromosome Disorders]]></field>
  <field name="articleDescriptor"><![CDATA[Female]]></field>
  <field name="articleDescriptor"><![CDATA[Follow-Up Studies]]></field>
  <field name="articleDescriptor"><![CDATA[Genes, Dominant]]></field>
  <field name="articleDescriptor"><![CDATA[Humans]]></field>
  <field name="articleDescriptor"><![CDATA[Infant]]></field>
  <field name="articleDescriptor"><![CDATA[Male]]></field>
  <field name="articleDescriptor"><![CDATA[Pedigree]]></field>
 </doc>
 <doc>
  <field name="id"><![CDATA[6288948]]></field>
  <field name="articleCreationDate"><![CDATA[1982-12-02T00:00:00Z]]></field>
  <field name="articleYear"><![CDATA[1982]]></field>
  <field name="articleCompletionDate"><![CDATA[1982-12-02T00:00:00Z]]></field>
  <field name="articleRevisionDate"><![CDATA[2009-11-18T00:00:00Z]]></field>
  <field name="articlePubmodel"><![CDATA[Print]]></field>
  <field name="journalTitle"><![CDATA[Journal of medical genetics]]></field>
  <field name="journalTitleAbrv"><![CDATA[J. Med. Genet.]]></field>
  <field name="articleTitle"><![CDATA[Familial Poland anomaly.]]></field>
  <field name="articleAbstract"><![CDATA[The Poland anomaly is usually a non-genetic malformation syndrome. This paper reports two second cousins who both had a typical left sided Poland anomaly, and this constitutes the first recorded case of this condition affecting more than one member of a family. Despite this, for the purposes of genetic counselling, the Poland anomaly can be regarded as a sporadic condition with an extremely low recurrence risk.]]></field>
  <field name="author"><![CDATA[David T J]]></field>
  <field name="articleLang"><![CDATA[eng]]></field>
  <field name="publicationType"><![CDATA[Case Reports]]></field>
  <field name="publicationType"><![CDATA[Journal Article]]></field>
  <field name="articleDescriptor"><![CDATA[Adult]]></field>
  <field name="articleDescriptor"><![CDATA[Child]]></field>
  <field name="articleDescriptor"><![CDATA[Dermatoglyphics]]></field>
  <field name="articleDescriptor"><![CDATA[Female]]></field>
  <field name="articleDescriptor"><![CDATA[Functional Laterality]]></field>
  <field name="articleDescriptor"><![CDATA[Humans]]></field>
  <field name="articleDescriptor"><![CDATA[Male]]></field>
  <field name="articleDescriptor"><![CDATA[Muscles]]></field>
  <field name="articleQualifier"><![CDATA[abnormalities]]></field>
  <field name="articleDescriptor"><![CDATA[Muscular Diseases]]></field>
  <field name="articleQualifier"><![CDATA[genetics]]></field>
  <field name="articleDescriptor"><![CDATA[Syndactyly]]></field>
  <field name="articleQualifier"><![CDATA[genetics]]></field>
  <field name="articleQualifier"><![CDATA[surgery]]></field>
 </doc>
 <doc>
  <field name="id"><![CDATA[6889654]]></field>
  <field name="articleCreationDate"><![CDATA[1982-12-02T00:00:00Z]]></field>
  <field name="articleYear"><![CDATA[1982]]></field>
  <field name="articleCompletionDate"><![CDATA[1982-12-02T00:00:00Z]]></field>
  <field name="articleRevisionDate"><![CDATA[2009-11-18T00:00:00Z]]></field>
  <field name="articlePubmodel"><![CDATA[Print]]></field>
  <field name="journalTitle"><![CDATA[Journal of medical genetics]]></field>
  <field name="journalTitleAbrv"><![CDATA[J. Med. Genet.]]></field>
  <field name="articleTitle"><![CDATA[Human chromosomal heteromorphisms in American blacks. VI. Higher incidence of longer Y owing to non-fluorescent (nf) segment.]]></field>
  <field name="articleAbstract"><![CDATA[Sixty normal male American blacks were selected to study the length of fluorescent (f), non-fluorescent (nf), and total length of the Y chromosome by the QFQ technique. The length of the Y chromosome was classified into five groups: very small, small, average, large, and very large. The frequencies of Y/F indices for these groups were 0.0, 3.33, 56.67, 30.00, and 10.00%, respectively. The variation in the total length of the Y chromosome was accounted for by variations in the length of the nf as well as the f segment. A longer Y was noted in blacks owing to an increase in size of the nf segment in comparison with a normal Caucasian population. Forty percent of American blacks had large or very large Y chromosomes, while this class comprised only 18.3% of Caucasians, which is significantly different (p less than 0.05). Furthermore, the length of the Y chromosome was normally distributed among Caucasians, while among blacks the distribution was skewed to the left. The mean Y/F, f/F, and nf/F indices were 1.09 +/- 0.10, 0.42 +/- 0.09, and 0.67 +/- 0.04, respectively.]]></field>
  <field name="author"><![CDATA[Verma R S]]></field>
  <field name="author"><![CDATA[Evans-McCalla M]]></field>
  <field name="author"><![CDATA[Dosik H]]></field>
  <field name="articleLang"><![CDATA[eng]]></field>
  <field name="publicationType"><![CDATA[Journal Article]]></field>
  <field name="publicationType"><![CDATA[Research Support, Non-U.S. Gov't]]></field>
  <field name="publicationType"><![CDATA[Research Support, U.S. Gov't, P.H.S.]]></field>
  <field name="articleDescriptor"><![CDATA[African Continental Ancestry Group]]></field>
  <field name="articleDescriptor"><![CDATA[Humans]]></field>
  <field name="articleDescriptor"><![CDATA[Male]]></field>
  <field name="articleDescriptor"><![CDATA[Microscopy, Fluorescence]]></field>
  <field name="articleDescriptor"><![CDATA[Sex Chromosome Aberrations]]></field>
  <field name="articleQualifier"><![CDATA[epidemiology]]></field>
  <field name="articleDescriptor"><![CDATA[Sex Chromosomes]]></field>
  <field name="articleDescriptor"><![CDATA[United States]]></field>
  <field name="articleDescriptor"><![CDATA[Y Chromosome]]></field>
 </doc>
 <doc>
  <field name="id"><![CDATA[7120321]]></field>
  <field name="articleCreationDate"><![CDATA[1982-12-02T00:00:00Z]]></field>
  <field name="articleYear"><![CDATA[1982]]></field>
  <field name="articleCompletionDate"><![CDATA[1982-12-02T00:00:00Z]]></field>
  <field name="articleRevisionDate"><![CDATA[2009-11-18T00:00:00Z]]></field>
  <field name="articlePubmodel"><![CDATA[Print]]></field>
  <field name="journalTitle"><![CDATA[Journal of medical genetics]]></field>
  <field name="journalTitleAbrv"><![CDATA[J. Med. Genet.]]></field>
  <field name="articleTitle"><![CDATA[X long arm deletion with oligomenorrhoea.]]></field>
  <field name="articleAbstract"><![CDATA[A 35-year-old female patient with oligomenorrhoea had a deletion of the long arm of the X chromosome. The breakpoint at band q23 caused infertility in spite of excessive pituitary stimulation. The aberrant X chromosome was inactivated in all cells analysed.]]></field>
  <field name="author"><![CDATA[Mijin K]]></field>
  <field name="author"><![CDATA[Stolević E]]></field>
  <field name="author"><![CDATA[Adzić S]]></field>
  <field name="author"><![CDATA[Laća Z]]></field>
  <field name="author"><![CDATA[Marković S]]></field>
  <field name="articleLang"><![CDATA[eng]]></field>
  <field name="publicationType"><![CDATA[Case Reports]]></field>
  <field name="publicationType"><![CDATA[Journal Article]]></field>
  <field name="articleDescriptor"><![CDATA[Adult]]></field>
  <field name="articleDescriptor"><![CDATA[Chromosome Aberrations]]></field>
  <field name="articleDescriptor"><![CDATA[Chromosome Banding]]></field>
  <field name="articleDescriptor"><![CDATA[Chromosome Deletion]]></field>
  <field name="articleDescriptor"><![CDATA[Chromosome Disorders]]></field>
  <field name="articleDescriptor"><![CDATA[Female]]></field>
  <field name="articleDescriptor"><![CDATA[Humans]]></field>
  <field name="articleDescriptor"><![CDATA[Karyotyping]]></field>
  <field name="articleDescriptor"><![CDATA[Menstruation Disturbances]]></field>
  <field name="articleQualifier"><![CDATA[genetics]]></field>
  <field name="articleDescriptor"><![CDATA[Oligomenorrhea]]></field>
  <field name="articleQualifier"><![CDATA[genetics]]></field>
  <field name="articleDescriptor"><![CDATA[Sex Chromosomes]]></field>
  <field name="articleDescriptor"><![CDATA[X Chromosome]]></field>
 </doc>
 <doc>
  <field name="id"><![CDATA[7120322]]></field>
  <field name="articleCreationDate"><![CDATA[1982-12-02T00:00:00Z]]></field>
  <field name="articleYear"><![CDATA[1982]]></field>
  <field name="articleCompletionDate"><![CDATA[1982-12-02T00:00:00Z]]></field>
  <field name="articleRevisionDate"><![CDATA[2009-11-18T00:00:00Z]]></field>
  <field name="articlePubmodel"><![CDATA[Print]]></field>
  <field name="journalTitle"><![CDATA[Journal of medical genetics]]></field>
  <field name="journalTitleAbrv"><![CDATA[J. Med. Genet.]]></field>
  <field name="articleTitle"><![CDATA[Cd branding studies in a homologous Robertsonian 13;13 translocation.]]></field>
  <field name="articleAbstract"><![CDATA[A phenotypically normal female with a history of two miscarriages was found to have the karyotype 45,XX,t(13p:13p). C banding showed the translocation to have two regions of centromeric constitutive heterochromatin, silver staining showed an active NOR in 60% of the cells screened, and Cd banding studies showed a single Cd band with absence of the Cd band at the suppressed centromere.]]></field>
  <field name="author"><![CDATA[Romain D R]]></field>
  <field name="author"><![CDATA[Columbano-Green L]]></field>
  <field name="author"><![CDATA[Sullivan J]]></field>
  <field name="author"><![CDATA[Smythe R H]]></field>
  <field name="author"><![CDATA[Gebbie O]]></field>
  <field name="author"><![CDATA[Parfitt R]]></field>
  <field name="author"><![CDATA[Chapman C]]></field>
  <field name="articleLang"><![CDATA[eng]]></field>
  <field name="publicationType"><![CDATA[Case Reports]]></field>
  <field name="publicationType"><![CDATA[Journal Article]]></field>
  <field name="substanceName"><![CDATA[Heterochromatin]]></field>
  <field name="articleDescriptor"><![CDATA[Chromosome Banding]]></field>
  <field name="articleDescriptor"><![CDATA[Chromosomes, Human, 13-15]]></field>
  <field name="articleDescriptor"><![CDATA[Female]]></field>
  <field name="articleDescriptor"><![CDATA[Heterochromatin]]></field>
  <field name="articleQualifier"><![CDATA[ultrastructure]]></field>
  <field name="articleDescriptor"><![CDATA[Humans]]></field>
  <field name="articleDescriptor"><![CDATA[Phenotype]]></field>
  <field name="articleDescriptor"><![CDATA[Polymorphism, Genetic]]></field>
  <field name="articleDescriptor"><![CDATA[Translocation, Genetic]]></field>
 </doc>
 <doc>
  <field name="id"><![CDATA[7120329]]></field>
  <field name="articleCreationDate"><![CDATA[1982-12-02T00:00:00Z]]></field>
  <field name="articleYear"><![CDATA[1982]]></field>
  <field name="articleCompletionDate"><![CDATA[1982-12-02T00:00:00Z]]></field>
  <field name="articleRevisionDate"><![CDATA[2007-11-15T00:00:00Z]]></field>
  <field name="articlePubmodel"><![CDATA[Print]]></field>
  <field name="journalTitle"><![CDATA[Journal of medical education]]></field>
  <field name="journalTitleAbrv"><![CDATA[J Med Educ]]></field>
  <field name="articleTitle"><![CDATA[Subjective and objective admissions factors as predictors of clinical clerkship performance.]]></field>
  <field name="articleAbstract"><![CDATA[Subjective and objective measures available at the time of medical school admission were related to subjective and objective clinical performance measures during medical school. Strategies were developed for coding narrative faculty comments from admissions interviews and clinical performance evaluations. Factor analysis was used to examine underlying structures for both admission and clinical performance measures. Summed scores were calculated to represent each factor, and multiple regression was used in predicting each of the clinical factors from the admission factors. Multiple regression showed that admission interview comments best predict narrative clerkship performance, while objective scores best predict an objective measure of clinical knowledge. Conclusions were: (a) narrative information can be coded reliably. (b) Objective and subjective measures are distinct, identifiable structures both at admission and during the third year of medical school. (c) Prediction formulas will vary depending on what outcome variables are chosen.]]></field>
  <field name="author"><![CDATA[Meredith K E]]></field>
  <field name="author"><![CDATA[Dunlap M R]]></field>
  <field name="author"><![CDATA[Baker H H]]></field>
  <field name="articleLang"><![CDATA[eng]]></field>
  <field name="publicationType"><![CDATA[Journal Article]]></field>
  <field name="publicationType"><![CDATA[Research Support, U.S. Gov't, P.H.S.]]></field>
  <field name="articleDescriptor"><![CDATA[Achievement]]></field>
  <field name="articleDescriptor"><![CDATA[Clinical Clerkship]]></field>
  <field name="articleDescriptor"><![CDATA[College Admission Test]]></field>
  <field name="articleDescriptor"><![CDATA[Education, Medical, Undergraduate]]></field>
  <field name="articleDescriptor"><![CDATA[Educational Measurement]]></field>
  <field name="articleDescriptor"><![CDATA[Interviews as Topic]]></field>
  <field name="articleDescriptor"><![CDATA[Regression Analysis]]></field>
  <field name="articleDescriptor"><![CDATA[School Admission Criteria]]></field>
  <field name="articleDescriptor"><![CDATA[Schools, Medical]]></field>
 </doc>
 <doc>
  <field name="id"><![CDATA[7120330]]></field>
  <field name="articleCreationDate"><![CDATA[1982-12-02T00:00:00Z]]></field>
  <field name="articleYear"><![CDATA[1982]]></field>
  <field name="articleCompletionDate"><![CDATA[1982-12-02T00:00:00Z]]></field>
  <field name="articleRevisionDate"><![CDATA[2007-11-15T00:00:00Z]]></field>
  <field name="articlePubmodel"><![CDATA[Print]]></field>
  <field name="journalTitle"><![CDATA[Journal of medical education]]></field>
  <field name="journalTitleAbrv"><![CDATA[J Med Educ]]></field>
  <field name="articleTitle"><![CDATA[How physicians view the process of change in their practice behavior.]]></field>
  <field name="articleAbstract"><![CDATA[The changes all physicians make in their treatment of patients constitute a neglected but key issue in the operation of the health care system. Identification of a model of this crucial change process was the purpose of this study. Interviews with a random sample of 66 physicians representing five specialties produced data on 182 changes. The fundamental stages in the change process were priming (coming to feel dissatisfaction with some aspect of practice behavior), focusing (learning of alternative practice behavior), and follow-up (obtaining further information or advice regarding the possible change). Any of a variety of information sources may focus a change, but follow-up is overridingly dependent on colleague communication (representing local professional opinion) and journals (representing an authoritative professional perspective). This change process model provides a basis for orienting continuing medical education activities to the achievement of behavioral outcomes.]]></field>
  <field name="author"><![CDATA[Geertsma R H]]></field>
  <field name="author"><![CDATA[Parker R C]]></field>
  <field name="author"><![CDATA[Whitbourne S K]]></field>
  <field name="articleLang"><![CDATA[eng]]></field>
  <field name="publicationType"><![CDATA[Journal Article]]></field>
  <field name="publicationType"><![CDATA[Research Support, Non-U.S. Gov't]]></field>
  <field name="articleDescriptor"><![CDATA[Behavior]]></field>
  <field name="articleDescriptor"><![CDATA[Drug Therapy]]></field>
  <field name="articleQualifier"><![CDATA[education]]></field>
  <field name="articleDescriptor"><![CDATA[Education, Medical, Continuing]]></field>
  <field name="articleDescriptor"><![CDATA[Humans]]></field>
  <field name="articleDescriptor"><![CDATA[Periodicals as Topic]]></field>
  <field name="articleDescriptor"><![CDATA[Physicians]]></field>
  <field name="articleDescriptor"><![CDATA[Private Practice]]></field>
 </doc>
 <doc>
  <field name="id"><![CDATA[6750128]]></field>
  <field name="articleCreationDate"><![CDATA[1982-12-02T00:00:00Z]]></field>
  <field name="articleYear"><![CDATA[1982]]></field>
  <field name="articleCompletionDate"><![CDATA[1982-12-02T00:00:00Z]]></field>
  <field name="articleRevisionDate"><![CDATA[2006-11-15T00:00:00Z]]></field>
  <field name="articlePubmodel"><![CDATA[Print]]></field>
  <field name="journalTitle"><![CDATA[Journal of medical education]]></field>
  <field name="journalTitleAbrv"><![CDATA[J Med Educ]]></field>
  <field name="articleTitle"><![CDATA[Guidelines for graduate medical education in geriatrics.]]></field>
  <field name="articleAbstract"><![CDATA[There has been a substantial increase in training programs in geriatrics over the past several years. In this paper the authors propose guidelines for geriatric training at the graduate medical educational level, both for specialized training (geriatric fellowship) and training in geriatrics as part of other specialty training (internal medicine, family practice, psychiatry, and neurology). Experts from relevant specialty boards and societies, an advisory group in geriatrics, and the faculty of the University of California-Los Angeles Multicampus Division of Geriatrics participated in a modified Delphi study which provided the information used to formulate the guidelines. Performance objectives, core content, training experiences, and clinical exposure and program evaluations are described for geriatric fellows and house staff members in internal medicine, family practice, neurology, and psychiatry. Recommendations included here may be of use to deans, faculty members, and educators responsible for the development of the many new geriatric training programs.]]></field>
  <field name="author"><![CDATA[Robbins A S]]></field>
  <field name="author"><![CDATA[Beck J C]]></field>
  <field name="articleLang"><![CDATA[eng]]></field>
  <field name="publicationType"><![CDATA[Journal Article]]></field>
  <field name="publicationType"><![CDATA[Research Support, U.S. Gov't, Non-P.H.S.]]></field>
  <field name="articleDescriptor"><![CDATA[Aged]]></field>
  <field name="articleDescriptor"><![CDATA[Curriculum]]></field>
  <field name="articleDescriptor"><![CDATA[Delphi Technique]]></field>
  <field name="articleDescriptor"><![CDATA[Education, Medical, Graduate]]></field>
  <field name="articleQualifier"><![CDATA[standards]]></field>
  <field name="articleDescriptor"><![CDATA[Faculty, Medical]]></field>
  <field name="articleDescriptor"><![CDATA[Fellowships and Scholarships]]></field>
  <field name="articleDescriptor"><![CDATA[Geriatrics]]></field>
  <field name="articleQualifier"><![CDATA[education]]></field>
  <field name="articleDescriptor"><![CDATA[Humans]]></field>
  <field name="articleDescriptor"><![CDATA[Internship and Residency]]></field>
  <field name="articleDescriptor"><![CDATA[United States]]></field>
 </doc>
 <doc>
  <field name="id"><![CDATA[7120331]]></field>
  <field name="articleCreationDate"><![CDATA[1982-12-02T00:00:00Z]]></field>
  <field name="articleYear"><![CDATA[1982]]></field>
  <field name="articleCompletionDate"><![CDATA[1982-12-02T00:00:00Z]]></field>
  <field name="articleRevisionDate"><![CDATA[2011-11-17T00:00:00Z]]></field>
  <field name="articlePubmodel"><![CDATA[Print]]></field>
  <field name="journalTitle"><![CDATA[Journal of medical education]]></field>
  <field name="journalTitleAbrv"><![CDATA[J Med Educ]]></field>
  <field name="articleTitle"><![CDATA[Modification of decision-making behavior of third-year medical students.]]></field>
  <field name="articleAbstract"><![CDATA[Modification of physician behavior has been suggested as one approach to controlling health care expenditures. Third-year students participated in an experimental program which attempted both to construct an educational approach that included aspects of such expenditures and to measure the effectiveness of the approach. Students were divided between experimental and control groups, with the former receiving information relative to the appropriate use and costs of diagnostic procedures. Both groups were presented with case studies dealing with specific disease processes discussed in the program. Members of the experimental group scored significantly better in their ability to determine diagnoses, make patient-management decisions, and choose essential diagnostic procedures. Average charges generated by the experimental student group were half the amount generated by the control group. Future studies will be required to determine whether the behavior modification carries forward in practice and to provide a standardized methodology for use by members of the faculty and house staff in educating future medical students.]]></field>
  <field name="author"><![CDATA[Spiegel C T]]></field>
  <field name="author"><![CDATA[Kemp B A]]></field>
  <field name="author"><![CDATA[Newman M A]]></field>
  <field name="author"><![CDATA[Birnbaum P S]]></field>
  <field name="author"><![CDATA[Alter C L]]></field>
  <field name="articleLang"><![CDATA[eng]]></field>
  <field name="publicationType"><![CDATA[Journal Article]]></field>
  <field name="articleDescriptor"><![CDATA[Clinical Laboratory Techniques]]></field>
  <field name="articleDescriptor"><![CDATA[Cost Control]]></field>
  <field name="articleDescriptor"><![CDATA[Decision Making]]></field>
  <field name="articleDescriptor"><![CDATA[Diagnosis]]></field>
  <field name="articleDescriptor"><![CDATA[Diagnosis, Differential]]></field>
  <field name="articleDescriptor"><![CDATA[Education, Medical]]></field>
  <field name="articleDescriptor"><![CDATA[Students, Medical]]></field>
  <field name="articleQualifier"><![CDATA[psychology]]></field>
 </doc>
 <doc>
  <field name="id"><![CDATA[7120332]]></field>
  <field name="articleCreationDate"><![CDATA[1982-12-02T00:00:00Z]]></field>
  <field name="articleYear"><![CDATA[1982]]></field>
  <field name="articleCompletionDate"><![CDATA[1982-12-02T00:00:00Z]]></field>
  <field name="articleRevisionDate"><![CDATA[2007-11-14T00:00:00Z]]></field>
  <field name="articlePubmodel"><![CDATA[Print]]></field>
  <field name="journalTitle"><![CDATA[Journal of medical education]]></field>
  <field name="journalTitleAbrv"><![CDATA[J Med Educ]]></field>
  <field name="articleTitle"><![CDATA[Intensive medical student support groups: format, outcome, and leadership guidelines.]]></field>
  <field name="articleAbstract"><![CDATA[The authors report on a five-year experience with process-oriented discussion groups at annual four-day, off-campus retreats attended by students, faculty members, and "significant others." Group sessions comprised 17 hours of each retreat, which also included community activities and recreation time. Group leaders represented a diversity of professional backgrounds. In response to questionnaires sent from one to two months after the retreats, participants rated group experiences highly, although they also considered a significant amount of time for unstructured interpersonal interaction and recreation important. Participants enjoyed meeting students and faculty members in a relatively "role-free" setting, and students derived an enhanced sense of self-awareness from group discussions. The most highly valued group leader behaviors were participation as a group member, facilitation of interpersonal communication, and attention to group members' needs. Guidance and direction by the leaders were also considered valuable, provided that they did not impose inappropriate expectations on their groups.]]></field>
  <field name="author"><![CDATA[Plaut S M]]></field>
  <field name="author"><![CDATA[Hunt G J]]></field>
  <field name="author"><![CDATA[Johnson F P]]></field>
  <field name="author"><![CDATA[Brown R M]]></field>
  <field name="author"><![CDATA[Hobbins T E]]></field>
  <field name="articleLang"><![CDATA[eng]]></field>
  <field name="publicationType"><![CDATA[Journal Article]]></field>
  <field name="publicationType"><![CDATA[Research Support, U.S. Gov't, P.H.S.]]></field>
  <field name="articleDescriptor"><![CDATA[Education, Medical]]></field>
  <field name="articleDescriptor"><![CDATA[Faculty, Medical]]></field>
  <field name="articleDescriptor"><![CDATA[Group Processes]]></field>
  <field name="articleDescriptor"><![CDATA[Humans]]></field>
  <field name="articleDescriptor"><![CDATA[Interpersonal Relations]]></field>
  <field name="articleDescriptor"><![CDATA[Leadership]]></field>
  <field name="articleDescriptor"><![CDATA[Recreation]]></field>
  <field name="articleDescriptor"><![CDATA[Social Support]]></field>
  <field name="articleDescriptor"><![CDATA[Students, Medical]]></field>
 </doc>
 <doc>
  <field name="id"><![CDATA[7120333]]></field>
  <field name="articleCreationDate"><![CDATA[1982-12-02T00:00:00Z]]></field>
  <field name="articleYear"><![CDATA[1982]]></field>
  <field name="articleCompletionDate"><![CDATA[1982-12-02T00:00:00Z]]></field>
  <field name="articleRevisionDate"><![CDATA[2004-11-17T00:00:00Z]]></field>
  <field name="articlePubmodel"><![CDATA[Print]]></field>
  <field name="journalTitle"><![CDATA[Journal of medical education]]></field>
  <field name="journalTitleAbrv"><![CDATA[J Med Educ]]></field>
  <field name="articleTitle"><![CDATA[Clinical medical education in the nursing home: opportunities and limits.]]></field>
  <field name="articleAbstract"><![CDATA[The nursing home has been proposed as a potential site for clinical medical education. Before medical schools can reasonably devote increasingly scarce resources to such an endeavor, questions of what the nursing home might uniquely provide to medical students and whether such experiences are really necessary must be clearly answered. Evidence is presented to support the development of the nursing home as a required clinical educational site. Analogies and differences between the current situation in the nursing home and the situation of the hospital in medical education in the early 20th century are explored as a means of understanding the potential and limits of the nursing home's role in medical education.]]></field>
  <field name="author"><![CDATA[Pawlson L G]]></field>
  <field name="articleLang"><![CDATA[eng]]></field>
  <field name="publicationType"><![CDATA[Journal Article]]></field>
  <field name="articleDescriptor"><![CDATA[Aged]]></field>
  <field name="articleDescriptor"><![CDATA[Chronic Disease]]></field>
  <field name="articleDescriptor"><![CDATA[Education, Medical]]></field>
  <field name="articleDescriptor"><![CDATA[Faculty, Medical]]></field>
  <field name="articleDescriptor"><![CDATA[Geriatrics]]></field>
  <field name="articleQualifier"><![CDATA[education]]></field>
  <field name="articleDescriptor"><![CDATA[Humans]]></field>
  <field name="articleDescriptor"><![CDATA[Institutionalization]]></field>
  <field name="articleDescriptor"><![CDATA[Mental Disorders]]></field>
  <field name="articleQualifier"><![CDATA[therapy]]></field>
  <field name="articleDescriptor"><![CDATA[Nursing Homes]]></field>
  <field name="articleDescriptor"><![CDATA[Research]]></field>
 </doc>
 <doc>
  <field name="id"><![CDATA[7120349]]></field>
  <field name="articleCreationDate"><![CDATA[1982-12-02T00:00:00Z]]></field>
  <field name="articleYear"><![CDATA[1982]]></field>
  <field name="articleCompletionDate"><![CDATA[1982-12-02T00:00:00Z]]></field>
  <field name="articleRevisionDate"><![CDATA[2009-11-19T00:00:00Z]]></field>
  <field name="articlePubmodel"><![CDATA[Print]]></field>
  <field name="journalTitle"><![CDATA[Journal of medical engineering & technology]]></field>
  <field name="journalTitleAbrv"><![CDATA[J Med Eng Technol]]></field>
  <field name="articleTitle"><![CDATA[EEG alpha-biofeedback training: an experimental technique for the management of anxiety.]]></field>
  <field name="articleAbstract"><![CDATA[This paper outlines the design of a specialized alpha-biofeedback system for use in the treatment of anxiety. The relationship of electroencephalographic (EEG) alpha activity to various anxiety states is described, and the rationale for use of alpha-biofeedback training with chronic anxiety patients is explained. Those features of the specialized system, and associated training methods, which are considered essential for this particular application are described and include the following: (1) use of visual feedback and eyes-open training; (2) use of oculomotor influences to facilitate alpha production; (3) encouragement of a passive attitude in the patient by using both verbal instructions and 'low-information' feedback with covert shaping. The training procedures used and the design and function of the instrument are described. The initial clinical results obtained with this equipment are also presented.]]></field>
  <field name="author"><![CDATA[Hare J F]]></field>
  <field name="author"><![CDATA[Timmons B H]]></field>
  <field name="author"><![CDATA[Roberts J R]]></field>
  <field name="author"><![CDATA[Burman A S]]></field>
  <field name="articleLang"><![CDATA[eng]]></field>
  <field name="publicationType"><![CDATA[Journal Article]]></field>
  <field name="articleDescriptor"><![CDATA[Alpha Rhythm]]></field>
  <field name="articleDescriptor"><![CDATA[Anxiety]]></field>
  <field name="articleQualifier"><![CDATA[therapy]]></field>
  <field name="articleDescriptor"><![CDATA[Biofeedback, Psychology]]></field>
  <field name="articleDescriptor"><![CDATA[Eye Movements]]></field>
  <field name="articleDescriptor"><![CDATA[Humans]]></field>
  <field name="articleDescriptor"><![CDATA[Monitoring, Physiologic]]></field>
 </doc>
 <doc>
  <field name="id"><![CDATA[7120353]]></field>
  <field name="articleCreationDate"><![CDATA[1982-12-02T00:00:00Z]]></field>
  <field name="articleYear"><![CDATA[1982]]></field>
  <field name="articleCompletionDate"><![CDATA[1982-12-02T00:00:00Z]]></field>
  <field name="articleRevisionDate"><![CDATA[2007-11-14T00:00:00Z]]></field>
  <field name="articlePubmodel"><![CDATA[Print]]></field>
  <field name="journalTitle"><![CDATA[Journal of medical microbiology]]></field>
  <field name="journalTitleAbrv"><![CDATA[J. Med. Microbiol.]]></field>
  <field name="articleTitle"><![CDATA[Calcium requirement and virulence of Yersinia enterocolitica.]]></field>
  <field name="articleAbstract"><![CDATA[At an optimal concentration of magnesium, highly virulent wild strains of Yersinia enterocolitica serotype O:8, with an LD50, for mice, of less than 10(3) cell intravenously, had an in-vitro requirement for calcium at 37 degrees C but not at 26 degrees C. Avirulent wild strains of Y. enterocolitica (LD50 greater than 10(7) cells intravenously) did not have this calcium dependence. When grown on calcium-depleted media at 37 degrees C, eight highly virulent strains yielded 0.5--6% large calcium non-requiring, avirulent colonies; the remaining colonies were slow growing, calcium dependent and highly virulent. Like wild avirulent strains, these calcium non-requiring mutants were quickly destroyed in organs within 48 h, even after large intravenous challenge. In contrast the slow-growing calcium-dependent colonies were highly virulent on intravenous inoculation, growing rapidly in the liver, spleen and lungs to produce multiple abscesses. Homogenates of heavily infected organs produced the original proportion of calcium non-requiring colonies when plated on media without calcium. Results of a fluctuation test suggested that the emergence of calcium non-requiring mutants is the result of induction rather than spontaneous mutation.]]></field>
  <field name="author"><![CDATA[Berche P A]]></field>
  <field name="author"><![CDATA[Carter P B]]></field>
  <field name="articleLang"><![CDATA[eng]]></field>
  <field name="publicationType"><![CDATA[Journal Article]]></field>
  <field name="publicationType"><![CDATA[Research Support, Non-U.S. Gov't]]></field>
  <field name="publicationType"><![CDATA[Research Support, U.S. Gov't, P.H.S.]]></field>
  <field name="substanceName"><![CDATA[Culture Media]]></field>
  <field name="substanceName"><![CDATA[Calcium]]></field>
  <field name="articleDescriptor"><![CDATA[Animals]]></field>
  <field name="articleDescriptor"><![CDATA[Calcium]]></field>
  <field name="articleQualifier"><![CDATA[pharmacology]]></field>
  <field name="articleDescriptor"><![CDATA[Culture Media]]></field>
  <field name="articleDescriptor"><![CDATA[Female]]></field>
  <field name="articleDescriptor"><![CDATA[Lethal Dose 50]]></field>
  <field name="articleDescriptor"><![CDATA[Liver]]></field>
  <field name="articleQualifier"><![CDATA[microbiology]]></field>
  <field name="articleDescriptor"><![CDATA[Lung]]></field>
  <field name="articleQualifier"><![CDATA[microbiology]]></field>
  <field name="articleDescriptor"><![CDATA[Male]]></field>
  <field name="articleDescriptor"><![CDATA[Mice]]></field>
  <field name="articleDescriptor"><![CDATA[Spleen]]></field>
  <field name="articleQualifier"><![CDATA[microbiology]]></field>
  <field name="articleDescriptor"><![CDATA[Temperature]]></field>
  <field name="articleDescriptor"><![CDATA[Yersinia enterocolitica]]></field>
  <field name="articleQualifier"><![CDATA[growth & development]]></field>
  <field name="articleQualifier"><![CDATA[pathogenicity]]></field>
 </doc>
 <doc>
  <field name="id"><![CDATA[6288950]]></field>
  <field name="articleCreationDate"><![CDATA[1982-12-02T00:00:00Z]]></field>
  <field name="articleYear"><![CDATA[1982]]></field>
  <field name="articleCompletionDate"><![CDATA[1982-12-02T00:00:00Z]]></field>
  <field name="articleRevisionDate"><![CDATA[2004-11-17T00:00:00Z]]></field>
  <field name="articlePubmodel"><![CDATA[Print]]></field>
  <field name="journalTitle"><![CDATA[Journal of medical microbiology]]></field>
  <field name="journalTitleAbrv"><![CDATA[J. Med. Microbiol.]]></field>
  <field name="articleTitle"><![CDATA[Age-related changes in the prevalence of precipitating antibodies to BK virus in infants and children.]]></field>
  <field name="articleAbstract"><![CDATA[Nearly 1000 sera from children were tested by immunoelectro-osmophoresis against BK virus, and age-specific prevalence rates were estimated from birth until the age of 12 years. Declining rates during the first 12 months showed the waning of passive immunity, which at birth reflects the mother's immune status. The changes of prevalence suggested that the peak incidence of primary infections occurred at about 2 years, with an estimated peak annual rate of 24.6%.]]></field>
  <field name="author"><![CDATA[Dei R]]></field>
  <field name="author"><![CDATA[Marmo F]]></field>
  <field name="author"><![CDATA[Corte D]]></field>
  <field name="author"><![CDATA[Sampietro M G]]></field>
  <field name="author"><![CDATA[Franceschini E]]></field>
  <field name="author"><![CDATA[Urbano P]]></field>
  <field name="articleLang"><![CDATA[eng]]></field>
  <field name="publicationType"><![CDATA[Journal Article]]></field>
  <field name="substanceName"><![CDATA[Antibodies, Viral]]></field>
  <field name="articleDescriptor"><![CDATA[Aging]]></field>
  <field name="articleDescriptor"><![CDATA[Animals]]></field>
  <field name="articleDescriptor"><![CDATA[Antibodies, Viral]]></field>
  <field name="articleQualifier"><![CDATA[analysis]]></field>
  <field name="articleDescriptor"><![CDATA[BK Virus]]></field>
  <field name="articleQualifier"><![CDATA[immunology]]></field>
  <field name="articleDescriptor"><![CDATA[Child]]></field>
  <field name="articleDescriptor"><![CDATA[Child, Preschool]]></field>
  <field name="articleDescriptor"><![CDATA[Counterimmunoelectrophoresis]]></field>
  <field name="articleDescriptor"><![CDATA[Female]]></field>
  <field name="articleDescriptor"><![CDATA[Humans]]></field>
  <field name="articleDescriptor"><![CDATA[Immunity, Maternally-Acquired]]></field>
  <field name="articleDescriptor"><![CDATA[Infant]]></field>
  <field name="articleDescriptor"><![CDATA[Infant, Newborn]]></field>
  <field name="articleDescriptor"><![CDATA[Male]]></field>
  <field name="articleDescriptor"><![CDATA[Polyomavirus]]></field>
  <field name="articleQualifier"><![CDATA[immunology]]></field>
  <field name="articleDescriptor"><![CDATA[Precipitin Tests]]></field>
  <field name="articleDescriptor"><![CDATA[Tumor Virus Infections]]></field>
  <field name="articleQualifier"><![CDATA[epidemiology]]></field>
  <field name="articleQualifier"><![CDATA[immunology]]></field>
 </doc>
 <doc>
  <field name="id"><![CDATA[7120354]]></field>
  <field name="articleCreationDate"><![CDATA[1982-12-02T00:00:00Z]]></field>
  <field name="articleYear"><![CDATA[1982]]></field>
  <field name="articleCompletionDate"><![CDATA[1982-12-02T00:00:00Z]]></field>
  <field name="articleRevisionDate"><![CDATA[2004-11-17T00:00:00Z]]></field>
  <field name="articlePubmodel"><![CDATA[Print]]></field>
  <field name="journalTitle"><![CDATA[Journal of medical microbiology]]></field>
  <field name="journalTitleAbrv"><![CDATA[J. Med. Microbiol.]]></field>
  <field name="articleTitle"><![CDATA[A reassessment of the microbial flora of the female genital tract, with special reference to the occurrence of Bacteroides species.]]></field>
  <field name="articleAbstract"><![CDATA[Two hundred and twelve randomly selected vaginal or uterine cervical specimens were investigated for the presence of anaerobic and aerobic bacteria and yeasts. Anaerobes of possible clinical significance, including Bacteroidaceae, Peptococcaceae and clostridia were isolated from 34% of the specimens and were identified to specific or generic level. Among the Bacteroidaceae isolated, B. bivius was the most common, followed by other propionate-negative species. Members of the Bacteroides fragilis group were seldom isolated. Of the aerobic or facultatively anaerobic isolates, enterococci and Escherichia coli were most often found. The results show that clinically significant anaerobes, especially Bacteroides species, are not regular members of the vaginal flora and that the species distribution of anaerobes occurring in the genital tract is significantly different from that of the intestinal tract.]]></field>
  <field name="author"><![CDATA[Hammann R]]></field>
  <field name="articleLang"><![CDATA[eng]]></field>
  <field name="publicationType"><![CDATA[Journal Article]]></field>
  <field name="articleDescriptor"><![CDATA[Bacteria]]></field>
  <field name="articleQualifier"><![CDATA[isolation & purification]]></field>
  <field name="articleDescriptor"><![CDATA[Bacteroides]]></field>
  <field name="articleQualifier"><![CDATA[classification]]></field>
  <field name="articleQualifier"><![CDATA[isolation & purification]]></field>
  <field name="articleDescriptor"><![CDATA[Cervix Uteri]]></field>
  <field name="articleQualifier"><![CDATA[microbiology]]></field>
  <field name="articleDescriptor"><![CDATA[Enterobacteriaceae]]></field>
  <field name="articleQualifier"><![CDATA[isolation & purification]]></field>
  <field name="articleDescriptor"><![CDATA[Eubacterium]]></field>
  <field name="articleQualifier"><![CDATA[isolation & purification]]></field>
  <field name="articleDescriptor"><![CDATA[Female]]></field>
  <field name="articleDescriptor"><![CDATA[Humans]]></field>
  <field name="articleDescriptor"><![CDATA[Peptococcaceae]]></field>
  <field name="articleDescriptor"><![CDATA[Streptococcus]]></field>
  <field name="articleQualifier"><![CDATA[isolation & purification]]></field>
  <field name="articleDescriptor"><![CDATA[Vagina]]></field>
  <field name="articleQualifier"><![CDATA[microbiology]]></field>
  <field name="articleDescriptor"><![CDATA[Yeasts]]></field>
  <field name="articleQualifier"><![CDATA[isolation & purification]]></field>
 </doc>
 <doc>
  <field name="id"><![CDATA[6126593]]></field>
  <field name="articleCreationDate"><![CDATA[1982-12-02T00:00:00Z]]></field>
  <field name="articleYear"><![CDATA[1982]]></field>
  <field name="articleCompletionDate"><![CDATA[1982-12-02T00:00:00Z]]></field>
  <field name="articleRevisionDate"><![CDATA[2006-11-15T00:00:00Z]]></field>
  <field name="articlePubmodel"><![CDATA[Print]]></field>
  <field name="journalTitle"><![CDATA[Journal of medical microbiology]]></field>
  <field name="journalTitleAbrv"><![CDATA[J. Med. Microbiol.]]></field>
  <field name="articleTitle"><![CDATA[Virulence of Escherichia coli in ascending urinary-tract infection in mice.]]></field>
  <field name="articleAbstract"><![CDATA[The virulence of Escherichia coli strains in ascending urinary-tract infection was studied in mice drinking a 5% glucose solution; factors determining the virulence were examined. Of 33 strains, 8 (group I) infected the bladder and kidney, 10 (group II) infected only the bladder, while the remaining 15 strains (group III) did not cause infection. The adherence of group-I and group-II strains to bladder epithelial cells in vitro was inhibited by D-mannose. In group III, 13 strains barely adhered to the epithelial cells, while two strains showed an adherence unaffected by D-mannose. Most strains in groups I and II agglutinated erythrocytes of guinea-pig, chicken, and horse, and cells of Candida albicans in a mannose-sensitive manner. All strains in groups I and II had fimbriae. Virulence for the urinary tract was not directly related with O-serotype, intraperitoneal virulence, ability to grow in mouse urine, ability to ferment dulcitol, production of haemolysin, susceptibility to serum bactericidal activity, or susceptibility to antibiotics. These results suggest that the adherence of the E. coli to mouse-bladder epithelial cells in a mannose-sensitive manner plays an important role in the development of urinary-tract infection in mice and that the adherence is probably mediated by type-1 or closely related fimbriae.]]></field>
  <field name="author"><![CDATA[Iwahi T]]></field>
  <field name="author"><![CDATA[Abe Y]]></field>
  <field name="author"><![CDATA[Tsuchiya K]]></field>
  <field name="articleLang"><![CDATA[eng]]></field>
  <field name="publicationType"><![CDATA[Journal Article]]></field>
  <field name="substanceName"><![CDATA[Anti-Bacterial Agents]]></field>
  <field name="articleDescriptor"><![CDATA[Adhesiveness]]></field>
  <field name="articleDescriptor"><![CDATA[Agglutination]]></field>
  <field name="articleDescriptor"><![CDATA[Animals]]></field>
  <field name="articleDescriptor"><![CDATA[Anti-Bacterial Agents]]></field>
  <field name="articleQualifier"><![CDATA[pharmacology]]></field>
  <field name="articleDescriptor"><![CDATA[Blood Bactericidal Activity]]></field>
  <field name="articleDescriptor"><![CDATA[Escherichia coli]]></field>
  <field name="articleQualifier"><![CDATA[pathogenicity]]></field>
  <field name="articleQualifier"><![CDATA[physiology]]></field>
  <field name="articleQualifier"><![CDATA[ultrastructure]]></field>
  <field name="articleDescriptor"><![CDATA[Female]]></field>
  <field name="articleDescriptor"><![CDATA[Fimbriae, Bacterial]]></field>
  <field name="articleQualifier"><![CDATA[ultrastructure]]></field>
  <field name="articleDescriptor"><![CDATA[Hemagglutination]]></field>
  <field name="articleDescriptor"><![CDATA[Kidney]]></field>
  <field name="articleQualifier"><![CDATA[microbiology]]></field>
  <field name="articleDescriptor"><![CDATA[Mice]]></field>
  <field name="articleDescriptor"><![CDATA[Serotyping]]></field>
  <field name="articleDescriptor"><![CDATA[Urinary Bladder]]></field>
  <field name="articleQualifier"><![CDATA[microbiology]]></field>
 </doc>
 <doc>
  <field name="id"><![CDATA[7120355]]></field>
  <field name="articleCreationDate"><![CDATA[1982-12-02T00:00:00Z]]></field>
  <field name="articleYear"><![CDATA[1982]]></field>
  <field name="articleCompletionDate"><![CDATA[1982-12-02T00:00:00Z]]></field>
  <field name="articleRevisionDate"><![CDATA[2004-11-17T00:00:00Z]]></field>
  <field name="articlePubmodel"><![CDATA[Print]]></field>
  <field name="journalTitle"><![CDATA[Journal of medical microbiology]]></field>
  <field name="journalTitleAbrv"><![CDATA[J. Med. Microbiol.]]></field>
  <field name="articleTitle"><![CDATA[Pathological and biochemical features of Legionella pneumophila infection in guinea-pigs.]]></field>
  <field name="articleAbstract"><![CDATA[The main pathological feature of experimental legionellosis produced by the intraperitoneal inoculation of guinea-pigs was a fibrinopurulent peritonitis, especially over the liver and spleen. Foci of necrosis were present in these organs from the second to seventh day after infection. Early biochemical changes in the serum included significant decreases in the concentration of zinc and iron, and increases in copper and triglycerides. Phenylalanine to tyrosine ratios increased strikingly, but free amino acid decreased slightly. The total protein concentration did not change, but acute-phase proteins increased. Serum lysozyme activity increased as leucocytosis developed but fell during the subsequent leucopenia. In the later stages of the disease the activity of alkaline phosphatase, gamma-glutamyl transpeptidase, and creatine kinase decreased; that of dehydrogenases and transaminase increased.]]></field>
  <field name="author"><![CDATA[Hambleton P]]></field>
  <field name="author"><![CDATA[Baskerville A]]></field>
  <field name="author"><![CDATA[Fitzgeorge R B]]></field>
  <field name="author"><![CDATA[Bailey N E]]></field>
  <field name="articleLang"><![CDATA[eng]]></field>
  <field name="publicationType"><![CDATA[Journal Article]]></field>
  <field name="substanceName"><![CDATA[Amino Acids]]></field>
  <field name="substanceName"><![CDATA[Blood Proteins]]></field>
  <field name="substanceName"><![CDATA[Enzymes]]></field>
  <field name="substanceName"><![CDATA[Trace Elements]]></field>
  <field name="substanceName"><![CDATA[Triglycerides]]></field>
  <field name="substanceName"><![CDATA[Calcium]]></field>
  <field name="articleDescriptor"><![CDATA[Amino Acids]]></field>
  <field name="articleQualifier"><![CDATA[blood]]></field>
  <field name="articleDescriptor"><![CDATA[Animals]]></field>
  <field name="articleDescriptor"><![CDATA[Bacterial Infections]]></field>
  <field name="articleQualifier"><![CDATA[blood]]></field>
  <field name="articleQualifier"><![CDATA[pathology]]></field>
  <field name="articleDescriptor"><![CDATA[Blood Proteins]]></field>
  <field name="articleQualifier"><![CDATA[analysis]]></field>
  <field name="articleDescriptor"><![CDATA[Calcium]]></field>
  <field name="articleQualifier"><![CDATA[blood]]></field>
  <field name="articleDescriptor"><![CDATA[Enzymes]]></field>
  <field name="articleQualifier"><![CDATA[blood]]></field>
  <field name="articleDescriptor"><![CDATA[Guinea Pigs]]></field>
  <field name="articleDescriptor"><![CDATA[Humans]]></field>
  <field name="articleDescriptor"><![CDATA[Legionella]]></field>
  <field name="articleDescriptor"><![CDATA[Leukocytosis]]></field>
  <field name="articleDescriptor"><![CDATA[Liver]]></field>
  <field name="articleQualifier"><![CDATA[pathology]]></field>
  <field name="articleDescriptor"><![CDATA[Spleen]]></field>
  <field name="articleQualifier"><![CDATA[pathology]]></field>
  <field name="articleDescriptor"><![CDATA[Trace Elements]]></field>
  <field name="articleQualifier"><![CDATA[blood]]></field>
  <field name="articleDescriptor"><![CDATA[Triglycerides]]></field>
  <field name="articleQualifier"><![CDATA[blood]]></field>
 </doc>
 <doc>
  <field name="id"><![CDATA[6811746]]></field>
  <field name="articleCreationDate"><![CDATA[1982-12-02T00:00:00Z]]></field>
  <field name="articleYear"><![CDATA[1982]]></field>
  <field name="articleCompletionDate"><![CDATA[1982-12-02T00:00:00Z]]></field>
  <field name="articleRevisionDate"><![CDATA[2007-11-14T00:00:00Z]]></field>
  <field name="articlePubmodel"><![CDATA[Print]]></field>
  <field name="journalTitle"><![CDATA[Journal of medical microbiology]]></field>
  <field name="journalTitleAbrv"><![CDATA[J. Med. Microbiol.]]></field>
  <field name="articleTitle"><![CDATA[Epidemiological value of lipopolysaccharide and heat-modifiable outer-membrane protein serotyping of group-A strains of Neisseria meningitidis.]]></field>
  <field name="articleAbstract"><![CDATA[The lipopolysaccharide (LPS) and heat-modifiable outer-membrane protein (P') serotypes of 39 coded strains of group-A Neisseria meningitidis isolated from patients during seven geographically and temporally separate outbreaks of infection were determined blindly. LPS serotype discriminated between strains from different outbreaks and between strains of differing sulphadiazine sensitivity within a single outbreak. Thirty-seven strains were of three separate serotypes and no strain was of multiple serotypes. In contrast, P' serotypes did not discriminate between strains. Multiple serotypes for single strains and among strains from a single outbreak were the rule. LPS serotyping appears to be a useful epidemiological tool for distinguishing group-A strains of N. meningitidis.]]></field>
  <field name="author"><![CDATA[Griffiss J M]]></field>
  <field name="articleLang"><![CDATA[eng]]></field>
  <field name="publicationType"><![CDATA[Journal Article]]></field>
  <field name="publicationType"><![CDATA[Research Support, U.S. Gov't, P.H.S.]]></field>
  <field name="substanceName"><![CDATA[Bacterial Outer Membrane Proteins]]></field>
  <field name="substanceName"><![CDATA[Bacterial Proteins]]></field>
  <field name="substanceName"><![CDATA[Lipopolysaccharides]]></field>
  <field name="substanceName"><![CDATA[Membrane Proteins]]></field>
  <field name="substanceName"><![CDATA[Sulfadiazine]]></field>
  <field name="articleDescriptor"><![CDATA[Bacterial Outer Membrane Proteins]]></field>
  <field name="articleDescriptor"><![CDATA[Bacterial Proteins]]></field>
  <field name="articleQualifier"><![CDATA[classification]]></field>
  <field name="articleDescriptor"><![CDATA[Lipopolysaccharides]]></field>
  <field name="articleQualifier"><![CDATA[classification]]></field>
  <field name="articleDescriptor"><![CDATA[Membrane Proteins]]></field>
  <field name="articleQualifier"><![CDATA[classification]]></field>
  <field name="articleDescriptor"><![CDATA[Meningococcal Infections]]></field>
  <field name="articleQualifier"><![CDATA[microbiology]]></field>
  <field name="articleDescriptor"><![CDATA[Neisseria meningitidis]]></field>
  <field name="articleQualifier"><![CDATA[classification]]></field>
  <field name="articleQualifier"><![CDATA[drug effects]]></field>
  <field name="articleDescriptor"><![CDATA[Serotyping]]></field>
  <field name="articleDescriptor"><![CDATA[Sulfadiazine]]></field>
  <field name="articleQualifier"><![CDATA[pharmacology]]></field>
 </doc>
 <doc>
  <field name="id"><![CDATA[6288951]]></field>
  <field name="articleCreationDate"><![CDATA[1982-12-02T00:00:00Z]]></field>
  <field name="articleYear"><![CDATA[1982]]></field>
  <field name="articleCompletionDate"><![CDATA[1982-12-02T00:00:00Z]]></field>
  <field name="articleRevisionDate"><![CDATA[2006-11-15T00:00:00Z]]></field>
  <field name="articlePubmodel"><![CDATA[Print]]></field>
  <field name="journalTitle"><![CDATA[Journal of medical microbiology]]></field>
  <field name="journalTitleAbrv"><![CDATA[J. Med. Microbiol.]]></field>
  <field name="articleTitle"><![CDATA[Differentiation of subtypes within Leptospira interrogans serovars Hardjo, Balcanica and Tarassovi, by bacterial restriction-endonuclease DNA analysis (BRENDA).]]></field>
  <field name="articleAbstract"><![CDATA[Various strains of Leptospira interrogans were compared by bacterial restriction-endonuclease DNA analysis (BRENDA). Field strains of serovar hardjo isolated from domestic animals in New Zealand, Australia and Northern Ireland were indistinguishable from one another but differed strikingly from the hardjo reference strain Hardjoprajitno. Similarly, field isolates of balcanica and tarassovi differed from their serovar reference strains, probably owing to a difference in epidemiological niche. Subdivision of these serovars into distinct subtypes as defined by BRENDA is therefore useful and justified. In contrast, analysis of serovars pomona, ballum and copenhageni shows that field and reference strains were identical, or differed only by a single band. It is suggested that BRENDA will overcome many of the problems associated with serological methods of identifying serovars and allow more precise definition of epidemiological relationships between strains and their hosts.]]></field>
  <field name="author"><![CDATA[Robinson A J]]></field>
  <field name="author"><![CDATA[Ramadass P]]></field>
  <field name="author"><![CDATA[Lee A]]></field>
  <field name="author"><![CDATA[Marshall R B]]></field>
  <field name="articleLang"><![CDATA[eng]]></field>
  <field name="publicationType"><![CDATA[Journal Article]]></field>
  <field name="substanceName"><![CDATA[DNA, Bacterial]]></field>
  <field name="substanceName"><![CDATA[DNA Restriction Enzymes]]></field>
  <field name="substanceName"><![CDATA[Deoxyribonuclease BamHI]]></field>
  <field name="substanceName"><![CDATA[Deoxyribonuclease EcoRI]]></field>
  <field name="substanceName"><![CDATA[Deoxyribonuclease HindIII]]></field>
  <field name="articleDescriptor"><![CDATA[Base Sequence]]></field>
  <field name="articleDescriptor"><![CDATA[DNA Restriction Enzymes]]></field>
  <field name="articleDescriptor"><![CDATA[DNA, Bacterial]]></field>
  <field name="articleQualifier"><![CDATA[analysis]]></field>
  <field name="articleDescriptor"><![CDATA[Deoxyribonuclease BamHI]]></field>
  <field name="articleDescriptor"><![CDATA[Deoxyribonuclease EcoRI]]></field>
  <field name="articleDescriptor"><![CDATA[Deoxyribonuclease HindIII]]></field>
  <field name="articleDescriptor"><![CDATA[Leptospira interrogans]]></field>
  <field name="articleQualifier"><![CDATA[analysis]]></field>
  <field name="articleQualifier"><![CDATA[classification]]></field>
  <field name="articleDescriptor"><![CDATA[Serotyping]]></field>
 </doc>
 <doc>
  <field name="id"><![CDATA[6811747]]></field>
  <field name="articleCreationDate"><![CDATA[1982-12-02T00:00:00Z]]></field>
  <field name="articleYear"><![CDATA[1982]]></field>
  <field name="articleCompletionDate"><![CDATA[1982-12-02T00:00:00Z]]></field>
  <field name="articleRevisionDate"><![CDATA[2006-11-15T00:00:00Z]]></field>
  <field name="articlePubmodel"><![CDATA[Print]]></field>
  <field name="journalTitle"><![CDATA[Journal of medical microbiology]]></field>
  <field name="journalTitleAbrv"><![CDATA[J. Med. Microbiol.]]></field>
  <field name="articleTitle"><![CDATA[Immunisation of rhesus monkeys with Streptococcus mutans, Lactobacillus acidophilus and lipoteichoic acid for protection against dental caries.]]></field>
  <field name="articleAbstract"><![CDATA[An attempt was made to protect rhesus monkeys from dental caries by immunisation with Streptococcus mutans, Lactobacillus acidophilus and lipoteichoic acid (LTA). The vaccine composed of S. mutans gave significant protection against caries, a decrease in the number of S. mutans, an increase in IgG antibodies and a moderate increase in complement-fixing antibodies to LTA. When LTA was used as immunogen, there was only a small reduction in caries, without any detectable antibodies to LTA and a slight increase in IgG antibodies to cell of S. mutans. Vaccines of L. acidophilus or L. fermentum gave no protection. A combined vaccine of S. mutans and L. acidophilus did not reduce the incidence of caries but the antibody titre to cells of S. mutans was raised to a level comparable with that in the S. mutans-immunised monkeys. The results of this investigation in a subhuman primate confirm that immunisation with S. mutans induces protection against caries, unlike the attempt to immunise with two selected strains of lactobacilli. More studies are required to establish the role of specific serotypes of lactobacilli in the development of dental caries.]]></field>
  <field name="author"><![CDATA[Caldwell J]]></field>
  <field name="author"><![CDATA[Lehner T]]></field>
  <field name="articleLang"><![CDATA[eng]]></field>
  <field name="publicationType"><![CDATA[Journal Article]]></field>
  <field name="publicationType"><![CDATA[Research Support, Non-U.S. Gov't]]></field>
  <field name="substanceName"><![CDATA[Antibodies, Bacterial]]></field>
  <field name="substanceName"><![CDATA[Immunoglobulin G]]></field>
  <field name="substanceName"><![CDATA[Lipopolysaccharides]]></field>
  <field name="substanceName"><![CDATA[Phosphatidic Acids]]></field>
  <field name="substanceName"><![CDATA[Teichoic Acids]]></field>
  <field name="substanceName"><![CDATA[lipoteichoic acid]]></field>
  <field name="articleDescriptor"><![CDATA[Animals]]></field>
  <field name="articleDescriptor"><![CDATA[Antibodies, Bacterial]]></field>
  <field name="articleQualifier"><![CDATA[analysis]]></field>
  <field name="articleDescriptor"><![CDATA[Dental Caries]]></field>
  <field name="articleQualifier"><![CDATA[prevention & control]]></field>
  <field name="articleDescriptor"><![CDATA[Dental Plaque]]></field>
  <field name="articleQualifier"><![CDATA[microbiology]]></field>
  <field name="articleDescriptor"><![CDATA[Immunization]]></field>
  <field name="articleDescriptor"><![CDATA[Immunoglobulin G]]></field>
  <field name="articleQualifier"><![CDATA[analysis]]></field>
  <field name="articleDescriptor"><![CDATA[Lactobacillus]]></field>
  <field name="articleQualifier"><![CDATA[isolation & purification]]></field>
  <field name="articleDescriptor"><![CDATA[Lactobacillus acidophilus]]></field>
  <field name="articleQualifier"><![CDATA[immunology]]></field>
  <field name="articleDescriptor"><![CDATA[Lipopolysaccharides]]></field>
  <field name="articleDescriptor"><![CDATA[Macaca mulatta]]></field>
  <field name="articleDescriptor"><![CDATA[Phosphatidic Acids]]></field>
  <field name="articleQualifier"><![CDATA[immunology]]></field>
  <field name="articleDescriptor"><![CDATA[Streptococcus mutans]]></field>
  <field name="articleQualifier"><![CDATA[immunology]]></field>
  <field name="articleQualifier"><![CDATA[isolation & purification]]></field>
  <field name="articleDescriptor"><![CDATA[Teichoic Acids]]></field>
  <field name="articleQualifier"><![CDATA[immunology]]></field>
 </doc>
 <doc>
  <field name="id"><![CDATA[6126594]]></field>
  <field name="articleCreationDate"><![CDATA[1982-12-02T00:00:00Z]]></field>
  <field name="articleYear"><![CDATA[1982]]></field>
  <field name="articleCompletionDate"><![CDATA[1982-12-02T00:00:00Z]]></field>
  <field name="articleRevisionDate"><![CDATA[2005-11-17T00:00:00Z]]></field>
  <field name="articlePubmodel"><![CDATA[Print]]></field>
  <field name="journalTitle"><![CDATA[Journal of medical microbiology]]></field>
  <field name="journalTitleAbrv"><![CDATA[J. Med. Microbiol.]]></field>
  <field name="articleTitle"><![CDATA[Impairment by Bacteroides species of opsonisation and phagocytosis of enterobacteria.]]></field>
  <field name="articleAbstract"><![CDATA[The ability of human polymorphonuclear leucocytes to phagocytose and kill Proteus mirabilis was impaired in vitro when the human serum, used to opsonise the target bacteria, was pretreated with cultures of various Bacteroides species. Live and dead, either heat-killed or clindamycin-treated, bacteroides cells elicited the same phenomenon. When bacteroides-treated serum was used to opsonise different Proteus species, the subsequent uptake of all strains by polymorphonuclear leucocytes was inhibited, whereas bacteroides-treated serum inhibited the uptake of some but not all of the test strains of Escherichia coli. The opsonic activity of untreated human serum was reduced when the classical complement pathway was inhibited by ethyleneglycol-bis-(beta-aminoethyl ether)N,N'-tetra-acetic acid (EGTA); subsequent treatment with bacteroides did not further reduce the opsonic activity of the serum for P. mirabilis.]]></field>
  <field name="author"><![CDATA[Jones G R]]></field>
  <field name="author"><![CDATA[Gemmell C G]]></field>
  <field name="articleLang"><![CDATA[eng]]></field>
  <field name="publicationType"><![CDATA[Journal Article]]></field>
  <field name="substanceName"><![CDATA[Opsonin Proteins]]></field>
  <field name="articleDescriptor"><![CDATA[Bacteroides]]></field>
  <field name="articleQualifier"><![CDATA[physiology]]></field>
  <field name="articleDescriptor"><![CDATA[Enterobacteriaceae]]></field>
  <field name="articleQualifier"><![CDATA[immunology]]></field>
  <field name="articleDescriptor"><![CDATA[Escherichia coli]]></field>
  <field name="articleQualifier"><![CDATA[immunology]]></field>
  <field name="articleDescriptor"><![CDATA[Humans]]></field>
  <field name="articleDescriptor"><![CDATA[Neutrophils]]></field>
  <field name="articleQualifier"><![CDATA[immunology]]></field>
  <field name="articleDescriptor"><![CDATA[Opsonin Proteins]]></field>
  <field name="articleQualifier"><![CDATA[immunology]]></field>
  <field name="articleDescriptor"><![CDATA[Phagocytosis]]></field>
  <field name="articleDescriptor"><![CDATA[Prevotella melaninogenica]]></field>
  <field name="articleQualifier"><![CDATA[immunology]]></field>
  <field name="articleDescriptor"><![CDATA[Proteus]]></field>
  <field name="articleQualifier"><![CDATA[immunology]]></field>
  <field name="articleDescriptor"><![CDATA[Proteus mirabilis]]></field>
  <field name="articleQualifier"><![CDATA[immunology]]></field>
 </doc>
 <doc>
  <field name="id"><![CDATA[6288952]]></field>
  <field name="articleCreationDate"><![CDATA[1982-12-02T00:00:00Z]]></field>
  <field name="articleYear"><![CDATA[1982]]></field>
  <field name="articleCompletionDate"><![CDATA[1982-12-02T00:00:00Z]]></field>
  <field name="articleRevisionDate"><![CDATA[2004-11-17T00:00:00Z]]></field>
  <field name="articlePubmodel"><![CDATA[Print]]></field>
  <field name="journalTitle"><![CDATA[Journal of medical microbiology]]></field>
  <field name="journalTitleAbrv"><![CDATA[J. Med. Microbiol.]]></field>
  <field name="articleTitle"><![CDATA[Binding of type-III group-B streptococci to buccal epithelial cells.]]></field>
  <field name="articleAbstract"><![CDATA[A binding assay was used to study the attachment of type-III group-B streptococci (GBS) to buccal epithelial cells. Results indicate that an adhesin, with the characteristics of a protein, is the molecule at the streptococcal cell surface responsible for attachment to the buccal cells. The bacterial adhesin probably recognises a sugar on the surface of the mucosal cell, because periodate oxidation of the buccal cells caused a significant reduction in subsequent adherence of GBS. A sonicate to type-III GBS blocked the binding of the organism to buccal cells. The effects of physical and chemical modifications of the sonicate on its ability to prevent bacterial attachment are described; these corroborate the evidence gained from heat and periodate treatments of the buccal cells and GBS. Results suggest a lectin type of attachment mechanism for type-III BGS which can be blocked by N-acetyl-D-glucosamine, rather than attachment by means of a lipoteichoic acid as described for group-A streptococci.]]></field>
  <field name="author"><![CDATA[Bagg J]]></field>
  <field name="author"><![CDATA[Poxton I R]]></field>
  <field name="author"><![CDATA[Weir D M]]></field>
  <field name="author"><![CDATA[Ross P W]]></field>
  <field name="articleLang"><![CDATA[eng]]></field>
  <field name="publicationType"><![CDATA[Journal Article]]></field>
  <field name="substanceName"><![CDATA[Bacterial Proteins]]></field>
  <field name="substanceName"><![CDATA[Carbohydrates]]></field>
  <field name="substanceName"><![CDATA[Lipopolysaccharides]]></field>
  <field name="substanceName"><![CDATA[Membrane Proteins]]></field>
  <field name="substanceName"><![CDATA[Phosphatidic Acids]]></field>
  <field name="substanceName"><![CDATA[Teichoic Acids]]></field>
  <field name="substanceName"><![CDATA[Periodic Acid]]></field>
  <field name="substanceName"><![CDATA[lipoteichoic acid]]></field>
  <field name="substanceName"><![CDATA[Acetylglucosamine]]></field>
  <field name="substanceName"><![CDATA[metaperiodate]]></field>
  <field name="articleDescriptor"><![CDATA[Acetylglucosamine]]></field>
  <field name="articleQualifier"><![CDATA[pharmacology]]></field>
  <field name="articleDescriptor"><![CDATA[Adhesiveness]]></field>
  <field name="articleDescriptor"><![CDATA[Bacterial Proteins]]></field>
  <field name="articleQualifier"><![CDATA[metabolism]]></field>
  <field name="articleDescriptor"><![CDATA[Carbohydrates]]></field>
  <field name="articleQualifier"><![CDATA[pharmacology]]></field>
  <field name="articleDescriptor"><![CDATA[Cheek]]></field>
  <field name="articleDescriptor"><![CDATA[Epithelium]]></field>
  <field name="articleQualifier"><![CDATA[microbiology]]></field>
  <field name="articleDescriptor"><![CDATA[Humans]]></field>
  <field name="articleDescriptor"><![CDATA[Lipopolysaccharides]]></field>
  <field name="articleDescriptor"><![CDATA[Male]]></field>
  <field name="articleDescriptor"><![CDATA[Membrane Proteins]]></field>
  <field name="articleQualifier"><![CDATA[metabolism]]></field>
  <field name="articleDescriptor"><![CDATA[Mouth Mucosa]]></field>
  <field name="articleQualifier"><![CDATA[microbiology]]></field>
  <field name="articleDescriptor"><![CDATA[Periodic Acid]]></field>
  <field name="articleQualifier"><![CDATA[pharmacology]]></field>
  <field name="articleDescriptor"><![CDATA[Phosphatidic Acids]]></field>
  <field name="articleQualifier"><![CDATA[pharmacology]]></field>
  <field name="articleDescriptor"><![CDATA[Streptococcus agalactiae]]></field>
  <field name="articleQualifier"><![CDATA[metabolism]]></field>
  <field name="articleDescriptor"><![CDATA[Teichoic Acids]]></field>
  <field name="articleQualifier"><![CDATA[pharmacology]]></field>
 </doc>
 <doc>
  <field name="id"><![CDATA[7120356]]></field>
  <field name="articleCreationDate"><![CDATA[1982-12-02T00:00:00Z]]></field>
  <field name="articleYear"><![CDATA[1982]]></field>
  <field name="articleCompletionDate"><![CDATA[1982-12-02T00:00:00Z]]></field>
  <field name="articleRevisionDate"><![CDATA[2006-11-15T00:00:00Z]]></field>
  <field name="articlePubmodel"><![CDATA[Print]]></field>
  <field name="journalTitle"><![CDATA[Journal of medical microbiology]]></field>
  <field name="journalTitleAbrv"><![CDATA[J. Med. Microbiol.]]></field>
  <field name="articleTitle"><![CDATA[Intraphagocytic protection of staphylococci from extracellular penicillin.]]></field>
  <field name="articleAbstract"><![CDATA[In a system in which unphagocytosed bacteria were removed by differential centrifugation after a 30-min phagocytosis period, staphylococci associated with rabbit polymorphonulcear (PMN) leukocytes were completely protected from the effects of benzyl penicillin 1 microgram/ml, but not completely protected from the effects of 5 micrograms/ml. When unphagocytosed bacteria were lysed with lysostaphin, effective protection could be observed over a range of penicillin concentrations from 0.25 to 200 micrograms/ml. 14C-benzyl penicillin failed to accumulate in rabbit PMN leukocytes, whether or not they had previously phagocytosed staphylococci, in conditions in which mouse peritoneal macrophages readily accumulated penicillin. Mixed granule extracts prepared from the PMN leukocytes interacted synergically with penicillin against staphylococci at physiological pH (7.2) but failed to show synergy at an intraphagolysosomal pH of 5.0 unless the bacteria were first sublethally treated with penicillin. Experiments in which the pH value of culture media was changed either from 7.2 to 5.0 or from 5.0 to 7.2 indicated that the partial nature of the protective effect of the intraphagolysosomal environment could be attributed to the growth-limiting effects of the low phagolysosomal pH, which prevents full expression of the synergic potential of granule contents and penicillin. The concentration-dependent nature of the protection and its incompleteness are explained by supposing that a proportion of the staphylococci not ingested during the 30-min phagocytosis period are modified by penicillin in a way that opsonises them and potentiates the intrinsic bactericidal mechanisms of the PMN leukocytes when the bacteria are subsequently ingested.]]></field>
  <field name="author"><![CDATA[Lam C]]></field>
  <field name="author"><![CDATA[Mathison G E]]></field>
  <field name="articleLang"><![CDATA[eng]]></field>
  <field name="publicationType"><![CDATA[Journal Article]]></field>
  <field name="publicationType"><![CDATA[Research Support, Non-U.S. Gov't]]></field>
  <field name="substanceName"><![CDATA[Penicillin G]]></field>
  <field name="articleDescriptor"><![CDATA[Animals]]></field>
  <field name="articleDescriptor"><![CDATA[Dose-Response Relationship, Drug]]></field>
  <field name="articleDescriptor"><![CDATA[Hydrogen-Ion Concentration]]></field>
  <field name="articleDescriptor"><![CDATA[Lysosomes]]></field>
  <field name="articleQualifier"><![CDATA[metabolism]]></field>
  <field name="articleDescriptor"><![CDATA[Macrophages]]></field>
  <field name="articleQualifier"><![CDATA[metabolism]]></field>
  <field name="articleDescriptor"><![CDATA[Mice]]></field>
  <field name="articleDescriptor"><![CDATA[Neutrophils]]></field>
  <field name="articleQualifier"><![CDATA[immunology]]></field>
  <field name="articleQualifier"><![CDATA[metabolism]]></field>
  <field name="articleQualifier"><![CDATA[microbiology]]></field>
  <field name="articleDescriptor"><![CDATA[Penicillin G]]></field>
  <field name="articleQualifier"><![CDATA[metabolism]]></field>
  <field name="articleQualifier"><![CDATA[pharmacology]]></field>
  <field name="articleDescriptor"><![CDATA[Phagocytosis]]></field>
  <field name="articleQualifier"><![CDATA[drug effects]]></field>
  <field name="articleDescriptor"><![CDATA[Rabbits]]></field>
  <field name="articleDescriptor"><![CDATA[Staphylococcus aureus]]></field>
  <field name="articleQualifier"><![CDATA[drug effects]]></field>
  <field name="articleQualifier"><![CDATA[immunology]]></field>
 </doc>
 <doc>
  <field name="id"><![CDATA[6126595]]></field>
  <field name="articleCreationDate"><![CDATA[1982-12-02T00:00:00Z]]></field>
  <field name="articleYear"><![CDATA[1982]]></field>
  <field name="articleCompletionDate"><![CDATA[1982-12-02T00:00:00Z]]></field>
  <field name="articleRevisionDate"><![CDATA[2000-12-18T00:00:00Z]]></field>
  <field name="articlePubmodel"><![CDATA[Print]]></field>
  <field name="journalTitle"><![CDATA[Journal of medical microbiology]]></field>
  <field name="journalTitleAbrv"><![CDATA[J. Med. Microbiol.]]></field>
  <field name="articleTitle"><![CDATA[A bacteriocin typing scheme for Bacteroides.]]></field>
  <field name="articleAbstract"><![CDATA[Epidemiological studies of Bacteroides spp. have been hindered because a suitable typing method is not available. In preliminary studies, 50 strains of Bacteroides were screened against each other for bacteriocin production and sensitivity; 54% of them produced bacteriocin(s) and more than 90% were sensitive to at least one bacteriocin. After calculation of similarity values for these 50 isolates, a typing set of six bacteriocinogenic strains was selected for a typing method based on bacteriocin sensitivity. With this typing set c. 90% of strains could be typed and tests of reproducibility suggested that acceptable accuracy and discrimination could be obtained without applying any one-reaction or two-reaction difference rules. Isolates from four hospitals gave a similar spectrum of typing patterns with 18 bacteriocin types being demonstrated. There was not correlation between bacteriocin type and species of Bacteroides.]]></field>
  <field name="author"><![CDATA[Riley T V]]></field>
  <field name="author"><![CDATA[Mee B J]]></field>
  <field name="articleLang"><![CDATA[eng]]></field>
  <field name="publicationType"><![CDATA[Journal Article]]></field>
  <field name="substanceName"><![CDATA[Bacteriocins]]></field>
  <field name="articleDescriptor"><![CDATA[Bacteriocins]]></field>
  <field name="articleQualifier"><![CDATA[biosynthesis]]></field>
  <field name="articleQualifier"><![CDATA[pharmacology]]></field>
  <field name="articleDescriptor"><![CDATA[Bacteriological Techniques]]></field>
  <field name="articleDescriptor"><![CDATA[Bacteroides]]></field>
  <field name="articleQualifier"><![CDATA[classification]]></field>
  <field name="articleQualifier"><![CDATA[drug effects]]></field>
  <field name="articleQualifier"><![CDATA[metabolism]]></field>
  <field name="articleDescriptor"><![CDATA[Bacteroides fragilis]]></field>
  <field name="articleQualifier"><![CDATA[classification]]></field>
  <field name="articleDescriptor"><![CDATA[Prevotella melaninogenica]]></field>
  <field name="articleQualifier"><![CDATA[classification]]></field>
 </doc>
 <doc>
  <field name="id"><![CDATA[7120357]]></field>
  <field name="articleCreationDate"><![CDATA[1982-12-02T00:00:00Z]]></field>
  <field name="articleYear"><![CDATA[1982]]></field>
  <field name="articleCompletionDate"><![CDATA[1982-12-02T00:00:00Z]]></field>
  <field name="articleRevisionDate"><![CDATA[2007-11-14T00:00:00Z]]></field>
  <field name="articlePubmodel"><![CDATA[Print]]></field>
  <field name="journalTitle"><![CDATA[Journal of medical primatology]]></field>
  <field name="journalTitleAbrv"><![CDATA[J. Med. Primatol.]]></field>
  <field name="articleTitle"><![CDATA[Survey of serum cholesterol and triglyceride concentration and lipoprotein electrophoretic pattern in rhesus monkeys (Macaca mulatta).]]></field>
  <field name="articleAbstract"><![CDATA[Serum lipids and lipoproteins were surveyed during quarantine of a group of 811 wild-caught rhesus monkeys. No abnormalities indicative of dyslipoproteinemia analogous to the familial hyperlipoproteinemias in man were observed. Males had significantly lower mean cholesterol (134 mg/dl) and higher mean triglyceride (41.9 mg/dl) concentrations than females (155 and 37.5 mg/dl, respectively). Electrophoretic distribution of lipoproteins differed with sex. Cholesterol concentration and electrophoretic pattern had not attained steady state by ten weeks either in animals recently imported or in those conditioned in another laboratory for six months or more after import.]]></field>
  <field name="author"><![CDATA[Eggen D A]]></field>
  <field name="author"><![CDATA[Abee C R]]></field>
  <field name="author"><![CDATA[Malcom G T]]></field>
  <field name="author"><![CDATA[Strong J P]]></field>
  <field name="articleLang"><![CDATA[eng]]></field>
  <field name="publicationType"><![CDATA[Comparative Study]]></field>
  <field name="publicationType"><![CDATA[Journal Article]]></field>
  <field name="publicationType"><![CDATA[Research Support, U.S. Gov't, Non-P.H.S.]]></field>
  <field name="publicationType"><![CDATA[Research Support, U.S. Gov't, P.H.S.]]></field>
  <field name="substanceName"><![CDATA[Lipids]]></field>
  <field name="substanceName"><![CDATA[Lipoproteins]]></field>
  <field name="substanceName"><![CDATA[Triglycerides]]></field>
  <field name="substanceName"><![CDATA[Cholesterol]]></field>
  <field name="articleDescriptor"><![CDATA[Animals]]></field>
  <field name="articleDescriptor"><![CDATA[Cholesterol]]></field>
  <field name="articleQualifier"><![CDATA[blood]]></field>
  <field name="articleDescriptor"><![CDATA[Electrophoresis, Agar Gel]]></field>
  <field name="articleDescriptor"><![CDATA[Female]]></field>
  <field name="articleDescriptor"><![CDATA[Lipids]]></field>
  <field name="articleQualifier"><![CDATA[blood]]></field>
  <field name="articleDescriptor"><![CDATA[Lipoproteins]]></field>
  <field name="articleQualifier"><![CDATA[blood]]></field>
  <field name="articleDescriptor"><![CDATA[Macaca]]></field>
  <field name="articleQualifier"><![CDATA[blood]]></field>
  <field name="articleDescriptor"><![CDATA[Macaca mulatta]]></field>
  <field name="articleQualifier"><![CDATA[blood]]></field>
  <field name="articleDescriptor"><![CDATA[Male]]></field>
  <field name="articleDescriptor"><![CDATA[Sex Factors]]></field>
  <field name="articleDescriptor"><![CDATA[Triglycerides]]></field>
  <field name="articleQualifier"><![CDATA[blood]]></field>
 </doc>
 <doc>
  <field name="id"><![CDATA[7120358]]></field>
  <field name="articleCreationDate"><![CDATA[1982-12-02T00:00:00Z]]></field>
  <field name="articleYear"><![CDATA[1982]]></field>
  <field name="articleCompletionDate"><![CDATA[1982-12-02T00:00:00Z]]></field>
  <field name="articleRevisionDate"><![CDATA[2006-11-15T00:00:00Z]]></field>
  <field name="articlePubmodel"><![CDATA[Print]]></field>
  <field name="journalTitle"><![CDATA[Journal of medical primatology]]></field>
  <field name="journalTitleAbrv"><![CDATA[J. Med. Primatol.]]></field>
  <field name="articleTitle"><![CDATA[Normal and pathological electrocardiographic patterns in the Cebus monkey.]]></field>
  <field name="articleAbstract"><![CDATA[The normal electrocardiographic (ECG) pattern was determined for Cebus monkeys and compared with those obtained in animals subjected to experimental heart damage. ECG patterns were related to the anatomopathological findings in both normal and treated animals. The anatomic study revealed a vertical heart in which both ventricles constituted the frontal aspect. The experimental heart injury either through the inoculation of Trypanosoma cruzi or after the treatment with isoproterenol induced ECG changes which were correlated with specific anatomopathological lesions.]]></field>
  <field name="author"><![CDATA[Milei J]]></field>
  <field name="author"><![CDATA[Bolomo N J]]></field>
  <field name="author"><![CDATA[Vazquez A]]></field>
  <field name="author"><![CDATA[Nagle C A]]></field>
  <field name="articleLang"><![CDATA[eng]]></field>
  <field name="publicationType"><![CDATA[Comparative Study]]></field>
  <field name="publicationType"><![CDATA[Journal Article]]></field>
  <field name="publicationType"><![CDATA[Research Support, Non-U.S. Gov't]]></field>
  <field name="articleDescriptor"><![CDATA[Animals]]></field>
  <field name="articleDescriptor"><![CDATA[Cebidae]]></field>
  <field name="articleQualifier"><![CDATA[physiology]]></field>
  <field name="articleDescriptor"><![CDATA[Cebus]]></field>
  <field name="articleQualifier"><![CDATA[physiology]]></field>
  <field name="articleDescriptor"><![CDATA[Chagas Cardiomyopathy]]></field>
  <field name="articleQualifier"><![CDATA[physiopathology]]></field>
  <field name="articleDescriptor"><![CDATA[Coronary Disease]]></field>
  <field name="articleQualifier"><![CDATA[physiopathology]]></field>
  <field name="articleDescriptor"><![CDATA[Electrocardiography]]></field>
  <field name="articleQualifier"><![CDATA[veterinary]]></field>
  <field name="articleDescriptor"><![CDATA[Male]]></field>
 </doc>
 <doc>
  <field name="id"><![CDATA[6288953]]></field>
  <field name="articleCreationDate"><![CDATA[1982-12-02T00:00:00Z]]></field>
  <field name="articleYear"><![CDATA[1982]]></field>
  <field name="articleCompletionDate"><![CDATA[1982-12-02T00:00:00Z]]></field>
  <field name="articleRevisionDate"><![CDATA[2006-11-15T00:00:00Z]]></field>
  <field name="articlePubmodel"><![CDATA[Print]]></field>
  <field name="journalTitle"><![CDATA[Journal of medical primatology]]></field>
  <field name="journalTitleAbrv"><![CDATA[J. Med. Primatol.]]></field>
  <field name="articleTitle"><![CDATA[Influence of sulpiride-induced hyperprolactinemia on baboon menstrual cycles: a longitudinal study.]]></field>
  <field name="articleAbstract"><![CDATA[The influence of sulpiride-induced hyperprolactinemia on the hypothalamic-pituitary-ovarian function of the baboon (Papio cynocephalus) was investigated. Plasma levels of prolactin, LH, FSH, estrone, estradiol, 17-hydroxyprogesterone, progesterone and 20 alpha-dihydroprogesterone in control and consecutive treatment cycles (sulpiride i.m. injections 100 mg/day) were determined serially. The hormonal changes indicate that the ovary is the most sensitive site to the direct inhibitory action of sulpiride-induced hyperprolactinemia.]]></field>
  <field name="author"><![CDATA[Aso T]]></field>
  <field name="author"><![CDATA[Matsuoka M]]></field>
  <field name="author"><![CDATA[Su J]]></field>
  <field name="author"><![CDATA[Horie K]]></field>
  <field name="author"><![CDATA[Taii S]]></field>
  <field name="author"><![CDATA[Motohashi T]]></field>
  <field name="author"><![CDATA[Nishimura T]]></field>
  <field name="articleLang"><![CDATA[eng]]></field>
  <field name="publicationType"><![CDATA[Comparative Study]]></field>
  <field name="publicationType"><![CDATA[Journal Article]]></field>
  <field name="publicationType"><![CDATA[Research Support, Non-U.S. Gov't]]></field>
  <field name="substanceName"><![CDATA[Estrogens]]></field>
  <field name="substanceName"><![CDATA[Estrogens, Conjugated (USP)]]></field>
  <field name="substanceName"><![CDATA[Progestins]]></field>
  <field name="substanceName"><![CDATA[Sulpiride]]></field>
  <field name="substanceName"><![CDATA[Prolactin]]></field>
  <field name="substanceName"><![CDATA[Luteinizing Hormone]]></field>
  <field name="substanceName"><![CDATA[Follicle Stimulating Hormone]]></field>
  <field name="articleDescriptor"><![CDATA[Animals]]></field>
  <field name="articleDescriptor"><![CDATA[Estrogens]]></field>
  <field name="articleQualifier"><![CDATA[blood]]></field>
  <field name="articleDescriptor"><![CDATA[Estrogens, Conjugated (USP)]]></field>
  <field name="articleQualifier"><![CDATA[pharmacology]]></field>
  <field name="articleDescriptor"><![CDATA[Female]]></field>
  <field name="articleDescriptor"><![CDATA[Follicle Stimulating Hormone]]></field>
  <field name="articleQualifier"><![CDATA[blood]]></field>
  <field name="articleDescriptor"><![CDATA[Luteinizing Hormone]]></field>
  <field name="articleQualifier"><![CDATA[blood]]></field>
  <field name="articleDescriptor"><![CDATA[Menstruation]]></field>
  <field name="articleQualifier"><![CDATA[drug effects]]></field>
  <field name="articleDescriptor"><![CDATA[Ovary]]></field>
  <field name="articleQualifier"><![CDATA[drug effects]]></field>
  <field name="articleDescriptor"><![CDATA[Papio]]></field>
  <field name="articleQualifier"><![CDATA[physiology]]></field>
  <field name="articleDescriptor"><![CDATA[Progestins]]></field>
  <field name="articleQualifier"><![CDATA[blood]]></field>
  <field name="articleDescriptor"><![CDATA[Prolactin]]></field>
  <field name="articleQualifier"><![CDATA[blood]]></field>
  <field name="articleDescriptor"><![CDATA[Sulpiride]]></field>
  <field name="articleQualifier"><![CDATA[pharmacology]]></field>
 </doc>
 <doc>
  <field name="id"><![CDATA[6288954]]></field>
  <field name="articleCreationDate"><![CDATA[1982-12-02T00:00:00Z]]></field>
  <field name="articleYear"><![CDATA[1982]]></field>
  <field name="articleCompletionDate"><![CDATA[1982-12-02T00:00:00Z]]></field>
  <field name="articleRevisionDate"><![CDATA[2007-11-14T00:00:00Z]]></field>
  <field name="articlePubmodel"><![CDATA[Print]]></field>
  <field name="journalTitle"><![CDATA[Journal of medical primatology]]></field>
  <field name="journalTitleAbrv"><![CDATA[J. Med. Primatol.]]></field>
  <field name="articleTitle"><![CDATA[Rotavirus antibodies in hanuman langurs (Presbytis entellus).]]></field>
  <field name="articleAbstract"><![CDATA[Serum samples from wild Hanuman langurs (Presbytis entellus) from Mysore State, India, were compared to samples from a laboratory colony from Davis, Calif., for antibodies to rotavirus, which is an important cause of gastroenteritis in mammals. Animals from the laboratory colony had a higher frequency and higher levels of antibody than wild animals. It is likely that wild populations of langurs have a much lower incidence of rotaviral infection than laboratory populations, which are exposed to both crowded conditions and rotaviruses from other species.]]></field>
  <field name="author"><![CDATA[Hrdy D B]]></field>
  <field name="articleLang"><![CDATA[eng]]></field>
  <field name="publicationType"><![CDATA[Journal Article]]></field>
  <field name="publicationType"><![CDATA[Research Support, U.S. Gov't, Non-P.H.S.]]></field>
  <field name="publicationType"><![CDATA[Research Support, U.S. Gov't, P.H.S.]]></field>
  <field name="substanceName"><![CDATA[Antibodies, Viral]]></field>
  <field name="articleDescriptor"><![CDATA[Animals]]></field>
  <field name="articleDescriptor"><![CDATA[Antibodies, Viral]]></field>
  <field name="articleDescriptor"><![CDATA[Cercopithecidae]]></field>
  <field name="articleQualifier"><![CDATA[microbiology]]></field>
  <field name="articleDescriptor"><![CDATA[Gastroenteritis]]></field>
  <field name="articleQualifier"><![CDATA[veterinary]]></field>
  <field name="articleDescriptor"><![CDATA[Rotavirus]]></field>
  <field name="articleQualifier"><![CDATA[immunology]]></field>
  <field name="articleDescriptor"><![CDATA[Rotavirus Infections]]></field>
  <field name="articleQualifier"><![CDATA[veterinary]]></field>
 </doc>
 <doc>
  <field name="id"><![CDATA[7120359]]></field>
  <field name="articleCreationDate"><![CDATA[1982-12-02T00:00:00Z]]></field>
  <field name="articleYear"><![CDATA[1982]]></field>
  <field name="articleCompletionDate"><![CDATA[1982-12-02T00:00:00Z]]></field>
  <field name="articleRevisionDate"><![CDATA[2006-11-15T00:00:00Z]]></field>
  <field name="articlePubmodel"><![CDATA[Print]]></field>
  <field name="journalTitle"><![CDATA[Journal of medical primatology]]></field>
  <field name="journalTitleAbrv"><![CDATA[J. Med. Primatol.]]></field>
  <field name="articleTitle"><![CDATA[Blood coagulation tests of gorillas.]]></field>
  <field name="articleAbstract"><![CDATA[In coagulation tests on five lowland gorillas, values within or close to the normal human range were found with the following tests: partial thromboplastin time, prothrombin time, thrombin time, factor XIII screen, factor II assay, factor V assay, fibrinogen and antithrombin III. Factor XII levels were very high. Factor VIII coagulant activity was moderately elevated but factor VIII antigen was very high in all and ristocetin cofactor activity was low in four of five.]]></field>
  <field name="author"><![CDATA[Perkins H A]]></field>
  <field name="author"><![CDATA[Hymas P G]]></field>
  <field name="author"><![CDATA[Perkins F S]]></field>
  <field name="author"><![CDATA[Bachelor M]]></field>
  <field name="author"><![CDATA[Kitchener S]]></field>
  <field name="articleLang"><![CDATA[eng]]></field>
  <field name="publicationType"><![CDATA[Comparative Study]]></field>
  <field name="publicationType"><![CDATA[Journal Article]]></field>
  <field name="articleDescriptor"><![CDATA[Animals]]></field>
  <field name="articleDescriptor"><![CDATA[Blood Coagulation]]></field>
  <field name="articleDescriptor"><![CDATA[Blood Coagulation Tests]]></field>
  <field name="articleQualifier"><![CDATA[veterinary]]></field>
  <field name="articleDescriptor"><![CDATA[Female]]></field>
  <field name="articleDescriptor"><![CDATA[Gorilla gorilla]]></field>
  <field name="articleQualifier"><![CDATA[blood]]></field>
  <field name="articleDescriptor"><![CDATA[Male]]></field>
 </doc>
 <doc>
  <field name="id"><![CDATA[6811748]]></field>
  <field name="articleCreationDate"><![CDATA[1982-12-02T00:00:00Z]]></field>
  <field name="articleYear"><![CDATA[1982]]></field>
  <field name="articleCompletionDate"><![CDATA[1982-12-02T00:00:00Z]]></field>
  <field name="articleRevisionDate"><![CDATA[2006-11-15T00:00:00Z]]></field>
  <field name="articlePubmodel"><![CDATA[Print]]></field>
  <field name="journalTitle"><![CDATA[Journal of medical primatology]]></field>
  <field name="journalTitleAbrv"><![CDATA[J. Med. Primatol.]]></field>
  <field name="articleTitle"><![CDATA[Plasma progesterone levels throughout the ovarian cycle of the common marmoset (Callithrix jacchus).]]></field>
  <field name="articleAbstract"><![CDATA[Radioimmunoassay of progesterone in marmoset plasma has been used to determine ovarian cycle length. Total cycle length was 30.1 +/- 3.8 days (mean +/- SD, n = 30, range 24-41 days, median 29.5 days). The pre-ovulatory (follicular) phase, during which progesterone levels were below 10 ng/ml, lasted for 8.8 +/- 3.7 days (mean +/- SD, n = 30, range 3-20 days, median 8.5 days). The post-ovulatory (luteal) phase, during which progesterone levels were greater than 10 ng/ml, lasted for 21.5 +/- 2.2 days (mean +/- SD, n = 30, range 14-29 days, median 21.5 days). Total cycle length was almost twice that recorded in an earlier study. The reasons for this difference are discussed.]]></field>
  <field name="author"><![CDATA[Harding R D]]></field>
  <field name="author"><![CDATA[Hulme M J]]></field>
  <field name="author"><![CDATA[Lunn S F]]></field>
  <field name="author"><![CDATA[Henderson C]]></field>
  <field name="author"><![CDATA[Aitken R J]]></field>
  <field name="articleLang"><![CDATA[eng]]></field>
  <field name="publicationType"><![CDATA[Comparative Study]]></field>
  <field name="publicationType"><![CDATA[Journal Article]]></field>
  <field name="publicationType"><![CDATA[Research Support, Non-U.S. Gov't]]></field>
  <field name="substanceName"><![CDATA[Progesterone]]></field>
  <field name="articleDescriptor"><![CDATA[Animals]]></field>
  <field name="articleDescriptor"><![CDATA[Callithrix]]></field>
  <field name="articleQualifier"><![CDATA[physiology]]></field>
  <field name="articleDescriptor"><![CDATA[Callitrichinae]]></field>
  <field name="articleQualifier"><![CDATA[physiology]]></field>
  <field name="articleDescriptor"><![CDATA[Female]]></field>
  <field name="articleDescriptor"><![CDATA[Follicular Phase]]></field>
  <field name="articleDescriptor"><![CDATA[Luteal Phase]]></field>
  <field name="articleDescriptor"><![CDATA[Menstruation]]></field>
  <field name="articleDescriptor"><![CDATA[Ovary]]></field>
  <field name="articleQualifier"><![CDATA[physiology]]></field>
  <field name="articleDescriptor"><![CDATA[Progesterone]]></field>
  <field name="articleQualifier"><![CDATA[blood]]></field>
  <field name="articleDescriptor"><![CDATA[Time Factors]]></field>
 </doc>
 <doc>
  <field name="id"><![CDATA[6811749]]></field>
  <field name="articleCreationDate"><![CDATA[1982-12-02T00:00:00Z]]></field>
  <field name="articleYear"><![CDATA[1982]]></field>
  <field name="articleCompletionDate"><![CDATA[1982-12-02T00:00:00Z]]></field>
  <field name="articleRevisionDate"><![CDATA[2011-11-17T00:00:00Z]]></field>
  <field name="articlePubmodel"><![CDATA[Print]]></field>
  <field name="journalTitle"><![CDATA[The Journal of membrane biology]]></field>
  <field name="journalTitleAbrv"><![CDATA[J. Membr. Biol.]]></field>
  <field name="articleTitle"><![CDATA[Amino acid transport in isolated rat hepatocytes.]]></field>
  <field name="articleAbstract"><![CDATA[Improvements in the collagenase perfusion techniques have made isolated rat hepatocytes a popular model in which to study hepatic function. Our knowledge of hepatic amino acid transport has been advanced as a result of this methodology. Translocation across the hepatocyte plasma membrane can, in some instances, represent the rate-limiting step in the overall metabolism of certain amino acids. Furthermore, regulation of amino acid uptake by hepatocytes appears to play a role in diabetes, and perhaps in malignant transformation. Comparisons between normal adult hepatocytes and several hepatoma cell lines show basic differences in amino acid transport. There are at least eight distinct systems in normal hepatocytes for transport of the hormones. Systems A and N exhibit enhanced uptake rates after the cells have been maintained in the absence of extracellular amino acids, a phenomenon termed adaptive control. Further studies using isolated hepatocytes will increase our basic understanding of membrane transport processes and their regulation.]]></field>
  <field name="author"><![CDATA[Kilberg M S]]></field>
  <field name="articleLang"><![CDATA[eng]]></field>
  <field name="publicationType"><![CDATA[In Vitro]]></field>
  <field name="publicationType"><![CDATA[Journal Article]]></field>
  <field name="publicationType"><![CDATA[Research Support, Non-U.S. Gov't]]></field>
  <field name="publicationType"><![CDATA[Research Support, U.S. Gov't, P.H.S.]]></field>
  <field name="publicationType"><![CDATA[Review]]></field>
  <field name="substanceName"><![CDATA[Amino Acids]]></field>
  <field name="substanceName"><![CDATA[Aminoisobutyric Acids]]></field>
  <field name="substanceName"><![CDATA[Catecholamines]]></field>
  <field name="substanceName"><![CDATA[Glucocorticoids]]></field>
  <field name="substanceName"><![CDATA[Insulin]]></field>
  <field name="substanceName"><![CDATA[2-(methylamino)isobutyric acid]]></field>
  <field name="substanceName"><![CDATA[Cysteine]]></field>
  <field name="substanceName"><![CDATA[Glycine]]></field>
  <field name="substanceName"><![CDATA[Glutamine]]></field>
  <field name="substanceName"><![CDATA[Lysine]]></field>
  <field name="substanceName"><![CDATA[Histidine]]></field>
  <field name="substanceName"><![CDATA[Glucagon]]></field>
  <field name="articleDescriptor"><![CDATA[Amino Acids]]></field>
  <field name="articleQualifier"><![CDATA[metabolism]]></field>
  <field name="articleDescriptor"><![CDATA[Aminoisobutyric Acids]]></field>
  <field name="articleQualifier"><![CDATA[metabolism]]></field>
  <field name="articleDescriptor"><![CDATA[Animals]]></field>
  <field name="articleDescriptor"><![CDATA[Biological Transport]]></field>
  <field name="articleQualifier"><![CDATA[drug effects]]></field>
  <field name="articleDescriptor"><![CDATA[Catecholamines]]></field>
  <field name="articleQualifier"><![CDATA[pharmacology]]></field>
  <field name="articleDescriptor"><![CDATA[Cell Membrane]]></field>
  <field name="articleQualifier"><![CDATA[metabolism]]></field>
  <field name="articleDescriptor"><![CDATA[Cells, Cultured]]></field>
  <field name="articleDescriptor"><![CDATA[Cysteine]]></field>
  <field name="articleQualifier"><![CDATA[metabolism]]></field>
  <field name="articleDescriptor"><![CDATA[Glucagon]]></field>
  <field name="articleQualifier"><![CDATA[pharmacology]]></field>
  <field name="articleDescriptor"><![CDATA[Glucocorticoids]]></field>
  <field name="articleQualifier"><![CDATA[pharmacology]]></field>
  <field name="articleDescriptor"><![CDATA[Glutamine]]></field>
  <field name="articleQualifier"><![CDATA[metabolism]]></field>
  <field name="articleDescriptor"><![CDATA[Glycine]]></field>
  <field name="articleQualifier"><![CDATA[metabolism]]></field>
  <field name="articleDescriptor"><![CDATA[Histidine]]></field>
  <field name="articleQualifier"><![CDATA[metabolism]]></field>
  <field name="articleDescriptor"><![CDATA[Insulin]]></field>
  <field name="articleQualifier"><![CDATA[pharmacology]]></field>
  <field name="articleDescriptor"><![CDATA[Kinetics]]></field>
  <field name="articleDescriptor"><![CDATA[Liver]]></field>
  <field name="articleQualifier"><![CDATA[drug effects]]></field>
  <field name="articleQualifier"><![CDATA[metabolism]]></field>
  <field name="articleDescriptor"><![CDATA[Lysine]]></field>
  <field name="articleQualifier"><![CDATA[metabolism]]></field>
  <field name="articleDescriptor"><![CDATA[Rats]]></field>
 </doc>
 <doc>
  <field name="id"><![CDATA[6288956]]></field>
  <field name="articleCreationDate"><![CDATA[1982-12-02T00:00:00Z]]></field>
  <field name="articleYear"><![CDATA[1982]]></field>
  <field name="articleCompletionDate"><![CDATA[1982-12-02T00:00:00Z]]></field>
  <field name="articleRevisionDate"><![CDATA[2007-11-15T00:00:00Z]]></field>
  <field name="articlePubmodel"><![CDATA[Print]]></field>
  <field name="journalTitle"><![CDATA[The Journal of membrane biology]]></field>
  <field name="journalTitleAbrv"><![CDATA[J. Membr. Biol.]]></field>
  <field name="articleTitle"><![CDATA[Characteristics of antibodies to guinea pig (Na+ + K+)-adenosine triphosphatase and their use in cell-free synthesis studies.]]></field>
  <field name="articleAbstract"><![CDATA[Antibodies have been produced, in three rabbits, to Na/K-ATPase purified from guinea pig renal outer medulla. Each rabbit produced antibodies to both the alpha (catalytic) and the beta (glycoprotein) subunits of Na/K-ATPase. The titers of the anti-alpha and anti-beta antibodies varied with time and between rabbits. None of the antisera inhibited Na/K-ATPase activity under various preincubation conditions. A method is presented for separating small amounts of anti-alpha subunit from anti-beta subunit antibodies. There was no cross-reactivity of antibodies to one subunit with the other subunit. The alpha subunit of the Na/K-ATPase was cleaved into a 41,000-dalton peptide (that contains the ATP phosphorylating site) and a 58,000-dalton hydrophobic peptide as described by Castro and Farley (Castro, J., Farley, R.A., 1979, J. Biol. Chem. 254: 2221-2228). Anti-alpha antibodies from all of the rabbits reacted with both proteolytic fragments. The anti-guinea pig Na/K-ATPase antisera (pooled) cross-reacted with the alpha subunit of Na/K-ATPase from human, cow, dog, rabbit, rat, mouse, turtle, and toad; and with the beta subunit from human, rat, and mouse. The loci of cross-reactivity were investigated using partially purified canine kidney Na/K-ATPase cleaved with trypsin as described above. The anti-sera from rabbits 1 and 2 cross-reacted with the 41,000-dalton peptide from the dog but very little with the 58,000-dalton peptide. No cross-reactivity was observed with antiserum from rabbit 3 to either fragment. Guinea pig kidney RNA was translated in a rabbit reticulocyte lysate system followed by immunoprecipitation with the antisera. The molecular weight of the cell-free synthesized alpha chain was 96,000 daltons. Its identity was established with purified anti-alpha antibodies and by immunocompetition with purified Na/K-ATPase and Ca-ATPase. Translation of the beta subunit was not detected in this system.]]></field>
  <field name="author"><![CDATA[McDonough A A]]></field>
  <field name="author"><![CDATA[Hiatt A]]></field>
  <field name="author"><![CDATA[Edelman I S]]></field>
  <field name="articleLang"><![CDATA[eng]]></field>
  <field name="publicationType"><![CDATA[Journal Article]]></field>
  <field name="publicationType"><![CDATA[Research Support, U.S. Gov't, P.H.S.]]></field>
  <field name="substanceName"><![CDATA[Antibodies]]></field>
  <field name="substanceName"><![CDATA[Antigen-Antibody Complex]]></field>
  <field name="substanceName"><![CDATA[Macromolecular Substances]]></field>
  <field name="substanceName"><![CDATA[RNA, Messenger]]></field>
  <field name="substanceName"><![CDATA[Sodium-Potassium-Exchanging ATPase]]></field>
  <field name="articleDescriptor"><![CDATA[Animals]]></field>
  <field name="articleDescriptor"><![CDATA[Antibodies]]></field>
  <field name="articleQualifier"><![CDATA[isolation & purification]]></field>
  <field name="articleDescriptor"><![CDATA[Antigen-Antibody Complex]]></field>
  <field name="articleQualifier"><![CDATA[analysis]]></field>
  <field name="articleDescriptor"><![CDATA[Cross Reactions]]></field>
  <field name="articleDescriptor"><![CDATA[Guinea Pigs]]></field>
  <field name="articleDescriptor"><![CDATA[Kidney Medulla]]></field>
  <field name="articleQualifier"><![CDATA[enzymology]]></field>
  <field name="articleDescriptor"><![CDATA[Macromolecular Substances]]></field>
  <field name="articleDescriptor"><![CDATA[Molecular Weight]]></field>
  <field name="articleDescriptor"><![CDATA[Protein Biosynthesis]]></field>
  <field name="articleDescriptor"><![CDATA[RNA, Messenger]]></field>
  <field name="articleQualifier"><![CDATA[genetics]]></field>
  <field name="articleDescriptor"><![CDATA[Sodium-Potassium-Exchanging ATPase]]></field>
  <field name="articleQualifier"><![CDATA[genetics]]></field>
  <field name="articleQualifier"><![CDATA[immunology]]></field>
  <field name="articleQualifier"><![CDATA[isolation & purification]]></field>
 </doc>
 <doc>
  <field name="id"><![CDATA[6288957]]></field>
  <field name="articleCreationDate"><![CDATA[1982-12-02T00:00:00Z]]></field>
  <field name="articleYear"><![CDATA[1982]]></field>
  <field name="articleCompletionDate"><![CDATA[1982-12-02T00:00:00Z]]></field>
  <field name="articleRevisionDate"><![CDATA[2007-11-15T00:00:00Z]]></field>
  <field name="articlePubmodel"><![CDATA[Print]]></field>
  <field name="journalTitle"><![CDATA[The Journal of membrane biology]]></field>
  <field name="journalTitleAbrv"><![CDATA[J. Membr. Biol.]]></field>
  <field name="articleTitle"><![CDATA[Progesterone-induced down-regulation of electrogenic Na+, K+-ATPase during the first meiotic division in amphibian oocytes.]]></field>
  <field name="articleAbstract"><![CDATA[Progesterone initiates the resumption of the meiotic divisions in the amphibian oocyte. Depolarization of the Rama pipiens oocyte plasma membrane begins 6-10 hr after exposure to progesterone (1-2 hr before nuclear breakdown). The oocyte cytoplasm becomes essentially isopotential with the medium by the end of the first meiotic division (20-22 hr). Voltage-clamp studies indicate that the depolarization coincides with the disappearance of an electrogenic Na+, K+-pump, and other electrophysiological studies indicate a decrease in both K+ and Cl- conductances of the oocyte plasma membrane. Measurement of [3H]-ouabain binding to the plasma-vitelline membrane complex indicates that there are high-affinity (Kd = 4.2 x 10-8M), K+-sensitive ouabain-binding sites on the unstimulated (prophase-arrest) oocyte and that ouabain binding virtually disappears during membrane depolarization. [3H]-Leucine incorporation into the plasma-vitelline membrane complex increased ninefold during depolarization with no significant change in uptake or incorporation into cytoplasmic proteins or acid soluble pool(s). This together with previous findings suggest that progesterone acts at a translational level to produce a cytoplasmic factor(s) that down-regulates the membrane Na+, K+-ATPase and alters the ion permeability and transport properties of both nuclear and plasma membranes.]]></field>
  <field name="author"><![CDATA[Weinstein S P]]></field>
  <field name="author"><![CDATA[Kostellow A B]]></field>
  <field name="author"><![CDATA[Ziegler D H]]></field>
  <field name="author"><![CDATA[Morrill G A]]></field>
  <field name="articleLang"><![CDATA[eng]]></field>
  <field name="publicationType"><![CDATA[Journal Article]]></field>
  <field name="publicationType"><![CDATA[Research Support, U.S. Gov't, P.H.S.]]></field>
  <field name="substanceName"><![CDATA[Progesterone]]></field>
  <field name="substanceName"><![CDATA[Ouabain]]></field>
  <field name="substanceName"><![CDATA[Potassium]]></field>
  <field name="substanceName"><![CDATA[Sodium]]></field>
  <field name="substanceName"><![CDATA[Sodium-Potassium-Exchanging ATPase]]></field>
  <field name="articleDescriptor"><![CDATA[Animals]]></field>
  <field name="articleDescriptor"><![CDATA[Biological Transport, Active]]></field>
  <field name="articleDescriptor"><![CDATA[Female]]></field>
  <field name="articleDescriptor"><![CDATA[Kinetics]]></field>
  <field name="articleDescriptor"><![CDATA[Meiosis]]></field>
  <field name="articleQualifier"><![CDATA[drug effects]]></field>
  <field name="articleDescriptor"><![CDATA[Oocytes]]></field>
  <field name="articleQualifier"><![CDATA[drug effects]]></field>
  <field name="articleQualifier"><![CDATA[physiology]]></field>
  <field name="articleDescriptor"><![CDATA[Ouabain]]></field>
  <field name="articleQualifier"><![CDATA[metabolism]]></field>
  <field name="articleDescriptor"><![CDATA[Ovum]]></field>
  <field name="articleQualifier"><![CDATA[physiology]]></field>
  <field name="articleDescriptor"><![CDATA[Potassium]]></field>
  <field name="articleQualifier"><![CDATA[metabolism]]></field>
  <field name="articleDescriptor"><![CDATA[Progesterone]]></field>
  <field name="articleQualifier"><![CDATA[pharmacology]]></field>
  <field name="articleDescriptor"><![CDATA[Protein Biosynthesis]]></field>
  <field name="articleQualifier"><![CDATA[drug effects]]></field>
  <field name="articleDescriptor"><![CDATA[Rana pipiens]]></field>
  <field name="articleDescriptor"><![CDATA[Sodium]]></field>
  <field name="articleQualifier"><![CDATA[metabolism]]></field>
  <field name="articleDescriptor"><![CDATA[Sodium-Potassium-Exchanging ATPase]]></field>
  <field name="articleQualifier"><![CDATA[metabolism]]></field>
 </doc>
 <doc>
  <field name="id"><![CDATA[6126596]]></field>
  <field name="articleCreationDate"><![CDATA[1982-12-02T00:00:00Z]]></field>
  <field name="articleYear"><![CDATA[1982]]></field>
  <field name="articleCompletionDate"><![CDATA[1982-12-02T00:00:00Z]]></field>
  <field name="articleRevisionDate"><![CDATA[2010-11-18T00:00:00Z]]></field>
  <field name="articlePubmodel"><![CDATA[Print]]></field>
  <field name="journalTitle"><![CDATA[The Journal of membrane biology]]></field>
  <field name="journalTitleAbrv"><![CDATA[J. Membr. Biol.]]></field>
  <field name="articleTitle"><![CDATA[Modulation of ATPase activities of human erythrocyte membranes by free fatty acids or phospholipase A2.]]></field>
  <field name="articleAbstract"><![CDATA[The artificial insertion of increasing amounts of unsaturated fatty acids into human erythrocyte membranes modulated ATPase activities in a biphasic manner, depending on the number and position of double bonds, their configuration, and the chain length. Uncharged long-chain fatty acid derivatives with double bonds and short-chain fatty acids were ineffective. Stearic acid stimulated Na+ K+-ATPase only. Anionic and non-ionic detergents and alpha-lysophosphatidylcholine failed to stimulate ATPase activities at low, and inhibited them at high concentrations. Mg2+-AtPase activity was maximally enhanced by a factor of 2 in the presence of monoenoic fatty acids; half-maximal stimulation was achieved at a molar ratio of cis(trans)-configurated C18 acids/membrane phospholipid of 0.16 (0.26). Na+K+-ATPase activity was maximally augmented by 20% in the presence of monoenoic C18 fatty acids at 37 degrees C. Half-maximal effects were attained at a molar ratio oleic (elaidic) acid/phospholipid of 0.032 (0.075). Concentrations of free fatty acids which inhibited ATPases activities at 37 degrees C were most stimulatory at reduced temperatures. At 10 degrees C, oleic acid increased Na+K+-ATPase activity fivefold (molar ratio 0.22). Unsaturated fatty acids simulated the effects of calmodulin on Ca2+-ATPase of native erythrocyte membranes (i.e., increase of Vmax from 1.6 to 5 mumol PO43- . phospholipid-1 . hr-1, decrease of K'Ca from 6 microM to 1.4-1.8 microM). Stearic acid decreased K'Ca (2 microM) only, probably due to an increase of negative surface charges. A stimulation of Mg2+-ATPase, Na+K+-ATPase, and Ca2+-ATPase could be achieved by incubation of the membranes with phospholipase A2. An electrostatic segregation of free fatty acids by ATPases with ensuing alterations of surface charge densities and disordering of the hydrophobic environment of the enzymes provides an explanation of the results.]]></field>
  <field name="author"><![CDATA[Schmalzing G]]></field>
  <field name="author"><![CDATA[Kutschera P]]></field>
  <field name="articleLang"><![CDATA[eng]]></field>
  <field name="publicationType"><![CDATA[Journal Article]]></field>
  <field name="publicationType"><![CDATA[Research Support, Non-U.S. Gov't]]></field>
  <field name="substanceName"><![CDATA[Fatty Acids, Nonesterified]]></field>
  <field name="substanceName"><![CDATA[Fatty Acids, Unsaturated]]></field>
  <field name="substanceName"><![CDATA[Membrane Lipids]]></field>
  <field name="substanceName"><![CDATA[Phospholipids]]></field>
  <field name="substanceName"><![CDATA[Phospholipases]]></field>
  <field name="substanceName"><![CDATA[Phospholipases A]]></field>
  <field name="substanceName"><![CDATA[Phospholipases A2]]></field>
  <field name="substanceName"><![CDATA[Adenosine Triphosphatases]]></field>
  <field name="substanceName"><![CDATA[Ca(2+) Mg(2+)-ATPase]]></field>
  <field name="substanceName"><![CDATA[Calcium-Transporting ATPases]]></field>
  <field name="articleDescriptor"><![CDATA[Adenosine Triphosphatases]]></field>
  <field name="articleQualifier"><![CDATA[blood]]></field>
  <field name="articleDescriptor"><![CDATA[Ca(2+) Mg(2+)-ATPase]]></field>
  <field name="articleDescriptor"><![CDATA[Calcium-Transporting ATPases]]></field>
  <field name="articleQualifier"><![CDATA[blood]]></field>
  <field name="articleDescriptor"><![CDATA[Erythrocyte Membrane]]></field>
  <field name="articleQualifier"><![CDATA[enzymology]]></field>
  <field name="articleDescriptor"><![CDATA[Erythrocytes]]></field>
  <field name="articleQualifier"><![CDATA[enzymology]]></field>
  <field name="articleDescriptor"><![CDATA[Fatty Acids, Nonesterified]]></field>
  <field name="articleQualifier"><![CDATA[pharmacology]]></field>
  <field name="articleDescriptor"><![CDATA[Fatty Acids, Unsaturated]]></field>
  <field name="articleQualifier"><![CDATA[pharmacology]]></field>
  <field name="articleDescriptor"><![CDATA[Humans]]></field>
  <field name="articleDescriptor"><![CDATA[Kinetics]]></field>
  <field name="articleDescriptor"><![CDATA[Membrane Lipids]]></field>
  <field name="articleQualifier"><![CDATA[blood]]></field>
  <field name="articleDescriptor"><![CDATA[Phospholipases]]></field>
  <field name="articleQualifier"><![CDATA[pharmacology]]></field>
  <field name="articleDescriptor"><![CDATA[Phospholipases A]]></field>
  <field name="articleQualifier"><![CDATA[pharmacology]]></field>
  <field name="articleDescriptor"><![CDATA[Phospholipases A2]]></field>
  <field name="articleDescriptor"><![CDATA[Phospholipids]]></field>
  <field name="articleQualifier"><![CDATA[blood]]></field>
  <field name="articleDescriptor"><![CDATA[Structure-Activity Relationship]]></field>
 </doc>
 <doc>
  <field name="id"><![CDATA[7120364]]></field>
  <field name="articleCreationDate"><![CDATA[1982-12-02T00:00:00Z]]></field>
  <field name="articleYear"><![CDATA[1982]]></field>
  <field name="articleCompletionDate"><![CDATA[1982-12-02T00:00:00Z]]></field>
  <field name="articleRevisionDate"><![CDATA[2007-11-14T00:00:00Z]]></field>
  <field name="articlePubmodel"><![CDATA[Print]]></field>
  <field name="journalTitle"><![CDATA[The Journal of membrane biology]]></field>
  <field name="journalTitleAbrv"><![CDATA[J. Membr. Biol.]]></field>
  <field name="articleTitle"><![CDATA[Sodium-calcium ion exchange in skeletal muscle sarcolemmal vesicles.]]></field>
  <field name="articleAbstract"><![CDATA[The Ca2+ permeability of rabbit skeletal muscle sarcolemmal vesicles was investigated by means of radioisotope flux measurements. A membrane vesicle fraction highly enriched in sarcolemma, as revealed by enzymatic markers, was obtained from the 22-27% region of sucrose gradients after isopycnic centrifugation. The ability of sarcolemmal vesicles to exchange Na+ for Ca2+ was investigated by measuring Ca2+ influx into and efflux from sarcolemmal vesicles in the presence and absence of a Na+ gradient. It was found that Ca2+ movements were enhanced in the direction of the higher Na+ concentration. When intra-and extravesicular Na+ concentrations were high, Na+-Na+ exchanged predominated and Na+-Ca2+ exchange was low or absent. The presence of the Ca2+ ionophore A23187 in the dilution medium resulted in the rapid release of Ca2+ and the elimination of the Na+-enhanced efflux of Ca2+, suggesting that internal rather than bound external Ca2+ was exchanged with Na+ . La3+ abolished Na+-Ca4+ exchanged was not due to sarcoplasmic reticulum or mitochondrial contaminants. This investigation suggests that skeletal muscle, like cardiac muscle and neurons, is capable of a transmembranous Na/-Ca2+ exchange.]]></field>
  <field name="author"><![CDATA[Gilbert J R]]></field>
  <field name="author"><![CDATA[Meissner G]]></field>
  <field name="articleLang"><![CDATA[eng]]></field>
  <field name="publicationType"><![CDATA[Journal Article]]></field>
  <field name="publicationType"><![CDATA[Research Support, U.S. Gov't, P.H.S.]]></field>
  <field name="substanceName"><![CDATA[Magnesium]]></field>
  <field name="substanceName"><![CDATA[Rubidium]]></field>
  <field name="substanceName"><![CDATA[Sodium]]></field>
  <field name="substanceName"><![CDATA[Calcium]]></field>
  <field name="articleDescriptor"><![CDATA[Animals]]></field>
  <field name="articleDescriptor"><![CDATA[Biological Transport, Active]]></field>
  <field name="articleQualifier"><![CDATA[drug effects]]></field>
  <field name="articleDescriptor"><![CDATA[Calcium]]></field>
  <field name="articleQualifier"><![CDATA[metabolism]]></field>
  <field name="articleDescriptor"><![CDATA[Kinetics]]></field>
  <field name="articleDescriptor"><![CDATA[Magnesium]]></field>
  <field name="articleQualifier"><![CDATA[pharmacology]]></field>
  <field name="articleDescriptor"><![CDATA[Muscles]]></field>
  <field name="articleQualifier"><![CDATA[metabolism]]></field>
  <field name="articleDescriptor"><![CDATA[Permeability]]></field>
  <field name="articleDescriptor"><![CDATA[Rabbits]]></field>
  <field name="articleDescriptor"><![CDATA[Rubidium]]></field>
  <field name="articleQualifier"><![CDATA[metabolism]]></field>
  <field name="articleDescriptor"><![CDATA[Sarcolemma]]></field>
  <field name="articleQualifier"><![CDATA[metabolism]]></field>
  <field name="articleDescriptor"><![CDATA[Sodium]]></field>
  <field name="articleQualifier"><![CDATA[metabolism]]></field>
 </doc>
 <doc>
  <field name="id"><![CDATA[7120365]]></field>
  <field name="articleCreationDate"><![CDATA[1982-12-02T00:00:00Z]]></field>
  <field name="articleYear"><![CDATA[1982]]></field>
  <field name="articleCompletionDate"><![CDATA[1982-12-02T00:00:00Z]]></field>
  <field name="articleRevisionDate"><![CDATA[2006-11-15T00:00:00Z]]></field>
  <field name="articlePubmodel"><![CDATA[Print]]></field>
  <field name="journalTitle"><![CDATA[Journal of microscopy]]></field>
  <field name="journalTitleAbrv"><![CDATA[J Microsc]]></field>
  <field name="articleTitle"><![CDATA[The correlation averaging of a regularly arranged bacterial cell envelope protein.]]></field>
  <field name="articleAbstract"><![CDATA[An adaptation of the 'correlation averaging' method is described which allows reliable and almost fully automatic image averaging in the case of near-periodic structures notwithstanding the presence of substantial crystal imperfections; methods for assessing resolution and symmetry without reliance on crystallinity are also discussed. Electron micrographs of negatively stained and rotary shadowed preparations of the HPI-layer protein from the cell envelope of Micrococcus radiodurans have been averaged using the method, and the projected structure is described to a resolution of about 1.9 nm.]]></field>
  <field name="author"><![CDATA[Saxton W O]]></field>
  <field name="author"><![CDATA[Baumeister W]]></field>
  <field name="articleLang"><![CDATA[eng]]></field>
  <field name="publicationType"><![CDATA[Journal Article]]></field>
  <field name="publicationType"><![CDATA[Research Support, Non-U.S. Gov't]]></field>
  <field name="substanceName"><![CDATA[Membrane Proteins]]></field>
  <field name="articleDescriptor"><![CDATA[Cell Membrane]]></field>
  <field name="articleQualifier"><![CDATA[ultrastructure]]></field>
  <field name="articleDescriptor"><![CDATA[Membrane Proteins]]></field>
  <field name="articleQualifier"><![CDATA[analysis]]></field>
  <field name="articleDescriptor"><![CDATA[Micrococcus]]></field>
  <field name="articleQualifier"><![CDATA[ultrastructure]]></field>
  <field name="articleDescriptor"><![CDATA[Microscopy, Electron]]></field>
  <field name="articleQualifier"><![CDATA[methods]]></field>
 </doc>
 <doc>
  <field name="id"><![CDATA[6181261]]></field>
  <field name="articleCreationDate"><![CDATA[1982-12-02T00:00:00Z]]></field>
  <field name="articleYear"><![CDATA[1982]]></field>
  <field name="articleCompletionDate"><![CDATA[1982-12-02T00:00:00Z]]></field>
  <field name="articleRevisionDate"><![CDATA[2007-11-15T00:00:00Z]]></field>
  <field name="articlePubmodel"><![CDATA[Print]]></field>
  <field name="journalTitle"><![CDATA[Journal of microscopy]]></field>
  <field name="journalTitleAbrv"><![CDATA[J Microsc]]></field>
  <field name="articleTitle"><![CDATA[Glycol methacrylate embedding of bone and cartilage for light microscopic staining.]]></field>
  <field name="articleAbstract"><![CDATA[A method is described for embedding bone and cartilage in glycol methacrylate (GMA) for light microscopy. Dehydration-infiltration of the hard tissue is with aqueous GMA solutions minimizing solvent and dehydration artefact, and polymerization is by UV light in the cold to minimize thermal damage. Over fifty stains, enzyme localizations and related histochemical methods for 0.5-3.0 micrometer thick sections of GMA embedded tissue are listed. The increased resolution plus the localization of cellular and extracellular chemical moieties is now easier and more accurate providing an improved method for the study of the musculo-skeletal system by light microscopy histochemistry.]]></field>
  <field name="author"><![CDATA[Cole M B]]></field>
  <field name="articleLang"><![CDATA[eng]]></field>
  <field name="publicationType"><![CDATA[Journal Article]]></field>
  <field name="publicationType"><![CDATA[Research Support, U.S. Gov't, Non-P.H.S.]]></field>
  <field name="substanceName"><![CDATA[Polyhydroxyethyl Methacrylate]]></field>
  <field name="articleDescriptor"><![CDATA[Animals]]></field>
  <field name="articleDescriptor"><![CDATA[Bone and Bones]]></field>
  <field name="articleQualifier"><![CDATA[cytology]]></field>
  <field name="articleQualifier"><![CDATA[ultrastructure]]></field>
  <field name="articleDescriptor"><![CDATA[Cartilage]]></field>
  <field name="articleQualifier"><![CDATA[cytology]]></field>
  <field name="articleQualifier"><![CDATA[ultrastructure]]></field>
  <field name="articleDescriptor"><![CDATA[Embryo, Mammalian]]></field>
  <field name="articleDescriptor"><![CDATA[Female]]></field>
  <field name="articleDescriptor"><![CDATA[Histological Techniques]]></field>
  <field name="articleDescriptor"><![CDATA[Microscopy, Electron]]></field>
  <field name="articleDescriptor"><![CDATA[Polyhydroxyethyl Methacrylate]]></field>
  <field name="articleDescriptor"><![CDATA[Pregnancy]]></field>
  <field name="articleDescriptor"><![CDATA[Rats]]></field>
  <field name="articleDescriptor"><![CDATA[Staining and Labeling]]></field>
 </doc>
 <doc>
  <field name="id"><![CDATA[6750130]]></field>
  <field name="articleCreationDate"><![CDATA[1982-12-02T00:00:00Z]]></field>
  <field name="articleYear"><![CDATA[1982]]></field>
  <field name="articleCompletionDate"><![CDATA[1982-12-02T00:00:00Z]]></field>
  <field name="articleRevisionDate"><![CDATA[2006-08-08T00:00:00Z]]></field>
  <field name="articlePubmodel"><![CDATA[Print]]></field>
  <field name="journalTitle"><![CDATA[Journal of microscopy]]></field>
  <field name="journalTitleAbrv"><![CDATA[J Microsc]]></field>
  <field name="articleTitle"><![CDATA[Improved handling of embedding plastics for electron microscopy.]]></field>
  <field name="articleAbstract"><![CDATA[An improved, safer, rapid method for preparing embedding plastics for electron microscopy is described. The method consists of contained storage and dispensing of individual plastic components on an automatic tare balance. The proportions are based on weight measurements and may be calculated from volume or proportion recipes. The usual problems in and resulting from embedding plastic handling have been eliminated.]]></field>
  <field name="author"><![CDATA[Shannon W A]]></field>
  <field name="articleLang"><![CDATA[eng]]></field>
  <field name="publicationType"><![CDATA[Journal Article]]></field>
  <field name="substanceName"><![CDATA[Plastics]]></field>
  <field name="articleDescriptor"><![CDATA[Animals]]></field>
  <field name="articleDescriptor"><![CDATA[Cells]]></field>
  <field name="articleQualifier"><![CDATA[ultrastructure]]></field>
  <field name="articleDescriptor"><![CDATA[Histological Techniques]]></field>
  <field name="articleDescriptor"><![CDATA[Humans]]></field>
  <field name="articleDescriptor"><![CDATA[Microscopy, Electron]]></field>
  <field name="articleQualifier"><![CDATA[methods]]></field>
  <field name="articleDescriptor"><![CDATA[Plastics]]></field>
 </doc>
 <doc>
  <field name="id"><![CDATA[7120366]]></field>
  <field name="articleCreationDate"><![CDATA[1982-12-02T00:00:00Z]]></field>
  <field name="articleYear"><![CDATA[1982]]></field>
  <field name="articleCompletionDate"><![CDATA[1982-12-02T00:00:00Z]]></field>
  <field name="articleRevisionDate"><![CDATA[2006-11-15T00:00:00Z]]></field>
  <field name="articlePubmodel"><![CDATA[Print]]></field>
  <field name="journalTitle"><![CDATA[Journal of microscopy]]></field>
  <field name="journalTitleAbrv"><![CDATA[J Microsc]]></field>
  <field name="articleTitle"><![CDATA[A television system for point counting morphometry in high resolution light microscopy.]]></field>
  <field name="articleAbstract"><![CDATA[High resolution light microscopical images that can be superimposed on a test system for the estimation of stereological parameters are obtained by a television system modified for point-counting morphometry. The full resolving power of the light microscope is exploited and a test system applied in the same plane as the microscopical image displayed on the monitor screen. Volume fraction estimates of nuclei and zymogen granules from the rat pancreas made with the television microscopical system and with electron-microscopic micrographs rendered the same precision, and showed that the volume fraction of objects as small as zymogen granules was measurable with the light microscope. The measuring with the television microscopical system was about 15 times faster than with electron-microscopic micrography and about 5 times faster than with conventional photomicrography and the light microscope.]]></field>
  <field name="author"><![CDATA[Nielsen H W]]></field>
  <field name="articleLang"><![CDATA[eng]]></field>
  <field name="publicationType"><![CDATA[Comparative Study]]></field>
  <field name="publicationType"><![CDATA[Journal Article]]></field>
  <field name="publicationType"><![CDATA[Research Support, Non-U.S. Gov't]]></field>
  <field name="articleDescriptor"><![CDATA[Animals]]></field>
  <field name="articleDescriptor"><![CDATA[Microscopy]]></field>
  <field name="articleQualifier"><![CDATA[instrumentation]]></field>
  <field name="articleQualifier"><![CDATA[methods]]></field>
  <field name="articleDescriptor"><![CDATA[Microscopy, Electron]]></field>
  <field name="articleDescriptor"><![CDATA[Pancreas]]></field>
  <field name="articleQualifier"><![CDATA[cytology]]></field>
  <field name="articleQualifier"><![CDATA[ultrastructure]]></field>
  <field name="articleDescriptor"><![CDATA[Rats]]></field>
  <field name="articleDescriptor"><![CDATA[Television]]></field>
 </doc>
 <doc>
  <field name="id"><![CDATA[7120367]]></field>
  <field name="articleCreationDate"><![CDATA[1982-12-02T00:00:00Z]]></field>
  <field name="articleYear"><![CDATA[1982]]></field>
  <field name="articleCompletionDate"><![CDATA[1982-12-02T00:00:00Z]]></field>
  <field name="articleRevisionDate"><![CDATA[2006-11-15T00:00:00Z]]></field>
  <field name="articlePubmodel"><![CDATA[Print]]></field>
  <field name="journalTitle"><![CDATA[Journal of microscopy]]></field>
  <field name="journalTitleAbrv"><![CDATA[J Microsc]]></field>
  <field name="articleTitle"><![CDATA[Automated cell counting in tissue sections: a new approach by 'multiple grey-level analysis'.]]></field>
  <field name="articleAbstract"><![CDATA[A system is described for the automated quantitation in tissue sections of the follicular and stromal cell populations of the thyroid gland, using a computer-linked TV image analyser. The paper illustrates how the problems of variable staining intensity and clustering of images (nuclei) may be overcome by a novel approach, in which multiple analyses of each field are made at increasing grey-level thresholds, and then 'synthesized' by computer to give a composite image. Discrimination between cell (nuclear) types was by a single minimum width criterion. The results were highly reproducible and correlated well with counts obtained by a comparable manual method.]]></field>
  <field name="author"><![CDATA[Wynford-Thomas D]]></field>
  <field name="author"><![CDATA[Garrahan N]]></field>
  <field name="author"><![CDATA[Jasani B]]></field>
  <field name="author"><![CDATA[Williams E D]]></field>
  <field name="articleLang"><![CDATA[eng]]></field>
  <field name="publicationType"><![CDATA[Comparative Study]]></field>
  <field name="publicationType"><![CDATA[Journal Article]]></field>
  <field name="publicationType"><![CDATA[Research Support, Non-U.S. Gov't]]></field>
  <field name="substanceName"><![CDATA[Thyrotropin]]></field>
  <field name="articleDescriptor"><![CDATA[Animals]]></field>
  <field name="articleDescriptor"><![CDATA[Autoanalysis]]></field>
  <field name="articleDescriptor"><![CDATA[Cell Count]]></field>
  <field name="articleQualifier"><![CDATA[methods]]></field>
  <field name="articleDescriptor"><![CDATA[Computers]]></field>
  <field name="articleDescriptor"><![CDATA[Hyperthyroidism]]></field>
  <field name="articleQualifier"><![CDATA[pathology]]></field>
  <field name="articleDescriptor"><![CDATA[Rats]]></field>
  <field name="articleDescriptor"><![CDATA[Thyroid Gland]]></field>
  <field name="articleQualifier"><![CDATA[cytology]]></field>
  <field name="articleQualifier"><![CDATA[pathology]]></field>
  <field name="articleDescriptor"><![CDATA[Thyrotropin]]></field>
  <field name="articleQualifier"><![CDATA[blood]]></field>
 </doc>
 <doc>
  <field name="id"><![CDATA[7120368]]></field>
  <field name="articleCreationDate"><![CDATA[1982-12-02T00:00:00Z]]></field>
  <field name="articleYear"><![CDATA[1982]]></field>
  <field name="articleCompletionDate"><![CDATA[1982-12-02T00:00:00Z]]></field>
  <field name="articleRevisionDate"><![CDATA[2006-08-08T00:00:00Z]]></field>
  <field name="articlePubmodel"><![CDATA[Print]]></field>
  <field name="journalTitle"><![CDATA[Journal of microscopy]]></field>
  <field name="journalTitleAbrv"><![CDATA[J Microsc]]></field>
  <field name="articleTitle"><![CDATA[Multiple image integration: a new method in electron microscopy.]]></field>
  <field name="articleAbstract"><![CDATA[An optical 'flicker' method is described for the precise azimuthal and translational co-registration of many noisy but identical molecular images. Starting with a real micrograph of known biological objects showing no visible detail below 4 nm, a lattice of images of individual objects was synthesized by computer and translationally filtered, using real experimental data throughout. Detail was recovered conforming with known structural features of the object down to about 1.5 nm, and rotational analysis showed that the registration accuracy of the lattice elements was better than 0.5 nm on the object. Application to the straightening of real two-dimensional lattices with long-range distortion is discussed.]]></field>
  <field name="author"><![CDATA[Wrigley N G]]></field>
  <field name="author"><![CDATA[Chillingworth R K]]></field>
  <field name="author"><![CDATA[Brown E]]></field>
  <field name="author"><![CDATA[Barrett A N]]></field>
  <field name="articleLang"><![CDATA[eng]]></field>
  <field name="publicationType"><![CDATA[Journal Article]]></field>
  <field name="articleDescriptor"><![CDATA[Animals]]></field>
  <field name="articleDescriptor"><![CDATA[Cells]]></field>
  <field name="articleQualifier"><![CDATA[ultrastructure]]></field>
  <field name="articleDescriptor"><![CDATA[Microscopy, Electron]]></field>
  <field name="articleQualifier"><![CDATA[instrumentation]]></field>
  <field name="articleQualifier"><![CDATA[methods]]></field>
 </doc>
 <doc>
  <field name="id"><![CDATA[6750131]]></field>
  <field name="articleCreationDate"><![CDATA[1982-12-02T00:00:00Z]]></field>
  <field name="articleYear"><![CDATA[1982]]></field>
  <field name="articleCompletionDate"><![CDATA[1982-12-02T00:00:00Z]]></field>
  <field name="articleRevisionDate"><![CDATA[2011-11-17T00:00:00Z]]></field>
  <field name="articlePubmodel"><![CDATA[Print]]></field>
  <field name="journalTitle"><![CDATA[Journal of microscopy]]></field>
  <field name="journalTitleAbrv"><![CDATA[J Microsc]]></field>
  <field name="articleTitle"><![CDATA[Freeze-substitution.]]></field>
  <field name="articleAbstract"><![CDATA[Freeze-substitution is a technique suitable for the preparation of unicellular and multi-cellular plant and animal specimens for conventional light microscopy, TEM and SEM. It is also widely used as a means of preparing animal and plant tissues for the localization of water soluble substances by analytical electron microscopy, autoradiography or visual detection of precipitates. The technical requirements of preparation, together with an evaluation of the procedures, are presented for various applications. Careful selection and evaluation of freezing technique, substitution solvent and regime are required for meaningful results.]]></field>
  <field name="author"><![CDATA[Harvey D M]]></field>
  <field name="articleLang"><![CDATA[eng]]></field>
  <field name="publicationType"><![CDATA[Comparative Study]]></field>
  <field name="publicationType"><![CDATA[Journal Article]]></field>
  <field name="publicationType"><![CDATA[Research Support, Non-U.S. Gov't]]></field>
  <field name="substanceName"><![CDATA[Indicators and Reagents]]></field>
  <field name="articleDescriptor"><![CDATA[Animals]]></field>
  <field name="articleDescriptor"><![CDATA[Autoradiography]]></field>
  <field name="articleQualifier"><![CDATA[methods]]></field>
  <field name="articleDescriptor"><![CDATA[Cells]]></field>
  <field name="articleQualifier"><![CDATA[cytology]]></field>
  <field name="articleQualifier"><![CDATA[ultrastructure]]></field>
  <field name="articleDescriptor"><![CDATA[Freezing]]></field>
  <field name="articleDescriptor"><![CDATA[Histological Techniques]]></field>
  <field name="articleDescriptor"><![CDATA[Indicators and Reagents]]></field>
  <field name="articleDescriptor"><![CDATA[Microscopy, Electron]]></field>
  <field name="articleQualifier"><![CDATA[methods]]></field>
  <field name="articleDescriptor"><![CDATA[Plant Cells]]></field>
  <field name="articleDescriptor"><![CDATA[Plants]]></field>
  <field name="articleQualifier"><![CDATA[ultrastructure]]></field>
 </doc>
 <doc>
  <field name="id"><![CDATA[7120370]]></field>
  <field name="articleCreationDate"><![CDATA[1982-12-02T00:00:00Z]]></field>
  <field name="articleYear"><![CDATA[1982]]></field>
  <field name="articleCompletionDate"><![CDATA[1982-12-02T00:00:00Z]]></field>
  <field name="articleRevisionDate"><![CDATA[2006-08-08T00:00:00Z]]></field>
  <field name="articlePubmodel"><![CDATA[Print]]></field>
  <field name="journalTitle"><![CDATA[Journal of microscopy]]></field>
  <field name="journalTitleAbrv"><![CDATA[J Microsc]]></field>
  <field name="articleTitle"><![CDATA[An improved specimen table for the Balzers freeze etching system BAF 400.]]></field>
  <field name="articleAbstract"><![CDATA[A time saving, simple and inexpensive adaptation of a Balzers specimen table is described. This specimen table is used in combination with the small specimen holders originally developed for the Denton Freeze-etching module. They are in particular suited for cell suspensions, and are easy to handle for freezing procedures. Ten replicas are produced routinely per freeze fracture run, with the aid of this combined system.]]></field>
  <field name="author"><![CDATA[Wisse D M]]></field>
  <field name="author"><![CDATA[Spies F]]></field>
  <field name="articleLang"><![CDATA[eng]]></field>
  <field name="publicationType"><![CDATA[Journal Article]]></field>
  <field name="substanceName"><![CDATA[Hemoglobins]]></field>
  <field name="articleDescriptor"><![CDATA[Blood Platelets]]></field>
  <field name="articleQualifier"><![CDATA[ultrastructure]]></field>
  <field name="articleDescriptor"><![CDATA[Cell Membrane]]></field>
  <field name="articleQualifier"><![CDATA[ultrastructure]]></field>
  <field name="articleDescriptor"><![CDATA[Erythrocyte Membrane]]></field>
  <field name="articleQualifier"><![CDATA[ultrastructure]]></field>
  <field name="articleDescriptor"><![CDATA[Erythrocytes]]></field>
  <field name="articleQualifier"><![CDATA[ultrastructure]]></field>
  <field name="articleDescriptor"><![CDATA[Freeze Etching]]></field>
  <field name="articleQualifier"><![CDATA[instrumentation]]></field>
  <field name="articleQualifier"><![CDATA[methods]]></field>
  <field name="articleDescriptor"><![CDATA[Hemoglobins]]></field>
  <field name="articleQualifier"><![CDATA[analysis]]></field>
  <field name="articleDescriptor"><![CDATA[Humans]]></field>
  <field name="articleDescriptor"><![CDATA[Microscopy, Electron]]></field>
  <field name="articleQualifier"><![CDATA[methods]]></field>
 </doc>
 <doc>
  <field name="id"><![CDATA[7120372]]></field>
  <field name="articleCreationDate"><![CDATA[1982-12-02T00:00:00Z]]></field>
  <field name="articleYear"><![CDATA[1982]]></field>
  <field name="articleCompletionDate"><![CDATA[1982-12-02T00:00:00Z]]></field>
  <field name="articleRevisionDate"><![CDATA[2007-11-14T00:00:00Z]]></field>
  <field name="articlePubmodel"><![CDATA[Print]]></field>
  <field name="journalTitle"><![CDATA[Journal of behavioral medicine]]></field>
  <field name="journalTitleAbrv"><![CDATA[J Behav Med]]></field>
  <field name="articleTitle"><![CDATA[Long-term follow-up of a pilot project on smoking prevention with adolescents.]]></field>
  <field name="articleAbstract"><![CDATA[Seventh graders (N = 353) in one junior high school received an experimental smoking prevention program aimed at teaching students to resist the social pressures to smoke cigarettes. Seventh graders (N = 217) in another school served as controls. Teams of high-school students trained in basic behavior change skills led seven classroom sessions of instruction in counter-arguing during the school year. Significant differences were found between groups in reported smoking at a 9-month posttest. Results were maintained at 21- and 33-month follow-ups.]]></field>
  <field name="author"><![CDATA[Telch M J]]></field>
  <field name="author"><![CDATA[Killen J D]]></field>
  <field name="author"><![CDATA[McAlister A L]]></field>
  <field name="author"><![CDATA[Perry C L]]></field>
  <field name="author"><![CDATA[Maccoby N]]></field>
  <field name="articleLang"><![CDATA[eng]]></field>
  <field name="publicationType"><![CDATA[Journal Article]]></field>
  <field name="publicationType"><![CDATA[Research Support, Non-U.S. Gov't]]></field>
  <field name="publicationType"><![CDATA[Research Support, U.S. Gov't, P.H.S.]]></field>
  <field name="articleDescriptor"><![CDATA[Adolescent]]></field>
  <field name="articleDescriptor"><![CDATA[Female]]></field>
  <field name="articleDescriptor"><![CDATA[Follow-Up Studies]]></field>
  <field name="articleDescriptor"><![CDATA[Humans]]></field>
  <field name="articleDescriptor"><![CDATA[Leadership]]></field>
  <field name="articleDescriptor"><![CDATA[Male]]></field>
  <field name="articleDescriptor"><![CDATA[Peer Group]]></field>
  <field name="articleDescriptor"><![CDATA[Pilot Projects]]></field>
  <field name="articleDescriptor"><![CDATA[Smoking]]></field>
  <field name="articleQualifier"><![CDATA[prevention & control]]></field>
  <field name="articleDescriptor"><![CDATA[Social Facilitation]]></field>
 </doc>
 <doc>
  <field name="id"><![CDATA[7120373]]></field>
  <field name="articleCreationDate"><![CDATA[1982-12-02T00:00:00Z]]></field>
  <field name="articleYear"><![CDATA[1982]]></field>
  <field name="articleCompletionDate"><![CDATA[1982-12-02T00:00:00Z]]></field>
  <field name="articleRevisionDate"><![CDATA[2009-11-19T00:00:00Z]]></field>
  <field name="articlePubmodel"><![CDATA[Print]]></field>
  <field name="journalTitle"><![CDATA[Journal of behavioral medicine]]></field>
  <field name="journalTitleAbrv"><![CDATA[J Behav Med]]></field>
  <field name="articleTitle"><![CDATA[A factorial comparison of schedule and bilateral locus of diastolic blood pressure-contingent feedback.]]></field>
  <field name="articleAbstract"><![CDATA[The purpose of this study was twofold: (a) to compare and determine the effects of a partial and a continuous schedule of feedback on the acquisition and subsequent extinction of bidirectional diastolic blood pressure changes in human subjects; and (b) to examine the result of the administration of response-contingent feedback at specific sites on the bilateral axis between left and right arms on diastolic blood pressure changes at those sites. Subjects were 36 normotensive volunteer college students, ages 18-40 years. A 3 X 3 design was used in which three schedules of feedback (0, 25, and 50%) were factorially compared with three sites of feedback (left arm, both arms, and right arm). The results indicated that varying schedules of feedback differentially affected the acquisition and extinction of diastolic blood pressure response changes. The data also suggested that diastolic blood pressure changes could be produced at specific sites on the bilateral axis, although not completely independent of changes at other sites. Extinction was observed to be rapid in most cases, although a number of subjects with partial feedback schedules showed a somewhat greater resistance to extinction.]]></field>
  <field name="author"><![CDATA[Gamble E H]]></field>
  <field name="author"><![CDATA[Elder S T]]></field>
  <field name="articleLang"><![CDATA[eng]]></field>
  <field name="publicationType"><![CDATA[Clinical Trial]]></field>
  <field name="publicationType"><![CDATA[Journal Article]]></field>
  <field name="publicationType"><![CDATA[Randomized Controlled Trial]]></field>
  <field name="publicationType"><![CDATA[Research Support, Non-U.S. Gov't]]></field>
  <field name="articleDescriptor"><![CDATA[Adult]]></field>
  <field name="articleDescriptor"><![CDATA[Biofeedback, Psychology]]></field>
  <field name="articleDescriptor"><![CDATA[Blood Pressure]]></field>
  <field name="articleDescriptor"><![CDATA[Extinction, Psychological]]></field>
  <field name="articleDescriptor"><![CDATA[Female]]></field>
  <field name="articleDescriptor"><![CDATA[Heart Rate]]></field>
  <field name="articleDescriptor"><![CDATA[Humans]]></field>
  <field name="articleDescriptor"><![CDATA[Male]]></field>
  <field name="articleDescriptor"><![CDATA[Respiration]]></field>
 </doc>
 <doc>
  <field name="id"><![CDATA[7120374]]></field>
  <field name="articleCreationDate"><![CDATA[1982-12-02T00:00:00Z]]></field>
  <field name="articleYear"><![CDATA[1982]]></field>
  <field name="articleCompletionDate"><![CDATA[1982-12-02T00:00:00Z]]></field>
  <field name="articleRevisionDate"><![CDATA[2004-11-17T00:00:00Z]]></field>
  <field name="articlePubmodel"><![CDATA[Print]]></field>
  <field name="journalTitle"><![CDATA[Journal of behavioral medicine]]></field>
  <field name="journalTitleAbrv"><![CDATA[J Behav Med]]></field>
  <field name="articleTitle"><![CDATA[A cognitive-behavioral model for the treatment of chronic vomiting.]]></field>
  <field name="articleAbstract"><![CDATA[The treatment approaches for chronic vomiting have primarily utilized behavior conditioning models and have largely focused on hospitalized infants, retarded patients, or trauma patients. A substantial number of patients who exhibit the symptoms of vomiting could be diagnosed as neurotic vomiters or "bulimics," and there is a dearth of information on the treatment of these patients. This paper presents a case study of a 26-year-old woman diagnosed as suffering from bulimia of 10 years' duration. The treatment program involved three basic components: self-monitoring, stimulus control, and cognitive restructuring. The treatment components were instituted sequentially. The treatment program was successful, and a 1-year follow-up found that the patient has maintained her progress and not vomited in over 5 months. The discussion focuses on the advantages of this treatment model in dealing with bulimia, which is conceptualized as a habit-type behavior disorder.]]></field>
  <field name="author"><![CDATA[Grinc G A]]></field>
  <field name="articleLang"><![CDATA[eng]]></field>
  <field name="publicationType"><![CDATA[Case Reports]]></field>
  <field name="publicationType"><![CDATA[Journal Article]]></field>
  <field name="articleDescriptor"><![CDATA[Adult]]></field>
  <field name="articleDescriptor"><![CDATA[Behavior Therapy]]></field>
  <field name="articleQualifier"><![CDATA[methods]]></field>
  <field name="articleDescriptor"><![CDATA[Chronic Disease]]></field>
  <field name="articleDescriptor"><![CDATA[Cognition]]></field>
  <field name="articleDescriptor"><![CDATA[Female]]></field>
  <field name="articleDescriptor"><![CDATA[Humans]]></field>
  <field name="articleDescriptor"><![CDATA[Hyperphagia]]></field>
  <field name="articleQualifier"><![CDATA[psychology]]></field>
  <field name="articleQualifier"><![CDATA[therapy]]></field>
  <field name="articleDescriptor"><![CDATA[Vomiting]]></field>
  <field name="articleQualifier"><![CDATA[psychology]]></field>
  <field name="articleQualifier"><![CDATA[therapy]]></field>
 </doc>
 <doc>
  <field name="id"><![CDATA[7120375]]></field>
  <field name="articleCreationDate"><![CDATA[1982-12-02T00:00:00Z]]></field>
  <field name="articleYear"><![CDATA[1982]]></field>
  <field name="articleCompletionDate"><![CDATA[1982-12-02T00:00:00Z]]></field>
  <field name="articleRevisionDate"><![CDATA[2004-11-17T00:00:00Z]]></field>
  <field name="articlePubmodel"><![CDATA[Print]]></field>
  <field name="journalTitle"><![CDATA[Journal of behavioral medicine]]></field>
  <field name="journalTitleAbrv"><![CDATA[J Behav Med]]></field>
  <field name="articleTitle"><![CDATA[Toward the automated measurement of the type-A behavior pattern.]]></field>
  <field name="articleAbstract"><![CDATA[Sixty-six structured interviews that were rated by Rosenman on a 5-point Type A/B behavior pattern scale, were scored by means of a semi-automated system for verbosity, voice volume and the temporal pacing of speech. A significant negative correlation obtained between interviewees' A/B ratings and their reaction-time scores; significant positive correlations obtained between their behavior type ratings and their voice volume and duration of vocalization scores. A regression equation consisting of reaction-time and voice volume scores correctly classified the A/B ratings of 89 percent of the interviewees. The significant correlations that were obtained between the interviewer's and the interviewees' speech patterns emphasize the need for standardizing the interviewer's style. Finally, the findings suggest that anxiety-arousal is a mediating variable in the relationship between Type-A behavior and coronary heart disease.]]></field>
  <field name="author"><![CDATA[Howland E W]]></field>
  <field name="author"><![CDATA[Siegman A W]]></field>
  <field name="articleLang"><![CDATA[eng]]></field>
  <field name="publicationType"><![CDATA[Journal Article]]></field>
  <field name="articleDescriptor"><![CDATA[Adult]]></field>
  <field name="articleDescriptor"><![CDATA[Aged]]></field>
  <field name="articleDescriptor"><![CDATA[Computers]]></field>
  <field name="articleDescriptor"><![CDATA[Coronary Disease]]></field>
  <field name="articleQualifier"><![CDATA[psychology]]></field>
  <field name="articleDescriptor"><![CDATA[Humans]]></field>
  <field name="articleDescriptor"><![CDATA[Interview, Psychological]]></field>
  <field name="articleDescriptor"><![CDATA[Male]]></field>
  <field name="articleDescriptor"><![CDATA[Middle Aged]]></field>
  <field name="articleDescriptor"><![CDATA[Personality]]></field>
  <field name="articleDescriptor"><![CDATA[Speech Production Measurement]]></field>
  <field name="articleQualifier"><![CDATA[instrumentation]]></field>
  <field name="articleDescriptor"><![CDATA[Tape Recording]]></field>
  <field name="articleDescriptor"><![CDATA[Verbal Behavior]]></field>
 </doc>
 <doc>
  <field name="id"><![CDATA[7120376]]></field>
  <field name="articleCreationDate"><![CDATA[1982-12-02T00:00:00Z]]></field>
  <field name="articleYear"><![CDATA[1982]]></field>
  <field name="articleCompletionDate"><![CDATA[1982-12-02T00:00:00Z]]></field>
  <field name="articleRevisionDate"><![CDATA[2007-11-14T00:00:00Z]]></field>
  <field name="articlePubmodel"><![CDATA[Print]]></field>
  <field name="journalTitle"><![CDATA[Journal of behavioral medicine]]></field>
  <field name="journalTitleAbrv"><![CDATA[J Behav Med]]></field>
  <field name="articleTitle"><![CDATA[Competitive two-persons interactions of type-A and type-B individuals.]]></field>
  <field name="articleAbstract"><![CDATA[Forty subjects classified as either coronary-prone (Type A) or coronary-resistant (Type B) interacted in a mixed-motive game in pairs by pressing buttons which transmitted messages through a television screen while an electrocardiogram and digital blood volume pulse were computer monitored. Subjects could cooperate, compete, punish, reward, or withdraw during each interaction and could send 1 of 55 messages communicating feelings, requests, and intentions between interactions. Paired Type A's interacted more competitively and aggressively than paired Type B's. There were no significant differences between Type A's and Type B's in heart rate or digital vasomotor response during the interpersonal game. The behavioral results but not the physiological results confirm findings from an earlier experiment.]]></field>
  <field name="author"><![CDATA[Van Egeren L F]]></field>
  <field name="author"><![CDATA[Sniderman L D]]></field>
  <field name="author"><![CDATA[Roggelin M S]]></field>
  <field name="articleLang"><![CDATA[eng]]></field>
  <field name="publicationType"><![CDATA[Journal Article]]></field>
  <field name="publicationType"><![CDATA[Research Support, U.S. Gov't, P.H.S.]]></field>
  <field name="articleDescriptor"><![CDATA[Arousal]]></field>
  <field name="articleDescriptor"><![CDATA[Communication]]></field>
  <field name="articleDescriptor"><![CDATA[Competitive Behavior]]></field>
  <field name="articleDescriptor"><![CDATA[Computers]]></field>
  <field name="articleDescriptor"><![CDATA[Cooperative Behavior]]></field>
  <field name="articleDescriptor"><![CDATA[Coronary Disease]]></field>
  <field name="articleQualifier"><![CDATA[psychology]]></field>
  <field name="articleDescriptor"><![CDATA[Female]]></field>
  <field name="articleDescriptor"><![CDATA[Humans]]></field>
  <field name="articleDescriptor"><![CDATA[Interpersonal Relations]]></field>
  <field name="articleDescriptor"><![CDATA[Male]]></field>
  <field name="articleDescriptor"><![CDATA[Personality]]></field>
 </doc>
 <doc>
  <field name="id"><![CDATA[7120377]]></field>
  <field name="articleCreationDate"><![CDATA[1982-12-02T00:00:00Z]]></field>
  <field name="articleYear"><![CDATA[1982]]></field>
  <field name="articleCompletionDate"><![CDATA[1982-12-02T00:00:00Z]]></field>
  <field name="articleRevisionDate"><![CDATA[2007-11-14T00:00:00Z]]></field>
  <field name="articlePubmodel"><![CDATA[Print]]></field>
  <field name="journalTitle"><![CDATA[Journal of behavioral medicine]]></field>
  <field name="journalTitleAbrv"><![CDATA[J Behav Med]]></field>
  <field name="articleTitle"><![CDATA[Coping with a stressful sigmoidoscopy: evaluation of cognitive and relaxation preparations.]]></field>
  <field name="articleAbstract"><![CDATA[Sigmoidoscopy involves the insertion of a small scope into the anal cavity to inspect for abnormalities in the colon. Although the procedure is not believed to be painful, it is often noxious for patients because it produces embarassment and discomfort. We examined the effectiveness of two brief interventions designed to enhance coping: self-instructional training and relaxation. In the self-instructional conditions patients were given brief training to focus their attention on either their own (internal) or the doctor's (external) ability to regulate the situation. A third (control) group received attention but did not experience self-instructional training. Half of each of these three groups also received relaxation training, while the other half did not. Planned comparisons demonstrated that subjects in the self-instructional strategies rated themselves as less anxious, had fewer body movements during the exam, and emitted fewer verbalization than those in an attention control group. Patients in the external condition estimated that the exam took less time but tended to have elevated heart rates during the procedure. Those experiencing relaxation training tended to overestimate the duration of the exam, but made fewer requests to stop the exam and rated themselves as less anxious than patients who did not receive relaxation training.]]></field>
  <field name="author"><![CDATA[Kaplan R M]]></field>
  <field name="author"><![CDATA[Atkins C J]]></field>
  <field name="author"><![CDATA[Lenhard L]]></field>
  <field name="articleLang"><![CDATA[eng]]></field>
  <field name="publicationType"><![CDATA[Clinical Trial]]></field>
  <field name="publicationType"><![CDATA[Journal Article]]></field>
  <field name="publicationType"><![CDATA[Randomized Controlled Trial]]></field>
  <field name="publicationType"><![CDATA[Research Support, U.S. Gov't, P.H.S.]]></field>
  <field name="articleDescriptor"><![CDATA[Adaptation, Psychological]]></field>
  <field name="articleDescriptor"><![CDATA[Anxiety]]></field>
  <field name="articleQualifier"><![CDATA[psychology]]></field>
  <field name="articleDescriptor"><![CDATA[Behavior Therapy]]></field>
  <field name="articleQualifier"><![CDATA[methods]]></field>
  <field name="articleDescriptor"><![CDATA[Cognition]]></field>
  <field name="articleDescriptor"><![CDATA[Female]]></field>
  <field name="articleDescriptor"><![CDATA[Humans]]></field>
  <field name="articleDescriptor"><![CDATA[Internal-External Control]]></field>
  <field name="articleDescriptor"><![CDATA[Male]]></field>
  <field name="articleDescriptor"><![CDATA[Motor Activity]]></field>
  <field name="articleDescriptor"><![CDATA[Muscle Contraction]]></field>
  <field name="articleDescriptor"><![CDATA[Muscle Relaxation]]></field>
  <field name="articleDescriptor"><![CDATA[Set (Psychology)]]></field>
  <field name="articleDescriptor"><![CDATA[Sigmoidoscopy]]></field>
  <field name="articleQualifier"><![CDATA[psychology]]></field>
  <field name="articleDescriptor"><![CDATA[Stress, Psychological]]></field>
  <field name="articleQualifier"><![CDATA[psychology]]></field>
  <field name="articleDescriptor"><![CDATA[Verbal Behavior]]></field>
 </doc>
 <doc>
  <field name="id"><![CDATA[7120378]]></field>
  <field name="articleCreationDate"><![CDATA[1982-12-02T00:00:00Z]]></field>
  <field name="articleYear"><![CDATA[1982]]></field>
  <field name="articleCompletionDate"><![CDATA[1982-12-02T00:00:00Z]]></field>
  <field name="articleRevisionDate"><![CDATA[2006-11-15T00:00:00Z]]></field>
  <field name="articlePubmodel"><![CDATA[Print]]></field>
  <field name="journalTitle"><![CDATA[Journal of behavioral medicine]]></field>
  <field name="journalTitleAbrv"><![CDATA[J Behav Med]]></field>
  <field name="articleTitle"><![CDATA[Coronary-prone behavior in the Netherlands: a cross-cultural validation study.]]></field>
  <field name="articleAbstract"><![CDATA[As part of the Kaunas-Rotterdam Intervention Study (KRIS), the Jenkins Activity Survey (JAS), designed to measure the coronary-prone behavior pattern type A, was administered to 2712 males who participated in a health intervention program. A JAS score was computed by a maximum-likelihood method for item analysis and test scoring using the structured interview as the criterion. The Dutch adaptation classified 73% of the subjects correctly. Those who were treated at the moment of screening for one or more cardiovascular risk factors and those who suffered from angina pectoris had higher mean JAS scores that those without concurrent cardiovascular complaints. Those results provide some evidence that the type A coronary-prone behavior pattern, as measured by the JAS, is linked to coronary heart disease outside the United States.]]></field>
  <field name="author"><![CDATA[Appels A]]></field>
  <field name="author"><![CDATA[Jenkins C D]]></field>
  <field name="author"><![CDATA[Rosenman R H]]></field>
  <field name="articleLang"><![CDATA[eng]]></field>
  <field name="publicationType"><![CDATA[Comparative Study]]></field>
  <field name="publicationType"><![CDATA[Journal Article]]></field>
  <field name="articleDescriptor"><![CDATA[Angina Pectoris]]></field>
  <field name="articleQualifier"><![CDATA[psychology]]></field>
  <field name="articleDescriptor"><![CDATA[Coronary Disease]]></field>
  <field name="articleQualifier"><![CDATA[psychology]]></field>
  <field name="articleDescriptor"><![CDATA[Cross-Cultural Comparison]]></field>
  <field name="articleDescriptor"><![CDATA[Humans]]></field>
  <field name="articleDescriptor"><![CDATA[Male]]></field>
  <field name="articleDescriptor"><![CDATA[Middle Aged]]></field>
  <field name="articleDescriptor"><![CDATA[Myocardial Infarction]]></field>
  <field name="articleQualifier"><![CDATA[psychology]]></field>
  <field name="articleDescriptor"><![CDATA[Netherlands]]></field>
  <field name="articleDescriptor"><![CDATA[Personality]]></field>
  <field name="articleDescriptor"><![CDATA[Personality Tests]]></field>
  <field name="articleDescriptor"><![CDATA[Prospective Studies]]></field>
 </doc>
 <doc>
  <field name="id"><![CDATA[7120379]]></field>
  <field name="articleCreationDate"><![CDATA[1982-12-02T00:00:00Z]]></field>
  <field name="articleYear"><![CDATA[1982]]></field>
  <field name="articleCompletionDate"><![CDATA[1982-12-02T00:00:00Z]]></field>
  <field name="articleRevisionDate"><![CDATA[2004-11-17T00:00:00Z]]></field>
  <field name="articlePubmodel"><![CDATA[Print]]></field>
  <field name="journalTitle"><![CDATA[Journal of behavioral medicine]]></field>
  <field name="journalTitleAbrv"><![CDATA[J Behav Med]]></field>
  <field name="articleTitle"><![CDATA[Metrological study of psychological questionnaires with reference to social variables: the Belgian Heart Disease Prevention Project (BHDPP).]]></field>
  <field name="articleAbstract"><![CDATA[In the framework of a controlled trial on the multifactorial prevention of coronary heart disease, two measures of type A behavior--determined by the Bortner scale and the Jenkins Activity Survey (JAS)--and one personality questionnaire--the Sandler Hazary Questionnaire and Eysenck Personality Inventory (SHEPI)--were used. Their interrelations and relations with social variables are analyzed. It appears that the Bortner scale and the JAS do not measure the overall syndrome of the coronary-prone behavior pattern (CPBP), but similar and different specific aspects of it. There exists a direct relation of the Bortner score, JAS-AB, JAS'-S, and JAS-J with the study level and the socioprofessional class. Neuroticism or emotional hyperreactivity determined by the SHEPI is highly correlated with these scores. No or small relations of social variables with personality traits are found.]]></field>
  <field name="author"><![CDATA[Kittel F]]></field>
  <field name="author"><![CDATA[Kornitzer M]]></field>
  <field name="author"><![CDATA[De Backer G]]></field>
  <field name="author"><![CDATA[Dramaix M]]></field>
  <field name="articleLang"><![CDATA[eng]]></field>
  <field name="publicationType"><![CDATA[Clinical Trial]]></field>
  <field name="publicationType"><![CDATA[Journal Article]]></field>
  <field name="publicationType"><![CDATA[Randomized Controlled Trial]]></field>
  <field name="articleDescriptor"><![CDATA[Adult]]></field>
  <field name="articleDescriptor"><![CDATA[Belgium]]></field>
  <field name="articleDescriptor"><![CDATA[Coronary Disease]]></field>
  <field name="articleQualifier"><![CDATA[prevention & control]]></field>
  <field name="articleQualifier"><![CDATA[psychology]]></field>
  <field name="articleDescriptor"><![CDATA[Female]]></field>
  <field name="articleDescriptor"><![CDATA[Humans]]></field>
  <field name="articleDescriptor"><![CDATA[International Cooperation]]></field>
  <field name="articleDescriptor"><![CDATA[Male]]></field>
  <field name="articleDescriptor"><![CDATA[Middle Aged]]></field>
  <field name="articleDescriptor"><![CDATA[Personality]]></field>
  <field name="articleDescriptor"><![CDATA[Psychological Tests]]></field>
  <field name="articleDescriptor"><![CDATA[Socioeconomic Factors]]></field>
 </doc>
 <doc>
  <field name="id"><![CDATA[7120380]]></field>
  <field name="articleCreationDate"><![CDATA[1982-12-02T00:00:00Z]]></field>
  <field name="articleYear"><![CDATA[1982]]></field>
  <field name="articleCompletionDate"><![CDATA[1982-12-02T00:00:00Z]]></field>
  <field name="articleRevisionDate"><![CDATA[2008-11-21T00:00:00Z]]></field>
  <field name="articlePubmodel"><![CDATA[Print]]></field>
  <field name="journalTitle"><![CDATA[Journal of behavioral medicine]]></field>
  <field name="journalTitleAbrv"><![CDATA[J Behav Med]]></field>
  <field name="articleTitle"><![CDATA[Behavioral treatment of hyperlipidemia: techniques, results, and future directions.]]></field>
  <field name="articleAbstract"><![CDATA[The present review examines the role of several target behaviors in the treatment of hyperlipidemia, including diet, exercise, cigarette smoking, Type A pattern, and medication adherence. Modification of the typical American diet (high in cholesterol, fat, and sodium) is emphasized in the treatment of hyperlipidemia since a multitude of laboratory, clinical, and epidemiological studies have shown that diet plays a crucial role in the pathogenesis of this condition and an increase in coronary risk. Factors affecting patient compliance such as health beliefs and family support are discussed in terms of their impact on behavior change efforts aimed at reducing plasma lipids through dietary and drug regimens. Intervention studies are reviewed in the behavioral treatment of hyperlipidemia. These programs have focused on diet modification, exercise, and medication adherence to reduce plasma lipids and coronary risk. The role of other target behaviors (i.e., Type A pattern and smoking) is explored not only in determining coronary risk but also in terms of their direct impact on plasma lipids. Further research is necessary to clarify the relationship between these target behaviors and plasma lipid levels and to investigate the effects of innovative family- and group-based intervention procedures in promoting and maintaining habit change related to coronary risk reduction.]]></field>
  <field name="author"><![CDATA[Carmody T P]]></field>
  <field name="author"><![CDATA[Fey S G]]></field>
  <field name="author"><![CDATA[Pierce D K]]></field>
  <field name="author"><![CDATA[Connor W E]]></field>
  <field name="author"><![CDATA[Matarazzo J D]]></field>
  <field name="articleLang"><![CDATA[eng]]></field>
  <field name="publicationType"><![CDATA[Journal Article]]></field>
  <field name="publicationType"><![CDATA[Research Support, U.S. Gov't, P.H.S.]]></field>
  <field name="substanceName"><![CDATA[Dietary Fats]]></field>
  <field name="substanceName"><![CDATA[Triglycerides]]></field>
  <field name="substanceName"><![CDATA[Cholesterol]]></field>
  <field name="articleDescriptor"><![CDATA[Behavior Therapy]]></field>
  <field name="articleQualifier"><![CDATA[methods]]></field>
  <field name="articleDescriptor"><![CDATA[Cholesterol]]></field>
  <field name="articleQualifier"><![CDATA[blood]]></field>
  <field name="articleDescriptor"><![CDATA[Coronary Disease]]></field>
  <field name="articleQualifier"><![CDATA[prevention & control]]></field>
  <field name="articleQualifier"><![CDATA[psychology]]></field>
  <field name="articleDescriptor"><![CDATA[Diet, Reducing]]></field>
  <field name="articleQualifier"><![CDATA[psychology]]></field>
  <field name="articleDescriptor"><![CDATA[Dietary Fats]]></field>
  <field name="articleQualifier"><![CDATA[administration & dosage]]></field>
  <field name="articleDescriptor"><![CDATA[Forecasting]]></field>
  <field name="articleDescriptor"><![CDATA[Humans]]></field>
  <field name="articleDescriptor"><![CDATA[Hyperlipidemias]]></field>
  <field name="articleQualifier"><![CDATA[psychology]]></field>
  <field name="articleQualifier"><![CDATA[therapy]]></field>
  <field name="articleDescriptor"><![CDATA[Male]]></field>
  <field name="articleDescriptor"><![CDATA[Middle Aged]]></field>
  <field name="articleDescriptor"><![CDATA[Personality]]></field>
  <field name="articleDescriptor"><![CDATA[Physical Exertion]]></field>
  <field name="articleDescriptor"><![CDATA[Risk]]></field>
  <field name="articleDescriptor"><![CDATA[Smoking]]></field>
  <field name="articleQualifier"><![CDATA[prevention & control]]></field>
  <field name="articleDescriptor"><![CDATA[Triglycerides]]></field>
  <field name="articleQualifier"><![CDATA[blood]]></field>
 </doc>
 <doc>
  <field name="id"><![CDATA[6181265]]></field>
  <field name="articleCreationDate"><![CDATA[1982-12-02T00:00:00Z]]></field>
  <field name="articleYear"><![CDATA[1982]]></field>
  <field name="articleCompletionDate"><![CDATA[1982-12-02T00:00:00Z]]></field>
  <field name="articleRevisionDate"><![CDATA[2011-12-06T00:00:00Z]]></field>
  <field name="articlePubmodel"><![CDATA[Print]]></field>
  <field name="journalTitle"><![CDATA[Journal of morphology]]></field>
  <field name="journalTitleAbrv"><![CDATA[J. Morphol.]]></field>
  <field name="articleTitle"><![CDATA[Histology and histochemistry of the parotid and the principal and accessory submandibular glands of the little brown bat.]]></field>
  <field name="articleAbstract"><![CDATA[The parotid and the principal and accessory submandibular glands of the little brown bat. Myotis lucifugus (Vespertilionidae), were examined using light microscopy and staining methods for mucosubstances. The parotid gland is a compound tubuloacinar seromucous gland. Parotid gland secretory cells contain both neutral and nonsulfated acidic mucosubstances. The principal and accessory submandibular glands are compound tubuloacinar mucus-secreting glands. They contain somewhat atypical mucus-secreting demilunar cells that often appear to be interspersed between mucous tubule cells. The mucous tubule cells in both the principal and accessory submandibular glands contain sulfonmucins. Demilunar cells of the principal submandibular gland contain moderate amounts of nonsulfated acidic mucosubstances, but the corresponding cells of the accessory submandibular gland contain considerable neutral mucosubstance with very little acid mucosubstance. Intercalated ducts composed of cuboidal or low columnar epithelial cells are present in all three glands. Striated ducts in all glands are composed of columnar cells whose apices bulge into the ductal lumina. Excretory ducts are composed of simple columnar epithelium, with occasional basal cells that suggest a possible pseudostratified nature. The cells of the excretory ducts also have bulging apices. All duct types contain apical cytoplasmic secretory material that is a periodic acid-Schiff positive, neutral mucosubstance. Ductal apical secretory material is more evident in intercalated and striated ducts than in excretory ducts.]]></field>
  <field name="author"><![CDATA[Pinkstaff C A]]></field>
  <field name="author"><![CDATA[Tandler B]]></field>
  <field name="author"><![CDATA[Cohan R P]]></field>
  <field name="articleLang"><![CDATA[eng]]></field>
  <field name="publicationType"><![CDATA[Journal Article]]></field>
  <field name="publicationType"><![CDATA[Research Support, Non-U.S. Gov't]]></field>
  <field name="publicationType"><![CDATA[Research Support, U.S. Gov't, P.H.S.]]></field>
  <field name="substanceName"><![CDATA[Carbohydrates]]></field>
  <field name="articleDescriptor"><![CDATA[Animals]]></field>
  <field name="articleDescriptor"><![CDATA[Carbohydrates]]></field>
  <field name="articleQualifier"><![CDATA[physiology]]></field>
  <field name="articleDescriptor"><![CDATA[Chiroptera]]></field>
  <field name="articleQualifier"><![CDATA[anatomy & histology]]></field>
  <field name="articleDescriptor"><![CDATA[Female]]></field>
  <field name="articleDescriptor"><![CDATA[Histocytochemistry]]></field>
  <field name="articleDescriptor"><![CDATA[Male]]></field>
  <field name="articleDescriptor"><![CDATA[Parotid Gland]]></field>
  <field name="articleQualifier"><![CDATA[anatomy & histology]]></field>
  <field name="articleQualifier"><![CDATA[cytology]]></field>
  <field name="articleQualifier"><![CDATA[physiology]]></field>
  <field name="articleDescriptor"><![CDATA[Salivary Glands]]></field>
  <field name="articleQualifier"><![CDATA[anatomy & histology]]></field>
  <field name="articleDescriptor"><![CDATA[Staining and Labeling]]></field>
  <field name="articleDescriptor"><![CDATA[Submandibular Gland]]></field>
  <field name="articleQualifier"><![CDATA[anatomy & histology]]></field>
  <field name="articleQualifier"><![CDATA[cytology]]></field>
  <field name="articleQualifier"><![CDATA[physiology]]></field>
 </doc>
 <doc>
  <field name="id"><![CDATA[6811761]]></field>
  <field name="articleCreationDate"><![CDATA[1982-12-02T00:00:00Z]]></field>
  <field name="articleYear"><![CDATA[1982]]></field>
  <field name="articleCompletionDate"><![CDATA[1982-12-02T00:00:00Z]]></field>
  <field name="articleRevisionDate"><![CDATA[2007-11-14T00:00:00Z]]></field>
  <field name="articlePubmodel"><![CDATA[Print]]></field>
  <field name="journalTitle"><![CDATA[Journal of morphology]]></field>
  <field name="journalTitleAbrv"><![CDATA[J. Morphol.]]></field>
  <field name="articleTitle"><![CDATA[Abnormal differentiation of selected nuclear centers in the brain of a duck embryo associated with partial duplication of the primitive streak.]]></field>
  <field name="articleAbstract"><![CDATA[In a control set of duck embryos, an abnormal duck embryo of 16 days incubation was found which had two beaks as the only outward sign of duplication. The beaks were of equal size, each with upper and lower bills. Bill-clapping movements were absent. The embryo had two normal eyes placed one on either side of the head, and the rest of the body was normal in external appearance. Sections through the head revealed further duplication of the fore-, mid-, and hindbrain divisions. The medial half of each of the embryonic brain divisions, however, was greatly reduced. Two additional optic primordia were also noticed in sections, each of which was reduced to a mass of tissue representing a lens and a much-folded pigment epithelium. The orbital tissues associated with the rudimentary eyes were greatly disorganized. Abnormal differentiation associated with duplication of the brain divisions was determined by cell counts in selected nuclear centers. Cell numbers in each case appeared to be remarkably proportional to the size of the innervation field. Our data, based on cell counts in the nuclear centers chosen for this study in the abnormal embryo and normal control embryos of the same age, are consistent with the hypothesis that cell survival in related parts of the nervous system may be regulated by their peripheral field of innervation.]]></field>
  <field name="author"><![CDATA[Narayanan C H]]></field>
  <field name="author"><![CDATA[Narayanan Y]]></field>
  <field name="articleLang"><![CDATA[eng]]></field>
  <field name="publicationType"><![CDATA[Journal Article]]></field>
  <field name="publicationType"><![CDATA[Research Support, U.S. Gov't, P.H.S.]]></field>
  <field name="articleDescriptor"><![CDATA[Animals]]></field>
  <field name="articleDescriptor"><![CDATA[Brain]]></field>
  <field name="articleQualifier"><![CDATA[abnormalities]]></field>
  <field name="articleDescriptor"><![CDATA[Cell Count]]></field>
  <field name="articleDescriptor"><![CDATA[Ducks]]></field>
  <field name="articleQualifier"><![CDATA[embryology]]></field>
  <field name="articleDescriptor"><![CDATA[Eye Abnormalities]]></field>
  <field name="articleDescriptor"><![CDATA[Ganglia, Parasympathetic]]></field>
  <field name="articleQualifier"><![CDATA[abnormalities]]></field>
  <field name="articleQualifier"><![CDATA[cytology]]></field>
  <field name="articleDescriptor"><![CDATA[Oculomotor Nerve]]></field>
  <field name="articleQualifier"><![CDATA[abnormalities]]></field>
  <field name="articleQualifier"><![CDATA[cytology]]></field>
  <field name="articleDescriptor"><![CDATA[Telencephalon]]></field>
  <field name="articleQualifier"><![CDATA[embryology]]></field>
  <field name="articleDescriptor"><![CDATA[Trochlear Nerve]]></field>
  <field name="articleQualifier"><![CDATA[abnormalities]]></field>
  <field name="articleQualifier"><![CDATA[cytology]]></field>
 </doc>
 <doc>
  <field name="id"><![CDATA[7120419]]></field>
  <field name="articleCreationDate"><![CDATA[1982-12-02T00:00:00Z]]></field>
  <field name="articleYear"><![CDATA[1982]]></field>
  <field name="articleCompletionDate"><![CDATA[1982-12-02T00:00:00Z]]></field>
  <field name="articleRevisionDate"><![CDATA[2003-11-14T00:00:00Z]]></field>
  <field name="articlePubmodel"><![CDATA[Print]]></field>
  <field name="journalTitle"><![CDATA[Journal of morphology]]></field>
  <field name="journalTitleAbrv"><![CDATA[J. Morphol.]]></field>
  <field name="articleTitle"><![CDATA[Limb regenerative capacity of four species of Japanese frogs of the families Hylidae and Ranidae.]]></field>
  <field name="articleAbstract"><![CDATA[The regenerative capacity of limbs was investigated by amputation of limbs at the zeugopodium in postmetamorphic froglets and adults of various sizes in four species of Japanese frogs, all of which showed some regeneration at these ages. In Hyla arborea japonica and Rana brevipoda porosa most young froglets regenerated their limbs well; however, the rate of regeneration decreased with the age of amputation, and the limb became nonregenerative in adults. Limbs of adults in Rana rugosa and R. japonica, on the other hand, exhibited good regeneration. All of the regenerates in the four species were heteromorphic, consisting histologically of well-developed cartilaginous rods surrounded by connective tissue and skin. Limited development of muscle was apparent in regenerates of the three ranid species. The relations between body size, innervation of limbs, and regenerative capacity are discussed.]]></field>
  <field name="author"><![CDATA[Kurabuchi S]]></field>
  <field name="author"><![CDATA[Inoue S]]></field>
  <field name="articleLang"><![CDATA[eng]]></field>
  <field name="publicationType"><![CDATA[Journal Article]]></field>
  <field name="articleDescriptor"><![CDATA[Animals]]></field>
  <field name="articleDescriptor"><![CDATA[Anura]]></field>
  <field name="articleQualifier"><![CDATA[physiology]]></field>
  <field name="articleDescriptor"><![CDATA[Extremities]]></field>
  <field name="articleQualifier"><![CDATA[physiology]]></field>
  <field name="articleDescriptor"><![CDATA[Ranidae]]></field>
  <field name="articleQualifier"><![CDATA[physiology]]></field>
  <field name="articleDescriptor"><![CDATA[Regeneration]]></field>
 </doc>
 <doc>
  <field name="id"><![CDATA[7120420]]></field>
  <field name="articleCreationDate"><![CDATA[1982-12-02T00:00:00Z]]></field>
  <field name="articleYear"><![CDATA[1982]]></field>
  <field name="articleCompletionDate"><![CDATA[1982-12-02T00:00:00Z]]></field>
  <field name="articleRevisionDate"><![CDATA[2006-11-15T00:00:00Z]]></field>
  <field name="articlePubmodel"><![CDATA[Print]]></field>
  <field name="journalTitle"><![CDATA[Journal of morphology]]></field>
  <field name="journalTitleAbrv"><![CDATA[J. Morphol.]]></field>
  <field name="articleTitle"><![CDATA[Abnormal development of vertebrae in paralyzed chick embryos.]]></field>
  <field name="articleAbstract"><![CDATA[Ventral bars, cartilaginous projections from the ventral aspect of the synsacrum that contact and form a joint with the ilium, were found in all normal chick embryos of age E9 and older. Bars were absent in a number of embryos which had been paralyzed from age E4 by the use of the acetylcholine receptor blocker alpha-bungarotoxin. They were also absent in some embryos that had been paralyzed between ages E4 and E10 but allowed to move thereafter. The bars, already formed, remained present in a third group of embryos in which paralysis was initiated age E10. Apparently, normal embryonic movements induce the formation of bars. In support of this conclusion is the observation that two of three embryos which had had their hindlimb buds amputated at age E3 lacked bars. In these embryos with amputations, the ilium was present at least in part, but the forces exerted on the region where the bars develop would have been greatly reduced because of the lack of hind limb musculature. It is concluded that the bars, which form part of the iliosynsacral joint, are induced epigenetically by normal embryonic movements.]]></field>
  <field name="author"><![CDATA[Laing N G]]></field>
  <field name="articleLang"><![CDATA[eng]]></field>
  <field name="publicationType"><![CDATA[Journal Article]]></field>
  <field name="publicationType"><![CDATA[Research Support, Non-U.S. Gov't]]></field>
  <field name="substanceName"><![CDATA[Bungarotoxins]]></field>
  <field name="articleDescriptor"><![CDATA[Animals]]></field>
  <field name="articleDescriptor"><![CDATA[Bungarotoxins]]></field>
  <field name="articleDescriptor"><![CDATA[Chick Embryo]]></field>
  <field name="articleDescriptor"><![CDATA[Lumbar Vertebrae]]></field>
  <field name="articleQualifier"><![CDATA[embryology]]></field>
  <field name="articleQualifier"><![CDATA[pathology]]></field>
  <field name="articleDescriptor"><![CDATA[Paralysis]]></field>
  <field name="articleQualifier"><![CDATA[chemically induced]]></field>
  <field name="articleQualifier"><![CDATA[embryology]]></field>
  <field name="articleQualifier"><![CDATA[pathology]]></field>
  <field name="articleDescriptor"><![CDATA[Thoracic Vertebrae]]></field>
  <field name="articleQualifier"><![CDATA[embryology]]></field>
  <field name="articleQualifier"><![CDATA[pathology]]></field>
 </doc>
 <doc>
  <field name="id"><![CDATA[7120421]]></field>
  <field name="articleCreationDate"><![CDATA[1982-12-02T00:00:00Z]]></field>
  <field name="articleYear"><![CDATA[1982]]></field>
  <field name="articleCompletionDate"><![CDATA[1982-12-02T00:00:00Z]]></field>
  <field name="articleRevisionDate"><![CDATA[2006-11-15T00:00:00Z]]></field>
  <field name="articlePubmodel"><![CDATA[Print]]></field>
  <field name="journalTitle"><![CDATA[Journal of morphology]]></field>
  <field name="journalTitleAbrv"><![CDATA[J. Morphol.]]></field>
  <field name="articleTitle"><![CDATA[Architecture of the hind limb muscles of cats: functional significance.]]></field>
  <field name="articleAbstract"><![CDATA[Force, velocity, and displacement properties of a muscle are determined in large part by its architectural design. The relative effect of muscle architecture on these physiological variables was studied by determining muscle weight, fiber length, average sarcomere length, and approximate angle of pinnation of 24 cat hind limb muscles. Muscle lengths ranged from 28.3 to 144 mm, whereas fiber lengths ranged from 8.4 to 105.5 mm. Generally, fiber to muscle length ratios were similar throughout a muscle. Estimated angles of pinnation of muscle fibers varied from 0 to 21 degrees with most having an angle of less than 10 degrees. The cross-sectional area of the knee extensors was similar to the knee flexors (16.43 vs. 16.83 cm2) whereas the cross-sectional area of the ankle extensors was more than six times greater than the ankle flexors (18.59 vs. 2.83 cm2). There was a 6.7-fold difference in the maximal force between muscles, when normalized to a constant weight, that could be attributed to architectural features. Ratios of wet weight to predicted maximal tetanic tension for each muscle and muscle group were calculated to compare the relative priority of muscle force versus muscle length-velocity for a given mass of muscle. These ratios varied from 0.4 to 4.84. The ratios suggest that velocity and/or displacement is a priority for the hamstrings, whereas force is a priority for the quadriceps and lower leg muscles. As much as a 12.6-fold difference in maximal velocity between muscles can be attributed to differences in fiber lengths. This can be compared to approximately a 2.5-fold difference in maximal velocity reported to occur as a result of biochemical (intrinsic) differences.]]></field>
  <field name="author"><![CDATA[Sacks R D]]></field>
  <field name="author"><![CDATA[Roy R R]]></field>
  <field name="articleLang"><![CDATA[eng]]></field>
  <field name="publicationType"><![CDATA[Journal Article]]></field>
  <field name="publicationType"><![CDATA[Research Support, U.S. Gov't, P.H.S.]]></field>
  <field name="articleDescriptor"><![CDATA[Animals]]></field>
  <field name="articleDescriptor"><![CDATA[Cats]]></field>
  <field name="articleQualifier"><![CDATA[anatomy & histology]]></field>
  <field name="articleDescriptor"><![CDATA[Hindlimb]]></field>
  <field name="articleQualifier"><![CDATA[anatomy & histology]]></field>
  <field name="articleQualifier"><![CDATA[physiology]]></field>
  <field name="articleDescriptor"><![CDATA[Muscles]]></field>
  <field name="articleQualifier"><![CDATA[anatomy & histology]]></field>
 </doc>
 <doc>
  <field name="id"><![CDATA[7120422]]></field>
  <field name="articleCreationDate"><![CDATA[1982-12-02T00:00:00Z]]></field>
  <field name="articleYear"><![CDATA[1982]]></field>
  <field name="articleCompletionDate"><![CDATA[1982-12-02T00:00:00Z]]></field>
  <field name="articleRevisionDate"><![CDATA[2008-11-21T00:00:00Z]]></field>
  <field name="articlePubmodel"><![CDATA[Print]]></field>
  <field name="journalTitle"><![CDATA[Journal of morphology]]></field>
  <field name="journalTitleAbrv"><![CDATA[J. Morphol.]]></field>
  <field name="articleTitle"><![CDATA[The photoreceptors of the West Indian manatee.]]></field>
  <field name="articleAbstract"><![CDATA[Using light and electron microscopy we found that the manatee retina has both rodlike and conelike photoreceptors in accord with its diurnal behavior pattern. Outer segment disks in both cell types appear to be enclosed along most of their length within the plasma membrane. The synaptic terminals are simple, with small, superficial postsynaptic contacts. The cones have long inner segments, short, conical outer segments and terminals with numerous synaptic ribons and deeply embedded postsynaptic elements. There are two cone subclasses that may subserve color vision. Morphometry shows that there are more ganglion cells of small size ventrally, and that the thickness of the nerve fiber layer there is reduced, suggesting the presence of a specialized visual area in the retina. However, there were no pronounced differences in cone cell density in any of the regions examined.]]></field>
  <field name="author"><![CDATA[Cohen J L]]></field>
  <field name="author"><![CDATA[Tucker G S]]></field>
  <field name="author"><![CDATA[Odell D K]]></field>
  <field name="articleLang"><![CDATA[eng]]></field>
  <field name="publicationType"><![CDATA[Journal Article]]></field>
  <field name="articleDescriptor"><![CDATA[Animals]]></field>
  <field name="articleDescriptor"><![CDATA[Mammals]]></field>
  <field name="articleDescriptor"><![CDATA[Photoreceptor Cells]]></field>
  <field name="articleQualifier"><![CDATA[cytology]]></field>
  <field name="articleQualifier"><![CDATA[ultrastructure]]></field>
 </doc>
 <doc>
  <field name="id"><![CDATA[7120436]]></field>
  <field name="articleCreationDate"><![CDATA[1982-12-02T00:00:00Z]]></field>
  <field name="articleYear"><![CDATA[1982]]></field>
  <field name="articleCompletionDate"><![CDATA[1982-12-02T00:00:00Z]]></field>
  <field name="articleRevisionDate"><![CDATA[2004-11-17T00:00:00Z]]></field>
  <field name="articlePubmodel"><![CDATA[Print]]></field>
  <field name="journalTitle"><![CDATA[Journal of sex & marital therapy]]></field>
  <field name="journalTitleAbrv"><![CDATA[J Sex Marital Ther]]></field>
  <field name="articleTitle"><![CDATA[Short- and long-term effects of a marital enrichment program upon couple functioning.]]></field>
  <field name="articleAbstract"><![CDATA[Short- and long-term effects of a new marital enrichment program (MEP), based upon Sager's contractual model of couple functioning, were evaluated using both self-inventories (DAS, MCI) and behavioral scales (MICS). Couples were randomly assigned to either no-treatment control conditions or the 20-hour long MEP. Evaluations of marital functioning of both groups were repeatedly done during the experimentation, at pretest, midtest, posttest and follow-up 1 (two months after completion of the program). A second follow-up on the experimental couples was done a year after the end of MEP. Significant results were obtained for five of the seven criterion variables (marital adjustment and communication and certain aspects of problem-solving behavior). Positive gains shown by the experimental couples in the subjective measures were maintained for an entire year following MEP. It was concluded that the program succeeded in meeting both its short- and long-term goals, thus representing a most promising preventative strategy to modern couple living.]]></field>
  <field name="author"><![CDATA[Adam D]]></field>
  <field name="author"><![CDATA[Gingras M]]></field>
  <field name="articleLang"><![CDATA[eng]]></field>
  <field name="publicationType"><![CDATA[Clinical Trial]]></field>
  <field name="publicationType"><![CDATA[Journal Article]]></field>
  <field name="publicationType"><![CDATA[Randomized Controlled Trial]]></field>
  <field name="articleDescriptor"><![CDATA[Adult]]></field>
  <field name="articleDescriptor"><![CDATA[Behavior]]></field>
  <field name="articleDescriptor"><![CDATA[Communication]]></field>
  <field name="articleDescriptor"><![CDATA[Female]]></field>
  <field name="articleDescriptor"><![CDATA[Follow-Up Studies]]></field>
  <field name="articleDescriptor"><![CDATA[Humans]]></field>
  <field name="articleDescriptor"><![CDATA[Male]]></field>
  <field name="articleDescriptor"><![CDATA[Marital Therapy]]></field>
  <field name="articleQualifier"><![CDATA[methods]]></field>
  <field name="articleDescriptor"><![CDATA[Marriage]]></field>
  <field name="articleDescriptor"><![CDATA[Problem Solving]]></field>
  <field name="articleDescriptor"><![CDATA[Time Factors]]></field>
 </doc>
 <doc>
  <field name="id"><![CDATA[7120439]]></field>
  <field name="articleCreationDate"><![CDATA[1982-12-02T00:00:00Z]]></field>
  <field name="articleYear"><![CDATA[1982]]></field>
  <field name="articleCompletionDate"><![CDATA[1982-12-02T00:00:00Z]]></field>
  <field name="articleRevisionDate"><![CDATA[2010-10-26T00:00:00Z]]></field>
  <field name="articlePubmodel"><![CDATA[Print]]></field>
  <field name="journalTitle"><![CDATA[Journal of the National Medical Association]]></field>
  <field name="journalTitleAbrv"><![CDATA[J Natl Med Assoc]]></field>
  <field name="articleTitle"><![CDATA[Trichostasis spinulosa.]]></field>
  <field name="articleAbstract"><![CDATA[Usually occurring on the mid-face, especially on the nose, trichostasis spinulosa occurs more commonly in young, adult black women. The lesions of trichostasis spinulosa resemble open comedones (blackheads). It may be treated with tweezing, dipilatory wax, and topical retinoic acid.]]></field>
  <field name="author"><![CDATA[White S W]]></field>
  <field name="author"><![CDATA[Rodman O G]]></field>
  <field name="articleLang"><![CDATA[eng]]></field>
  <field name="publicationType"><![CDATA[Case Reports]]></field>
  <field name="publicationType"><![CDATA[Journal Article]]></field>
  <field name="articleDescriptor"><![CDATA[Adult]]></field>
  <field name="articleDescriptor"><![CDATA[Facial Dermatoses]]></field>
  <field name="articleQualifier"><![CDATA[pathology]]></field>
  <field name="articleDescriptor"><![CDATA[Female]]></field>
  <field name="articleDescriptor"><![CDATA[Hair]]></field>
  <field name="articleDescriptor"><![CDATA[Humans]]></field>
  <field name="articleDescriptor"><![CDATA[Nose]]></field>
  <field name="articleQualifier"><![CDATA[pathology]]></field>
 </doc>
 <doc>
  <field name="id"><![CDATA[7120440]]></field>
  <field name="articleCreationDate"><![CDATA[1982-12-02T00:00:00Z]]></field>
  <field name="articleYear"><![CDATA[1982]]></field>
  <field name="articleCompletionDate"><![CDATA[1982-12-02T00:00:00Z]]></field>
  <field name="articleRevisionDate"><![CDATA[2010-10-26T00:00:00Z]]></field>
  <field name="articlePubmodel"><![CDATA[Print]]></field>
  <field name="journalTitle"><![CDATA[Journal of the National Medical Association]]></field>
  <field name="journalTitleAbrv"><![CDATA[J Natl Med Assoc]]></field>
  <field name="articleTitle"><![CDATA[Tumors of extramammary breast tissue.]]></field>
  <field name="articleAbstract"><![CDATA[Polymastia is described and tumor formation in this condition is discussed. Two cases of carcinoma is aberrant breast tissue and one of fibroadenoma in a supernumerary breast are reported.]]></field>
  <field name="author"><![CDATA[Khan T]]></field>
  <field name="author"><![CDATA[James C R]]></field>
  <field name="author"><![CDATA[White J E]]></field>
  <field name="articleLang"><![CDATA[eng]]></field>
  <field name="publicationType"><![CDATA[Case Reports]]></field>
  <field name="publicationType"><![CDATA[Journal Article]]></field>
  <field name="articleDescriptor"><![CDATA[Adenofibroma]]></field>
  <field name="articleQualifier"><![CDATA[pathology]]></field>
  <field name="articleDescriptor"><![CDATA[Adult]]></field>
  <field name="articleDescriptor"><![CDATA[Aged]]></field>
  <field name="articleDescriptor"><![CDATA[Axilla]]></field>
  <field name="articleDescriptor"><![CDATA[Breast]]></field>
  <field name="articleDescriptor"><![CDATA[Carcinoma]]></field>
  <field name="articleQualifier"><![CDATA[pathology]]></field>
  <field name="articleDescriptor"><![CDATA[Choristoma]]></field>
  <field name="articleQualifier"><![CDATA[pathology]]></field>
  <field name="articleDescriptor"><![CDATA[Female]]></field>
  <field name="articleDescriptor"><![CDATA[Humans]]></field>
  <field name="articleDescriptor"><![CDATA[Thoracic Neoplasms]]></field>
  <field name="articleQualifier"><![CDATA[pathology]]></field>
 </doc>
 <doc>
  <field name="id"><![CDATA[7120441]]></field>
  <field name="articleCreationDate"><![CDATA[1982-12-02T00:00:00Z]]></field>
  <field name="articleYear"><![CDATA[1982]]></field>
  <field name="articleCompletionDate"><![CDATA[1982-12-02T00:00:00Z]]></field>
  <field name="articleRevisionDate"><![CDATA[2010-10-26T00:00:00Z]]></field>
  <field name="articlePubmodel"><![CDATA[Print]]></field>
  <field name="journalTitle"><![CDATA[Journal of the National Medical Association]]></field>
  <field name="journalTitleAbrv"><![CDATA[J Natl Med Assoc]]></field>
  <field name="articleTitle"><![CDATA[Adolescent pregnancy: a twenty year review.]]></field>
  <field name="articleAbstract"><![CDATA[In 20 years, from 1957 through 1977, there were 2,280 cases of adolescent pregnancy. The number one problem was low birth weight which occurred in 17 percent of all patients. The second significant obstetrical risk was toxemia of pregnancy, occurring in 15 percent of the cases. The cesarean section rate was 6.7 percent. There were 1.8 percent stillbirths and one maternal death.]]></field>
  <field name="author"><![CDATA[Clark J F]]></field>
  <field name="author"><![CDATA[Smith E S]]></field>
  <field name="author"><![CDATA[Hopkins E L]]></field>
  <field name="articleLang"><![CDATA[eng]]></field>
  <field name="publicationType"><![CDATA[Journal Article]]></field>
  <field name="articleDescriptor"><![CDATA[Adolescent]]></field>
  <field name="articleDescriptor"><![CDATA[Child]]></field>
  <field name="articleDescriptor"><![CDATA[District of Columbia]]></field>
  <field name="articleDescriptor"><![CDATA[Female]]></field>
  <field name="articleDescriptor"><![CDATA[Humans]]></field>
  <field name="articleDescriptor"><![CDATA[Infant, Low Birth Weight]]></field>
  <field name="articleDescriptor"><![CDATA[Infant, Newborn]]></field>
  <field name="articleDescriptor"><![CDATA[Pre-Eclampsia]]></field>
  <field name="articleQualifier"><![CDATA[epidemiology]]></field>
  <field name="articleDescriptor"><![CDATA[Pregnancy]]></field>
  <field name="articleDescriptor"><![CDATA[Pregnancy Complications]]></field>
  <field name="articleQualifier"><![CDATA[epidemiology]]></field>
  <field name="articleDescriptor"><![CDATA[Pregnancy in Adolescence]]></field>
 </doc>
 <doc>
  <field name="id"><![CDATA[7120442]]></field>
  <field name="articleCreationDate"><![CDATA[1982-12-02T00:00:00Z]]></field>
  <field name="articleYear"><![CDATA[1982]]></field>
  <field name="articleCompletionDate"><![CDATA[1982-12-02T00:00:00Z]]></field>
  <field name="articleRevisionDate"><![CDATA[2010-10-26T00:00:00Z]]></field>
  <field name="articlePubmodel"><![CDATA[Print]]></field>
  <field name="journalTitle"><![CDATA[Journal of the National Medical Association]]></field>
  <field name="journalTitleAbrv"><![CDATA[J Natl Med Assoc]]></field>
  <field name="articleTitle"><![CDATA[Maturation vs age: assessing blood pressure by height.]]></field>
  <field name="articleAbstract"><![CDATA[The Minneapolis Children's Blood Pressure Study surveyed 9,977 school children aged 6 to 9 years. Analyses revealed that both age and height should be considered in determining whether a child's blood pressure is within "normal limits." Because of the wide range of physiologic maturation seen at any given year of chronologic age, use of blood pressure norms presented by age only may result in important errors in the classification of blood pressure. It is emphasized that repeated measurements over time are important but that this does not eliminate the need to consider height as a measure of maturation.]]></field>
  <field name="author"><![CDATA[Gillum R F]]></field>
  <field name="author"><![CDATA[Prineas R J]]></field>
  <field name="author"><![CDATA[Horibe H]]></field>
  <field name="articleLang"><![CDATA[eng]]></field>
  <field name="publicationType"><![CDATA[Journal Article]]></field>
  <field name="publicationType"><![CDATA[Research Support, U.S. Gov't, P.H.S.]]></field>
  <field name="articleDescriptor"><![CDATA[Blood Pressure Determination]]></field>
  <field name="articleQualifier"><![CDATA[standards]]></field>
  <field name="articleDescriptor"><![CDATA[Body Height]]></field>
  <field name="articleDescriptor"><![CDATA[Child]]></field>
  <field name="articleDescriptor"><![CDATA[Humans]]></field>
  <field name="articleDescriptor"><![CDATA[Hypertension]]></field>
  <field name="articleQualifier"><![CDATA[diagnosis]]></field>
  <field name="articleDescriptor"><![CDATA[Male]]></field>
 </doc>
 <doc>
  <field name="id"><![CDATA[7120443]]></field>
  <field name="articleCreationDate"><![CDATA[1982-12-02T00:00:00Z]]></field>
  <field name="articleYear"><![CDATA[1982]]></field>
  <field name="articleCompletionDate"><![CDATA[1982-12-02T00:00:00Z]]></field>
  <field name="articleRevisionDate"><![CDATA[2011-11-17T00:00:00Z]]></field>
  <field name="articlePubmodel"><![CDATA[Print]]></field>
  <field name="journalTitle"><![CDATA[Journal of the National Medical Association]]></field>
  <field name="journalTitleAbrv"><![CDATA[J Natl Med Assoc]]></field>
  <field name="articleTitle"><![CDATA[Treatment of patients with chest pain in a large city hospital.]]></field>
  <field name="articleAbstract"><![CDATA[A subspecialty clinic was established in a large city hospital in order to evaluate and treat patients with chest pain syndromes and to assess the relative efficiency of isosorbide dinitrate and propranolol in the treatment of angina pectoris. The intensive subspecialty approach proved superior to the standard evaluation and treatment that these patients received in the general medicine clinics. Almost 50 percent of referred patients with the diagnosis of longstanding angina pectoris did not have this disease. Of the patients with chest pain due to coronary artery disease, the clinic provided an expedient, efficient, and effective means of evaluation and treatment. Isosorbide dinitrate was shown to be as effective an antianginal drug as propranolol.]]></field>
  <field name="author"><![CDATA[Akman D]]></field>
  <field name="articleLang"><![CDATA[eng]]></field>
  <field name="publicationType"><![CDATA[Comparative Study]]></field>
  <field name="publicationType"><![CDATA[Journal Article]]></field>
  <field name="substanceName"><![CDATA[Propranolol]]></field>
  <field name="substanceName"><![CDATA[Isosorbide Dinitrate]]></field>
  <field name="articleDescriptor"><![CDATA[Angina Pectoris]]></field>
  <field name="articleQualifier"><![CDATA[drug therapy]]></field>
  <field name="articleDescriptor"><![CDATA[Humans]]></field>
  <field name="articleDescriptor"><![CDATA[Isosorbide Dinitrate]]></field>
  <field name="articleQualifier"><![CDATA[therapeutic use]]></field>
  <field name="articleDescriptor"><![CDATA[Louisiana]]></field>
  <field name="articleDescriptor"><![CDATA[Outpatient Clinics, Hospital]]></field>
  <field name="articleDescriptor"><![CDATA[Pain Management]]></field>
  <field name="articleDescriptor"><![CDATA[Propranolol]]></field>
  <field name="articleQualifier"><![CDATA[therapeutic use]]></field>
  <field name="articleDescriptor"><![CDATA[Thorax]]></field>
 </doc>
 <doc>
  <field name="id"><![CDATA[6956750]]></field>
  <field name="articleCreationDate"><![CDATA[1982-12-02T00:00:00Z]]></field>
  <field name="articleYear"><![CDATA[1982]]></field>
  <field name="articleCompletionDate"><![CDATA[1982-12-02T00:00:00Z]]></field>
  <field name="articleRevisionDate"><![CDATA[2010-10-26T00:00:00Z]]></field>
  <field name="articlePubmodel"><![CDATA[Print]]></field>
  <field name="journalTitle"><![CDATA[Journal of the National Medical Association]]></field>
  <field name="journalTitleAbrv"><![CDATA[J Natl Med Assoc]]></field>
  <field name="articleTitle"><![CDATA[Primary malignant tumors of bone: incidence in Ibadan, Nigeria.]]></field>
  <field name="articleAbstract"><![CDATA[An account of primary malignant bone tumors in Africans is presented in this series. The study analyzes 170 Nigerians with bone neoplasms diagnosed over the 17-year period 1960-1976. It accounted for 1.28 percent of tumors registered in the Cancer Registry of the University College Hospital, Ibadan. There were 119 male and 51 female patients, with ages ranging from 4 to 75 years. The most common symptom was painful swelling. Trauma was associated with this condition. The pattern of behavior of these tumors conforms with other reports in the literature, but it showed some geographical variations. The most common tumor in the series was osteosarcoma, although there was no association of Paget's disease, which is very rare in Nigerians. Attention is also called to the presence of osteolytic conditions in the metaphysical region of a long bone, which may be due to osteomyelitis caused by Histoplasma duboisii and which has been confused with a malignant bone tumor in this environment.]]></field>
  <field name="author"><![CDATA[Oyemade G A]]></field>
  <field name="author"><![CDATA[Abioye A A]]></field>
  <field name="articleLang"><![CDATA[eng]]></field>
  <field name="publicationType"><![CDATA[Journal Article]]></field>
  <field name="articleDescriptor"><![CDATA[Adolescent]]></field>
  <field name="articleDescriptor"><![CDATA[Adult]]></field>
  <field name="articleDescriptor"><![CDATA[Aged]]></field>
  <field name="articleDescriptor"><![CDATA[Bone Neoplasms]]></field>
  <field name="articleQualifier"><![CDATA[epidemiology]]></field>
  <field name="articleDescriptor"><![CDATA[Child]]></field>
  <field name="articleDescriptor"><![CDATA[Child, Preschool]]></field>
  <field name="articleDescriptor"><![CDATA[Female]]></field>
  <field name="articleDescriptor"><![CDATA[Giant Cell Tumors]]></field>
  <field name="articleQualifier"><![CDATA[epidemiology]]></field>
  <field name="articleDescriptor"><![CDATA[Humans]]></field>
  <field name="articleDescriptor"><![CDATA[Male]]></field>
  <field name="articleDescriptor"><![CDATA[Middle Aged]]></field>
  <field name="articleDescriptor"><![CDATA[Nigeria]]></field>
  <field name="articleDescriptor"><![CDATA[Osteosarcoma]]></field>
  <field name="articleQualifier"><![CDATA[epidemiology]]></field>
 </doc>
 <doc>
  <field name="id"><![CDATA[7120444]]></field>
  <field name="articleCreationDate"><![CDATA[1982-12-02T00:00:00Z]]></field>
  <field name="articleYear"><![CDATA[1982]]></field>
  <field name="articleCompletionDate"><![CDATA[1982-12-02T00:00:00Z]]></field>
  <field name="articleRevisionDate"><![CDATA[2010-10-26T00:00:00Z]]></field>
  <field name="articlePubmodel"><![CDATA[Print]]></field>
  <field name="journalTitle"><![CDATA[Journal of the National Medical Association]]></field>
  <field name="journalTitleAbrv"><![CDATA[J Natl Med Assoc]]></field>
  <field name="articleTitle"><![CDATA[Experimental study of thallium 201 redistribution in transient myocardial ischemia.]]></field>
  <field name="articleAbstract"><![CDATA[The influence of differential washout on the redistribution phenomenon of thallium 201 chloride deposited in ischemic myocardium was investigated. Two groups of dogs had serial scintigraphic images and tissue counting performed. The first group had ischemia produced prior to the injection of the thallium and, following the control image after production of ischemia, the occlusion was released and serial images obtained over a three-hour period. The second group received thallium initially and after a control scintigraph was taken, ischemia was created and maintained for three hours via transthoracic ligature. Activity distribution was followed by serial images. Thallium content of ischemic areas was compared to the normal area by computer assisted data analysis. Tissues from the ischemic and normal areas from both groups were obtained after the serial images and counted. In the first group, prompt redistribution of activity into the ischemic areas was seen within 30 minutes of releasing the occlusion and was verified by tissue counting. Neither scintigraphic image changes nor tissue uptake differences were observed in the second group. The restoration of blood flow and consequently increased avidity for thallium probably accounted for the redistribution seen in the first group as there appeared to be no differential washout of activity in the second group from either the ischemic or normal areas to contribute to the redistribution phenomenon.]]></field>
  <field name="author"><![CDATA[Tanaka T]]></field>
  <field name="author"><![CDATA[Mandal A K]]></field>
  <field name="author"><![CDATA[Wong D Q]]></field>
  <field name="articleLang"><![CDATA[eng]]></field>
  <field name="publicationType"><![CDATA[Journal Article]]></field>
  <field name="substanceName"><![CDATA[Radioisotopes]]></field>
  <field name="substanceName"><![CDATA[Thallium]]></field>
  <field name="articleDescriptor"><![CDATA[Animals]]></field>
  <field name="articleDescriptor"><![CDATA[Coronary Disease]]></field>
  <field name="articleQualifier"><![CDATA[radionuclide imaging]]></field>
  <field name="articleDescriptor"><![CDATA[Dogs]]></field>
  <field name="articleDescriptor"><![CDATA[Radioisotopes]]></field>
  <field name="articleQualifier"><![CDATA[analysis]]></field>
  <field name="articleDescriptor"><![CDATA[Thallium]]></field>
  <field name="articleQualifier"><![CDATA[analysis]]></field>
 </doc>
 <doc>
  <field name="id"><![CDATA[7120445]]></field>
  <field name="articleCreationDate"><![CDATA[1982-12-02T00:00:00Z]]></field>
  <field name="articleYear"><![CDATA[1982]]></field>
  <field name="articleCompletionDate"><![CDATA[1982-12-02T00:00:00Z]]></field>
  <field name="articleRevisionDate"><![CDATA[2010-10-26T00:00:00Z]]></field>
  <field name="articlePubmodel"><![CDATA[Print]]></field>
  <field name="journalTitle"><![CDATA[Journal of the National Medical Association]]></field>
  <field name="journalTitleAbrv"><![CDATA[J Natl Med Assoc]]></field>
  <field name="articleTitle"><![CDATA[The role of the Federal Government in mental health.]]></field>
  <field name="articleAbstract"><![CDATA[This paper reports a survey of public opinion regarding the role of the federal government in mental health. The impact of cuts in federal funding for mental health care is analyzed and discussed.]]></field>
  <field name="author"><![CDATA[Newton P A]]></field>
  <field name="articleLang"><![CDATA[eng]]></field>
  <field name="publicationType"><![CDATA[Journal Article]]></field>
  <field name="articleDescriptor"><![CDATA[Adolescent]]></field>
  <field name="articleDescriptor"><![CDATA[Adult]]></field>
  <field name="articleDescriptor"><![CDATA[Female]]></field>
  <field name="articleDescriptor"><![CDATA[Financing, Government]]></field>
  <field name="articleQualifier"><![CDATA[methods]]></field>
  <field name="articleDescriptor"><![CDATA[Health Policy]]></field>
  <field name="articleDescriptor"><![CDATA[Humans]]></field>
  <field name="articleDescriptor"><![CDATA[Male]]></field>
  <field name="articleDescriptor"><![CDATA[Mental Health Services]]></field>
  <field name="articleQualifier"><![CDATA[economics]]></field>
  <field name="articleDescriptor"><![CDATA[Middle Aged]]></field>
  <field name="articleDescriptor"><![CDATA[Public Opinion]]></field>
  <field name="articleDescriptor"><![CDATA[United States]]></field>
 </doc>
 <doc>
  <field name="id"><![CDATA[6981707]]></field>
  <field name="articleCreationDate"><![CDATA[1982-12-02T00:00:00Z]]></field>
  <field name="articleYear"><![CDATA[1982]]></field>
  <field name="articleCompletionDate"><![CDATA[1982-12-02T00:00:00Z]]></field>
  <field name="articleRevisionDate"><![CDATA[2010-10-26T00:00:00Z]]></field>
  <field name="articlePubmodel"><![CDATA[Print]]></field>
  <field name="journalTitle"><![CDATA[Journal of the National Medical Association]]></field>
  <field name="journalTitleAbrv"><![CDATA[J Natl Med Assoc]]></field>
  <field name="articleTitle"><![CDATA[An unusual cause of GI bleeding in a quadriplegic: report of a case and review of the literature.]]></field>
  <field name="articleAbstract"><![CDATA[The authors report a case of upper gastrointestinal hemorrhage in a quadriplegic. The cause was a Mallory-Weiss tear, a previously unrecognized problem in these patients. The incidence of bleeding in patients with spinal cord injury is as high as 25 percent in the few reported series. We feel that with the increased risk of gastrointestinal bleeding in the spinal cord patient and the accompanying significant mortality, early endoscopy is essential for accurate diagnosis since clues to the presence, etiology, and severity of the bleeding are often lacking.]]></field>
  <field name="author"><![CDATA[Joseph R E]]></field>
  <field name="author"><![CDATA[Epsten R]]></field>
  <field name="author"><![CDATA[Kowlessar O D]]></field>
  <field name="articleLang"><![CDATA[eng]]></field>
  <field name="publicationType"><![CDATA[Case Reports]]></field>
  <field name="publicationType"><![CDATA[Journal Article]]></field>
  <field name="articleDescriptor"><![CDATA[Adolescent]]></field>
  <field name="articleDescriptor"><![CDATA[Gastrointestinal Hemorrhage]]></field>
  <field name="articleQualifier"><![CDATA[etiology]]></field>
  <field name="articleDescriptor"><![CDATA[Humans]]></field>
  <field name="articleDescriptor"><![CDATA[Male]]></field>
  <field name="articleDescriptor"><![CDATA[Mallory-Weiss Syndrome]]></field>
  <field name="articleQualifier"><![CDATA[complications]]></field>
  <field name="articleDescriptor"><![CDATA[Quadriplegia]]></field>
  <field name="articleQualifier"><![CDATA[complications]]></field>
  <field name="articleDescriptor"><![CDATA[Spinal Cord Injuries]]></field>
  <field name="articleQualifier"><![CDATA[complications]]></field>
 </doc>
 <doc>
  <field name="id"><![CDATA[7120446]]></field>
  <field name="articleCreationDate"><![CDATA[1982-12-02T00:00:00Z]]></field>
  <field name="articleYear"><![CDATA[1982]]></field>
  <field name="articleCompletionDate"><![CDATA[1982-12-02T00:00:00Z]]></field>
  <field name="articleRevisionDate"><![CDATA[2010-10-26T00:00:00Z]]></field>
  <field name="articlePubmodel"><![CDATA[Print]]></field>
  <field name="journalTitle"><![CDATA[Journal of the National Medical Association]]></field>
  <field name="journalTitleAbrv"><![CDATA[J Natl Med Assoc]]></field>
  <field name="articleTitle"><![CDATA[Thrombosis and pancreatic carcinoma revisited.]]></field>
  <field name="articleAbstract"><![CDATA[A case of recurrent pulmonary embolism from thrombophlebitis associated with pancreatic carcinoma is reported. There is an increased incidence of thrombophlebitis with all tumors, but carcinoma of the pancreas is statistically more frequently responsible. The higher incidence of thrombophlebitis with tumors of the body and tail of the pancreas is probably due to the low trypsin levels associated with these tumors. Trypsin levels are directly related to plasma antithrombin levels and mucinous adenocarcinomas are more commonly associated with thrombus formation.]]></field>
  <field name="author"><![CDATA[Verghese A]]></field>
  <field name="author"><![CDATA[Haws C C]]></field>
  <field name="author"><![CDATA[Thomas E]]></field>
  <field name="articleLang"><![CDATA[eng]]></field>
  <field name="publicationType"><![CDATA[Case Reports]]></field>
  <field name="publicationType"><![CDATA[Journal Article]]></field>
  <field name="articleDescriptor"><![CDATA[Adenocarcinoma]]></field>
  <field name="articleQualifier"><![CDATA[complications]]></field>
  <field name="articleDescriptor"><![CDATA[Aged]]></field>
  <field name="articleDescriptor"><![CDATA[Humans]]></field>
  <field name="articleDescriptor"><![CDATA[Male]]></field>
  <field name="articleDescriptor"><![CDATA[Pancreatic Neoplasms]]></field>
  <field name="articleQualifier"><![CDATA[complications]]></field>
  <field name="articleDescriptor"><![CDATA[Thrombophlebitis]]></field>
  <field name="articleQualifier"><![CDATA[etiology]]></field>
 </doc>
 <doc>
  <field name="id"><![CDATA[7120447]]></field>
  <field name="articleCreationDate"><![CDATA[1982-12-02T00:00:00Z]]></field>
  <field name="articleYear"><![CDATA[1982]]></field>
  <field name="articleCompletionDate"><![CDATA[1982-12-02T00:00:00Z]]></field>
  <field name="articleRevisionDate"><![CDATA[2010-10-26T00:00:00Z]]></field>
  <field name="articlePubmodel"><![CDATA[Print]]></field>
  <field name="journalTitle"><![CDATA[Journal of the National Medical Association]]></field>
  <field name="journalTitleAbrv"><![CDATA[J Natl Med Assoc]]></field>
  <field name="articleTitle"><![CDATA[Blastomycosis.]]></field>
  <field name="articleAbstract"><![CDATA[Blastomycosis is a fungal disease with an endemic area identical to that of histoplasmosis in the United States. Disease states range from a subclinical pulmonary illness to a rapidly progressive and fatal disease. Cutaneous lesions are common although the lung is the portal of entry for blastomyces. The organisms are easily demonstrated with potassium hydroxide preparations of fresh sputum, pus from skin lesions, or other biologic material. Skin and serologic tests are unreliable, largely because of cross-reactivity with antigens of histoplasmosis. Because of the ever present potential for milder forms of illness to progress to severe disease, it is recommended that all patients with symptomatic or culture proven disease be treated with amphotericin B.]]></field>
  <field name="author"><![CDATA[Hicks K]]></field>
  <field name="author"><![CDATA[Smith G W]]></field>
  <field name="author"><![CDATA[Stinson J M]]></field>
  <field name="articleLang"><![CDATA[eng]]></field>
  <field name="publicationType"><![CDATA[Case Reports]]></field>
  <field name="publicationType"><![CDATA[Journal Article]]></field>
  <field name="publicationType"><![CDATA[Research Support, U.S. Gov't, P.H.S.]]></field>
  <field name="substanceName"><![CDATA[Amphotericin B]]></field>
  <field name="articleDescriptor"><![CDATA[Adult]]></field>
  <field name="articleDescriptor"><![CDATA[Amphotericin B]]></field>
  <field name="articleQualifier"><![CDATA[therapeutic use]]></field>
  <field name="articleDescriptor"><![CDATA[Blastomycosis]]></field>
  <field name="articleQualifier"><![CDATA[drug therapy]]></field>
  <field name="articleDescriptor"><![CDATA[Dermatomycoses]]></field>
  <field name="articleQualifier"><![CDATA[drug therapy]]></field>
  <field name="articleDescriptor"><![CDATA[Humans]]></field>
  <field name="articleDescriptor"><![CDATA[Male]]></field>
  <field name="articleDescriptor"><![CDATA[Skin Diseases, Infectious]]></field>
 </doc>
 <doc>
  <field name="id"><![CDATA[7120449]]></field>
  <field name="articleCreationDate"><![CDATA[1982-12-02T00:00:00Z]]></field>
  <field name="articleYear"><![CDATA[1982]]></field>
  <field name="articleCompletionDate"><![CDATA[1982-12-02T00:00:00Z]]></field>
  <field name="articleRevisionDate"><![CDATA[2010-10-26T00:00:00Z]]></field>
  <field name="articlePubmodel"><![CDATA[Print]]></field>
  <field name="journalTitle"><![CDATA[Journal of the National Medical Association]]></field>
  <field name="journalTitleAbrv"><![CDATA[J Natl Med Assoc]]></field>
  <field name="articleTitle"><![CDATA[An in-progress research report of perceptual-cognitive development of young black children in three cultures.]]></field>
  <field name="articleAbstract"><![CDATA[This paper examines a study of perceptual-cognitive development among black children from three cultures. The study investigates patterns of perceptual and cognitive functioning as a transaction among developmental, genetic, environmental, cultural, and child-rearing variables. The samples consisted of four and eight year olds from three distinct groups: (1) white and black middle socio-economic status (SES) children from the US; (2) lower and middle SES children from St. Kitts in the Caribbean; and (3) middle SES children from Nigeria. The research paradigm permits a cross-cultural comparison of three samples of middle-class, urban, English-speaking, black children in relation to six areas of perceptual-cognitive development, four anthropometric, and three physiological measures. Because of the inclusion of a white sample, the interactions of SES, race, culture, nutritional status, proximity to the equator, and physical growth and development can be correlated with the performance of black children on perceptual-cognitive tasks. Results of data analyzed thus far are reported and implications are discussed.]]></field>
  <field name="author"><![CDATA[Powell G J]]></field>
  <field name="author"><![CDATA[Gaines R]]></field>
  <field name="articleLang"><![CDATA[eng]]></field>
  <field name="publicationType"><![CDATA[Journal Article]]></field>
  <field name="publicationType"><![CDATA[Research Support, Non-U.S. Gov't]]></field>
  <field name="articleDescriptor"><![CDATA[African Americans]]></field>
  <field name="articleQualifier"><![CDATA[psychology]]></field>
  <field name="articleDescriptor"><![CDATA[African Continental Ancestry Group]]></field>
  <field name="articleDescriptor"><![CDATA[California]]></field>
  <field name="articleDescriptor"><![CDATA[Child]]></field>
  <field name="articleDescriptor"><![CDATA[Child Development]]></field>
  <field name="articleDescriptor"><![CDATA[Child, Preschool]]></field>
  <field name="articleDescriptor"><![CDATA[Cognition]]></field>
  <field name="articleDescriptor"><![CDATA[Cross-Cultural Comparison]]></field>
  <field name="articleDescriptor"><![CDATA[Female]]></field>
  <field name="articleDescriptor"><![CDATA[Humans]]></field>
  <field name="articleDescriptor"><![CDATA[Male]]></field>
  <field name="articleDescriptor"><![CDATA[Nigeria]]></field>
  <field name="articleDescriptor"><![CDATA[Perception]]></field>
  <field name="articleDescriptor"><![CDATA[West Indies]]></field>
 </doc>
 <doc>
  <field name="id"><![CDATA[7120450]]></field>
  <field name="articleCreationDate"><![CDATA[1982-12-02T00:00:00Z]]></field>
  <field name="articleYear"><![CDATA[1982]]></field>
  <field name="articleCompletionDate"><![CDATA[1982-12-02T00:00:00Z]]></field>
  <field name="articleRevisionDate"><![CDATA[2010-10-26T00:00:00Z]]></field>
  <field name="articlePubmodel"><![CDATA[Print]]></field>
  <field name="journalTitle"><![CDATA[Journal of the National Medical Association]]></field>
  <field name="journalTitleAbrv"><![CDATA[J Natl Med Assoc]]></field>
  <field name="articleTitle"><![CDATA[Practice patterns of black physicians: results of a survey of Howard University College of Medicine alumni.]]></field>
  <field name="articleAbstract"><![CDATA[Over 600 Howard University medical alumni of seven representative classes graduating from 1955 to 1975 were surveyed by questionnaire in 1975 and 1976. Replies of the 252 black respondents confirm that these graduates are providing substantial care to blacks, the economically disadvantaged, and residents of the inner city. Survey findings reaffirm the necessity to train more black physicians and to provide data on current and future practice patterns. Comparisons are made between the practice patterns of earlier (1955 to 1970) and later (1973 to 1975) black graduates. A general bibliography of publications relevant to the practice patterns of black physicians is included.]]></field>
  <field name="author"><![CDATA[Lloyd S M]]></field>
  <field name="author"><![CDATA[Johnson D G]]></field>
  <field name="articleLang"><![CDATA[eng]]></field>
  <field name="publicationType"><![CDATA[Journal Article]]></field>
  <field name="articleDescriptor"><![CDATA[African Americans]]></field>
  <field name="articleDescriptor"><![CDATA[Career Choice]]></field>
  <field name="articleDescriptor"><![CDATA[District of Columbia]]></field>
  <field name="articleDescriptor"><![CDATA[Physicians]]></field>
  <field name="articleDescriptor"><![CDATA[Professional Practice]]></field>
  <field name="articleQualifier"><![CDATA[trends]]></field>
  <field name="articleDescriptor"><![CDATA[United States]]></field>
 </doc>
 <doc>
  <field name="id"><![CDATA[6981708]]></field>
  <field name="articleCreationDate"><![CDATA[1982-12-02T00:00:00Z]]></field>
  <field name="articleYear"><![CDATA[1982]]></field>
  <field name="articleCompletionDate"><![CDATA[1982-12-02T00:00:00Z]]></field>
  <field name="articleRevisionDate"><![CDATA[2011-11-17T00:00:00Z]]></field>
  <field name="articlePubmodel"><![CDATA[Print]]></field>
  <field name="journalTitle"><![CDATA[Journal of the National Medical Association]]></field>
  <field name="journalTitleAbrv"><![CDATA[J Natl Med Assoc]]></field>
  <field name="articleTitle"><![CDATA[Pain: theories and a new approach to treatment.]]></field>
  <field name="articleAbstract"><![CDATA[Various theories of pain are reviewed in an attempt to understand its mode of action. The therapeutic effects of a new, noninvasive form of treating pain, utilizing electrical units which selectively stimulate the sensory nerves, are discussed.PATIENTS WITH PAIN OF VARYING DEGREES OF SEVERITY AND OF MANY DIFFERENT ETIOLOGIES WERE TREATED WITH A NEW FORM OF TREATMENT: transcutaneous electrical nerve stimulation (TENS). The authors' results have shown this method to be highly successful in the treatment of patients, most of whom had been treated unsuccessfully with conventional medical and surgical approaches.TENS affords a new dimension in the current concept of treating pain.]]></field>
  <field name="author"><![CDATA[Coffey G H]]></field>
  <field name="author"><![CDATA[Mahon M V]]></field>
  <field name="articleLang"><![CDATA[eng]]></field>
  <field name="publicationType"><![CDATA[Case Reports]]></field>
  <field name="publicationType"><![CDATA[Journal Article]]></field>
  <field name="articleDescriptor"><![CDATA[Adult]]></field>
  <field name="articleDescriptor"><![CDATA[Electric Stimulation Therapy]]></field>
  <field name="articleQualifier"><![CDATA[methods]]></field>
  <field name="articleDescriptor"><![CDATA[Female]]></field>
  <field name="articleDescriptor"><![CDATA[Humans]]></field>
  <field name="articleDescriptor"><![CDATA[Male]]></field>
  <field name="articleDescriptor"><![CDATA[Middle Aged]]></field>
  <field name="articleDescriptor"><![CDATA[Models, Neurological]]></field>
  <field name="articleDescriptor"><![CDATA[Pain]]></field>
  <field name="articleQualifier"><![CDATA[physiopathology]]></field>
  <field name="articleDescriptor"><![CDATA[Pain Management]]></field>
 </doc>
 <doc>
  <field name="id"><![CDATA[7120451]]></field>
  <field name="articleCreationDate"><![CDATA[1982-12-02T00:00:00Z]]></field>
  <field name="articleYear"><![CDATA[1982]]></field>
  <field name="articleCompletionDate"><![CDATA[1982-12-02T00:00:00Z]]></field>
  <field name="articleRevisionDate"><![CDATA[2010-10-26T00:00:00Z]]></field>
  <field name="articlePubmodel"><![CDATA[Print]]></field>
  <field name="journalTitle"><![CDATA[Journal of the National Medical Association]]></field>
  <field name="journalTitleAbrv"><![CDATA[J Natl Med Assoc]]></field>
  <field name="articleTitle"><![CDATA[Primary tumors of the jaw in Nigerian children.]]></field>
  <field name="articleAbstract"><![CDATA[Over a 13-year period at the University College Hospital in Ibadan, 152 cases of primary tumors of the jaw (excluding Burkett's lymphoma) were reported. These cases, which consisted entirely of Nigerian children under 19 years of age, were then reviewed and analyzed. The majority of the jaw tumors were benign with fibro-osseous lesions and ameloblastoma predominating.Common clinical features were late presentation and disfigurement which made aggressive surgery imperative. All cases of malignant tumors terminated fatally.]]></field>
  <field name="author"><![CDATA[Ajagbe H A]]></field>
  <field name="author"><![CDATA[Daramola J O]]></field>
  <field name="articleLang"><![CDATA[eng]]></field>
  <field name="publicationType"><![CDATA[Journal Article]]></field>
  <field name="articleDescriptor"><![CDATA[Adolescent]]></field>
  <field name="articleDescriptor"><![CDATA[Ameloblastoma]]></field>
  <field name="articleQualifier"><![CDATA[pathology]]></field>
  <field name="articleDescriptor"><![CDATA[Child]]></field>
  <field name="articleDescriptor"><![CDATA[Child, Preschool]]></field>
  <field name="articleDescriptor"><![CDATA[Female]]></field>
  <field name="articleDescriptor"><![CDATA[Fibrous Dysplasia of Bone]]></field>
  <field name="articleQualifier"><![CDATA[pathology]]></field>
  <field name="articleDescriptor"><![CDATA[Humans]]></field>
  <field name="articleDescriptor"><![CDATA[Infant]]></field>
  <field name="articleDescriptor"><![CDATA[Jaw Neoplasms]]></field>
  <field name="articleQualifier"><![CDATA[epidemiology]]></field>
  <field name="articleQualifier"><![CDATA[pathology]]></field>
  <field name="articleDescriptor"><![CDATA[Male]]></field>
  <field name="articleDescriptor"><![CDATA[Nigeria]]></field>
 </doc>
 <doc>
  <field name="id"><![CDATA[7120452]]></field>
  <field name="articleCreationDate"><![CDATA[1982-12-02T00:00:00Z]]></field>
  <field name="articleYear"><![CDATA[1982]]></field>
  <field name="articleCompletionDate"><![CDATA[1982-12-02T00:00:00Z]]></field>
  <field name="articleRevisionDate"><![CDATA[2010-10-26T00:00:00Z]]></field>
  <field name="articlePubmodel"><![CDATA[Print]]></field>
  <field name="journalTitle"><![CDATA[Journal of the National Medical Association]]></field>
  <field name="journalTitleAbrv"><![CDATA[J Natl Med Assoc]]></field>
  <field name="articleTitle"><![CDATA[A brief review of the adult respiratory distress syndrome.]]></field>
  <field name="articleAbstract"><![CDATA[The adult respiratory distress syndrome (ARDS) is seen with increasing frequency. It is associated with a variety of conditions even in the absence of preexisting pulmonary diseases. The treatment often includes intubation, using positive-end expiratory pressure (PEEP), and other ancillary support. The mortality rate is high, and physicians caring for such patients should be on guard for disseminated intravascular coagulation, gastrointestinal hemorrhage, and infection.]]></field>
  <field name="author"><![CDATA[Hassan S N]]></field>
  <field name="author"><![CDATA[Hackney R L]]></field>
  <field name="articleLang"><![CDATA[eng]]></field>
  <field name="publicationType"><![CDATA[Journal Article]]></field>
  <field name="articleDescriptor"><![CDATA[Adult]]></field>
  <field name="articleDescriptor"><![CDATA[Forced Expiratory Volume]]></field>
  <field name="articleDescriptor"><![CDATA[Humans]]></field>
  <field name="articleDescriptor"><![CDATA[Oxygenators, Membrane]]></field>
  <field name="articleDescriptor"><![CDATA[Respiratory Distress Syndrome, Adult]]></field>
  <field name="articleQualifier"><![CDATA[complications]]></field>
  <field name="articleQualifier"><![CDATA[therapy]]></field>
 </doc>
 <doc>
  <field name="id"><![CDATA[7120453]]></field>
  <field name="articleCreationDate"><![CDATA[1982-12-02T00:00:00Z]]></field>
  <field name="articleYear"><![CDATA[1982]]></field>
  <field name="articleCompletionDate"><![CDATA[1982-12-02T00:00:00Z]]></field>
  <field name="articleRevisionDate"><![CDATA[2010-10-26T00:00:00Z]]></field>
  <field name="articlePubmodel"><![CDATA[Print]]></field>
  <field name="journalTitle"><![CDATA[Journal of the National Medical Association]]></field>
  <field name="journalTitleAbrv"><![CDATA[J Natl Med Assoc]]></field>
  <field name="articleTitle"><![CDATA[X-ray pelvimetry in primiparas. I: Role of physiological maturity.]]></field>
  <field name="articleAbstract"><![CDATA[X-ray pelvimetry offers an accepted, objective, and reproducible method for evaluation of pelvic capacity. One hundred-thirty primiparous parturients, 16 years of age and younger, who had had x-ray pelvimetries when admitted for delivery at term were studied. These findings were contrasted with the findings on 150 primiparous parturients who were 20 years of age and older at term.The mean age for the adolescents was 15.4 years and for the older group, 24.1. The most common indication for pelvimetry was suspected disproportion (A = 60.8 percent, O = 65.3 percent). Contrary to expectations, many similarities were noted in the women of both groups. Four of the six diameters compared were similar when adolescents were contrasted with older women. Both diameters of the inlet were smaller among the adolescents as contrasted with the older women, who had a higher proportion of larger than average diameters. The clinical implications of these findings are presented.]]></field>
  <field name="author"><![CDATA[Poma P A]]></field>
  <field name="articleLang"><![CDATA[eng]]></field>
  <field name="publicationType"><![CDATA[Journal Article]]></field>
  <field name="articleDescriptor"><![CDATA[Adolescent]]></field>
  <field name="articleDescriptor"><![CDATA[Adult]]></field>
  <field name="articleDescriptor"><![CDATA[African Americans]]></field>
  <field name="articleDescriptor"><![CDATA[Age Factors]]></field>
  <field name="articleDescriptor"><![CDATA[Female]]></field>
  <field name="articleDescriptor"><![CDATA[Humans]]></field>
  <field name="articleDescriptor"><![CDATA[Pelvimetry]]></field>
  <field name="articleDescriptor"><![CDATA[Pelvis]]></field>
  <field name="articleQualifier"><![CDATA[anatomy & histology]]></field>
  <field name="articleQualifier"><![CDATA[radiography]]></field>
  <field name="articleDescriptor"><![CDATA[Pregnancy]]></field>
  <field name="articleDescriptor"><![CDATA[Pregnancy in Adolescence]]></field>
 </doc>
 <doc>
  <field name="id"><![CDATA[7120454]]></field>
  <field name="articleCreationDate"><![CDATA[1982-12-02T00:00:00Z]]></field>
  <field name="articleYear"><![CDATA[1982]]></field>
  <field name="articleCompletionDate"><![CDATA[1982-12-02T00:00:00Z]]></field>
  <field name="articleRevisionDate"><![CDATA[2010-10-26T00:00:00Z]]></field>
  <field name="articlePubmodel"><![CDATA[Print]]></field>
  <field name="journalTitle"><![CDATA[Journal of the National Medical Association]]></field>
  <field name="journalTitleAbrv"><![CDATA[J Natl Med Assoc]]></field>
  <field name="articleTitle"><![CDATA[Symptomatology of depression in black and white patients.]]></field>
  <field name="articleAbstract"><![CDATA[This study compares the symptoms of public mental health patients diagnosed as having a depressive disorder, and then relates its findings to the previous literature concerning black-white differences in mental illness. Results of this study corroborate previous observations that a somewhat smaller proportion of black admissions than white admissions are diagnosed with a depressive disorder and that a higher proportion of black admissions are diagnosed with a schizophrenic disorder. Some black-white differences in depressive symptoms were corroborated-notably, slightly higher percentages of hostility, dangerousness, and somatic complaints in blacks-and these appeared to be independent of socio-economic status.]]></field>
  <field name="author"><![CDATA[Adebimpe V R]]></field>
  <field name="author"><![CDATA[Hedlund J L]]></field>
  <field name="author"><![CDATA[Cho D W]]></field>
  <field name="author"><![CDATA[Wood J B]]></field>
  <field name="articleLang"><![CDATA[eng]]></field>
  <field name="publicationType"><![CDATA[Journal Article]]></field>
  <field name="articleDescriptor"><![CDATA[African Americans]]></field>
  <field name="articleQualifier"><![CDATA[psychology]]></field>
  <field name="articleDescriptor"><![CDATA[Depression]]></field>
  <field name="articleQualifier"><![CDATA[complications]]></field>
  <field name="articleQualifier"><![CDATA[diagnosis]]></field>
  <field name="articleDescriptor"><![CDATA[Diagnosis, Differential]]></field>
  <field name="articleDescriptor"><![CDATA[European Continental Ancestry Group]]></field>
  <field name="articleQualifier"><![CDATA[psychology]]></field>
  <field name="articleDescriptor"><![CDATA[Humans]]></field>
 </doc>
 <doc>
  <field name="id"><![CDATA[7120455]]></field>
  <field name="articleCreationDate"><![CDATA[1982-12-02T00:00:00Z]]></field>
  <field name="articleYear"><![CDATA[1982]]></field>
  <field name="articleCompletionDate"><![CDATA[1982-12-02T00:00:00Z]]></field>
  <field name="articleRevisionDate"><![CDATA[2010-10-26T00:00:00Z]]></field>
  <field name="articlePubmodel"><![CDATA[Print]]></field>
  <field name="journalTitle"><![CDATA[Journal of the National Medical Association]]></field>
  <field name="journalTitleAbrv"><![CDATA[J Natl Med Assoc]]></field>
  <field name="articleTitle"><![CDATA[Syndrome of inappropriate secretion of antidiuretic hormone in association with pulmonary carcinosarcoma.]]></field>
  <field name="articleAbstract"><![CDATA[A smoking patient presented with altered mental status, left sided weakness, and an opacity on the chest roentgenogram. During hospitalization he developed hyponatremia, which was corrected with hypertonic saline solution, fluid restriction, and demethylchlortetracycline. The clinical presentation and the laboratory findings supported the diagnosis of the syndrome of inappropriate secretion of antidiuretic hormone. This was believed to be associated with the pulmonary carcinosarcoma documented at necropsy.]]></field>
  <field name="author"><![CDATA[Nguyen-Dinh T]]></field>
  <field name="author"><![CDATA[Nath C R]]></field>
  <field name="author"><![CDATA[Titus-Dillon P Y]]></field>
  <field name="articleLang"><![CDATA[eng]]></field>
  <field name="publicationType"><![CDATA[Case Reports]]></field>
  <field name="publicationType"><![CDATA[Journal Article]]></field>
  <field name="articleDescriptor"><![CDATA[Aged]]></field>
  <field name="articleDescriptor"><![CDATA[Brain Neoplasms]]></field>
  <field name="articleQualifier"><![CDATA[secondary]]></field>
  <field name="articleDescriptor"><![CDATA[Carcinosarcoma]]></field>
  <field name="articleQualifier"><![CDATA[complications]]></field>
  <field name="articleDescriptor"><![CDATA[Humans]]></field>
  <field name="articleDescriptor"><![CDATA[Hyponatremia]]></field>
  <field name="articleQualifier"><![CDATA[etiology]]></field>
  <field name="articleDescriptor"><![CDATA[Inappropriate ADH Syndrome]]></field>
  <field name="articleQualifier"><![CDATA[etiology]]></field>
  <field name="articleDescriptor"><![CDATA[Lung Neoplasms]]></field>
  <field name="articleQualifier"><![CDATA[complications]]></field>
  <field name="articleDescriptor"><![CDATA[Male]]></field>
 </doc>
 <doc>
  <field name="id"><![CDATA[7120456]]></field>
  <field name="articleCreationDate"><![CDATA[1982-12-02T00:00:00Z]]></field>
  <field name="articleYear"><![CDATA[1982]]></field>
  <field name="articleCompletionDate"><![CDATA[1982-12-02T00:00:00Z]]></field>
  <field name="articleRevisionDate"><![CDATA[2010-10-26T00:00:00Z]]></field>
  <field name="articlePubmodel"><![CDATA[Print]]></field>
  <field name="journalTitle"><![CDATA[Journal of the National Medical Association]]></field>
  <field name="journalTitleAbrv"><![CDATA[J Natl Med Assoc]]></field>
  <field name="articleTitle"><![CDATA[Vitiligo associated with Kaposi's sarcoma.]]></field>
  <field name="articleAbstract"><![CDATA[A patient who had Kaposi's sarcoma and an associated vitiligo is reported. This is the first known case of Kaposi's sarcoma associated with vitiligo.]]></field>
  <field name="author"><![CDATA[Alexander G A]]></field>
  <field name="articleLang"><![CDATA[eng]]></field>
  <field name="publicationType"><![CDATA[Case Reports]]></field>
  <field name="publicationType"><![CDATA[Journal Article]]></field>
  <field name="articleDescriptor"><![CDATA[Foot Diseases]]></field>
  <field name="articleQualifier"><![CDATA[complications]]></field>
  <field name="articleDescriptor"><![CDATA[Humans]]></field>
  <field name="articleDescriptor"><![CDATA[Male]]></field>
  <field name="articleDescriptor"><![CDATA[Middle Aged]]></field>
  <field name="articleDescriptor"><![CDATA[Sarcoma, Kaposi]]></field>
  <field name="articleQualifier"><![CDATA[complications]]></field>
  <field name="articleDescriptor"><![CDATA[Vitiligo]]></field>
  <field name="articleQualifier"><![CDATA[complications]]></field>
 </doc>
 <doc>
  <field name="id"><![CDATA[7120458]]></field>
  <field name="articleCreationDate"><![CDATA[1982-12-02T00:00:00Z]]></field>
  <field name="articleYear"><![CDATA[1982]]></field>
  <field name="articleCompletionDate"><![CDATA[1982-12-02T00:00:00Z]]></field>
  <field name="articleRevisionDate"><![CDATA[2011-08-01T00:00:00Z]]></field>
  <field name="articlePubmodel"><![CDATA[Print]]></field>
  <field name="journalTitle"><![CDATA[Journal of the National Medical Association]]></field>
  <field name="journalTitleAbrv"><![CDATA[J Natl Med Assoc]]></field>
  <field name="articleTitle"><![CDATA[The anatomy of hope.]]></field>
  <field name="articleAbstract"><![CDATA[Hope is commonly regarded as the feeling that what is desired is also possible. Today, the concensus is that this feeling can increase one's overall ability to cope with stress by reducing fears and anxieties. It is our assumption, therefore, that much of the illness of mankind can be eliminated by enhancing the hope of human individuals.To be able to enhance hope, one must first know what hope actually is and from where it comes by identifying its true determinants. We have, therefore, chosen the task of defining hope and attempting to dissect it into its relevant components so that this important health related property of the human individual may no longer remain in abstraction. This paper reports our approach to this task, the methods used, results obtained, and conclusions drawn.]]></field>
  <field name="author"><![CDATA[Obayuwana A O]]></field>
  <field name="author"><![CDATA[Carter A L]]></field>
  <field name="articleLang"><![CDATA[eng]]></field>
  <field name="publicationType"><![CDATA[Comparative Study]]></field>
  <field name="publicationType"><![CDATA[Journal Article]]></field>
  <field name="articleDescriptor"><![CDATA[Attitude to Death]]></field>
  <field name="articleDescriptor"><![CDATA[Attitude to Health]]></field>
  <field name="articleDescriptor"><![CDATA[Holistic Health]]></field>
  <field name="articleDescriptor"><![CDATA[Humans]]></field>
  <field name="articleDescriptor"><![CDATA[Neoplasms]]></field>
  <field name="articleQualifier"><![CDATA[psychology]]></field>
 </doc>
 <doc>
  <field name="id"><![CDATA[7120459]]></field>
  <field name="articleCreationDate"><![CDATA[1982-12-02T00:00:00Z]]></field>
  <field name="articleYear"><![CDATA[1982]]></field>
  <field name="articleCompletionDate"><![CDATA[1982-12-02T00:00:00Z]]></field>
  <field name="articleRevisionDate"><![CDATA[2010-10-26T00:00:00Z]]></field>
  <field name="articlePubmodel"><![CDATA[Print]]></field>
  <field name="journalTitle"><![CDATA[Journal of the National Medical Association]]></field>
  <field name="journalTitleAbrv"><![CDATA[J Natl Med Assoc]]></field>
  <field name="articleTitle"><![CDATA[Increases in diagnostic yield of fiberoptic bronchoscopy by fluoroscopy.]]></field>
  <field name="articleAbstract"><![CDATA[Fiberoptic bronchoscopy was performed in 46 patients in the evaluation of pulmonary lesions. Twenty-five of the patients had lung cancer; the remainder had benign lesions. Definitive diagnosis was established in all patients by a combination of forceps biopsy, brush biopsy, bronchial aspiration, and post-bronchoscopy sputum studies. All endoscopically visible lesions were diagnosed by forceps biopsy. Fluoroscopic localization of biopsy forceps and brush made the yield in peripheral, nonvisualized lesions almost equal to that of more central lesions. Fluoroscopic control markedly increases the diagnostic yield in fiberoptic bronchoscopy.]]></field>
  <field name="author"><![CDATA[Cummings C L]]></field>
  <field name="author"><![CDATA[Brooks I O]]></field>
  <field name="author"><![CDATA[Stinson J M]]></field>
  <field name="articleLang"><![CDATA[eng]]></field>
  <field name="publicationType"><![CDATA[Journal Article]]></field>
  <field name="articleDescriptor"><![CDATA[Adult]]></field>
  <field name="articleDescriptor"><![CDATA[Aged]]></field>
  <field name="articleDescriptor"><![CDATA[Bronchoscopy]]></field>
  <field name="articleDescriptor"><![CDATA[Female]]></field>
  <field name="articleDescriptor"><![CDATA[Fiber Optic Technology]]></field>
  <field name="articleDescriptor"><![CDATA[Fluoroscopy]]></field>
  <field name="articleDescriptor"><![CDATA[Humans]]></field>
  <field name="articleDescriptor"><![CDATA[Lung Diseases]]></field>
  <field name="articleQualifier"><![CDATA[diagnosis]]></field>
  <field name="articleDescriptor"><![CDATA[Lung Neoplasms]]></field>
  <field name="articleQualifier"><![CDATA[diagnosis]]></field>
  <field name="articleDescriptor"><![CDATA[Male]]></field>
  <field name="articleDescriptor"><![CDATA[Middle Aged]]></field>
 </doc>
 <doc>
  <field name="id"><![CDATA[7120460]]></field>
  <field name="articleCreationDate"><![CDATA[1982-12-02T00:00:00Z]]></field>
  <field name="articleYear"><![CDATA[1982]]></field>
  <field name="articleCompletionDate"><![CDATA[1982-12-02T00:00:00Z]]></field>
  <field name="articleRevisionDate"><![CDATA[2010-10-26T00:00:00Z]]></field>
  <field name="articlePubmodel"><![CDATA[Print]]></field>
  <field name="journalTitle"><![CDATA[Journal of the National Medical Association]]></field>
  <field name="journalTitleAbrv"><![CDATA[J Natl Med Assoc]]></field>
  <field name="articleTitle"><![CDATA[The black executive: a challenge for psychiatry.]]></field>
  <field name="articleAbstract"><![CDATA[The task of developing a body of knowledge about specific problems, both intrapsychic and psychosocial, which influence a black executive's maturation, must be initiated. There is currently a definite interest, among black executives, in obtaining access to appropriate psychotherapeutic intervention. A psychobiographical approach facilitates development of a construct for analysis of, and insight into, transference phenomena that translate into organization based behavioral responses to the black executive. Analysis of frequently encountered organizational ethos and also stimulus-response mechanisms in the black executive lead to formulation of viable conclusions for resolution of conflict. Modes of recognition of specific conflict with authority in the black executive psychotherapy patient include examination of (1) defense mechanisms frequently encountered in response to authority conflicts, (2) stated intentions of the patient in relation to career development, and (3) the affective stance of the patient. Psychobiographical issues very often have a direct developmental influence on black familial conceptualizations of authority. Childrearing practices and parentally based ego ideals and other aspects of development are linked to analogues in adult human behavior frequently observed among black executives. Suggestions for therapeutic directions involve affective and thematic strategies, all contingent upon a productive, informed, therapeutic effort. The therapeutic relationship is a most important element in the treatment strategy with the black executive.]]></field>
  <field name="author"><![CDATA[Boone L R]]></field>
  <field name="articleLang"><![CDATA[eng]]></field>
  <field name="publicationType"><![CDATA[Journal Article]]></field>
  <field name="articleDescriptor"><![CDATA[Administrative Personnel]]></field>
  <field name="articleQualifier"><![CDATA[psychology]]></field>
  <field name="articleDescriptor"><![CDATA[African Americans]]></field>
  <field name="articleQualifier"><![CDATA[psychology]]></field>
  <field name="articleDescriptor"><![CDATA[Female]]></field>
  <field name="articleDescriptor"><![CDATA[Humans]]></field>
  <field name="articleDescriptor"><![CDATA[Male]]></field>
  <field name="articleDescriptor"><![CDATA[Occupational Diseases]]></field>
  <field name="articleQualifier"><![CDATA[therapy]]></field>
  <field name="articleDescriptor"><![CDATA[Psychotherapy]]></field>
  <field name="articleDescriptor"><![CDATA[United States]]></field>
 </doc>
 <doc>
  <field name="id"><![CDATA[7120461]]></field>
  <field name="articleCreationDate"><![CDATA[1982-12-02T00:00:00Z]]></field>
  <field name="articleYear"><![CDATA[1982]]></field>
  <field name="articleCompletionDate"><![CDATA[1982-12-02T00:00:00Z]]></field>
  <field name="articleRevisionDate"><![CDATA[2010-10-26T00:00:00Z]]></field>
  <field name="articlePubmodel"><![CDATA[Print]]></field>
  <field name="journalTitle"><![CDATA[Journal of the National Medical Association]]></field>
  <field name="journalTitleAbrv"><![CDATA[J Natl Med Assoc]]></field>
  <field name="articleTitle"><![CDATA[Rising lung cancer death rates among black men: the importance of occupation and social class.]]></field>
  <field name="articleAbstract"><![CDATA[From 1950 to 1977 the age-adjusted cancer death rates for nonwhite men in the United States rose an astonishing 63.2 percent, while rates for white men increased 22.2 percent and fell slightly for women of both races. The bulk of this increase can be accounted for by cancer of the lung. As a serious health problem that is increasing in severity, cancer in black men deserves close attention and definitive action. This discussion focuses on basic epidemiological relationships in the origins of this epidemic, particularly in regard to the relative importance of occupation, cigarette smoking, and social class.]]></field>
  <field name="author"><![CDATA[Miller W J]]></field>
  <field name="author"><![CDATA[Cooper R]]></field>
  <field name="articleLang"><![CDATA[eng]]></field>
  <field name="publicationType"><![CDATA[Journal Article]]></field>
  <field name="articleDescriptor"><![CDATA[African Americans]]></field>
  <field name="articleDescriptor"><![CDATA[Female]]></field>
  <field name="articleDescriptor"><![CDATA[Humans]]></field>
  <field name="articleDescriptor"><![CDATA[Lung Neoplasms]]></field>
  <field name="articleQualifier"><![CDATA[mortality]]></field>
  <field name="articleDescriptor"><![CDATA[Male]]></field>
  <field name="articleDescriptor"><![CDATA[Occupations]]></field>
  <field name="articleDescriptor"><![CDATA[Sex Factors]]></field>
  <field name="articleDescriptor"><![CDATA[Social Class]]></field>
  <field name="articleDescriptor"><![CDATA[United States]]></field>
  <field name="keyword"><![CDATA[Americas]]></field>
  <field name="keyword"><![CDATA[Behavior]]></field>
  <field name="keyword"><![CDATA[Blacks]]></field>
  <field name="keyword"><![CDATA[Cancer]]></field>
  <field name="keyword"><![CDATA[Cultural Background]]></field>
  <field name="keyword"><![CDATA[Demographic Factors]]></field>
  <field name="keyword"><![CDATA[Developed Countries]]></field>
  <field name="keyword"><![CDATA[Differential Mortality]]></field>
  <field name="keyword"><![CDATA[Diseases]]></field>
  <field name="keyword"><![CDATA[Economic Factors]]></field>
  <field name="keyword"><![CDATA[Epidemiologic Methods]]></field>
  <field name="keyword"><![CDATA[Ethnic Groups]]></field>
  <field name="keyword"><![CDATA[Human Resources]]></field>
  <field name="keyword"><![CDATA[Mortality--men]]></field>
  <field name="keyword"><![CDATA[Neoplasms]]></field>
  <field name="keyword"><![CDATA[North America]]></field>
  <field name="keyword"><![CDATA[Northern America]]></field>
  <field name="keyword"><![CDATA[Occupations]]></field>
  <field name="keyword"><![CDATA[Population]]></field>
  <field name="keyword"><![CDATA[Population Characteristics]]></field>
  <field name="keyword"><![CDATA[Population Dynamics]]></field>
  <field name="keyword"><![CDATA[Research Methodology]]></field>
  <field name="keyword"><![CDATA[Smoking]]></field>
  <field name="keyword"><![CDATA[Social Class]]></field>
  <field name="keyword"><![CDATA[Socioeconomic Factors]]></field>
  <field name="keyword"><![CDATA[Socioeconomic Status]]></field>
  <field name="keyword"><![CDATA[United States]]></field>
 </doc>
 <doc>
  <field name="id"><![CDATA[7120462]]></field>
  <field name="articleCreationDate"><![CDATA[1982-12-02T00:00:00Z]]></field>
  <field name="articleYear"><![CDATA[1982]]></field>
  <field name="articleCompletionDate"><![CDATA[1982-12-02T00:00:00Z]]></field>
  <field name="articleRevisionDate"><![CDATA[2010-10-26T00:00:00Z]]></field>
  <field name="articlePubmodel"><![CDATA[Print]]></field>
  <field name="journalTitle"><![CDATA[Journal of the National Medical Association]]></field>
  <field name="journalTitleAbrv"><![CDATA[J Natl Med Assoc]]></field>
  <field name="articleTitle"><![CDATA[Intraluminal radiation for esophageal cancer: a Howard University technique.]]></field>
  <field name="articleAbstract"><![CDATA[The objective of radiotherapeutic management in esophageal cancer is to accomplish maximum tumor sterilization with minimal normal tissue damage. This sincere effort is most often countered by the differential in tumor dose response vs normal tissue tolerance. Intraluminal isotope radiation, with its inherent advantage of rapid dose falloff, spares the lungs, the spinal cord, and other vital structures, yet yields adequately high doses to esophageal tumor. Though in existence since the turn of the century, the method of intracavitary radium bougie application dropped out of favor due to technical difficulties imposed by the size of the radium source and radiation exposure to the personnel involved. The authors describe a simple "iridium 192 afterloading intraluminal technique" that eliminates technical problems and reduces radiation exposure considerably.]]></field>
  <field name="author"><![CDATA[Moorthy C R]]></field>
  <field name="author"><![CDATA[Nibhanupudy J R]]></field>
  <field name="author"><![CDATA[Ashayeri E]]></field>
  <field name="author"><![CDATA[Goldson A L]]></field>
  <field name="author"><![CDATA[Espinoza M C]]></field>
  <field name="author"><![CDATA[Nidiry J J]]></field>
  <field name="author"><![CDATA[Warner O G]]></field>
  <field name="author"><![CDATA[Roux V J]]></field>
  <field name="articleLang"><![CDATA[eng]]></field>
  <field name="publicationType"><![CDATA[Journal Article]]></field>
  <field name="articleDescriptor"><![CDATA[Brachytherapy]]></field>
  <field name="articleQualifier"><![CDATA[methods]]></field>
  <field name="articleDescriptor"><![CDATA[Esophageal Neoplasms]]></field>
  <field name="articleQualifier"><![CDATA[radiotherapy]]></field>
  <field name="articleDescriptor"><![CDATA[Humans]]></field>
 </doc>
 <doc>
  <field name="id"><![CDATA[7120463]]></field>
  <field name="articleCreationDate"><![CDATA[1982-12-02T00:00:00Z]]></field>
  <field name="articleYear"><![CDATA[1982]]></field>
  <field name="articleCompletionDate"><![CDATA[1982-12-02T00:00:00Z]]></field>
  <field name="articleRevisionDate"><![CDATA[2010-10-26T00:00:00Z]]></field>
  <field name="articlePubmodel"><![CDATA[Print]]></field>
  <field name="journalTitle"><![CDATA[Journal of the National Medical Association]]></field>
  <field name="journalTitleAbrv"><![CDATA[J Natl Med Assoc]]></field>
  <field name="articleTitle"><![CDATA[Value of X-ray pelvimetry in primiparas. II: influence on management of labor.]]></field>
  <field name="articleAbstract"><![CDATA[Despite its potential risks x-ray pelvimetry remains a common diagnostic procedure performed during labor. In order to determine whether x-ray pelvimetry measurements influence the outcome of labor (vaginal vs cesarean), 280 consecutive primiparous parturients were studied.Most parturients were black at term with a vertex presentation. Most pelvimetries were ordered for suspected cephalopelvic disproportion. Of the total number of parturients studied, 31.8 percent had cesarean deliveries, 85.4 percent of them because of CPD. The clinical characteristics compared were similar among the groups studied. X-ray pelvimetry values obtained by two techniques were similar to those previously reported. Although correlations between measurements and delivery route were noted, these values, by themselves, did not have a necessary correlation to the route of delivery in the majority of parturients studied.This finding, like others reported, emphasizes the need to abandon x-ray pelvimetry as a requirement for documenting contracted pelves before abdominal deliveries. CPD should be documented by evaluating the pelvis, quality of labor, and maternal-fetal well-being by other appropriate, less risky means readily available.]]></field>
  <field name="author"><![CDATA[Poma P A]]></field>
  <field name="articleLang"><![CDATA[eng]]></field>
  <field name="publicationType"><![CDATA[Journal Article]]></field>
  <field name="articleDescriptor"><![CDATA[Female]]></field>
  <field name="articleDescriptor"><![CDATA[Humans]]></field>
  <field name="articleDescriptor"><![CDATA[Obstetric Labor Complications]]></field>
  <field name="articleQualifier"><![CDATA[radiography]]></field>
  <field name="articleDescriptor"><![CDATA[Parity]]></field>
  <field name="articleDescriptor"><![CDATA[Pelvimetry]]></field>
  <field name="articleDescriptor"><![CDATA[Pelvis]]></field>
  <field name="articleQualifier"><![CDATA[radiography]]></field>
  <field name="articleDescriptor"><![CDATA[Pregnancy]]></field>
 </doc>
 <doc>
  <field name="id"><![CDATA[7120464]]></field>
  <field name="articleCreationDate"><![CDATA[1982-12-02T00:00:00Z]]></field>
  <field name="articleYear"><![CDATA[1982]]></field>
  <field name="articleCompletionDate"><![CDATA[1982-12-02T00:00:00Z]]></field>
  <field name="articleRevisionDate"><![CDATA[2010-10-26T00:00:00Z]]></field>
  <field name="articlePubmodel"><![CDATA[Print]]></field>
  <field name="journalTitle"><![CDATA[Journal of the National Medical Association]]></field>
  <field name="journalTitleAbrv"><![CDATA[J Natl Med Assoc]]></field>
  <field name="articleTitle"><![CDATA[Polymicrobial genital gangrene (Fournier's gangrene): clinical, microbiologic, and therapeutic features.]]></field>
  <field name="articleAbstract"><![CDATA[The microbiologic and therapeutic aspects of polymicrobial genital gangrene (Fournier's gangrene) studied in nine patients are presented. Seven patients had both aerobic and anaerobic bacteria isolated from the site of infection; four had Bacteroides and two, Clostridia. Broad-spectrum penicillins such as ticarcillin, mezlocillin, and piperacillin, or combined clindamycin and gentamicin therapy were used. One patient died of fulminating infection and eight patients were cured of their infections. Anaerobic bacteria and appropriate antibiotic therapy should be considered in all patients with genital gangrene.]]></field>
  <field name="author"><![CDATA[Thadepalli H]]></field>
  <field name="author"><![CDATA[Rao B]]></field>
  <field name="author"><![CDATA[Datta N K]]></field>
  <field name="author"><![CDATA[Zinner N]]></field>
  <field name="articleLang"><![CDATA[eng]]></field>
  <field name="publicationType"><![CDATA[Case Reports]]></field>
  <field name="publicationType"><![CDATA[Journal Article]]></field>
  <field name="substanceName"><![CDATA[Penicillins]]></field>
  <field name="articleDescriptor"><![CDATA[Adult]]></field>
  <field name="articleDescriptor"><![CDATA[Aged]]></field>
  <field name="articleDescriptor"><![CDATA[Gangrene]]></field>
  <field name="articleQualifier"><![CDATA[drug therapy]]></field>
  <field name="articleQualifier"><![CDATA[microbiology]]></field>
  <field name="articleDescriptor"><![CDATA[Genital Diseases, Male]]></field>
  <field name="articleQualifier"><![CDATA[drug therapy]]></field>
  <field name="articleQualifier"><![CDATA[microbiology]]></field>
  <field name="articleDescriptor"><![CDATA[Humans]]></field>
  <field name="articleDescriptor"><![CDATA[Male]]></field>
  <field name="articleDescriptor"><![CDATA[Middle Aged]]></field>
  <field name="articleDescriptor"><![CDATA[Penicillins]]></field>
  <field name="articleQualifier"><![CDATA[therapeutic use]]></field>
 </doc>
 <doc>
  <field name="id"><![CDATA[7120465]]></field>
  <field name="articleCreationDate"><![CDATA[1982-12-02T00:00:00Z]]></field>
  <field name="articleYear"><![CDATA[1982]]></field>
  <field name="articleCompletionDate"><![CDATA[1982-12-02T00:00:00Z]]></field>
  <field name="articleRevisionDate"><![CDATA[2010-10-26T00:00:00Z]]></field>
  <field name="articlePubmodel"><![CDATA[Print]]></field>
  <field name="journalTitle"><![CDATA[Journal of the National Medical Association]]></field>
  <field name="journalTitleAbrv"><![CDATA[J Natl Med Assoc]]></field>
  <field name="articleTitle"><![CDATA[Ileosigmoid volvulus and acute external hemorrhoids: a new entity?]]></field>
  <field name="articleAbstract"><![CDATA[An unusual association of small bowel volvulus and sigmoid volvulus occurring concurrently and causing gangrene in both organs is presented. The clinical and pathological correlations and surgical management of this rare entity are discussed.]]></field>
  <field name="author"><![CDATA[Olowofoyeku B V]]></field>
  <field name="author"><![CDATA[Callender C O]]></field>
  <field name="articleLang"><![CDATA[eng]]></field>
  <field name="publicationType"><![CDATA[Case Reports]]></field>
  <field name="publicationType"><![CDATA[Journal Article]]></field>
  <field name="articleDescriptor"><![CDATA[Adult]]></field>
  <field name="articleDescriptor"><![CDATA[Colon, Sigmoid]]></field>
  <field name="articleQualifier"><![CDATA[surgery]]></field>
  <field name="articleDescriptor"><![CDATA[Hemorrhoids]]></field>
  <field name="articleQualifier"><![CDATA[complications]]></field>
  <field name="articleDescriptor"><![CDATA[Humans]]></field>
  <field name="articleDescriptor"><![CDATA[Ileal Diseases]]></field>
  <field name="articleQualifier"><![CDATA[complications]]></field>
  <field name="articleDescriptor"><![CDATA[Ileum]]></field>
  <field name="articleQualifier"><![CDATA[surgery]]></field>
  <field name="articleDescriptor"><![CDATA[Intestinal Obstruction]]></field>
  <field name="articleQualifier"><![CDATA[complications]]></field>
  <field name="articleDescriptor"><![CDATA[Male]]></field>
  <field name="articleDescriptor"><![CDATA[Sigmoid Diseases]]></field>
  <field name="articleQualifier"><![CDATA[complications]]></field>
 </doc>
 <doc>
  <field name="id"><![CDATA[7120466]]></field>
  <field name="articleCreationDate"><![CDATA[1982-12-02T00:00:00Z]]></field>
  <field name="articleYear"><![CDATA[1982]]></field>
  <field name="articleCompletionDate"><![CDATA[1982-12-02T00:00:00Z]]></field>
  <field name="articleRevisionDate"><![CDATA[2010-10-26T00:00:00Z]]></field>
  <field name="articlePubmodel"><![CDATA[Print]]></field>
  <field name="journalTitle"><![CDATA[Journal of the National Medical Association]]></field>
  <field name="journalTitleAbrv"><![CDATA[J Natl Med Assoc]]></field>
  <field name="articleTitle"><![CDATA[Segmental ulcerative colitis: a case report and review of the literature.]]></field>
  <field name="articleAbstract"><![CDATA[Ulceractive colitis, a chronic diffuse inflammatory disease affecting the mucosa of the colon and rectum, is characterized by ulcerations with bleeding, mucosal crypt abscesses, and inflammatory pseudopolyps. Classically, it begins in the rectosigmoid but often extends to involve the entire colon. It is uncommon to find segmental involvement sparing the rectosigmoid.A case of segmental ulcerative colitis is presented with a brief comparison of segmental ulcerative colitis and segmental Crohn's colitis.]]></field>
  <field name="author"><![CDATA[Massac E]]></field>
  <field name="author"><![CDATA[Rawlings L]]></field>
  <field name="author"><![CDATA[Kurtz L]]></field>
  <field name="articleLang"><![CDATA[eng]]></field>
  <field name="publicationType"><![CDATA[Case Reports]]></field>
  <field name="publicationType"><![CDATA[Journal Article]]></field>
  <field name="articleDescriptor"><![CDATA[Aged]]></field>
  <field name="articleDescriptor"><![CDATA[Colitis, Ulcerative]]></field>
  <field name="articleQualifier"><![CDATA[radiography]]></field>
  <field name="articleDescriptor"><![CDATA[Crohn Disease]]></field>
  <field name="articleQualifier"><![CDATA[radiography]]></field>
  <field name="articleDescriptor"><![CDATA[Diagnosis, Differential]]></field>
  <field name="articleDescriptor"><![CDATA[Female]]></field>
  <field name="articleDescriptor"><![CDATA[Humans]]></field>
 </doc>
 <doc>
  <field name="id"><![CDATA[7120467]]></field>
  <field name="articleCreationDate"><![CDATA[1982-12-02T00:00:00Z]]></field>
  <field name="articleYear"><![CDATA[1982]]></field>
  <field name="articleCompletionDate"><![CDATA[1982-12-02T00:00:00Z]]></field>
  <field name="articleRevisionDate"><![CDATA[2010-10-26T00:00:00Z]]></field>
  <field name="articlePubmodel"><![CDATA[Print]]></field>
  <field name="journalTitle"><![CDATA[Journal of the National Medical Association]]></field>
  <field name="journalTitleAbrv"><![CDATA[J Natl Med Assoc]]></field>
  <field name="articleTitle"><![CDATA[A study of bone density in black women with hip fractures.]]></field>
  <field name="articleAbstract"><![CDATA[Fracture of the hip in black women is not a common injury. The cause of this decreased incidence is commonly stated to be the relative increase in density of the bones in black women as compared with whites. To test this hypothesis we studied the x-rays of 101 black women who had hip fractures. We found that there was a decrease in the mineral content of bone as measured by the Singh Index. We also studied the degree of kyphosis and found that this was increased over a control group. This study does not refute the lower incidence of hip fracture in black women but simply points out that when these fractures do occur, they occur in osteopenic bone.]]></field>
  <field name="author"><![CDATA[Pierce R O]]></field>
  <field name="articleLang"><![CDATA[eng]]></field>
  <field name="publicationType"><![CDATA[Journal Article]]></field>
  <field name="substanceName"><![CDATA[Minerals]]></field>
  <field name="articleDescriptor"><![CDATA[African Continental Ancestry Group]]></field>
  <field name="articleDescriptor"><![CDATA[Aged]]></field>
  <field name="articleDescriptor"><![CDATA[Bone and Bones]]></field>
  <field name="articleQualifier"><![CDATA[analysis]]></field>
  <field name="articleDescriptor"><![CDATA[Female]]></field>
  <field name="articleDescriptor"><![CDATA[Hip Fractures]]></field>
  <field name="articleQualifier"><![CDATA[epidemiology]]></field>
  <field name="articleDescriptor"><![CDATA[Humans]]></field>
  <field name="articleDescriptor"><![CDATA[Indiana]]></field>
  <field name="articleDescriptor"><![CDATA[Minerals]]></field>
  <field name="articleQualifier"><![CDATA[analysis]]></field>
 </doc>
 <doc>
  <field name="id"><![CDATA[7120468]]></field>
  <field name="articleCreationDate"><![CDATA[1982-12-02T00:00:00Z]]></field>
  <field name="articleYear"><![CDATA[1982]]></field>
  <field name="articleCompletionDate"><![CDATA[1982-12-02T00:00:00Z]]></field>
  <field name="articleRevisionDate"><![CDATA[2010-10-26T00:00:00Z]]></field>
  <field name="articlePubmodel"><![CDATA[Print]]></field>
  <field name="journalTitle"><![CDATA[Journal of the National Medical Association]]></field>
  <field name="journalTitleAbrv"><![CDATA[J Natl Med Assoc]]></field>
  <field name="articleTitle"><![CDATA[Insulin receptor characteristics of erythrocytes from human newborns.]]></field>
  <field name="articleAbstract"><![CDATA[Erythrocytes from human newborns were observed to have specific insulin receptors. The characteristics of these receptors were similar to those of the normal adult subjects. An observed slight increase in R(o) and a decrease in K̄(e) of insulin receptors in erythrocytes may be speculated to facilitate the transfer of insulin from the fetal erythrocytes to other rapidly growing fetal tissues at a rate faster than that present in the circulation of the adult subjects.]]></field>
  <field name="author"><![CDATA[Gambhir K K]]></field>
  <field name="author"><![CDATA[Nerurkar S G]]></field>
  <field name="author"><![CDATA[Allen T]]></field>
  <field name="author"><![CDATA[Hill R M]]></field>
  <field name="author"><![CDATA[Sekhon H S]]></field>
  <field name="author"><![CDATA[Westney L S]]></field>
  <field name="articleLang"><![CDATA[eng]]></field>
  <field name="publicationType"><![CDATA[Journal Article]]></field>
  <field name="publicationType"><![CDATA[Research Support, U.S. Gov't, P.H.S.]]></field>
  <field name="substanceName"><![CDATA[Receptor, Insulin]]></field>
  <field name="articleDescriptor"><![CDATA[Adolescent]]></field>
  <field name="articleDescriptor"><![CDATA[Adult]]></field>
  <field name="articleDescriptor"><![CDATA[Erythrocytes]]></field>
  <field name="articleQualifier"><![CDATA[metabolism]]></field>
  <field name="articleDescriptor"><![CDATA[Female]]></field>
  <field name="articleDescriptor"><![CDATA[Fetal Blood]]></field>
  <field name="articleQualifier"><![CDATA[metabolism]]></field>
  <field name="articleDescriptor"><![CDATA[Humans]]></field>
  <field name="articleDescriptor"><![CDATA[Infant, Newborn]]></field>
  <field name="articleDescriptor"><![CDATA[Receptor, Insulin]]></field>
  <field name="articleQualifier"><![CDATA[metabolism]]></field>
 </doc>
 <doc>
  <field name="id"><![CDATA[7120469]]></field>
  <field name="articleCreationDate"><![CDATA[1982-12-02T00:00:00Z]]></field>
  <field name="articleYear"><![CDATA[1982]]></field>
  <field name="articleCompletionDate"><![CDATA[1982-12-02T00:00:00Z]]></field>
  <field name="articleRevisionDate"><![CDATA[2010-10-26T00:00:00Z]]></field>
  <field name="articlePubmodel"><![CDATA[Print]]></field>
  <field name="journalTitle"><![CDATA[Journal of the National Medical Association]]></field>
  <field name="journalTitleAbrv"><![CDATA[J Natl Med Assoc]]></field>
  <field name="articleTitle"><![CDATA[Adult nephrotic syndrome and acquired coagulopathies: Hageman factor deficiency.]]></field>
  <field name="articleAbstract"><![CDATA[Analysis of tests of coagulation and fibrinolysis from 20 adult nephrotics prior to the onset of therapy disclosed that 40 percent had low factor XII levels. The mean factor XI was normal. The platelet count and fibrinogen concentration were elevated. The findings of this study on adults are similar to those of Honig and Lindley(21) in the nephrotic syndrome of childhood. Subjects with minimal change disease constituted a small (15 percent) but readily segregated subpopulation without evidence of fibrinolysis in association with low factor XII activity. Prolongation of the activated partial thromboplastin time corresponded in every instance with factor XII activities of ≤30 percent. Lengthening of the one stage prothrombin time was not directly attributable to factor deficiencies.]]></field>
  <field name="author"><![CDATA[Branson H E]]></field>
  <field name="author"><![CDATA[Vaziri N D]]></field>
  <field name="author"><![CDATA[Slater L M]]></field>
  <field name="articleLang"><![CDATA[eng]]></field>
  <field name="publicationType"><![CDATA[Journal Article]]></field>
  <field name="articleDescriptor"><![CDATA[Adult]]></field>
  <field name="articleDescriptor"><![CDATA[Aged]]></field>
  <field name="articleDescriptor"><![CDATA[Blood Coagulation Tests]]></field>
  <field name="articleDescriptor"><![CDATA[Factor XII Deficiency]]></field>
  <field name="articleQualifier"><![CDATA[complications]]></field>
  <field name="articleQualifier"><![CDATA[diagnosis]]></field>
  <field name="articleDescriptor"><![CDATA[Female]]></field>
  <field name="articleDescriptor"><![CDATA[Humans]]></field>
  <field name="articleDescriptor"><![CDATA[Male]]></field>
  <field name="articleDescriptor"><![CDATA[Middle Aged]]></field>
  <field name="articleDescriptor"><![CDATA[Nephrotic Syndrome]]></field>
  <field name="articleQualifier"><![CDATA[complications]]></field>
  <field name="articleQualifier"><![CDATA[diagnosis]]></field>
 </doc>
 <doc>
  <field name="id"><![CDATA[7120470]]></field>
  <field name="articleCreationDate"><![CDATA[1982-12-02T00:00:00Z]]></field>
  <field name="articleYear"><![CDATA[1982]]></field>
  <field name="articleCompletionDate"><![CDATA[1982-12-02T00:00:00Z]]></field>
  <field name="articleRevisionDate"><![CDATA[2010-10-26T00:00:00Z]]></field>
  <field name="articlePubmodel"><![CDATA[Print]]></field>
  <field name="journalTitle"><![CDATA[Journal of the National Medical Association]]></field>
  <field name="journalTitleAbrv"><![CDATA[J Natl Med Assoc]]></field>
  <field name="articleTitle"><![CDATA[Smoking cessation in the Chicago Coronary Prevention Evaluation Program.]]></field>
  <field name="articleAbstract"><![CDATA[Quit-rates for cigarette smokers in a lifestyle intervention program aimed at reducing coronary risk were 24 percent for all participants and 34 percent for non-dropouts. Recidivism remained very low during participation in the program. Half of the smokers who quit did so after being in the program more than two years. These data suggest that while engaging in an effort to make other changes in lifestyle, many smokers can be helped to quit. Sustained antismoking efforts in the clinical practice of medicine can be expected to share these same positive aspects. While mass public health programs to eliminate smoking and prevent young people from taking up the habit are being developed, health practitioners can make a significant contribution by including vigorous efforts at smoking cessation as part of routine practice.]]></field>
  <field name="author"><![CDATA[Cooper R]]></field>
  <field name="author"><![CDATA[Soltero I]]></field>
  <field name="author"><![CDATA[Stamler J]]></field>
  <field name="author"><![CDATA[Mojonnier L]]></field>
  <field name="author"><![CDATA[Hall Y]]></field>
  <field name="author"><![CDATA[Moss D]]></field>
  <field name="author"><![CDATA[Berkson D M]]></field>
  <field name="author"><![CDATA[Tokich T]]></field>
  <field name="articleLang"><![CDATA[eng]]></field>
  <field name="publicationType"><![CDATA[Journal Article]]></field>
  <field name="publicationType"><![CDATA[Research Support, Non-U.S. Gov't]]></field>
  <field name="publicationType"><![CDATA[Research Support, U.S. Gov't, P.H.S.]]></field>
  <field name="articleDescriptor"><![CDATA[Adult]]></field>
  <field name="articleDescriptor"><![CDATA[Chicago]]></field>
  <field name="articleDescriptor"><![CDATA[Coronary Disease]]></field>
  <field name="articleQualifier"><![CDATA[prevention & control]]></field>
  <field name="articleDescriptor"><![CDATA[Humans]]></field>
  <field name="articleDescriptor"><![CDATA[Male]]></field>
  <field name="articleDescriptor"><![CDATA[Middle Aged]]></field>
  <field name="articleDescriptor"><![CDATA[Patient Dropouts]]></field>
  <field name="articleDescriptor"><![CDATA[Smoking]]></field>
  <field name="articleQualifier"><![CDATA[prevention & control]]></field>
 </doc>
 <doc>
  <field name="id"><![CDATA[7120471]]></field>
  <field name="articleCreationDate"><![CDATA[1982-12-02T00:00:00Z]]></field>
  <field name="articleYear"><![CDATA[1982]]></field>
  <field name="articleCompletionDate"><![CDATA[1982-12-02T00:00:00Z]]></field>
  <field name="articleRevisionDate"><![CDATA[2010-10-26T00:00:00Z]]></field>
  <field name="articlePubmodel"><![CDATA[Print]]></field>
  <field name="journalTitle"><![CDATA[Journal of the National Medical Association]]></field>
  <field name="journalTitleAbrv"><![CDATA[J Natl Med Assoc]]></field>
  <field name="articleTitle"><![CDATA[Glassy cell carcinoma of the cervix: report of three cases.]]></field>
  <field name="articleAbstract"><![CDATA[Glassy cell carcinoma is a poorly differentiated adenosquamous carcinoma of the cervix, hallmarked by aggressive behavior, occurrence in association with pregnancy, and a poor patient survival rate. Three of these very rare cervical, primary malignancies are reported. At the time of this writing, only one patient has survived.]]></field>
  <field name="author"><![CDATA[Johnston G A]]></field>
  <field name="author"><![CDATA[Azizi F]]></field>
  <field name="author"><![CDATA[Reale F]]></field>
  <field name="author"><![CDATA[Jones H A]]></field>
  <field name="articleLang"><![CDATA[eng]]></field>
  <field name="publicationType"><![CDATA[Case Reports]]></field>
  <field name="publicationType"><![CDATA[Journal Article]]></field>
  <field name="articleDescriptor"><![CDATA[Adenocarcinoma]]></field>
  <field name="articleQualifier"><![CDATA[pathology]]></field>
  <field name="articleDescriptor"><![CDATA[Adult]]></field>
  <field name="articleDescriptor"><![CDATA[Carcinoma, Squamous Cell]]></field>
  <field name="articleQualifier"><![CDATA[pathology]]></field>
  <field name="articleDescriptor"><![CDATA[Female]]></field>
  <field name="articleDescriptor"><![CDATA[Humans]]></field>
  <field name="articleDescriptor"><![CDATA[Uterine Cervical Neoplasms]]></field>
  <field name="articleQualifier"><![CDATA[pathology]]></field>
 </doc>
 <doc>
  <field name="id"><![CDATA[7120472]]></field>
  <field name="articleCreationDate"><![CDATA[1982-12-02T00:00:00Z]]></field>
  <field name="articleYear"><![CDATA[1982]]></field>
  <field name="articleCompletionDate"><![CDATA[1982-12-02T00:00:00Z]]></field>
  <field name="articleRevisionDate"><![CDATA[2010-10-26T00:00:00Z]]></field>
  <field name="articlePubmodel"><![CDATA[Print]]></field>
  <field name="journalTitle"><![CDATA[Journal of the National Medical Association]]></field>
  <field name="journalTitleAbrv"><![CDATA[J Natl Med Assoc]]></field>
  <field name="articleTitle"><![CDATA[The relevance of occupational medicine.]]></field>
  <field name="articleAbstract"><![CDATA[As the burden-of-illness profile has shifted significantly in recent years, more attention is focused on occupational factors in disease, not only because of past developments and future aspects but mainly because of the numerous practical and theoretical implications and the involvement of many medical and social features.]]></field>
  <field name="author"><![CDATA[Walker B]]></field>
  <field name="articleLang"><![CDATA[eng]]></field>
  <field name="publicationType"><![CDATA[Journal Article]]></field>
  <field name="articleDescriptor"><![CDATA[Female]]></field>
  <field name="articleDescriptor"><![CDATA[Humans]]></field>
  <field name="articleDescriptor"><![CDATA[Infertility]]></field>
  <field name="articleQualifier"><![CDATA[etiology]]></field>
  <field name="articleDescriptor"><![CDATA[Male]]></field>
  <field name="articleDescriptor"><![CDATA[Neoplasms]]></field>
  <field name="articleQualifier"><![CDATA[etiology]]></field>
  <field name="articleDescriptor"><![CDATA[Occupational Diseases]]></field>
  <field name="articleQualifier"><![CDATA[etiology]]></field>
  <field name="articleDescriptor"><![CDATA[Occupational Medicine]]></field>
  <field name="articleDescriptor"><![CDATA[United States]]></field>
 </doc>
 <doc>
  <field name="id"><![CDATA[7120473]]></field>
  <field name="articleCreationDate"><![CDATA[1982-12-02T00:00:00Z]]></field>
  <field name="articleYear"><![CDATA[1982]]></field>
  <field name="articleCompletionDate"><![CDATA[1982-12-02T00:00:00Z]]></field>
  <field name="articleRevisionDate"><![CDATA[2010-10-26T00:00:00Z]]></field>
  <field name="articlePubmodel"><![CDATA[Print]]></field>
  <field name="journalTitle"><![CDATA[Journal of the National Medical Association]]></field>
  <field name="journalTitleAbrv"><![CDATA[J Natl Med Assoc]]></field>
  <field name="articleTitle"><![CDATA[Melanoma in black patients.]]></field>
  <field name="articleAbstract"><![CDATA[Melanoma in black patients is uncommon but not rare. This paper reports six cases seen in one general surgeon's practice in Arkansas during a 14-year period. A review of the current literature regarding melanoma in blacks is given.Characteristically, melanoma in blacks is found on the soles of the feet, palms of the hands, or mucous membranes. The tumor has a deadly potential unless it is treated at an early stage; four of the patients reported have died of metastatic disease. A public health program is needed to make physicians and the public aware of the incidence and location of this tumor.]]></field>
  <field name="author"><![CDATA[Smith R J]]></field>
  <field name="articleLang"><![CDATA[eng]]></field>
  <field name="publicationType"><![CDATA[Case Reports]]></field>
  <field name="publicationType"><![CDATA[Journal Article]]></field>
  <field name="articleDescriptor"><![CDATA[Adult]]></field>
  <field name="articleDescriptor"><![CDATA[African Continental Ancestry Group]]></field>
  <field name="articleDescriptor"><![CDATA[Aged]]></field>
  <field name="articleDescriptor"><![CDATA[Female]]></field>
  <field name="articleDescriptor"><![CDATA[Foot Diseases]]></field>
  <field name="articleQualifier"><![CDATA[pathology]]></field>
  <field name="articleDescriptor"><![CDATA[Humans]]></field>
  <field name="articleDescriptor"><![CDATA[Male]]></field>
  <field name="articleDescriptor"><![CDATA[Melanoma]]></field>
  <field name="articleQualifier"><![CDATA[pathology]]></field>
  <field name="articleDescriptor"><![CDATA[Middle Aged]]></field>
  <field name="articleDescriptor"><![CDATA[Neoplasm Metastasis]]></field>
  <field name="articleDescriptor"><![CDATA[Skin Neoplasms]]></field>
  <field name="articleQualifier"><![CDATA[pathology]]></field>
 </doc>
 <doc>
  <field name="id"><![CDATA[7120474]]></field>
  <field name="articleCreationDate"><![CDATA[1982-12-02T00:00:00Z]]></field>
  <field name="articleYear"><![CDATA[1982]]></field>
  <field name="articleCompletionDate"><![CDATA[1982-12-02T00:00:00Z]]></field>
  <field name="articleRevisionDate"><![CDATA[2010-10-26T00:00:00Z]]></field>
  <field name="articlePubmodel"><![CDATA[Print]]></field>
  <field name="journalTitle"><![CDATA[Journal of the National Medical Association]]></field>
  <field name="journalTitleAbrv"><![CDATA[J Natl Med Assoc]]></field>
  <field name="articleTitle"><![CDATA[Mediastinal hyperfunctioning parathyroid adenoma.]]></field>
  <field name="articleAbstract"><![CDATA[A patient presented with peptic ulcer disease and nephrolithiasis. Laboratory investigation disclosed hyperparathyroidism and following neck exploration, hypercalcemia persisted. After two years' follow-up, a retroesophageal mass that proved to be a parathyroid adenoma was discovered. This case is presented to illustrate the unusual occurrence of a posterior mediastinal tumor and the difficulty in managing ectopic parathyroid adenomas.]]></field>
  <field name="author"><![CDATA[Massac E]]></field>
  <field name="author"><![CDATA[Righini M]]></field>
  <field name="author"><![CDATA[Seremetis M]]></field>
  <field name="articleLang"><![CDATA[eng]]></field>
  <field name="publicationType"><![CDATA[Case Reports]]></field>
  <field name="publicationType"><![CDATA[Journal Article]]></field>
  <field name="articleDescriptor"><![CDATA[Adenoma]]></field>
  <field name="articleQualifier"><![CDATA[complications]]></field>
  <field name="articleDescriptor"><![CDATA[Humans]]></field>
  <field name="articleDescriptor"><![CDATA[Hypercalcemia]]></field>
  <field name="articleQualifier"><![CDATA[etiology]]></field>
  <field name="articleDescriptor"><![CDATA[Hyperparathyroidism]]></field>
  <field name="articleQualifier"><![CDATA[etiology]]></field>
  <field name="articleDescriptor"><![CDATA[Male]]></field>
  <field name="articleDescriptor"><![CDATA[Mediastinal Neoplasms]]></field>
  <field name="articleQualifier"><![CDATA[complications]]></field>
  <field name="articleDescriptor"><![CDATA[Middle Aged]]></field>
  <field name="articleDescriptor"><![CDATA[Parathyroid Neoplasms]]></field>
  <field name="articleQualifier"><![CDATA[complications]]></field>
  <field name="articleDescriptor"><![CDATA[Peptic Ulcer]]></field>
  <field name="articleQualifier"><![CDATA[etiology]]></field>
 </doc>
 <doc>
  <field name="id"><![CDATA[7120475]]></field>
  <field name="articleCreationDate"><![CDATA[1982-12-02T00:00:00Z]]></field>
  <field name="articleYear"><![CDATA[1982]]></field>
  <field name="articleCompletionDate"><![CDATA[1982-12-02T00:00:00Z]]></field>
  <field name="articleRevisionDate"><![CDATA[2010-10-26T00:00:00Z]]></field>
  <field name="articlePubmodel"><![CDATA[Print]]></field>
  <field name="journalTitle"><![CDATA[Journal of the National Medical Association]]></field>
  <field name="journalTitleAbrv"><![CDATA[J Natl Med Assoc]]></field>
  <field name="articleTitle"><![CDATA[Scrotal lymphedema praecox: disease and treatment.]]></field>
  <field name="articleAbstract"><![CDATA[Lymphedema of the scrotum and penis represents a debilitating but uncommon entity in countries spared of endemic filariasis. The clinical presentation and surgical management of one patient with idiopathic lymphedema praecox is discussed. A posterior based scrotal skin flap and a split thickness skin graft were used to reconstruct the scrotum and resurface the penis following radical excision of the edematous tissue. Limitation of the disease to the superficial tissues and relative sparing of the posterior scrotal skin represent the anatomic basis for success with this approach. The more deforming therapeutic alternative of excision of all lymphedematous tissue with transfer of the testes to the thigh and split thickness skin grafting to the exposed area would probably be best reserved for recurrence.]]></field>
  <field name="author"><![CDATA[Anderson B B]]></field>
  <field name="author"><![CDATA[Cadogan C A]]></field>
  <field name="articleLang"><![CDATA[eng]]></field>
  <field name="publicationType"><![CDATA[Case Reports]]></field>
  <field name="publicationType"><![CDATA[Journal Article]]></field>
  <field name="articleDescriptor"><![CDATA[Adolescent]]></field>
  <field name="articleDescriptor"><![CDATA[Genital Diseases, Male]]></field>
  <field name="articleQualifier"><![CDATA[surgery]]></field>
  <field name="articleDescriptor"><![CDATA[Humans]]></field>
  <field name="articleDescriptor"><![CDATA[Lymphedema]]></field>
  <field name="articleQualifier"><![CDATA[surgery]]></field>
  <field name="articleDescriptor"><![CDATA[Male]]></field>
  <field name="articleDescriptor"><![CDATA[Methods]]></field>
  <field name="articleDescriptor"><![CDATA[Penile Diseases]]></field>
  <field name="articleQualifier"><![CDATA[surgery]]></field>
  <field name="articleDescriptor"><![CDATA[Scrotum]]></field>
  <field name="articleQualifier"><![CDATA[surgery]]></field>
 </doc>
 <doc>
  <field name="id"><![CDATA[7120476]]></field>
  <field name="articleCreationDate"><![CDATA[1982-12-02T00:00:00Z]]></field>
  <field name="articleYear"><![CDATA[1982]]></field>
  <field name="articleCompletionDate"><![CDATA[1982-12-02T00:00:00Z]]></field>
  <field name="articleRevisionDate"><![CDATA[2010-10-26T00:00:00Z]]></field>
  <field name="articlePubmodel"><![CDATA[Print]]></field>
  <field name="journalTitle"><![CDATA[Journal of the National Medical Association]]></field>
  <field name="journalTitleAbrv"><![CDATA[J Natl Med Assoc]]></field>
  <field name="articleTitle"><![CDATA[Health care: lessons from China and Cuba.]]></field>
  <field name="articleAbstract"><![CDATA[Health has improved in Cuba and China during the past quarter of a century. Some of the improvements in health occurred as economic conditions improved in both countries, but there are other similarities of health care delivery in China and Cuba. Collective activity plays an important role in health care in both nations; both do health planning centrally, but local communities control the daily activities of the health services that they use. Techniques that have improved health in underdeveloped nations might be applied in underserved areas of the United States.]]></field>
  <field name="author"><![CDATA[Younge R G]]></field>
  <field name="articleLang"><![CDATA[eng]]></field>
  <field name="publicationType"><![CDATA[Journal Article]]></field>
  <field name="articleDescriptor"><![CDATA[China]]></field>
  <field name="articleDescriptor"><![CDATA[Consumer Participation]]></field>
  <field name="articleDescriptor"><![CDATA[Cuba]]></field>
  <field name="articleDescriptor"><![CDATA[Delivery of Health Care]]></field>
  <field name="articleQualifier"><![CDATA[organization & administration]]></field>
  <field name="articleDescriptor"><![CDATA[Health Planning]]></field>
  <field name="articleQualifier"><![CDATA[organization & administration]]></field>
  <field name="articleDescriptor"><![CDATA[Humans]]></field>
 </doc>
 <doc>
  <field name="id"><![CDATA[7120478]]></field>
  <field name="articleCreationDate"><![CDATA[1982-12-02T00:00:00Z]]></field>
  <field name="articleYear"><![CDATA[1982]]></field>
  <field name="articleCompletionDate"><![CDATA[1982-12-02T00:00:00Z]]></field>
  <field name="articleRevisionDate"><![CDATA[2010-10-26T00:00:00Z]]></field>
  <field name="articlePubmodel"><![CDATA[Print]]></field>
  <field name="journalTitle"><![CDATA[Journal of the National Medical Association]]></field>
  <field name="journalTitleAbrv"><![CDATA[J Natl Med Assoc]]></field>
  <field name="articleTitle"><![CDATA[Hypertension: an update.]]></field>
  <field name="articleAbstract"><![CDATA[Current advances in hypertension are examined from the perspectives of both the individual patient and the community at large. Great progress has been made in the control of hypertension using a multipronged approach beginning with public and professional education. The recent nationwide fall in cardiovascular mortality is due at least in part to progress in hypertension control. There remain, however, segments of our population that are hard to reach and will continue to require community screening and special treatment programs. Governmental budgeting restraints should not be permitted to jeopardize our highly successful hypertension control and research programs.]]></field>
  <field name="author"><![CDATA[Cooper E S]]></field>
  <field name="articleLang"><![CDATA[eng]]></field>
  <field name="publicationType"><![CDATA[Journal Article]]></field>
  <field name="substanceName"><![CDATA[Antihypertensive Agents]]></field>
  <field name="articleDescriptor"><![CDATA[Antihypertensive Agents]]></field>
  <field name="articleQualifier"><![CDATA[adverse effects]]></field>
  <field name="articleQualifier"><![CDATA[therapeutic use]]></field>
  <field name="articleDescriptor"><![CDATA[Humans]]></field>
  <field name="articleDescriptor"><![CDATA[Hypertension]]></field>
  <field name="articleQualifier"><![CDATA[drug therapy]]></field>
  <field name="articleDescriptor"><![CDATA[Primary Prevention]]></field>
 </doc>
 <doc>
  <field name="id"><![CDATA[6750141]]></field>
  <field name="articleCreationDate"><![CDATA[1982-12-02T00:00:00Z]]></field>
  <field name="articleYear"><![CDATA[1982]]></field>
  <field name="articleCompletionDate"><![CDATA[1982-12-02T00:00:00Z]]></field>
  <field name="articleRevisionDate"><![CDATA[2010-10-26T00:00:00Z]]></field>
  <field name="articlePubmodel"><![CDATA[Print]]></field>
  <field name="journalTitle"><![CDATA[Journal of the National Medical Association]]></field>
  <field name="journalTitleAbrv"><![CDATA[J Natl Med Assoc]]></field>
  <field name="articleTitle"><![CDATA[Clinical program for screening and treatment of hypertension in veterans.]]></field>
  <field name="articleAbstract"><![CDATA[Hypertension clinics, in which primary care is provided by specially trained nonphysician therapists under physician supervision, can provide very effective and relatively inexpensive control of hypertension for large numbers of patients. Since 1972, 32 VA Hypertension Screening and Treatment Clinics have screened about 500,000 veterans, 29 percent of whom have had diastolic pressures of 90 mmHg or more and 13 percent of whom have had diastolic pressures of 105 mmHg or more. Of subjects who returned for a second visit, 77 percent continued to have diastolic pressures of 90 mmHg or more. Blacks had a higher percentage of severe hypertension than whites.Since treatment became available in these clinics in 1974, 25,000 veterans have been treated. Computerized data are available for 10,777 of them who began treatment during 1974, 1975, or 1976. Of those with at least five treatment visits during that period, half had diastolic pressures below 90 mmHg at their most recent visit, and 80 percent had diastolic pressures below 100 mmHg. Moreover visit adherence was high, with two thirds of those who began treatment in these clinics during their first six months of operation continuing that treatment for two and a half years.]]></field>
  <field name="author"><![CDATA[Perry H M]]></field>
  <field name="author"><![CDATA[Schnaper H W]]></field>
  <field name="author"><![CDATA[Meyer G]]></field>
  <field name="author"><![CDATA[Swatzell R]]></field>
  <field name="articleLang"><![CDATA[eng]]></field>
  <field name="publicationType"><![CDATA[Journal Article]]></field>
  <field name="articleDescriptor"><![CDATA[Adult]]></field>
  <field name="articleDescriptor"><![CDATA[Aged]]></field>
  <field name="articleDescriptor"><![CDATA[Female]]></field>
  <field name="articleDescriptor"><![CDATA[Humans]]></field>
  <field name="articleDescriptor"><![CDATA[Hypertension]]></field>
  <field name="articleQualifier"><![CDATA[prevention & control]]></field>
  <field name="articleQualifier"><![CDATA[therapy]]></field>
  <field name="articleDescriptor"><![CDATA[Male]]></field>
  <field name="articleDescriptor"><![CDATA[Mass Screening]]></field>
  <field name="articleDescriptor"><![CDATA[Middle Aged]]></field>
  <field name="articleDescriptor"><![CDATA[United States]]></field>
  <field name="articleDescriptor"><![CDATA[United States Department of Veterans Affairs]]></field>
  <field name="articleDescriptor"><![CDATA[Veterans]]></field>
 </doc>
 <doc>
  <field name="id"><![CDATA[6889655]]></field>
  <field name="articleCreationDate"><![CDATA[1982-12-02T00:00:00Z]]></field>
  <field name="articleYear"><![CDATA[1982]]></field>
  <field name="articleCompletionDate"><![CDATA[1982-12-02T00:00:00Z]]></field>
  <field name="articleRevisionDate"><![CDATA[2010-10-26T00:00:00Z]]></field>
  <field name="articlePubmodel"><![CDATA[Print]]></field>
  <field name="journalTitle"><![CDATA[Journal of the National Medical Association]]></field>
  <field name="journalTitleAbrv"><![CDATA[J Natl Med Assoc]]></field>
  <field name="articleTitle"><![CDATA[Bronchogenic carcinoma, leukemoid reaction, marantic endocarditis, and consumptive thrombocytopathy.]]></field>
  <field name="articleAbstract"><![CDATA[This paper details the simultaneous occurrence of a severe leukemoid reaction, non-bacterial thrombotic endocarditis (NBTE) (marantic endocarditis), and a consumptive thrombocytopathy without signs of micro-angiopathic hemolysis on peripheral blood smear in a patient with terminal metastatic, undifferentiated, large cell bronchogenic carcinoma. The case is presented and the condition is discussed in detail.]]></field>
  <field name="author"><![CDATA[Chisholm J C]]></field>
  <field name="author"><![CDATA[Ireland C S]]></field>
  <field name="author"><![CDATA[Scott R N]]></field>
  <field name="articleLang"><![CDATA[eng]]></field>
  <field name="publicationType"><![CDATA[Case Reports]]></field>
  <field name="publicationType"><![CDATA[Journal Article]]></field>
  <field name="articleDescriptor"><![CDATA[Blood Platelet Disorders]]></field>
  <field name="articleQualifier"><![CDATA[complications]]></field>
  <field name="articleDescriptor"><![CDATA[Carcinoma, Bronchogenic]]></field>
  <field name="articleQualifier"><![CDATA[complications]]></field>
  <field name="articleDescriptor"><![CDATA[Endocarditis]]></field>
  <field name="articleQualifier"><![CDATA[complications]]></field>
  <field name="articleDescriptor"><![CDATA[Female]]></field>
  <field name="articleDescriptor"><![CDATA[Humans]]></field>
  <field name="articleDescriptor"><![CDATA[Leukemoid Reaction]]></field>
  <field name="articleQualifier"><![CDATA[complications]]></field>
  <field name="articleDescriptor"><![CDATA[Lung Neoplasms]]></field>
  <field name="articleQualifier"><![CDATA[complications]]></field>
  <field name="articleDescriptor"><![CDATA[Middle Aged]]></field>
  <field name="articleDescriptor"><![CDATA[Thrombosis]]></field>
  <field name="articleQualifier"><![CDATA[complications]]></field>
 </doc>
 <doc>
  <field name="id"><![CDATA[7120479]]></field>
  <field name="articleCreationDate"><![CDATA[1982-12-02T00:00:00Z]]></field>
  <field name="articleYear"><![CDATA[1982]]></field>
  <field name="articleCompletionDate"><![CDATA[1982-12-02T00:00:00Z]]></field>
  <field name="articleRevisionDate"><![CDATA[2010-10-26T00:00:00Z]]></field>
  <field name="articlePubmodel"><![CDATA[Print]]></field>
  <field name="journalTitle"><![CDATA[Journal of the National Medical Association]]></field>
  <field name="journalTitleAbrv"><![CDATA[J Natl Med Assoc]]></field>
  <field name="articleTitle"><![CDATA[Disseminated intravascular coagulation involving the brain: a topographical study.]]></field>
  <field name="articleAbstract"><![CDATA[Histopathological study on 723 brains from routine necropsies was performed. Ten brains (1.38 percent) were found to have histological lesions of disseminated intravascular coagulation (DIC) with multiple fresh fibrin and/or platelet thrombi in the cerebral microcirculation. Among them, premortem diagnosis was made in only one case, and only two cases also showed evidence of visceral involvement. Microthrombi were found most frequently in the cerebral cortex and hypothalamic region and in the cerebral white matter, brain stem, and cerebellum, in descending order. Neurological symptoms and signs, including lethargy, coma and seizure, were detected in all cases. The abnormal body temperature and/or urinary output observed in most patients appeared to be related to the frequent hypothalamic involvement by DIC. The exclusive or predominant involvement of the brain by multiple microthrombi may be considered as a localized form of DIC. It is probably related to cerebral ischemia since severe acute neuronal ischemic changes also were noted in most brains.]]></field>
  <field name="author"><![CDATA[Fan K J]]></field>
  <field name="author"><![CDATA[Scott-Cora J W]]></field>
  <field name="articleLang"><![CDATA[eng]]></field>
  <field name="publicationType"><![CDATA[Journal Article]]></field>
  <field name="articleDescriptor"><![CDATA[Adult]]></field>
  <field name="articleDescriptor"><![CDATA[Aged]]></field>
  <field name="articleDescriptor"><![CDATA[Brain]]></field>
  <field name="articleQualifier"><![CDATA[blood supply]]></field>
  <field name="articleQualifier"><![CDATA[pathology]]></field>
  <field name="articleDescriptor"><![CDATA[Disseminated Intravascular Coagulation]]></field>
  <field name="articleQualifier"><![CDATA[pathology]]></field>
  <field name="articleDescriptor"><![CDATA[Female]]></field>
  <field name="articleDescriptor"><![CDATA[Humans]]></field>
  <field name="articleDescriptor"><![CDATA[Male]]></field>
  <field name="articleDescriptor"><![CDATA[Middle Aged]]></field>
 </doc>
 <doc>
  <field name="id"><![CDATA[7120480]]></field>
  <field name="articleCreationDate"><![CDATA[1982-12-02T00:00:00Z]]></field>
  <field name="articleYear"><![CDATA[1982]]></field>
  <field name="articleCompletionDate"><![CDATA[1982-12-02T00:00:00Z]]></field>
  <field name="articleRevisionDate"><![CDATA[2010-10-26T00:00:00Z]]></field>
  <field name="articlePubmodel"><![CDATA[Print]]></field>
  <field name="journalTitle"><![CDATA[Journal of the National Medical Association]]></field>
  <field name="journalTitleAbrv"><![CDATA[J Natl Med Assoc]]></field>
  <field name="articleTitle"><![CDATA[Psychotherapy: patient-therapist matching reconsidered.]]></field>
  <field name="articleAbstract"><![CDATA[The personality of the therapist does influence the psychotherapeutic process. Given that therapists are human, they do, in fact, bring into the encounter their moral and cultural, and sometimes even racial, attitudes in spite of efforts to maintain objectivity and neutrality. Ignoring the impact of the therapist-client, organismic variables may lead to spurious research findings and impractical interventions. Research and practical intervention, therefore, should be concerned with matching clients with the most appropriate therapist.]]></field>
  <field name="author"><![CDATA[Anderson L]]></field>
  <field name="author"><![CDATA[Carter J H]]></field>
  <field name="articleLang"><![CDATA[eng]]></field>
  <field name="publicationType"><![CDATA[Journal Article]]></field>
  <field name="articleDescriptor"><![CDATA[Female]]></field>
  <field name="articleDescriptor"><![CDATA[Humans]]></field>
  <field name="articleDescriptor"><![CDATA[Male]]></field>
  <field name="articleDescriptor"><![CDATA[Professional-Patient Relations]]></field>
  <field name="articleDescriptor"><![CDATA[Psychotherapy]]></field>
  <field name="articleDescriptor"><![CDATA[Race Relations]]></field>
  <field name="articleDescriptor"><![CDATA[Sex Factors]]></field>
  <field name="articleDescriptor"><![CDATA[Socioeconomic Factors]]></field>
 </doc>
 <doc>
  <field name="id"><![CDATA[6288969]]></field>
  <field name="articleCreationDate"><![CDATA[1982-12-02T00:00:00Z]]></field>
  <field name="articleYear"><![CDATA[1982]]></field>
  <field name="articleCompletionDate"><![CDATA[1982-12-02T00:00:00Z]]></field>
  <field name="articleRevisionDate"><![CDATA[2010-10-26T00:00:00Z]]></field>
  <field name="articlePubmodel"><![CDATA[Print]]></field>
  <field name="journalTitle"><![CDATA[Journal of the National Medical Association]]></field>
  <field name="journalTitleAbrv"><![CDATA[J Natl Med Assoc]]></field>
  <field name="articleTitle"><![CDATA[Antibody to hepatitis A virus in healthy Nigerians.]]></field>
  <field name="articleAbstract"><![CDATA[Two hundred and fifty Nigerians (175 male and 75 female), whose ages ranged from 5 to 70 years, were surveyed for the presence of antibody to hepatitis A virus (anti-HAV). The prevalence was determined to be 82 percent. The rates were highest in blood donors (90 percent) and hospital workers (91.4 percent) and lowest in children under the age of 10 (25 percent). The prevalence rates were not related to socioeconomic groups, previous exposure, jaundice, or sex. The study confirms that HAV infection is endemic in Nigeria and that most infections are subclinical and occur early in life. Acute hepatitis in a Nigerian adult may therefore not be due to HAV.]]></field>
  <field name="author"><![CDATA[Ayoola E A]]></field>
  <field name="articleLang"><![CDATA[eng]]></field>
  <field name="publicationType"><![CDATA[Journal Article]]></field>
  <field name="substanceName"><![CDATA[Antibodies, Viral]]></field>
  <field name="articleDescriptor"><![CDATA[Adolescent]]></field>
  <field name="articleDescriptor"><![CDATA[Adult]]></field>
  <field name="articleDescriptor"><![CDATA[Aged]]></field>
  <field name="articleDescriptor"><![CDATA[Antibodies, Viral]]></field>
  <field name="articleQualifier"><![CDATA[analysis]]></field>
  <field name="articleDescriptor"><![CDATA[Child]]></field>
  <field name="articleDescriptor"><![CDATA[Child, Preschool]]></field>
  <field name="articleDescriptor"><![CDATA[Female]]></field>
  <field name="articleDescriptor"><![CDATA[Hepatitis A]]></field>
  <field name="articleQualifier"><![CDATA[epidemiology]]></field>
  <field name="articleQualifier"><![CDATA[immunology]]></field>
  <field name="articleDescriptor"><![CDATA[Hepatovirus]]></field>
  <field name="articleQualifier"><![CDATA[immunology]]></field>
  <field name="articleDescriptor"><![CDATA[Humans]]></field>
  <field name="articleDescriptor"><![CDATA[Male]]></field>
  <field name="articleDescriptor"><![CDATA[Middle Aged]]></field>
  <field name="articleDescriptor"><![CDATA[Nigeria]]></field>
 </doc>
 <doc>
  <field name="id"><![CDATA[7120481]]></field>
  <field name="articleCreationDate"><![CDATA[1982-12-02T00:00:00Z]]></field>
  <field name="articleYear"><![CDATA[1982]]></field>
  <field name="articleCompletionDate"><![CDATA[1982-12-02T00:00:00Z]]></field>
  <field name="articleRevisionDate"><![CDATA[2010-10-26T00:00:00Z]]></field>
  <field name="articlePubmodel"><![CDATA[Print]]></field>
  <field name="journalTitle"><![CDATA[Journal of the National Medical Association]]></field>
  <field name="journalTitleAbrv"><![CDATA[J Natl Med Assoc]]></field>
  <field name="articleTitle"><![CDATA[Gastrointestinal radiologic manifestations of proximal spinal muscular atrophy (Kugelberg-Welander syndrome).]]></field>
  <field name="articleAbstract"><![CDATA[Proximal spinal muscular atrophy (Kugelberg-Welander syndrome) is a degenerating disease of the anterior horn cells of the spinal cord with atrophy of the proximal muscles resembling muscular dystrophy. The patient in this report exhibits radiographic features in the gastrointestinal tract similar to those seen in the muscular dystrophies, including myotonic dystrophy.]]></field>
  <field name="author"><![CDATA[Karasick D]]></field>
  <field name="author"><![CDATA[Karasick S]]></field>
  <field name="author"><![CDATA[Mapp E]]></field>
  <field name="articleLang"><![CDATA[eng]]></field>
  <field name="publicationType"><![CDATA[Case Reports]]></field>
  <field name="publicationType"><![CDATA[Journal Article]]></field>
  <field name="articleDescriptor"><![CDATA[Diagnosis, Differential]]></field>
  <field name="articleDescriptor"><![CDATA[Digestive System]]></field>
  <field name="articleQualifier"><![CDATA[radiography]]></field>
  <field name="articleDescriptor"><![CDATA[Female]]></field>
  <field name="articleDescriptor"><![CDATA[Humans]]></field>
  <field name="articleDescriptor"><![CDATA[Middle Aged]]></field>
  <field name="articleDescriptor"><![CDATA[Muscular Atrophy]]></field>
  <field name="articleQualifier"><![CDATA[radiography]]></field>
  <field name="articleDescriptor"><![CDATA[Muscular Dystrophies]]></field>
  <field name="articleQualifier"><![CDATA[radiography]]></field>
  <field name="articleDescriptor"><![CDATA[Spinal Cord Diseases]]></field>
  <field name="articleQualifier"><![CDATA[radiography]]></field>
  <field name="articleDescriptor"><![CDATA[Syndrome]]></field>
 </doc>
 <doc>
  <field name="id"><![CDATA[7120482]]></field>
  <field name="articleCreationDate"><![CDATA[1982-12-02T00:00:00Z]]></field>
  <field name="articleYear"><![CDATA[1982]]></field>
  <field name="articleCompletionDate"><![CDATA[1982-12-02T00:00:00Z]]></field>
  <field name="articleRevisionDate"><![CDATA[2010-10-26T00:00:00Z]]></field>
  <field name="articlePubmodel"><![CDATA[Print]]></field>
  <field name="journalTitle"><![CDATA[Journal of the National Medical Association]]></field>
  <field name="journalTitleAbrv"><![CDATA[J Natl Med Assoc]]></field>
  <field name="articleTitle"><![CDATA[Spontaneous pneumothorax from bronchogenic carcinoma.]]></field>
  <field name="articleAbstract"><![CDATA[Spontaneous pneumothorax secondary to bronchogenic carcinoma is an unusual occurrence. Reported here is a patient with adenocarcinoma of the lung whose presenting symptom was spontaneous pneumothorax. A brief review of the literature is presented.]]></field>
  <field name="author"><![CDATA[Kabnick E M]]></field>
  <field name="author"><![CDATA[Sobo S]]></field>
  <field name="author"><![CDATA[Steinbaum S]]></field>
  <field name="author"><![CDATA[Alexander L L]]></field>
  <field name="author"><![CDATA[Nkongho A]]></field>
  <field name="articleLang"><![CDATA[eng]]></field>
  <field name="publicationType"><![CDATA[Case Reports]]></field>
  <field name="publicationType"><![CDATA[Journal Article]]></field>
  <field name="articleDescriptor"><![CDATA[Aged]]></field>
  <field name="articleDescriptor"><![CDATA[Carcinoma, Bronchogenic]]></field>
  <field name="articleQualifier"><![CDATA[complications]]></field>
  <field name="articleDescriptor"><![CDATA[Female]]></field>
  <field name="articleDescriptor"><![CDATA[Humans]]></field>
  <field name="articleDescriptor"><![CDATA[Lung Neoplasms]]></field>
  <field name="articleQualifier"><![CDATA[complications]]></field>
  <field name="articleDescriptor"><![CDATA[Pneumothorax]]></field>
  <field name="articleQualifier"><![CDATA[etiology]]></field>
  <field name="articleDescriptor"><![CDATA[Rupture, Spontaneous]]></field>
 </doc>
 <doc>
  <field name="id"><![CDATA[7120483]]></field>
  <field name="articleCreationDate"><![CDATA[1982-12-02T00:00:00Z]]></field>
  <field name="articleYear"><![CDATA[1982]]></field>
  <field name="articleCompletionDate"><![CDATA[1982-12-02T00:00:00Z]]></field>
  <field name="articleRevisionDate"><![CDATA[2010-10-26T00:00:00Z]]></field>
  <field name="articlePubmodel"><![CDATA[Print]]></field>
  <field name="journalTitle"><![CDATA[Journal of the National Medical Association]]></field>
  <field name="journalTitleAbrv"><![CDATA[J Natl Med Assoc]]></field>
  <field name="articleTitle"><![CDATA[The black dermatologist: 1990--a viewpoint.]]></field>
  <field name="articleAbstract"><![CDATA[Despite equivalent training in dermatology and dermatologic surgery, in a traditional sense black dermatologists are overtrained in the area of cancer surgery by virtue of the nature of their black practices. I believe that the survival of black dermatologists in the United States will one day depend upon the adjunctive dermatoplastic skills that they must develop, not only to meet the increasing demand for these procedures by their patients, but to assure a broadening of their economic base to meet their white competition.]]></field>
  <field name="author"><![CDATA[Pierce H E]]></field>
  <field name="articleLang"><![CDATA[eng]]></field>
  <field name="publicationType"><![CDATA[Journal Article]]></field>
  <field name="articleDescriptor"><![CDATA[African Americans]]></field>
  <field name="articleDescriptor"><![CDATA[Dermatology]]></field>
  <field name="articleQualifier"><![CDATA[trends]]></field>
  <field name="articleDescriptor"><![CDATA[Forecasting]]></field>
  <field name="articleDescriptor"><![CDATA[General Surgery]]></field>
  <field name="articleQualifier"><![CDATA[trends]]></field>
  <field name="articleDescriptor"><![CDATA[United States]]></field>
 </doc>
 <doc>
  <field name="id"><![CDATA[7120485]]></field>
  <field name="articleCreationDate"><![CDATA[1982-12-02T00:00:00Z]]></field>
  <field name="articleYear"><![CDATA[1982]]></field>
  <field name="articleCompletionDate"><![CDATA[1982-12-02T00:00:00Z]]></field>
  <field name="articleRevisionDate"><![CDATA[2010-10-26T00:00:00Z]]></field>
  <field name="articlePubmodel"><![CDATA[Print]]></field>
  <field name="journalTitle"><![CDATA[Journal of the National Medical Association]]></field>
  <field name="journalTitleAbrv"><![CDATA[J Natl Med Assoc]]></field>
  <field name="articleTitle"><![CDATA[Incest and child sexual abuse.]]></field>
  <field name="articleAbstract"><![CDATA[Child sexual abuse was examined nationally and in the Washington, DC and Howard University Hospital area. In an attempt to describe this widespread problem, two case histories are presented which reflect some of the typical characteristics of child sexual abuse cases seen at Howard University Hospital. Pertinent literature is reviewed citing the prevalence rates and the personality and environmental factors which may contribute to the sexual abuse of children in this country. Finally, the role of the physician in identifying and treating the physical and emotional effects of child abuse are discussed.]]></field>
  <field name="author"><![CDATA[Collins J L]]></field>
  <field name="author"><![CDATA[Hamlin W T]]></field>
  <field name="author"><![CDATA[Minor M A]]></field>
  <field name="author"><![CDATA[Knasel A L]]></field>
  <field name="articleLang"><![CDATA[eng]]></field>
  <field name="publicationType"><![CDATA[Case Reports]]></field>
  <field name="publicationType"><![CDATA[Journal Article]]></field>
  <field name="articleDescriptor"><![CDATA[Child]]></field>
  <field name="articleDescriptor"><![CDATA[Child Abuse]]></field>
  <field name="articleQualifier"><![CDATA[prevention & control]]></field>
  <field name="articleDescriptor"><![CDATA[Female]]></field>
  <field name="articleDescriptor"><![CDATA[Humans]]></field>
  <field name="articleDescriptor"><![CDATA[Incest]]></field>
  <field name="articleDescriptor"><![CDATA[Male]]></field>
  <field name="articleDescriptor"><![CDATA[Sex Offenses]]></field>
 </doc>
 <doc>
  <field name="id"><![CDATA[7120486]]></field>
  <field name="articleCreationDate"><![CDATA[1982-12-02T00:00:00Z]]></field>
  <field name="articleYear"><![CDATA[1982]]></field>
  <field name="articleCompletionDate"><![CDATA[1982-12-02T00:00:00Z]]></field>
  <field name="articleRevisionDate"><![CDATA[2010-10-26T00:00:00Z]]></field>
  <field name="articlePubmodel"><![CDATA[Print]]></field>
  <field name="journalTitle"><![CDATA[Journal of the National Medical Association]]></field>
  <field name="journalTitleAbrv"><![CDATA[J Natl Med Assoc]]></field>
  <field name="articleTitle"><![CDATA[Hepatic encephalopathy: a retrospective analysis.]]></field>
  <field name="articleAbstract"><![CDATA[A review of 34 patients was conducted to investigate the causes of hepatic encephalopathy. Hypokalemia, infection, and gastrointestinal tract bleeding were found to be the usual precipitating factors. Women are affected more commonly, and gastrointestinal tract hemorrhage is usually the terminal event.]]></field>
  <field name="author"><![CDATA[Hassan S N]]></field>
  <field name="author"><![CDATA[Townsend J L]]></field>
  <field name="author"><![CDATA[Curry S B]]></field>
  <field name="articleLang"><![CDATA[eng]]></field>
  <field name="publicationType"><![CDATA[Journal Article]]></field>
  <field name="articleDescriptor"><![CDATA[Adult]]></field>
  <field name="articleDescriptor"><![CDATA[Aged]]></field>
  <field name="articleDescriptor"><![CDATA[Female]]></field>
  <field name="articleDescriptor"><![CDATA[Hepatic Encephalopathy]]></field>
  <field name="articleQualifier"><![CDATA[etiology]]></field>
  <field name="articleDescriptor"><![CDATA[Humans]]></field>
  <field name="articleDescriptor"><![CDATA[Liver Cirrhosis, Alcoholic]]></field>
  <field name="articleQualifier"><![CDATA[etiology]]></field>
  <field name="articleDescriptor"><![CDATA[Male]]></field>
  <field name="articleDescriptor"><![CDATA[Middle Aged]]></field>
  <field name="articleDescriptor"><![CDATA[Retrospective Studies]]></field>
 </doc>
 <doc>
  <field name="id"><![CDATA[7120487]]></field>
  <field name="articleCreationDate"><![CDATA[1982-12-02T00:00:00Z]]></field>
  <field name="articleYear"><![CDATA[1982]]></field>
  <field name="articleCompletionDate"><![CDATA[1982-12-02T00:00:00Z]]></field>
  <field name="articleRevisionDate"><![CDATA[2010-10-26T00:00:00Z]]></field>
  <field name="articlePubmodel"><![CDATA[Print]]></field>
  <field name="journalTitle"><![CDATA[Journal of the National Medical Association]]></field>
  <field name="journalTitleAbrv"><![CDATA[J Natl Med Assoc]]></field>
  <field name="articleTitle"><![CDATA[The use of irradiation therapy in the treatment of tumors of the rectum and rectosigmoid.]]></field>
  <field name="articleAbstract"><![CDATA[As a means of increasing local control and disease-free survival in patients with carcinoma of the rectum and rectosigmoid, preoperative and postoperative irradiation therapy have been shown to be effective. The question of the sequence of delivering adjuvant radiation therapy is not settled; however, the benefits and deficits of irradiation therapy as an adjuvant to surgery preoperative or post-operative are reviewed. Basic principles of radiation oncology affecting the selection of the sequence and technique of treatment are discussed.]]></field>
  <field name="author"><![CDATA[Saxton J P]]></field>
  <field name="author"><![CDATA[Withers H R]]></field>
  <field name="author"><![CDATA[Romsdahl M M]]></field>
  <field name="author"><![CDATA[Borgelt B B]]></field>
  <field name="articleLang"><![CDATA[eng]]></field>
  <field name="publicationType"><![CDATA[Journal Article]]></field>
  <field name="publicationType"><![CDATA[Research Support, U.S. Gov't, P.H.S.]]></field>
  <field name="articleDescriptor"><![CDATA[Female]]></field>
  <field name="articleDescriptor"><![CDATA[Humans]]></field>
  <field name="articleDescriptor"><![CDATA[Male]]></field>
  <field name="articleDescriptor"><![CDATA[Neoplasm Staging]]></field>
  <field name="articleDescriptor"><![CDATA[Rectal Neoplasms]]></field>
  <field name="articleQualifier"><![CDATA[radiotherapy]]></field>
  <field name="articleDescriptor"><![CDATA[Sigmoid Neoplasms]]></field>
  <field name="articleQualifier"><![CDATA[radiotherapy]]></field>
 </doc>
 <doc>
  <field name="id"><![CDATA[7120488]]></field>
  <field name="articleCreationDate"><![CDATA[1982-12-02T00:00:00Z]]></field>
  <field name="articleYear"><![CDATA[1982]]></field>
  <field name="articleCompletionDate"><![CDATA[1982-12-02T00:00:00Z]]></field>
  <field name="articleRevisionDate"><![CDATA[2010-10-26T00:00:00Z]]></field>
  <field name="articlePubmodel"><![CDATA[Print]]></field>
  <field name="journalTitle"><![CDATA[Journal of the National Medical Association]]></field>
  <field name="journalTitleAbrv"><![CDATA[J Natl Med Assoc]]></field>
  <field name="articleTitle"><![CDATA[Hepatic resection in primary liver carcinoma: prolonged survival in two Nigerian patients.]]></field>
  <field name="articleAbstract"><![CDATA[Two Nigerian patients with primary liver carcinoma (PLC) who had wedge resection with prolonged survival are described. The localization of their tumors to the right hepatic lobe and their polypoidal nature were favorable factors that allowed early detection and treatment.The surgical treatment of PLC is reviewed. It is suggested that suitable African patients with PLC be offered resection as a modality of treatment coupled with adequate follow-up to detect and deal with recurrence early.]]></field>
  <field name="author"><![CDATA[Awojobi O A]]></field>
  <field name="author"><![CDATA[Ayoola E A]]></field>
  <field name="author"><![CDATA[Junaid T A]]></field>
  <field name="articleLang"><![CDATA[eng]]></field>
  <field name="publicationType"><![CDATA[Case Reports]]></field>
  <field name="publicationType"><![CDATA[Journal Article]]></field>
  <field name="articleDescriptor"><![CDATA[Adult]]></field>
  <field name="articleDescriptor"><![CDATA[Carcinoma]]></field>
  <field name="articleQualifier"><![CDATA[mortality]]></field>
  <field name="articleQualifier"><![CDATA[surgery]]></field>
  <field name="articleDescriptor"><![CDATA[Female]]></field>
  <field name="articleDescriptor"><![CDATA[Hepatectomy]]></field>
  <field name="articleDescriptor"><![CDATA[Humans]]></field>
  <field name="articleDescriptor"><![CDATA[Liver Neoplasms]]></field>
  <field name="articleQualifier"><![CDATA[mortality]]></field>
  <field name="articleQualifier"><![CDATA[surgery]]></field>
  <field name="articleDescriptor"><![CDATA[Male]]></field>
  <field name="articleDescriptor"><![CDATA[Nigeria]]></field>
 </doc>
 <doc>
  <field name="id"><![CDATA[6811763]]></field>
  <field name="articleCreationDate"><![CDATA[1982-12-02T00:00:00Z]]></field>
  <field name="articleYear"><![CDATA[1982]]></field>
  <field name="articleCompletionDate"><![CDATA[1982-12-02T00:00:00Z]]></field>
  <field name="articleRevisionDate"><![CDATA[2010-10-26T00:00:00Z]]></field>
  <field name="articlePubmodel"><![CDATA[Print]]></field>
  <field name="journalTitle"><![CDATA[Journal of the National Medical Association]]></field>
  <field name="journalTitleAbrv"><![CDATA[J Natl Med Assoc]]></field>
  <field name="articleTitle"><![CDATA[Home versus clinic blood pressure measurements.]]></field>
  <field name="articleAbstract"><![CDATA[To evaluate the cost effectiveness of home versus clinic blood pressure 11 patients with mild untreated hypertension were instructed in self-measurement of blood pressure with mercury manometers. The lower total cost of using home readings as well as problems of bias and blinding are discussed. Home blood pressure is a promising technique for clinical and epidemiologic research.]]></field>
  <field name="author"><![CDATA[Gillum R F]]></field>
  <field name="author"><![CDATA[Etemadi N]]></field>
  <field name="author"><![CDATA[Boen J R]]></field>
  <field name="author"><![CDATA[Kebede J]]></field>
  <field name="author"><![CDATA[Anderson P]]></field>
  <field name="author"><![CDATA[Prineas R J]]></field>
  <field name="articleLang"><![CDATA[eng]]></field>
  <field name="publicationType"><![CDATA[Comparative Study]]></field>
  <field name="publicationType"><![CDATA[Journal Article]]></field>
  <field name="publicationType"><![CDATA[Research Support, Non-U.S. Gov't]]></field>
  <field name="publicationType"><![CDATA[Research Support, U.S. Gov't, P.H.S.]]></field>
  <field name="articleDescriptor"><![CDATA[Blood Pressure Determination]]></field>
  <field name="articleDescriptor"><![CDATA[Cost-Benefit Analysis]]></field>
  <field name="articleDescriptor"><![CDATA[Humans]]></field>
  <field name="articleDescriptor"><![CDATA[Hypertension]]></field>
  <field name="articleQualifier"><![CDATA[diagnosis]]></field>
  <field name="articleDescriptor"><![CDATA[Male]]></field>
  <field name="articleDescriptor"><![CDATA[Middle Aged]]></field>
  <field name="articleDescriptor"><![CDATA[Self Care]]></field>
  <field name="articleQualifier"><![CDATA[methods]]></field>
 </doc>
 <doc>
  <field name="id"><![CDATA[7120489]]></field>
  <field name="articleCreationDate"><![CDATA[1982-12-02T00:00:00Z]]></field>
  <field name="articleYear"><![CDATA[1982]]></field>
  <field name="articleCompletionDate"><![CDATA[1982-12-02T00:00:00Z]]></field>
  <field name="articleRevisionDate"><![CDATA[2010-10-26T00:00:00Z]]></field>
  <field name="articlePubmodel"><![CDATA[Print]]></field>
  <field name="journalTitle"><![CDATA[Journal of the National Medical Association]]></field>
  <field name="journalTitleAbrv"><![CDATA[J Natl Med Assoc]]></field>
  <field name="articleTitle"><![CDATA[The clinical picture of mania in manic-depressive black patients.]]></field>
  <field name="articleAbstract"><![CDATA[Recent studies have shown that misdiagnosis of manic-depressive illness among blacks is a frequent occurrence. There are a number of historical and institutional dynamics involved in this process that have the roots of racism as their foundation. In light of this the authors decided to look at the clinical symptoms and behaviors of manic-depressive illness among black patients to see if their interpretation might be another contributing factor in misdiagnosis.The authors found the clinical symptoms of manic-depressive illness in black patients to be essentially what one would expect as determined by criteria in the Diagnostic and Statistical Manual (DSM III). However, there were cultural and socioeconomic determinants of behavior that affected the clinical manifestations.]]></field>
  <field name="author"><![CDATA[Jones B E]]></field>
  <field name="author"><![CDATA[Robinson W M]]></field>
  <field name="author"><![CDATA[Parson E B]]></field>
  <field name="author"><![CDATA[Gray B A]]></field>
  <field name="articleLang"><![CDATA[eng]]></field>
  <field name="publicationType"><![CDATA[Case Reports]]></field>
  <field name="publicationType"><![CDATA[Journal Article]]></field>
  <field name="articleDescriptor"><![CDATA[Adult]]></field>
  <field name="articleDescriptor"><![CDATA[Affective Disorders, Psychotic]]></field>
  <field name="articleQualifier"><![CDATA[diagnosis]]></field>
  <field name="articleDescriptor"><![CDATA[African Americans]]></field>
  <field name="articleQualifier"><![CDATA[psychology]]></field>
  <field name="articleDescriptor"><![CDATA[Bipolar Disorder]]></field>
  <field name="articleQualifier"><![CDATA[diagnosis]]></field>
  <field name="articleDescriptor"><![CDATA[Female]]></field>
  <field name="articleDescriptor"><![CDATA[Humans]]></field>
  <field name="articleDescriptor"><![CDATA[Male]]></field>
  <field name="articleDescriptor"><![CDATA[New York City]]></field>
 </doc>
 <doc>
  <field name="id"><![CDATA[7120490]]></field>
  <field name="articleCreationDate"><![CDATA[1982-12-02T00:00:00Z]]></field>
  <field name="articleYear"><![CDATA[1982]]></field>
  <field name="articleCompletionDate"><![CDATA[1982-12-02T00:00:00Z]]></field>
  <field name="articleRevisionDate"><![CDATA[2010-10-26T00:00:00Z]]></field>
  <field name="articlePubmodel"><![CDATA[Print]]></field>
  <field name="journalTitle"><![CDATA[Journal of the National Medical Association]]></field>
  <field name="journalTitleAbrv"><![CDATA[J Natl Med Assoc]]></field>
  <field name="articleTitle"><![CDATA[Biliary obstruction due to xanthogranulomatous pyelonephritis.]]></field>
  <field name="articleAbstract"><![CDATA[Presented here is an unusual case of extrinsic biliary obstruction due to a mass caused by xanthogranulomatous pyelonephritis, in itself a rare disease, of the right kidney. This phenomenon has not been described previously in the literature, and it should be brought to the attention of practitioners as another possible cause of biliary disease.]]></field>
  <field name="author"><![CDATA[Haycock C E]]></field>
  <field name="author"><![CDATA[Lazaro E J]]></field>
  <field name="author"><![CDATA[Chung H R]]></field>
  <field name="author"><![CDATA[Mohit-Tabatabai M]]></field>
  <field name="articleLang"><![CDATA[eng]]></field>
  <field name="publicationType"><![CDATA[Case Reports]]></field>
  <field name="publicationType"><![CDATA[Journal Article]]></field>
  <field name="articleDescriptor"><![CDATA[Aged]]></field>
  <field name="articleDescriptor"><![CDATA[Cholestasis]]></field>
  <field name="articleQualifier"><![CDATA[etiology]]></field>
  <field name="articleDescriptor"><![CDATA[Diagnosis, Differential]]></field>
  <field name="articleDescriptor"><![CDATA[Female]]></field>
  <field name="articleDescriptor"><![CDATA[Humans]]></field>
  <field name="articleDescriptor"><![CDATA[Pyelonephritis]]></field>
  <field name="articleQualifier"><![CDATA[complications]]></field>
  <field name="articleDescriptor"><![CDATA[Xanthomatosis]]></field>
  <field name="articleQualifier"><![CDATA[diagnosis]]></field>
 </doc>
 <doc>
  <field name="id"><![CDATA[7120491]]></field>
  <field name="articleCreationDate"><![CDATA[1982-12-02T00:00:00Z]]></field>
  <field name="articleYear"><![CDATA[1982]]></field>
  <field name="articleCompletionDate"><![CDATA[1982-12-02T00:00:00Z]]></field>
  <field name="articleRevisionDate"><![CDATA[2010-10-26T00:00:00Z]]></field>
  <field name="articlePubmodel"><![CDATA[Print]]></field>
  <field name="journalTitle"><![CDATA[Journal of the National Medical Association]]></field>
  <field name="journalTitleAbrv"><![CDATA[J Natl Med Assoc]]></field>
  <field name="articleTitle"><![CDATA[Papillary eccrine adenoma.]]></field>
  <field name="articleAbstract"><![CDATA[This benign tumor derived from eccrine sweat glands is usually found on the distal extremities. It is related to a syringoma and must be distinguished from a sweat gland carcinoma. It occurs most often in black patients. Complete surgical excision is the treatment.]]></field>
  <field name="author"><![CDATA[White S W]]></field>
  <field name="author"><![CDATA[Rodman O G]]></field>
  <field name="articleLang"><![CDATA[eng]]></field>
  <field name="publicationType"><![CDATA[Journal Article]]></field>
  <field name="articleDescriptor"><![CDATA[Adolescent]]></field>
  <field name="articleDescriptor"><![CDATA[Adult]]></field>
  <field name="articleDescriptor"><![CDATA[Aged]]></field>
  <field name="articleDescriptor"><![CDATA[Child]]></field>
  <field name="articleDescriptor"><![CDATA[Cystadenoma]]></field>
  <field name="articleQualifier"><![CDATA[pathology]]></field>
  <field name="articleQualifier"><![CDATA[surgery]]></field>
  <field name="articleDescriptor"><![CDATA[Eccrine Glands]]></field>
  <field name="articleDescriptor"><![CDATA[Female]]></field>
  <field name="articleDescriptor"><![CDATA[Humans]]></field>
  <field name="articleDescriptor"><![CDATA[Middle Aged]]></field>
  <field name="articleDescriptor"><![CDATA[Sweat Gland Neoplasms]]></field>
  <field name="articleQualifier"><![CDATA[pathology]]></field>
  <field name="articleQualifier"><![CDATA[surgery]]></field>
  <field name="articleDescriptor"><![CDATA[Sweat Glands]]></field>
 </doc>
 <doc>
  <field name="id"><![CDATA[7120493]]></field>
  <field name="articleCreationDate"><![CDATA[1982-12-02T00:00:00Z]]></field>
  <field name="articleYear"><![CDATA[1982]]></field>
  <field name="articleCompletionDate"><![CDATA[1982-12-02T00:00:00Z]]></field>
  <field name="articleRevisionDate"><![CDATA[2010-10-26T00:00:00Z]]></field>
  <field name="articlePubmodel"><![CDATA[Print]]></field>
  <field name="journalTitle"><![CDATA[Journal of the National Medical Association]]></field>
  <field name="journalTitleAbrv"><![CDATA[J Natl Med Assoc]]></field>
  <field name="articleTitle"><![CDATA[Predictors of performance of minority students in the first two years of a BA/MD program.]]></field>
  <field name="articleAbstract"><![CDATA[This study examines cognitive and noncognitive selection variables as predictors of multiple criteria of performance for minority and nonminority students entering the University of Missouri-Kansas City School of Medicine between 1972 and 1977. Data analysis aims at identifying characteristics associated with success in the crucial first two years of the combined BA/MD program. Pearson product moment correlations and multiple regression equations have been determined for all selection variables and three criteria measures. A number of nontraditional variables are significantly predictive of minority student performance. The cognitive variables of aptitude test and high school science/mathematics preparation are significant predictors of all three performance measures in both racial groups. The data support the position that separate equations are not necessary to predict performance of minority and nonminority students, but that admission committees, when selecting minority students, should recognize both personal attributes and academic preparation as indicators of potential success or failure.]]></field>
  <field name="author"><![CDATA[Calkins E V]]></field>
  <field name="author"><![CDATA[Willoughby T L]]></field>
  <field name="author"><![CDATA[Arnold L M]]></field>
  <field name="articleLang"><![CDATA[eng]]></field>
  <field name="publicationType"><![CDATA[Journal Article]]></field>
  <field name="articleDescriptor"><![CDATA[Adult]]></field>
  <field name="articleDescriptor"><![CDATA[Cognition]]></field>
  <field name="articleDescriptor"><![CDATA[Education, Medical, Undergraduate]]></field>
  <field name="articleQualifier"><![CDATA[standards]]></field>
  <field name="articleDescriptor"><![CDATA[Educational Measurement]]></field>
  <field name="articleDescriptor"><![CDATA[Female]]></field>
  <field name="articleDescriptor"><![CDATA[Humans]]></field>
  <field name="articleDescriptor"><![CDATA[Male]]></field>
  <field name="articleDescriptor"><![CDATA[Minority Groups]]></field>
  <field name="articleDescriptor"><![CDATA[Missouri]]></field>
  <field name="articleDescriptor"><![CDATA[School Admission Criteria]]></field>
 </doc>
 <doc>
  <field name="id"><![CDATA[7120494]]></field>
  <field name="articleCreationDate"><![CDATA[1982-12-02T00:00:00Z]]></field>
  <field name="articleYear"><![CDATA[1982]]></field>
  <field name="articleCompletionDate"><![CDATA[1982-12-02T00:00:00Z]]></field>
  <field name="articleRevisionDate"><![CDATA[2010-10-26T00:00:00Z]]></field>
  <field name="articlePubmodel"><![CDATA[Print]]></field>
  <field name="journalTitle"><![CDATA[Journal of the National Medical Association]]></field>
  <field name="journalTitleAbrv"><![CDATA[J Natl Med Assoc]]></field>
  <field name="articleTitle"><![CDATA[Clear cell adenocarcinoma of the vagina and cervix in black females.]]></field>
  <field name="articleAbstract"><![CDATA[Twenty-eight black females with clear cell adenocarcinoma of the vagina and cervix have been accessioned in the Registry for Research on Hormonal Transplacental Carcinogenesis. Most were born in the southern United States and histories of prenatal exposure to diethylstilbestrol were less frequent than with white patients. The characteristics of these cases were similar to those among whites in stage, variety of cell type, and patient survival.]]></field>
  <field name="author"><![CDATA[Johnston G A]]></field>
  <field name="author"><![CDATA[Anderson D]]></field>
  <field name="author"><![CDATA[Herbst A L]]></field>
  <field name="author"><![CDATA[Hubby M M]]></field>
  <field name="articleLang"><![CDATA[eng]]></field>
  <field name="publicationType"><![CDATA[Journal Article]]></field>
  <field name="articleDescriptor"><![CDATA[Adenocarcinoma]]></field>
  <field name="articleQualifier"><![CDATA[pathology]]></field>
  <field name="articleDescriptor"><![CDATA[Adolescent]]></field>
  <field name="articleDescriptor"><![CDATA[Adult]]></field>
  <field name="articleDescriptor"><![CDATA[Child]]></field>
  <field name="articleDescriptor"><![CDATA[Female]]></field>
  <field name="articleDescriptor"><![CDATA[Humans]]></field>
  <field name="articleDescriptor"><![CDATA[Uterine Cervical Neoplasms]]></field>
  <field name="articleQualifier"><![CDATA[pathology]]></field>
  <field name="articleDescriptor"><![CDATA[Vaginal Neoplasms]]></field>
  <field name="articleQualifier"><![CDATA[pathology]]></field>
 </doc>
 <doc>
  <field name="id"><![CDATA[7120495]]></field>
  <field name="articleCreationDate"><![CDATA[1982-12-02T00:00:00Z]]></field>
  <field name="articleYear"><![CDATA[1982]]></field>
  <field name="articleCompletionDate"><![CDATA[1982-12-02T00:00:00Z]]></field>
  <field name="articleRevisionDate"><![CDATA[2010-10-26T00:00:00Z]]></field>
  <field name="articlePubmodel"><![CDATA[Print]]></field>
  <field name="journalTitle"><![CDATA[Journal of the National Medical Association]]></field>
  <field name="journalTitleAbrv"><![CDATA[J Natl Med Assoc]]></field>
  <field name="articleTitle"><![CDATA[The role of the radiologist on the child abuse team.]]></field>
  <field name="articleAbstract"><![CDATA[Physicians in most jurisdictions are mandated to report all suspected cases of child abuse to the appropriate authorities. Often in a position to initially suspect child abuse, the radiologist must be aware of the roentgenographic manifestations of the various forms of child abuse. In recognition of the difficulty for an individual to maintain expertise in all aspects of child abuse, multidisciplinary teams have evolved to share responsibility in the diagnosis and treatment of child abuse as well as aid in prosecution of the perpetrator and in family therapy when applicable.]]></field>
  <field name="author"><![CDATA[Miller T Q]]></field>
  <field name="articleLang"><![CDATA[eng]]></field>
  <field name="publicationType"><![CDATA[Journal Article]]></field>
  <field name="articleDescriptor"><![CDATA[Child]]></field>
  <field name="articleDescriptor"><![CDATA[Child Abuse]]></field>
  <field name="articleDescriptor"><![CDATA[Humans]]></field>
  <field name="articleDescriptor"><![CDATA[Patient Care Team]]></field>
  <field name="articleDescriptor"><![CDATA[Radiography]]></field>
 </doc>
 <doc>
  <field name="id"><![CDATA[7120496]]></field>
  <field name="articleCreationDate"><![CDATA[1982-12-02T00:00:00Z]]></field>
  <field name="articleYear"><![CDATA[1982]]></field>
  <field name="articleCompletionDate"><![CDATA[1982-12-02T00:00:00Z]]></field>
  <field name="articleRevisionDate"><![CDATA[2010-10-26T00:00:00Z]]></field>
  <field name="articlePubmodel"><![CDATA[Print]]></field>
  <field name="journalTitle"><![CDATA[Journal of the National Medical Association]]></field>
  <field name="journalTitleAbrv"><![CDATA[J Natl Med Assoc]]></field>
  <field name="articleTitle"><![CDATA[Alcoholism in black Vietnam veterans: symptoms of posttraumatic stress disorder.]]></field>
  <field name="articleAbstract"><![CDATA[A definitive diagnosis of a posttraumatic stress disorder in black Vietnam veterans can be made when recognition is given, not only to the stressors of war but to racism. An aftermath of the war for black veterans has been an alarming increase in alcoholism, believed to be an attempt to reduce feeling of inadequacy, pessimism, and uncontrollable rage.Two cases are described that are illustrative of the posttraumatic stress disorder and alcoholism in black Vietnam veterans. A brief discussion of salient issues that are crucial to diagnosis and treatment is presented.]]></field>
  <field name="author"><![CDATA[Carter J H]]></field>
  <field name="articleLang"><![CDATA[eng]]></field>
  <field name="publicationType"><![CDATA[Case Reports]]></field>
  <field name="publicationType"><![CDATA[Journal Article]]></field>
  <field name="articleDescriptor"><![CDATA[Adult]]></field>
  <field name="articleDescriptor"><![CDATA[African Americans]]></field>
  <field name="articleQualifier"><![CDATA[psychology]]></field>
  <field name="articleDescriptor"><![CDATA[African Continental Ancestry Group]]></field>
  <field name="articleDescriptor"><![CDATA[Alcoholism]]></field>
  <field name="articleQualifier"><![CDATA[etiology]]></field>
  <field name="articleDescriptor"><![CDATA[Combat Disorders]]></field>
  <field name="articleQualifier"><![CDATA[complications]]></field>
  <field name="articleDescriptor"><![CDATA[Humans]]></field>
  <field name="articleDescriptor"><![CDATA[Male]]></field>
  <field name="articleDescriptor"><![CDATA[Prejudice]]></field>
  <field name="articleDescriptor"><![CDATA[Stress Disorders, Post-Traumatic]]></field>
  <field name="articleQualifier"><![CDATA[etiology]]></field>
  <field name="articleDescriptor"><![CDATA[United States]]></field>
  <field name="articleDescriptor"><![CDATA[Veterans]]></field>
  <field name="articleDescriptor"><![CDATA[Vietnam]]></field>
 </doc>
 <doc>
  <field name="id"><![CDATA[7120497]]></field>
  <field name="articleCreationDate"><![CDATA[1982-12-02T00:00:00Z]]></field>
  <field name="articleYear"><![CDATA[1982]]></field>
  <field name="articleCompletionDate"><![CDATA[1982-12-02T00:00:00Z]]></field>
  <field name="articleRevisionDate"><![CDATA[2010-10-26T00:00:00Z]]></field>
  <field name="articlePubmodel"><![CDATA[Print]]></field>
  <field name="journalTitle"><![CDATA[Journal of the National Medical Association]]></field>
  <field name="journalTitleAbrv"><![CDATA[J Natl Med Assoc]]></field>
  <field name="articleTitle"><![CDATA[Accidental overdose intoxication: a hazard of drug smuggling.]]></field>
  <field name="articleAbstract"><![CDATA[Three patients involved in illicit drug smuggling via the swallowing of high dose, high purity drugs packed in multiple condoms are reported. Two of these patients experienced drug overdose symptoms due to leakage or rupture of the condoms in the GI tract. They were treated successfully.]]></field>
  <field name="author"><![CDATA[Arora S]]></field>
  <field name="author"><![CDATA[Tafreshi M]]></field>
  <field name="author"><![CDATA[Sobo S]]></field>
  <field name="author"><![CDATA[Krochmal P]]></field>
  <field name="author"><![CDATA[Alexander L L]]></field>
  <field name="articleLang"><![CDATA[eng]]></field>
  <field name="publicationType"><![CDATA[Case Reports]]></field>
  <field name="publicationType"><![CDATA[Journal Article]]></field>
  <field name="substanceName"><![CDATA[Cannabinoids]]></field>
  <field name="substanceName"><![CDATA[Heroin]]></field>
  <field name="articleDescriptor"><![CDATA[Adult]]></field>
  <field name="articleDescriptor"><![CDATA[Cannabinoids]]></field>
  <field name="articleQualifier"><![CDATA[poisoning]]></field>
  <field name="articleDescriptor"><![CDATA[Cannabis]]></field>
  <field name="articleDescriptor"><![CDATA[Crime]]></field>
  <field name="articleDescriptor"><![CDATA[Drug and Narcotic Control]]></field>
  <field name="articleDescriptor"><![CDATA[Female]]></field>
  <field name="articleDescriptor"><![CDATA[Heroin]]></field>
  <field name="articleQualifier"><![CDATA[poisoning]]></field>
  <field name="articleDescriptor"><![CDATA[Humans]]></field>
  <field name="articleDescriptor"><![CDATA[Male]]></field>
  <field name="articleDescriptor"><![CDATA[New York City]]></field>
  <field name="articleDescriptor"><![CDATA[Substance-Related Disorders]]></field>
  <field name="articleQualifier"><![CDATA[etiology]]></field>
 </doc>
 <doc>
  <field name="id"><![CDATA[7120498]]></field>
  <field name="articleCreationDate"><![CDATA[1982-12-02T00:00:00Z]]></field>
  <field name="articleYear"><![CDATA[1982]]></field>
  <field name="articleCompletionDate"><![CDATA[1982-12-02T00:00:00Z]]></field>
  <field name="articleRevisionDate"><![CDATA[2010-10-26T00:00:00Z]]></field>
  <field name="articlePubmodel"><![CDATA[Print]]></field>
  <field name="journalTitle"><![CDATA[Journal of the National Medical Association]]></field>
  <field name="journalTitleAbrv"><![CDATA[J Natl Med Assoc]]></field>
  <field name="articleTitle"><![CDATA[Management of intraepithelial neoplasia of the uterine cervix in the black population.]]></field>
  <field name="articleAbstract"><![CDATA[The records of 2,277 patients referred to the Colposcopy Clinic at Cook County Hospital were reviewed, and those of 1,328 black patients who had a histological diagnosis of dysplasia or carcinoma in situ of the cervix were chosen for this study.Treatment modalities of intraepithelial cervical neoplasia are discussed and the conservative management of young patients is emphasized. Because of the effectiveness of outpatient management in cervical preinvasive lesions, health providers should make every attempt to motivate people particularly those at high risk, ie, black women, to undertake preventive measures.]]></field>
  <field name="author"><![CDATA[Dini M]]></field>
  <field name="author"><![CDATA[Jafari K]]></field>
  <field name="articleLang"><![CDATA[eng]]></field>
  <field name="publicationType"><![CDATA[Journal Article]]></field>
  <field name="articleDescriptor"><![CDATA[African Americans]]></field>
  <field name="articleDescriptor"><![CDATA[Carcinoma in Situ]]></field>
  <field name="articleQualifier"><![CDATA[diagnosis]]></field>
  <field name="articleQualifier"><![CDATA[therapy]]></field>
  <field name="articleDescriptor"><![CDATA[Chicago]]></field>
  <field name="articleDescriptor"><![CDATA[Colposcopy]]></field>
  <field name="articleDescriptor"><![CDATA[Female]]></field>
  <field name="articleDescriptor"><![CDATA[Humans]]></field>
  <field name="articleDescriptor"><![CDATA[Uterine Cervical Neoplasms]]></field>
  <field name="articleQualifier"><![CDATA[diagnosis]]></field>
  <field name="articleQualifier"><![CDATA[therapy]]></field>
 </doc>
 <doc>
  <field name="id"><![CDATA[6956751]]></field>
  <field name="articleCreationDate"><![CDATA[1982-12-02T00:00:00Z]]></field>
  <field name="articleYear"><![CDATA[1982]]></field>
  <field name="articleCompletionDate"><![CDATA[1982-12-02T00:00:00Z]]></field>
  <field name="articleRevisionDate"><![CDATA[2010-10-26T00:00:00Z]]></field>
  <field name="articlePubmodel"><![CDATA[Print]]></field>
  <field name="journalTitle"><![CDATA[Journal of the National Medical Association]]></field>
  <field name="journalTitleAbrv"><![CDATA[J Natl Med Assoc]]></field>
  <field name="articleTitle"><![CDATA[Tourette's syndrome in a black woman with associated triple X and 9p mosaicism.]]></field>
  <field name="articleAbstract"><![CDATA[A review of the literature and a rare case of Tourette's syndrome in a black woman in association with triple X and 9p mosaicism are presented.]]></field>
  <field name="author"><![CDATA[Singh D N]]></field>
  <field name="author"><![CDATA[Howe G L]]></field>
  <field name="author"><![CDATA[Jordan H W]]></field>
  <field name="author"><![CDATA[Hara S]]></field>
  <field name="articleLang"><![CDATA[eng]]></field>
  <field name="publicationType"><![CDATA[Case Reports]]></field>
  <field name="publicationType"><![CDATA[Journal Article]]></field>
  <field name="publicationType"><![CDATA[Research Support, U.S. Gov't, Non-P.H.S.]]></field>
  <field name="articleDescriptor"><![CDATA[Adult]]></field>
  <field name="articleDescriptor"><![CDATA[Chromosome Aberrations]]></field>
  <field name="articleDescriptor"><![CDATA[Chromosome Disorders]]></field>
  <field name="articleDescriptor"><![CDATA[Chromosomes, Human, 6-12 and X]]></field>
  <field name="articleDescriptor"><![CDATA[Female]]></field>
  <field name="articleDescriptor"><![CDATA[Humans]]></field>
  <field name="articleDescriptor"><![CDATA[Mosaicism]]></field>
  <field name="articleDescriptor"><![CDATA[Sex Chromosome Aberrations]]></field>
  <field name="articleDescriptor"><![CDATA[Tourette Syndrome]]></field>
  <field name="articleQualifier"><![CDATA[genetics]]></field>
  <field name="articleDescriptor"><![CDATA[X Chromosome]]></field>
 </doc>
 <doc>
  <field name="id"><![CDATA[7120500]]></field>
  <field name="articleCreationDate"><![CDATA[1982-12-02T00:00:00Z]]></field>
  <field name="articleYear"><![CDATA[1982]]></field>
  <field name="articleCompletionDate"><![CDATA[1982-12-02T00:00:00Z]]></field>
  <field name="articleRevisionDate"><![CDATA[2010-10-26T00:00:00Z]]></field>
  <field name="articlePubmodel"><![CDATA[Print]]></field>
  <field name="journalTitle"><![CDATA[Journal of the National Medical Association]]></field>
  <field name="journalTitleAbrv"><![CDATA[J Natl Med Assoc]]></field>
  <field name="articleTitle"><![CDATA[Complementary tube cecostomy in the management of strangulated right Richter's inguinal hernia of the cecum.]]></field>
  <field name="articleAbstract"><![CDATA[Strangulated right Richter's inguinal hernia of the cecum is relatively rare. A case of this unusual hernia was successfully managed with a wedge resection and closure of the infarcted bowel wall in conjunction with complementary tube cecostomy. The procedure is easy to perform and relatively safe and is therefore recommended for use in selected cases of Richter's hernia of the cecum.]]></field>
  <field name="author"><![CDATA[Oluwole S F]]></field>
  <field name="articleLang"><![CDATA[eng]]></field>
  <field name="publicationType"><![CDATA[Case Reports]]></field>
  <field name="publicationType"><![CDATA[Journal Article]]></field>
  <field name="articleDescriptor"><![CDATA[Acute Disease]]></field>
  <field name="articleDescriptor"><![CDATA[Adult]]></field>
  <field name="articleDescriptor"><![CDATA[Cecal Diseases]]></field>
  <field name="articleQualifier"><![CDATA[complications]]></field>
  <field name="articleQualifier"><![CDATA[surgery]]></field>
  <field name="articleDescriptor"><![CDATA[Cecum]]></field>
  <field name="articleQualifier"><![CDATA[surgery]]></field>
  <field name="articleDescriptor"><![CDATA[Hernia, Inguinal]]></field>
  <field name="articleQualifier"><![CDATA[complications]]></field>
  <field name="articleQualifier"><![CDATA[surgery]]></field>
  <field name="articleDescriptor"><![CDATA[Humans]]></field>
  <field name="articleDescriptor"><![CDATA[Intestinal Obstruction]]></field>
  <field name="articleQualifier"><![CDATA[etiology]]></field>
  <field name="articleDescriptor"><![CDATA[Male]]></field>
 </doc>
 <doc>
  <field name="id"><![CDATA[7120501]]></field>
  <field name="articleCreationDate"><![CDATA[1982-12-02T00:00:00Z]]></field>
  <field name="articleYear"><![CDATA[1982]]></field>
  <field name="articleCompletionDate"><![CDATA[1982-12-02T00:00:00Z]]></field>
  <field name="articleRevisionDate"><![CDATA[2010-10-26T00:00:00Z]]></field>
  <field name="articlePubmodel"><![CDATA[Print]]></field>
  <field name="journalTitle"><![CDATA[Journal of the National Medical Association]]></field>
  <field name="journalTitleAbrv"><![CDATA[J Natl Med Assoc]]></field>
  <field name="articleTitle"><![CDATA[Narcolepsy with concomitant features of obstructive sleep apnea.]]></field>
  <field name="articleAbstract"><![CDATA[A 17-year-old man presented with daytime sleepiness, episodic attacks of sleep and probable cataplexy. His EEG showed rapid eye movements and central sawtooth waves at sleep onset, and supported the clinical impression of narcolepsy. He improved with methylphenidate but died suddenly, and had cardiomegaly, right ventricular enlargement, and pulmonary hypertension at autopsy. These findings suggested concomitant features of sleep apnea which were not evident by history or examination.Central apneas have been frequently described in the sleep of narcoleptic patients. Few patients have had indications of obstructive or mixed apneas. This patient's course suggests that ventilation during sleep should be included in the polygraphic assessment of patients with suspected narcolepsy, as the agents used for treatment of narcolepsy may aggravate the cardiac complications of sleep apnea.]]></field>
  <field name="author"><![CDATA[Drake M E]]></field>
  <field name="articleLang"><![CDATA[eng]]></field>
  <field name="publicationType"><![CDATA[Case Reports]]></field>
  <field name="publicationType"><![CDATA[Journal Article]]></field>
  <field name="articleDescriptor"><![CDATA[Adolescent]]></field>
  <field name="articleDescriptor"><![CDATA[Humans]]></field>
  <field name="articleDescriptor"><![CDATA[Male]]></field>
  <field name="articleDescriptor"><![CDATA[Narcolepsy]]></field>
  <field name="articleQualifier"><![CDATA[complications]]></field>
  <field name="articleDescriptor"><![CDATA[Sleep Apnea Syndromes]]></field>
  <field name="articleQualifier"><![CDATA[complications]]></field>
 </doc>
 <doc>
  <field name="id"><![CDATA[7120502]]></field>
  <field name="articleCreationDate"><![CDATA[1982-12-02T00:00:00Z]]></field>
  <field name="articleYear"><![CDATA[1982]]></field>
  <field name="articleCompletionDate"><![CDATA[1982-12-02T00:00:00Z]]></field>
  <field name="articleRevisionDate"><![CDATA[2010-10-26T00:00:00Z]]></field>
  <field name="articlePubmodel"><![CDATA[Print]]></field>
  <field name="journalTitle"><![CDATA[Journal of the National Medical Association]]></field>
  <field name="journalTitleAbrv"><![CDATA[J Natl Med Assoc]]></field>
  <field name="articleTitle"><![CDATA[Intraoperative hypothermia in a patient with cold agglutinin disease.]]></field>
  <field name="articleAbstract"><![CDATA[A patient with cold agglutinin disease developed significant hemolysis after surgery because of intraoperative hypothermia. Convective heat losses from exposed viscera may be more significant than realized. A combination of cold-induced shivering heat loss, cold fluids, and long operations in which large surfaces are exposed can cause cardiac arrhythmias. The elderly patient is particularly susceptible to cold exposure and its consequences during surgery. In this situation of a patient with cold agglutinins, and in others with anitbody-related hemolytic disease, control of temperature during surgery is clearly very important.]]></field>
  <field name="author"><![CDATA[Guena L]]></field>
  <field name="author"><![CDATA[Addei K A]]></field>
  <field name="articleLang"><![CDATA[eng]]></field>
  <field name="publicationType"><![CDATA[Case Reports]]></field>
  <field name="publicationType"><![CDATA[Journal Article]]></field>
  <field name="articleDescriptor"><![CDATA[Aged]]></field>
  <field name="articleDescriptor"><![CDATA[Anemia, Hemolytic, Autoimmune]]></field>
  <field name="articleQualifier"><![CDATA[complications]]></field>
  <field name="articleQualifier"><![CDATA[immunology]]></field>
  <field name="articleDescriptor"><![CDATA[Female]]></field>
  <field name="articleDescriptor"><![CDATA[Humans]]></field>
  <field name="articleDescriptor"><![CDATA[Hypothermia, Induced]]></field>
  <field name="articleQualifier"><![CDATA[adverse effects]]></field>
  <field name="articleDescriptor"><![CDATA[Intraoperative Complications]]></field>
 </doc>
 <doc>
  <field name="id"><![CDATA[6214640]]></field>
  <field name="articleCreationDate"><![CDATA[1982-12-02T00:00:00Z]]></field>
  <field name="articleYear"><![CDATA[1982]]></field>
  <field name="articleCompletionDate"><![CDATA[1982-12-02T00:00:00Z]]></field>
  <field name="articleRevisionDate"><![CDATA[2010-10-26T00:00:00Z]]></field>
  <field name="articlePubmodel"><![CDATA[Print]]></field>
  <field name="journalTitle"><![CDATA[Journal of the National Medical Association]]></field>
  <field name="journalTitleAbrv"><![CDATA[J Natl Med Assoc]]></field>
  <field name="articleTitle"><![CDATA[Gastroschisis and ruptured omphalocele.]]></field>
  <field name="articleAbstract"><![CDATA[The surgeon who is faced with the management of a neonate with a prenatally ruptured omphalocele or a gastroschisis has a challenging problem. These anomalles are some of the most serious, lifethreatening neonatal surgical emergencies.]]></field>
  <field name="author"><![CDATA[Densler J F]]></field>
  <field name="articleLang"><![CDATA[eng]]></field>
  <field name="publicationType"><![CDATA[Journal Article]]></field>
  <field name="articleDescriptor"><![CDATA[Abdominal Muscles]]></field>
  <field name="articleQualifier"><![CDATA[abnormalities]]></field>
  <field name="articleQualifier"><![CDATA[surgery]]></field>
  <field name="articleDescriptor"><![CDATA[Hernia, Umbilical]]></field>
  <field name="articleQualifier"><![CDATA[surgery]]></field>
  <field name="articleDescriptor"><![CDATA[Humans]]></field>
  <field name="articleDescriptor"><![CDATA[Infant, Newborn]]></field>
  <field name="articleDescriptor"><![CDATA[Rupture, Spontaneous]]></field>
 </doc>
 <doc>
  <field name="id"><![CDATA[7120503]]></field>
  <field name="articleCreationDate"><![CDATA[1982-12-02T00:00:00Z]]></field>
  <field name="articleYear"><![CDATA[1982]]></field>
  <field name="articleCompletionDate"><![CDATA[1982-12-02T00:00:00Z]]></field>
  <field name="articleRevisionDate"><![CDATA[2006-11-15T00:00:00Z]]></field>
  <field name="articlePubmodel"><![CDATA[Print]]></field>
  <field name="journalTitle"><![CDATA[Journal of toxicology and environmental health]]></field>
  <field name="journalTitleAbrv"><![CDATA[J Toxicol Environ Health]]></field>
  <field name="articleTitle"><![CDATA[Effect of dose level and pregnancy on the distribution and toxicity of intravenous lead in rats.]]></field>
  <field name="articleAbstract"><![CDATA[Female Wistar rats were injected intravenously with tracer levels of 210Pb, alone or combined with carrier Pb(NO3)2 at 5 or 25 mg/kg body weight at 9 or 15 days of gestation (dg). Tissue 210Pb distribution and retention, and lead excretion, were measured several times during the first 30 h and at 20 dg. Toxic effects following the administration of 25 mg/kg (a teratogenic dose) included an early decrease in hematocrit, hematuria, gastrointestinal hemorrhage, and diarrhea, as well as an eventual loss of body weight and an increase in spleen and kidney weights. The stage of pregnancy at injection did not affect the retention and distribution of lead in major organs other than the reproductive system. Following injection of the 25-mg/kg dose, deposition of lead in the liver, kidney, spleen, and lung was elevated. Disproportionately high plasma lead levels were also observed at early times after the injection of the 25-mg/kg dose, and may act as a significant factor in placental lead transfer and subsequent malformations or fetal mortality.]]></field>
  <field name="author"><![CDATA[Hackett P L]]></field>
  <field name="author"><![CDATA[Hess J O]]></field>
  <field name="author"><![CDATA[Sikov M R]]></field>
  <field name="articleLang"><![CDATA[eng]]></field>
  <field name="publicationType"><![CDATA[Journal Article]]></field>
  <field name="publicationType"><![CDATA[Research Support, U.S. Gov't, Non-P.H.S.]]></field>
  <field name="substanceName"><![CDATA[Radioisotopes]]></field>
  <field name="substanceName"><![CDATA[Lead]]></field>
  <field name="articleDescriptor"><![CDATA[Animals]]></field>
  <field name="articleDescriptor"><![CDATA[Dose-Response Relationship, Drug]]></field>
  <field name="articleDescriptor"><![CDATA[Female]]></field>
  <field name="articleDescriptor"><![CDATA[Kinetics]]></field>
  <field name="articleDescriptor"><![CDATA[Lead]]></field>
  <field name="articleQualifier"><![CDATA[metabolism]]></field>
  <field name="articleQualifier"><![CDATA[toxicity]]></field>
  <field name="articleDescriptor"><![CDATA[Organ Size]]></field>
  <field name="articleQualifier"><![CDATA[drug effects]]></field>
  <field name="articleDescriptor"><![CDATA[Pregnancy]]></field>
  <field name="articleDescriptor"><![CDATA[Pregnancy, Animal]]></field>
  <field name="articleQualifier"><![CDATA[drug effects]]></field>
  <field name="articleDescriptor"><![CDATA[Radioisotopes]]></field>
  <field name="articleDescriptor"><![CDATA[Rats]]></field>
  <field name="articleDescriptor"><![CDATA[Rats, Inbred Strains]]></field>
  <field name="articleDescriptor"><![CDATA[Tissue Distribution]]></field>
 </doc>
 <doc>
  <field name="id"><![CDATA[7120504]]></field>
  <field name="articleCreationDate"><![CDATA[1982-12-02T00:00:00Z]]></field>
  <field name="articleYear"><![CDATA[1982]]></field>
  <field name="articleCompletionDate"><![CDATA[1982-12-02T00:00:00Z]]></field>
  <field name="articleRevisionDate"><![CDATA[2003-11-14T00:00:00Z]]></field>
  <field name="articlePubmodel"><![CDATA[Print]]></field>
  <field name="journalTitle"><![CDATA[Journal of toxicology and environmental health]]></field>
  <field name="journalTitleAbrv"><![CDATA[J Toxicol Environ Health]]></field>
  <field name="articleTitle"><![CDATA[Distribution and effects of intravenous lead in the fetoplacental unit of the rat.]]></field>
  <field name="articleAbstract"><![CDATA[Lead metabolism was studied in the fetoplacental unit (FPU) of Wistar rats during the genesis of developmental abnormalities and embryonic death. Female rats were injected iv with tracer 210Pb(NO3)2, alone or in combination with 5 or 25 mg Pb(NO3)2/kg, at 9 or 15 days of gestation (dg). The distribution of lead and its effects were determined in the FPUs during the ensuing 30-h period and at 20 dg. Hemorrhage of the egg cylinder was noted as early as 6 h postinjection of 25 mg/kg at 9 dg. By 20 dg, fetuses exhibited characteristic stunting and external malformations (gastroschisis and severe skeletal defects). Administration of this dose at 15 dg produced petechial hemorrhage in fetal brain within 90 min; more massive hemorrhage was a consistent observation by 24 h. At 20 dg, embryo mortality was 44% in rats injected with 25 mg/kg at 9 dg and 100% in those injected at 15 dg. At 90 min after injection, lead content of 15-dg FPUs was 10 times that of the 9-dg FPUs, but the weights of the 15-dg FPUs were 16 times greater. Values remained relatively constant in 15-dg FPUs for 30 h, but early clearance was observed after injection at 9 dg, with a return to 90-min values by 20 dg. In the 15-dg FPUs, placental clearance was followed by fetal lead incorporation, which reached a maximum at 6 h. Fetal lead values were constant from 6 to 30 h after injection at tracer and 5-mg/kg dose levels, but values increased progressively at 25 mg/kg. Both temporal and quantitative relationships of fetal lead metabolism were disrupted by the 25-mg/kg dose, but the nature of the effect was determined by the stage of fetal development at exposure.]]></field>
  <field name="author"><![CDATA[Hackett P L]]></field>
  <field name="author"><![CDATA[Hess J O]]></field>
  <field name="author"><![CDATA[Sikov M R]]></field>
  <field name="articleLang"><![CDATA[eng]]></field>
  <field name="publicationType"><![CDATA[Journal Article]]></field>
  <field name="substanceName"><![CDATA[Radioisotopes]]></field>
  <field name="substanceName"><![CDATA[Lead]]></field>
  <field name="articleDescriptor"><![CDATA[Animals]]></field>
  <field name="articleDescriptor"><![CDATA[Dose-Response Relationship, Drug]]></field>
  <field name="articleDescriptor"><![CDATA[Female]]></field>
  <field name="articleDescriptor"><![CDATA[Fetal Resorption]]></field>
  <field name="articleQualifier"><![CDATA[chemically induced]]></field>
  <field name="articleDescriptor"><![CDATA[Fetus]]></field>
  <field name="articleQualifier"><![CDATA[drug effects]]></field>
  <field name="articleDescriptor"><![CDATA[Injections, Intravenous]]></field>
  <field name="articleDescriptor"><![CDATA[Lead]]></field>
  <field name="articleQualifier"><![CDATA[metabolism]]></field>
  <field name="articleQualifier"><![CDATA[toxicity]]></field>
  <field name="articleDescriptor"><![CDATA[Pregnancy]]></field>
  <field name="articleDescriptor"><![CDATA[Pregnancy, Animal]]></field>
  <field name="articleQualifier"><![CDATA[drug effects]]></field>
  <field name="articleDescriptor"><![CDATA[Radioisotopes]]></field>
  <field name="articleDescriptor"><![CDATA[Rats]]></field>
  <field name="articleDescriptor"><![CDATA[Rats, Inbred Strains]]></field>
  <field name="articleDescriptor"><![CDATA[Time Factors]]></field>
 </doc>
 <doc>
  <field name="id"><![CDATA[7120505]]></field>
  <field name="articleCreationDate"><![CDATA[1982-12-02T00:00:00Z]]></field>
  <field name="articleYear"><![CDATA[1982]]></field>
  <field name="articleCompletionDate"><![CDATA[1982-12-02T00:00:00Z]]></field>
  <field name="articleRevisionDate"><![CDATA[2007-11-14T00:00:00Z]]></field>
  <field name="articlePubmodel"><![CDATA[Print]]></field>
  <field name="journalTitle"><![CDATA[Journal of toxicology and environmental health]]></field>
  <field name="journalTitleAbrv"><![CDATA[J Toxicol Environ Health]]></field>
  <field name="articleTitle"><![CDATA[Influence of spironolactone on cadmium-induced changes in hepatic and renal gluconeogenic enzymes in rats.]]></field>
  <field name="articleAbstract"><![CDATA[Serum glucose, serum protein, serum glutamic oxalacetic transaminase (SGOT), serum glutamic pyruvic transaminase (SGPT), and hepatic and renal gluconeogenic enzymes [pyruvate carboxylase (PC), phosphoenolpyruvate carboxykinase (PEPCK), fructose-1,6-diphosphatase (F-1,6-DPase), and glucose-6-phosphatase (G-6-Pase)] were determined in rats treated daily with cadmium alone (0.25 mg/kg X d, injected ip and in rats pretreated with spironolactone (50 mg/kg x d and 100 mg/kg X d, injected sc) prior to cadmium administration. Rats receiving no treatment, propylene glycol, or spironolactone (100 mg/kg X d, injected sc) were used as controls. The daily treatments were continued for an extended period of 90 d, and the rats were sacrificed at 30-, 60-, and 90-d intervals during the continuous daily treatment schedule. Cadmium treatment significantly increased the amount of serum protein, glucose, serum enzymes, and all the four key gluconeogenic enzymes as compared to controls. Pretreatment of rats with spironolactone 6 h prior to cadmium injection daily antagonized the cadmium effect of the above parameters. It appears from these results that spironolactone reduces the effects of cadmium on the key gluconeogenic enzymes in rat kidney and liver.]]></field>
  <field name="author"><![CDATA[Rajanna B]]></field>
  <field name="author"><![CDATA[Chapatwala K D]]></field>
  <field name="author"><![CDATA[Hobson M]]></field>
  <field name="author"><![CDATA[Desaiah D]]></field>
  <field name="articleLang"><![CDATA[eng]]></field>
  <field name="publicationType"><![CDATA[Journal Article]]></field>
  <field name="publicationType"><![CDATA[Research Support, U.S. Gov't, P.H.S.]]></field>
  <field name="substanceName"><![CDATA[Enzymes]]></field>
  <field name="substanceName"><![CDATA[Spironolactone]]></field>
  <field name="articleDescriptor"><![CDATA[Animals]]></field>
  <field name="articleDescriptor"><![CDATA[Cadmium Poisoning]]></field>
  <field name="articleQualifier"><![CDATA[prevention & control]]></field>
  <field name="articleDescriptor"><![CDATA[Enzymes]]></field>
  <field name="articleQualifier"><![CDATA[blood]]></field>
  <field name="articleDescriptor"><![CDATA[Kidney]]></field>
  <field name="articleQualifier"><![CDATA[enzymology]]></field>
  <field name="articleDescriptor"><![CDATA[Liver]]></field>
  <field name="articleQualifier"><![CDATA[enzymology]]></field>
  <field name="articleDescriptor"><![CDATA[Male]]></field>
  <field name="articleDescriptor"><![CDATA[Rats]]></field>
  <field name="articleDescriptor"><![CDATA[Rats, Inbred Strains]]></field>
  <field name="articleDescriptor"><![CDATA[Spironolactone]]></field>
  <field name="articleQualifier"><![CDATA[pharmacology]]></field>
 </doc>
 <doc>
  <field name="id"><![CDATA[6750143]]></field>
  <field name="articleCreationDate"><![CDATA[1982-12-02T00:00:00Z]]></field>
  <field name="articleYear"><![CDATA[1982]]></field>
  <field name="articleCompletionDate"><![CDATA[1982-12-02T00:00:00Z]]></field>
  <field name="articleRevisionDate"><![CDATA[2003-11-14T00:00:00Z]]></field>
  <field name="articlePubmodel"><![CDATA[Print]]></field>
  <field name="journalTitle"><![CDATA[Journal of toxicology and environmental health]]></field>
  <field name="journalTitleAbrv"><![CDATA[J Toxicol Environ Health]]></field>
  <field name="articleTitle"><![CDATA[A neuromuscular screen for use in industrial toxicology.]]></field>
  <field name="articleAbstract"><![CDATA[A short objective screening technique has been developed to identify those agents that have peripheral and/or central nervous effects in small laboratory rodents (when utilized as a feature in routine testing protocols). The technique initially utilizes a series of simple quantitative and qualitative measures of various aspects of sensory and motor function. The methodology has been designed for and utilized as modular additions in a large number and variety of toxicity studies performed on industrial compounds including macrocyclic ethers, aldehydes, urethane foam catalysts, and others. It is shown to be a more sensitive early indicator of toxicity than such classical measures as body weight or clinical chemistry in those cases (such as the macrocyclic ethers and amino propionitrile) where the nervous or muscular system are the ultimate target organs. It is also a noninvasive and relatively inexpensive methodology. The second phase (a series of isolated tissue assays) establishes the ability to differentiate between reversible (pharmacologic) and irreversible (toxicologic) sensory-neural responses. The development and validation of the procedure have involved its use in both acute and subchronic studies by the inhalation, oral, ip, and sc routes. As necessary, isolated tissue and biochemical assays have been done to verify mechanisms of action. In fact, decision-tree schemes have been developed as part of the screen. These schemes allow elucidation of mechanisms of action if such is desired and statistical evaluation of the diverse data generated.]]></field>
  <field name="author"><![CDATA[Gad S C]]></field>
  <field name="articleLang"><![CDATA[eng]]></field>
  <field name="publicationType"><![CDATA[Journal Article]]></field>
  <field name="publicationType"><![CDATA[Review]]></field>
  <field name="articleDescriptor"><![CDATA[Animals]]></field>
  <field name="articleDescriptor"><![CDATA[Drug Evaluation, Preclinical]]></field>
  <field name="articleQualifier"><![CDATA[methods]]></field>
  <field name="articleDescriptor"><![CDATA[Industry]]></field>
  <field name="articleDescriptor"><![CDATA[Neuromuscular Diseases]]></field>
  <field name="articleQualifier"><![CDATA[chemically induced]]></field>
  <field name="articleDescriptor"><![CDATA[Research Design]]></field>
  <field name="articleDescriptor"><![CDATA[Toxicology]]></field>
 </doc>
 <doc>
  <field name="id"><![CDATA[6811764]]></field>
  <field name="articleCreationDate"><![CDATA[1982-12-02T00:00:00Z]]></field>
  <field name="articleYear"><![CDATA[1982]]></field>
  <field name="articleCompletionDate"><![CDATA[1982-12-02T00:00:00Z]]></field>
  <field name="articleRevisionDate"><![CDATA[2006-11-15T00:00:00Z]]></field>
  <field name="articlePubmodel"><![CDATA[Print]]></field>
  <field name="journalTitle"><![CDATA[Journal of toxicology and environmental health]]></field>
  <field name="journalTitleAbrv"><![CDATA[J Toxicol Environ Health]]></field>
  <field name="articleTitle"><![CDATA[Multivariate statistical methods in toxicology. III. Specifying joint toxic interaction using multiple regression analysis.]]></field>
  <field name="articleAbstract"><![CDATA[Multiple regression is widely employed to study the contribution of components to the toxicologic effect of a mixture. Here, use is made of the fact that data obtained from standard curves of substances and from their mixtures are separable in regression analysis. Thus, under an assumption of additivity of responses, regression coefficients obtained for components in mixtures alone should be the same as for the individual substances. A t-test is developed such that nonsignificant t values support additivity, negative significant values support antagonism, and positive significant values support synergism. The results are applied to data on the mutagenicity of binary mixtures of azaserine, 4-nitroquinoline N-oxide, and 9-aminoacridine in TA 100 in the Ames assay.]]></field>
  <field name="author"><![CDATA[Schaeffer D J]]></field>
  <field name="author"><![CDATA[Glave W R]]></field>
  <field name="author"><![CDATA[Janardan K G]]></field>
  <field name="articleLang"><![CDATA[eng]]></field>
  <field name="publicationType"><![CDATA[In Vitro]]></field>
  <field name="publicationType"><![CDATA[Journal Article]]></field>
  <field name="publicationType"><![CDATA[Review]]></field>
  <field name="substanceName"><![CDATA[Aminoacridines]]></field>
  <field name="substanceName"><![CDATA[Mutagens]]></field>
  <field name="substanceName"><![CDATA[Azaserine]]></field>
  <field name="substanceName"><![CDATA[4-Nitroquinoline-1-oxide]]></field>
  <field name="articleDescriptor"><![CDATA[4-Nitroquinoline-1-oxide]]></field>
  <field name="articleQualifier"><![CDATA[toxicity]]></field>
  <field name="articleDescriptor"><![CDATA[Aminoacridines]]></field>
  <field name="articleQualifier"><![CDATA[toxicity]]></field>
  <field name="articleDescriptor"><![CDATA[Azaserine]]></field>
  <field name="articleQualifier"><![CDATA[toxicity]]></field>
  <field name="articleDescriptor"><![CDATA[Drug Interactions]]></field>
  <field name="articleDescriptor"><![CDATA[Models, Biological]]></field>
  <field name="articleDescriptor"><![CDATA[Mutagenicity Tests]]></field>
  <field name="articleDescriptor"><![CDATA[Mutagens]]></field>
  <field name="articleDescriptor"><![CDATA[Regression Analysis]]></field>
  <field name="articleDescriptor"><![CDATA[Toxicology]]></field>
 </doc>
 <doc>
  <field name="id"><![CDATA[7120506]]></field>
  <field name="articleCreationDate"><![CDATA[1982-12-02T00:00:00Z]]></field>
  <field name="articleYear"><![CDATA[1982]]></field>
  <field name="articleCompletionDate"><![CDATA[1982-12-02T00:00:00Z]]></field>
  <field name="articleRevisionDate"><![CDATA[2006-11-15T00:00:00Z]]></field>
  <field name="articlePubmodel"><![CDATA[Print]]></field>
  <field name="journalTitle"><![CDATA[Journal of toxicology and environmental health]]></field>
  <field name="journalTitleAbrv"><![CDATA[J Toxicol Environ Health]]></field>
  <field name="articleTitle"><![CDATA[Scaling toxicity from laboratory animals to people: an example with nitrogen dioxide.]]></field>
  <field name="articleAbstract"><![CDATA[Published data on the toxicity of nitrogen dioxide (as a model compound) from five laboratory animal species were utilized to scale the relationship of dose and toxic effect to the human species. A minute volume of inspired air was used as a metabolic scaling factor, predicting a median lethality during the time of exposure of 174 ppm NO2 for a 1-h exposure for people. This work demonstrates a method of predicting effects in people when only data for laboratory animals exist. It also shows the value of planning toxicology studies that utilize several animal species, so that their data may be applied to forecasting the human condition.]]></field>
  <field name="author"><![CDATA[Book S A]]></field>
  <field name="articleLang"><![CDATA[eng]]></field>
  <field name="publicationType"><![CDATA[Journal Article]]></field>
  <field name="publicationType"><![CDATA[Research Support, U.S. Gov't, Non-P.H.S.]]></field>
  <field name="substanceName"><![CDATA[Nitrogen Dioxide]]></field>
  <field name="articleDescriptor"><![CDATA[Animals]]></field>
  <field name="articleDescriptor"><![CDATA[Dogs]]></field>
  <field name="articleDescriptor"><![CDATA[Dose-Response Relationship, Drug]]></field>
  <field name="articleDescriptor"><![CDATA[Guinea Pigs]]></field>
  <field name="articleDescriptor"><![CDATA[Humans]]></field>
  <field name="articleDescriptor"><![CDATA[Lethal Dose 50]]></field>
  <field name="articleDescriptor"><![CDATA[Mice]]></field>
  <field name="articleDescriptor"><![CDATA[Models, Biological]]></field>
  <field name="articleDescriptor"><![CDATA[Nitrogen Dioxide]]></field>
  <field name="articleQualifier"><![CDATA[toxicity]]></field>
  <field name="articleDescriptor"><![CDATA[Rabbits]]></field>
  <field name="articleDescriptor"><![CDATA[Rats]]></field>
  <field name="articleDescriptor"><![CDATA[Research Design]]></field>
 </doc>
 <doc>
  <field name="id"><![CDATA[7120507]]></field>
  <field name="articleCreationDate"><![CDATA[1982-12-02T00:00:00Z]]></field>
  <field name="articleYear"><![CDATA[1982]]></field>
  <field name="articleCompletionDate"><![CDATA[1982-12-02T00:00:00Z]]></field>
  <field name="articleRevisionDate"><![CDATA[2007-11-14T00:00:00Z]]></field>
  <field name="articlePubmodel"><![CDATA[Print]]></field>
  <field name="journalTitle"><![CDATA[Journal of toxicology and environmental health]]></field>
  <field name="journalTitleAbrv"><![CDATA[J Toxicol Environ Health]]></field>
  <field name="articleTitle"><![CDATA[National Cooperative Gallstone Study: nonprimate toxicology of chenodeoxycholic acid.]]></field>
  <field name="articleAbstract"><![CDATA[A program involving acute, subacute, and chronic toxicity as well as reproduction studies was performed to evaluate the potential toxicity of chenodeoxycholic acid in rats, hamsters, and dogs. Acute oral toxicity studies showed that there were some species differences and that female hamsters were more sensitive to toxic doses than male hamsters. Subacute and chronic studies in hamsters showed the toxicity to be limited to effects on the liver, including proliferation of intrahepatic bile ducts in portal areas with elevations of serum glutamic-pyruvic transaminase and glutamic-oxaloacetic transaminase. No tumorigenic effect was observed. A series of reproduction studies showed no adverse effect on fertility, gestation, live birth indices, or skeletal or visceral development of fetuses. A dominant lethal study detected no biologically significant increases in proportions of embryo deaths. The changes in the animals were rather similar bile duct reduplications. The data suggest that at high doses in sensitive animals inflammation and scarring may develop. No other significant organ pathology was observed. The mechanism of toxicity of chenodeoxycholic acid remains speculative. Some chenodeoxycholic acid may be converted to lithocholic acid by bacteria in the large bowel. The lithocholic acid may be resorbed and cause lesions such as bile duct proliferation. This liver toxicity might not be expected in humans since lithocholic acid is sulfated to a large extent.]]></field>
  <field name="author"><![CDATA[Okun R]]></field>
  <field name="author"><![CDATA[Goldstein L I]]></field>
  <field name="author"><![CDATA[Van Gelder G A]]></field>
  <field name="author"><![CDATA[Goldenthal E I]]></field>
  <field name="author"><![CDATA[Wazeter F X]]></field>
  <field name="author"><![CDATA[Giel R G]]></field>
  <field name="articleLang"><![CDATA[eng]]></field>
  <field name="publicationType"><![CDATA[Journal Article]]></field>
  <field name="publicationType"><![CDATA[Research Support, U.S. Gov't, P.H.S.]]></field>
  <field name="substanceName"><![CDATA[Chenodeoxycholic Acid]]></field>
  <field name="articleDescriptor"><![CDATA[Animals]]></field>
  <field name="articleDescriptor"><![CDATA[Bile Ducts]]></field>
  <field name="articleQualifier"><![CDATA[drug effects]]></field>
  <field name="articleQualifier"><![CDATA[pathology]]></field>
  <field name="articleDescriptor"><![CDATA[Chenodeoxycholic Acid]]></field>
  <field name="articleQualifier"><![CDATA[toxicity]]></field>
  <field name="articleDescriptor"><![CDATA[Cricetinae]]></field>
  <field name="articleDescriptor"><![CDATA[Dogs]]></field>
  <field name="articleDescriptor"><![CDATA[Dose-Response Relationship, Drug]]></field>
  <field name="articleDescriptor"><![CDATA[Female]]></field>
  <field name="articleDescriptor"><![CDATA[Lethal Dose 50]]></field>
  <field name="articleDescriptor"><![CDATA[Liver]]></field>
  <field name="articleQualifier"><![CDATA[drug effects]]></field>
  <field name="articleQualifier"><![CDATA[pathology]]></field>
  <field name="articleDescriptor"><![CDATA[Male]]></field>
  <field name="articleDescriptor"><![CDATA[Rats]]></field>
  <field name="articleDescriptor"><![CDATA[Reproduction]]></field>
  <field name="articleQualifier"><![CDATA[drug effects]]></field>
  <field name="articleDescriptor"><![CDATA[Sex Factors]]></field>
  <field name="articleDescriptor"><![CDATA[Species Specificity]]></field>
 </doc>
 <doc>
  <field name="id"><![CDATA[7120508]]></field>
  <field name="articleCreationDate"><![CDATA[1982-12-02T00:00:00Z]]></field>
  <field name="articleYear"><![CDATA[1982]]></field>
  <field name="articleCompletionDate"><![CDATA[1982-12-02T00:00:00Z]]></field>
  <field name="articleRevisionDate"><![CDATA[2012-11-15T00:00:00Z]]></field>
  <field name="articlePubmodel"><![CDATA[Print]]></field>
  <field name="journalTitle"><![CDATA[Journal of toxicology and environmental health]]></field>
  <field name="journalTitleAbrv"><![CDATA[J Toxicol Environ Health]]></field>
  <field name="articleTitle"><![CDATA[Effects of inhalation exposure to hexachlorocyclopentadiene on rats and monkeys.]]></field>
  <field name="articleAbstract"><![CDATA[Hexachlorocyclopentadiene (Hex or C-56) is a highly reactive intermediate used in the production of some insecticides, flame retardants, and resins. The present study was conducted to evaluate the inhalation toxicity of high-purity Hex (97.7%) in rats and monkeys to provide information on the potential hazards of accidental exposure of workers to Hex vapors. Acute, range-finding (14-d), and subchronic (90-d) inhalation studies were conducted with Sprague-Dawley rats and subchronic (90-d) inhalation studies were conducted with cynomolgus monkeys. Both acute and range-finding studies with rats showed a steep dose-response curve, and male rats were more sensitive than females. In the range-finding study with rats the threshold of toxicity for Hex was 0.11-0.5 ppm. Histopathologic examination on rats in the 0.5 ppm group revealed lesions in the olfactory and bronchiolar epithelium and inflammatory exudate in the lumens of the respiratory tract; these changes were consistent with observed impaired respiratory function, confirming the lung as the main target organ. Recovery and regression of lung lesions in rats were noted 2-3 wk after termination of exposure. In the 90-d study, inhalation of Hex vapors at concentrations up to 0.2 ppm for 6 h/d, 5 d/wk, produced no detectable physical or clinical effect and no remarkable gross or histological alterations in rats or monkeys.]]></field>
  <field name="author"><![CDATA[Rand G M]]></field>
  <field name="author"><![CDATA[Nees P O]]></field>
  <field name="author"><![CDATA[Calo C J]]></field>
  <field name="author"><![CDATA[Alexander D J]]></field>
  <field name="author"><![CDATA[Clark G C]]></field>
  <field name="articleLang"><![CDATA[eng]]></field>
  <field name="publicationType"><![CDATA[Journal Article]]></field>
  <field name="substanceName"><![CDATA[Hydrocarbons, Chlorinated]]></field>
  <field name="substanceName"><![CDATA[hexachlorocyclopentadiene]]></field>
  <field name="articleDescriptor"><![CDATA[Animals]]></field>
  <field name="articleDescriptor"><![CDATA[Body Weight]]></field>
  <field name="articleQualifier"><![CDATA[drug effects]]></field>
  <field name="articleDescriptor"><![CDATA[Female]]></field>
  <field name="articleDescriptor"><![CDATA[Hydrocarbons, Chlorinated]]></field>
  <field name="articleQualifier"><![CDATA[toxicity]]></field>
  <field name="articleDescriptor"><![CDATA[Lethal Dose 50]]></field>
  <field name="articleDescriptor"><![CDATA[Lung]]></field>
  <field name="articleQualifier"><![CDATA[drug effects]]></field>
  <field name="articleDescriptor"><![CDATA[Macaca fascicularis]]></field>
  <field name="articleDescriptor"><![CDATA[Male]]></field>
  <field name="articleDescriptor"><![CDATA[Rats]]></field>
  <field name="articleDescriptor"><![CDATA[Rats, Inbred Strains]]></field>
  <field name="articleDescriptor"><![CDATA[Sex Factors]]></field>
 </doc>
 <doc>
  <field name="id"><![CDATA[7120509]]></field>
  <field name="articleCreationDate"><![CDATA[1982-12-02T00:00:00Z]]></field>
  <field name="articleYear"><![CDATA[1982]]></field>
  <field name="articleCompletionDate"><![CDATA[1982-12-02T00:00:00Z]]></field>
  <field name="articleRevisionDate"><![CDATA[2007-11-14T00:00:00Z]]></field>
  <field name="articlePubmodel"><![CDATA[Print]]></field>
  <field name="journalTitle"><![CDATA[Journal of toxicology and environmental health]]></field>
  <field name="journalTitleAbrv"><![CDATA[J Toxicol Environ Health]]></field>
  <field name="articleTitle"><![CDATA[Role of biotransformation in the potentiation of halocarbon hepatotoxicity by 2,5-hexanedione.]]></field>
  <field name="articleAbstract"><![CDATA[2,5-Hexanedione (2,5-HD) pretreatment potentiated CHCl3-induced hepatotoxicity. 2,5-HD significantly increased hepatic cytochrome P-450, NADPH cytochrome c reductase, aniline hydroxylation, p-nitroanisole O-demethylation, and aminopyrine N-demethylation in both male and female mice. 2,5-HD pretreatment potentiated CHCl3-induced centrilobular necrosis and increased serum alanine amino transferase (ALT) activity by 20 times more than CHCl3 alone. Similarly, 2,5-HD pretreatment potentiated CDCl3-induced hepatotoxicity as well as CCl4-induced hepatotoxicity in male mice, but did not potentiate trichloroethylene-, 1,1,2-trichloroethane-, or perchloroethylene-induced hepatotoxicity. In female mice, 2,5-HD pretreatment potentiated CHCl3- and CDCl3-induced hepatotoxicity as well as trichloroethylene-, 1,1,2-trichloroethane-, and carbon tetrachloride-induced hepatotoxicity, but not perchloroethylene-induced hepatotoxicity. 2,5-HD pretreatment had no preferential effect on either CHCl3- or CDCl3-induced hepatotoxicity in females. However, phenobarbital pretreatment did differentiate CHCl3- and CDCl3-induced hepatotoxicity in females. 2,5-HD-induced potentiation of halocarbon hepatotoxicity is sex dependent.]]></field>
  <field name="author"><![CDATA[Jernigan J D]]></field>
  <field name="author"><![CDATA[Harbison R D]]></field>
  <field name="articleLang"><![CDATA[eng]]></field>
  <field name="publicationType"><![CDATA[Journal Article]]></field>
  <field name="publicationType"><![CDATA[Research Support, U.S. Gov't, P.H.S.]]></field>
  <field name="substanceName"><![CDATA[Hexanones]]></field>
  <field name="substanceName"><![CDATA[Hydrocarbons, Chlorinated]]></field>
  <field name="substanceName"><![CDATA[Ketones]]></field>
  <field name="substanceName"><![CDATA[2,5-hexanedione]]></field>
  <field name="substanceName"><![CDATA[Chloroform]]></field>
  <field name="substanceName"><![CDATA[Glutathione]]></field>
  <field name="substanceName"><![CDATA[Cytochrome P-450 Enzyme System]]></field>
  <field name="substanceName"><![CDATA[Mixed Function Oxygenases]]></field>
  <field name="substanceName"><![CDATA[NADH Dehydrogenase]]></field>
  <field name="substanceName"><![CDATA[Alanine Transaminase]]></field>
  <field name="articleDescriptor"><![CDATA[Alanine Transaminase]]></field>
  <field name="articleQualifier"><![CDATA[blood]]></field>
  <field name="articleDescriptor"><![CDATA[Animals]]></field>
  <field name="articleDescriptor"><![CDATA[Biotransformation]]></field>
  <field name="articleDescriptor"><![CDATA[Chloroform]]></field>
  <field name="articleQualifier"><![CDATA[toxicity]]></field>
  <field name="articleDescriptor"><![CDATA[Cytochrome P-450 Enzyme System]]></field>
  <field name="articleQualifier"><![CDATA[analysis]]></field>
  <field name="articleDescriptor"><![CDATA[Drug Interactions]]></field>
  <field name="articleDescriptor"><![CDATA[Female]]></field>
  <field name="articleDescriptor"><![CDATA[Glutathione]]></field>
  <field name="articleQualifier"><![CDATA[metabolism]]></field>
  <field name="articleDescriptor"><![CDATA[Hexanones]]></field>
  <field name="articleQualifier"><![CDATA[pharmacology]]></field>
  <field name="articleDescriptor"><![CDATA[Hydrocarbons, Chlorinated]]></field>
  <field name="articleQualifier"><![CDATA[toxicity]]></field>
  <field name="articleDescriptor"><![CDATA[Ketones]]></field>
  <field name="articleQualifier"><![CDATA[pharmacology]]></field>
  <field name="articleDescriptor"><![CDATA[Liver]]></field>
  <field name="articleQualifier"><![CDATA[drug effects]]></field>
  <field name="articleQualifier"><![CDATA[pathology]]></field>
  <field name="articleDescriptor"><![CDATA[Male]]></field>
  <field name="articleDescriptor"><![CDATA[Mice]]></field>
  <field name="articleDescriptor"><![CDATA[Mice, Inbred ICR]]></field>
  <field name="articleDescriptor"><![CDATA[Mixed Function Oxygenases]]></field>
  <field name="articleQualifier"><![CDATA[metabolism]]></field>
  <field name="articleDescriptor"><![CDATA[NADH Dehydrogenase]]></field>
  <field name="articleQualifier"><![CDATA[metabolism]]></field>
  <field name="articleDescriptor"><![CDATA[Sex Factors]]></field>
 </doc>
 <doc>
  <field name="id"><![CDATA[7120510]]></field>
  <field name="articleCreationDate"><![CDATA[1982-12-02T00:00:00Z]]></field>
  <field name="articleYear"><![CDATA[1982]]></field>
  <field name="articleCompletionDate"><![CDATA[1982-12-02T00:00:00Z]]></field>
  <field name="articleRevisionDate"><![CDATA[2006-11-15T00:00:00Z]]></field>
  <field name="articlePubmodel"><![CDATA[Print]]></field>
  <field name="journalTitle"><![CDATA[Journal of toxicology and environmental health]]></field>
  <field name="journalTitleAbrv"><![CDATA[J Toxicol Environ Health]]></field>
  <field name="articleTitle"><![CDATA[Effects of 1,1,1-trichloroethane on a match-to-sample discrimination task in the baboon.]]></field>
  <field name="articleAbstract"><![CDATA[1,1,1-trichloroethane was evaluated for its effects on the delayed match-to-sample discrimination task in juvenile baboons. Acute 4-h exposures to 700, 1400, 1800, and 2100 ppm were conducted no more frequently than once a week. Three months later a subchronic exposure to 1200 ppm was conducted over a 7-d period in the same animals. The effects on accuracy of responding were minimal; however, 1,1,1-trichloroethane reduced the number of trials attempted by the animals, reduced the number of extra inconsequential responses during the delay intervals, and increased reaction times. The findings of these experiments illustrate the usefulness of the young baboon as a primate human surrogate model for testing this type of central nervous system depressant.]]></field>
  <field name="author"><![CDATA[Geller I]]></field>
  <field name="author"><![CDATA[Mendez V]]></field>
  <field name="author"><![CDATA[Hartmann R J]]></field>
  <field name="author"><![CDATA[Gause E]]></field>
  <field name="author"><![CDATA[Rippstein W J]]></field>
  <field name="articleLang"><![CDATA[eng]]></field>
  <field name="publicationType"><![CDATA[Journal Article]]></field>
  <field name="publicationType"><![CDATA[Research Support, U.S. Gov't, Non-P.H.S.]]></field>
  <field name="substanceName"><![CDATA[Hydrocarbons, Chlorinated]]></field>
  <field name="substanceName"><![CDATA[Trichloroethanes]]></field>
  <field name="substanceName"><![CDATA[1,1,1-trichloroethane]]></field>
  <field name="articleDescriptor"><![CDATA[Animals]]></field>
  <field name="articleDescriptor"><![CDATA[Atmosphere Exposure Chambers]]></field>
  <field name="articleDescriptor"><![CDATA[Dose-Response Relationship, Drug]]></field>
  <field name="articleDescriptor"><![CDATA[Hydrocarbons, Chlorinated]]></field>
  <field name="articleQualifier"><![CDATA[pharmacology]]></field>
  <field name="articleDescriptor"><![CDATA[Male]]></field>
  <field name="articleDescriptor"><![CDATA[Papio]]></field>
  <field name="articleDescriptor"><![CDATA[Perception]]></field>
  <field name="articleQualifier"><![CDATA[drug effects]]></field>
  <field name="articleDescriptor"><![CDATA[Reaction Time]]></field>
  <field name="articleQualifier"><![CDATA[drug effects]]></field>
  <field name="articleDescriptor"><![CDATA[Trichloroethanes]]></field>
  <field name="articleQualifier"><![CDATA[pharmacology]]></field>
 </doc>
 <doc>
  <field name="id"><![CDATA[6811765]]></field>
  <field name="articleCreationDate"><![CDATA[1982-12-02T00:00:00Z]]></field>
  <field name="articleYear"><![CDATA[1982]]></field>
  <field name="articleCompletionDate"><![CDATA[1982-12-02T00:00:00Z]]></field>
  <field name="articleRevisionDate"><![CDATA[2007-11-14T00:00:00Z]]></field>
  <field name="articlePubmodel"><![CDATA[Print]]></field>
  <field name="journalTitle"><![CDATA[Journal of toxicology and environmental health]]></field>
  <field name="journalTitleAbrv"><![CDATA[J Toxicol Environ Health]]></field>
  <field name="articleTitle"><![CDATA[Metabolism of [14C]trichloroethylene to 14CO2 and interaction of a metabolite with liver DNA in rats and mice.]]></field>
  <field name="articleAbstract"><![CDATA[Male Sprague-Dawley rats and male B6C3F1 mice excreted 5-15% of a tracer dose of [14C]trichloroethylene as 14CO2 within 24 h after ip injection of a single dose in a corn-oil vehicle. The proportion of the dose excreted as CO2 was greater in mice than in rats, but increased in the rats after starvation or pretreatment with phenobarbital. As the dose was increased toward the LD50 level, the proportion excreted as 14CO2 decreased slightly, but this was largely due to increased loss of unchanged trichloroethylene. The excretion of 14CO2 was thus correlated with the expected level of microsomal metabolism of trichloroethylene to an electrophilic intermediate capable of binding to glutathione or macromolecules. Liver protein labeling was observed to be relatively high (10,000-23,000 cpm/mg in the mouse), while DNA labeling was consistently observed to be very low, not allowing identification of any adducts by high-performance liquid chromatography (HPLC). Also, no effect on DNA fragmentation was seen by alkaline sucrose gradient centrifugation after injection of an LD50 dose of trichloroethylene. The ability of trichloroethylene to interact with DNA in vivo was thus observed to be very slight.]]></field>
  <field name="author"><![CDATA[Parchman L G]]></field>
  <field name="author"><![CDATA[Magee P N]]></field>
  <field name="articleLang"><![CDATA[eng]]></field>
  <field name="publicationType"><![CDATA[Journal Article]]></field>
  <field name="publicationType"><![CDATA[Research Support, Non-U.S. Gov't]]></field>
  <field name="publicationType"><![CDATA[Research Support, U.S. Gov't, P.H.S.]]></field>
  <field name="substanceName"><![CDATA[Carbon Dioxide]]></field>
  <field name="substanceName"><![CDATA[Trichloroethylene]]></field>
  <field name="substanceName"><![CDATA[DNA]]></field>
  <field name="substanceName"><![CDATA[Carboxyhemoglobin]]></field>
  <field name="articleDescriptor"><![CDATA[Animals]]></field>
  <field name="articleDescriptor"><![CDATA[Carbon Dioxide]]></field>
  <field name="articleQualifier"><![CDATA[urine]]></field>
  <field name="articleDescriptor"><![CDATA[Carboxyhemoglobin]]></field>
  <field name="articleQualifier"><![CDATA[analysis]]></field>
  <field name="articleDescriptor"><![CDATA[DNA]]></field>
  <field name="articleQualifier"><![CDATA[metabolism]]></field>
  <field name="articleDescriptor"><![CDATA[Liver]]></field>
  <field name="articleQualifier"><![CDATA[drug effects]]></field>
  <field name="articleDescriptor"><![CDATA[Male]]></field>
  <field name="articleDescriptor"><![CDATA[Mice]]></field>
  <field name="articleDescriptor"><![CDATA[Rats]]></field>
  <field name="articleDescriptor"><![CDATA[Rats, Inbred Strains]]></field>
  <field name="articleDescriptor"><![CDATA[Species Specificity]]></field>
  <field name="articleDescriptor"><![CDATA[Trichloroethylene]]></field>
  <field name="articleQualifier"><![CDATA[metabolism]]></field>
 </doc>
 <doc>
  <field name="id"><![CDATA[7120511]]></field>
  <field name="articleCreationDate"><![CDATA[1982-12-02T00:00:00Z]]></field>
  <field name="articleYear"><![CDATA[1982]]></field>
  <field name="articleCompletionDate"><![CDATA[1982-12-02T00:00:00Z]]></field>
  <field name="articleRevisionDate"><![CDATA[2007-11-14T00:00:00Z]]></field>
  <field name="articlePubmodel"><![CDATA[Print]]></field>
  <field name="journalTitle"><![CDATA[Journal of toxicology and environmental health]]></field>
  <field name="journalTitleAbrv"><![CDATA[J Toxicol Environ Health]]></field>
  <field name="articleTitle"><![CDATA[Age-dependent pulmonary response of rats to ozone exposure.]]></field>
  <field name="articleAbstract"><![CDATA[The influence of age on O3 effects in the lung was studied in 8 groups of Sprague-Dawley rats: 7, 12, and 18 d of age (neonatal); 24, 30, and 45 d of age (infant); and 60 and 90 d of age (adult). Lung weight, total lung protein and DNA contents, and a series of marker enzyme activities in lung tissue were determined. After exposure of rats from each group to 0.8 ppm (1568 microgram/m3) O3 continuously for 3 d, a biphasic effect was noted. The biochemical parameters, expressed per lung, in O3-exposed rats relative to their corresponding controls decreased in the 7- and 12-d-old groups, increased or remained unchanged in the 18-d-old group, and increased in the 24- to 90-d-old groups. However, the increases were much greater for 60- to 90-d-old rats than for 24- to 30-d-old rats. The increase in lung biochemical parameters is thought to occur in response to lung injury and subsequent repair processes, and greater increases in the lungs of older rats suggest that they are more responsive to O3 exposure than younger rats. The decrease in lung biochemical parameters and increased mortality in 7- and 24-d-old neonatal rats suggest that they are more susceptible to O3 stress than infant and adult rats.]]></field>
  <field name="author"><![CDATA[Elsayed N M]]></field>
  <field name="author"><![CDATA[Mustafa M G]]></field>
  <field name="author"><![CDATA[Postlethwait E M]]></field>
  <field name="articleLang"><![CDATA[eng]]></field>
  <field name="publicationType"><![CDATA[Journal Article]]></field>
  <field name="publicationType"><![CDATA[Research Support, Non-U.S. Gov't]]></field>
  <field name="publicationType"><![CDATA[Research Support, U.S. Gov't, Non-P.H.S.]]></field>
  <field name="publicationType"><![CDATA[Research Support, U.S. Gov't, P.H.S.]]></field>
  <field name="substanceName"><![CDATA[Ozone]]></field>
  <field name="articleDescriptor"><![CDATA[Aging]]></field>
  <field name="articleDescriptor"><![CDATA[Animals]]></field>
  <field name="articleDescriptor"><![CDATA[Animals, Newborn]]></field>
  <field name="articleDescriptor"><![CDATA[Lung]]></field>
  <field name="articleQualifier"><![CDATA[drug effects]]></field>
  <field name="articleDescriptor"><![CDATA[Male]]></field>
  <field name="articleDescriptor"><![CDATA[Oxygen Consumption]]></field>
  <field name="articleQualifier"><![CDATA[drug effects]]></field>
  <field name="articleDescriptor"><![CDATA[Ozone]]></field>
  <field name="articleQualifier"><![CDATA[pharmacology]]></field>
  <field name="articleDescriptor"><![CDATA[Rats]]></field>
  <field name="articleDescriptor"><![CDATA[Rats, Inbred Strains]]></field>
 </doc>
 <doc>
  <field name="id"><![CDATA[7120512]]></field>
  <field name="articleCreationDate"><![CDATA[1982-12-02T00:00:00Z]]></field>
  <field name="articleYear"><![CDATA[1982]]></field>
  <field name="articleCompletionDate"><![CDATA[1982-12-02T00:00:00Z]]></field>
  <field name="articleRevisionDate"><![CDATA[2004-11-17T00:00:00Z]]></field>
  <field name="articlePubmodel"><![CDATA[Print]]></field>
  <field name="journalTitle"><![CDATA[Journal of toxicology and environmental health]]></field>
  <field name="journalTitleAbrv"><![CDATA[J Toxicol Environ Health]]></field>
  <field name="articleTitle"><![CDATA[Influence of ozone and nitrogen dioxide on hepatic microsomal enzymes in mice.]]></field>
  <field name="articleAbstract"><![CDATA[Since ambient concentrations of ozone and nitrogen dioxide increase drug-induced sleeping time in female mice, potential mechanisms were sought by investigating the effects of these gases on hepatic microsomal mixed-function oxidases in female CD-1 mice. A 3-h exposure to 9800 microgram O3/m3 (5 ppm) or 9400 microgram NO2/m3 (5 ppm) did not change the concentration of cytochrome P-450 significantly. Aniline hydroxylase, but not aminopyrine N-demethylase or p-nitroanisole O-demethylase, activities were increased following a 3-h exposure to 9400 microgram O3/m3 (5 ppm). Aniline hydroxylase activity was also increased after a 2-d (5 h/d) exposure to 1960 microgram O3/m3 (1 ppm). None of these enzyme activities were affected by a 3-h exposure to 9400 microgram NO2/m3 (5 ppm). In these studies, O3 sometimes increased wet liver weight, and thus additional experiments were conducted. A 5-h exposure to 1960 microgram O3/m3 (1 ppm) caused a lesser decrease in body weight than the decrease observed after a similar air exposure. Liver wet weights were elevated after O3 exposure. However, there were no significant changes in liver dry weight, liver dry-to-wet-weight ratio, or ratios of liver (wet or dry) weight to body weight. From these data, it is concluded that mechanisms other than those investigated are responsible for the effect of O3 and NO2 on drug-induced sleeping time. However, the activity of one mixed-function oxidase was slightly increased by O3, indicating a hitherto unrecognized systemic effect of O3 exposure.]]></field>
  <field name="author"><![CDATA[Graham J A]]></field>
  <field name="author"><![CDATA[Miller F J]]></field>
  <field name="author"><![CDATA[Gardner D E]]></field>
  <field name="author"><![CDATA[Ward R]]></field>
  <field name="author"><![CDATA[Menzel D B]]></field>
  <field name="articleLang"><![CDATA[eng]]></field>
  <field name="publicationType"><![CDATA[Journal Article]]></field>
  <field name="substanceName"><![CDATA[Ozone]]></field>
  <field name="substanceName"><![CDATA[Nitrogen Dioxide]]></field>
  <field name="substanceName"><![CDATA[Cytochrome P-450 Enzyme System]]></field>
  <field name="articleDescriptor"><![CDATA[Animals]]></field>
  <field name="articleDescriptor"><![CDATA[Body Weight]]></field>
  <field name="articleQualifier"><![CDATA[drug effects]]></field>
  <field name="articleDescriptor"><![CDATA[Cytochrome P-450 Enzyme System]]></field>
  <field name="articleQualifier"><![CDATA[analysis]]></field>
  <field name="articleDescriptor"><![CDATA[Female]]></field>
  <field name="articleDescriptor"><![CDATA[Mice]]></field>
  <field name="articleDescriptor"><![CDATA[Microsomes, Liver]]></field>
  <field name="articleQualifier"><![CDATA[drug effects]]></field>
  <field name="articleQualifier"><![CDATA[enzymology]]></field>
  <field name="articleDescriptor"><![CDATA[Nitrogen Dioxide]]></field>
  <field name="articleQualifier"><![CDATA[pharmacology]]></field>
  <field name="articleDescriptor"><![CDATA[Organ Size]]></field>
  <field name="articleQualifier"><![CDATA[drug effects]]></field>
  <field name="articleDescriptor"><![CDATA[Ozone]]></field>
  <field name="articleQualifier"><![CDATA[pharmacology]]></field>
 </doc>
 <doc>
  <field name="id"><![CDATA[7120513]]></field>
  <field name="articleCreationDate"><![CDATA[1982-12-02T00:00:00Z]]></field>
  <field name="articleYear"><![CDATA[1982]]></field>
  <field name="articleCompletionDate"><![CDATA[1982-12-02T00:00:00Z]]></field>
  <field name="articleRevisionDate"><![CDATA[2007-11-14T00:00:00Z]]></field>
  <field name="articlePubmodel"><![CDATA[Print]]></field>
  <field name="journalTitle"><![CDATA[Journal of toxicology and environmental health]]></field>
  <field name="journalTitleAbrv"><![CDATA[J Toxicol Environ Health]]></field>
  <field name="articleTitle"><![CDATA[Comparison of pulmonary biochemical effects of low-level ozone exposure on mice and rats.]]></field>
  <field name="articleAbstract"><![CDATA[The biochemical effects of a 5-d continuous exposure to 0.45 ppm (882 microgram/m3) O3, were studied in the lungs of 2-mo-old male, specific-pathogen-free mice (Swiss Webster) and three strains of rats (Long-Evans, Wistar, and Sprague-Dawley). The results, expressed per lung, indicated a general increase in lung weight, DNA and protein contents, oxygen consumption, sulfhydryl metabolism, and the activities of several NADP+-reducing enzymes for all exposed animals relative to their controls. When the increases in the two species (mice versus three strains of rats) were compared, the mice showed significantly higher increases than the rats in several parameters. The responses among the three strains of rats were variable, but the differences were not significant. These observations suggest that Swiss Webster mice may offer a more sensitive animal model than rats for studying the pulmonary effects of a given low-level O3 exposure.]]></field>
  <field name="author"><![CDATA[Mustafa M G]]></field>
  <field name="author"><![CDATA[Elsayed N M]]></field>
  <field name="author"><![CDATA[Quinn C L]]></field>
  <field name="author"><![CDATA[Postlethwait E M]]></field>
  <field name="author"><![CDATA[Gardner D E]]></field>
  <field name="author"><![CDATA[Graham J A]]></field>
  <field name="articleLang"><![CDATA[eng]]></field>
  <field name="publicationType"><![CDATA[Comparative Study]]></field>
  <field name="publicationType"><![CDATA[Journal Article]]></field>
  <field name="publicationType"><![CDATA[Research Support, U.S. Gov't, Non-P.H.S.]]></field>
  <field name="publicationType"><![CDATA[Research Support, U.S. Gov't, P.H.S.]]></field>
  <field name="substanceName"><![CDATA[Ozone]]></field>
  <field name="substanceName"><![CDATA[Oxidoreductases]]></field>
  <field name="articleDescriptor"><![CDATA[Animals]]></field>
  <field name="articleDescriptor"><![CDATA[Lung]]></field>
  <field name="articleQualifier"><![CDATA[drug effects]]></field>
  <field name="articleQualifier"><![CDATA[enzymology]]></field>
  <field name="articleDescriptor"><![CDATA[Male]]></field>
  <field name="articleDescriptor"><![CDATA[Mice]]></field>
  <field name="articleDescriptor"><![CDATA[Oxidoreductases]]></field>
  <field name="articleQualifier"><![CDATA[metabolism]]></field>
  <field name="articleDescriptor"><![CDATA[Ozone]]></field>
  <field name="articleQualifier"><![CDATA[pharmacology]]></field>
  <field name="articleDescriptor"><![CDATA[Rats]]></field>
  <field name="articleDescriptor"><![CDATA[Rats, Inbred Strains]]></field>
  <field name="articleDescriptor"><![CDATA[Species Specificity]]></field>
 </doc>
 <doc>
  <field name="id"><![CDATA[7120514]]></field>
  <field name="articleCreationDate"><![CDATA[1982-12-02T00:00:00Z]]></field>
  <field name="articleYear"><![CDATA[1982]]></field>
  <field name="articleCompletionDate"><![CDATA[1982-12-02T00:00:00Z]]></field>
  <field name="articleRevisionDate"><![CDATA[2007-11-14T00:00:00Z]]></field>
  <field name="articlePubmodel"><![CDATA[Print]]></field>
  <field name="journalTitle"><![CDATA[Journal of toxicology and environmental health]]></field>
  <field name="journalTitleAbrv"><![CDATA[J Toxicol Environ Health]]></field>
  <field name="articleTitle"><![CDATA[Hepatotoxicity of orally and intraperitoneally administered folpet in male rats.]]></field>
  <field name="articleAbstract"><![CDATA[An ip LD50 value (68 mg/kg) for folpet, a widely used fungicide, was determined using adult male Sprague-Dawley rats. Next, the compound in sublethal doses was given to the animals orally as well as intraperitoneally (ip), and its effects on the levels of hepatic drug-metabolizing enzymes and serum glutamic oxalacetic transaminase (SGOT) were compared. An ip dose as small as 50 mg/kg was able to significantly alter the levels of these enzymes reflecting on liver damage, while an oral dose up to 10 times the ip dose did not have an appreciable effect on the enzymes and did not cause any visible toxic symptoms in the animals. In vitro incubation of folpet with rat liver microsomes with and without an NADPH-generating system showed that the fungicide may not require metabolism to exert inhibitory effect on the microsomal enzymes. In fact, the data suggest that the parent compound or its nonenzymatic degradation product(s) caused destruction of microsomal cytochrome P-450 in vitro. However, this loss of the hemoprotein by folpet could be prevented by prior addition of reduced glutathione in the incubation media.]]></field>
  <field name="author"><![CDATA[Ashley W M]]></field>
  <field name="author"><![CDATA[Smith R E]]></field>
  <field name="author"><![CDATA[Dalvi R R]]></field>
  <field name="articleLang"><![CDATA[eng]]></field>
  <field name="publicationType"><![CDATA[Journal Article]]></field>
  <field name="publicationType"><![CDATA[Research Support, U.S. Gov't, P.H.S.]]></field>
  <field name="substanceName"><![CDATA[Phthalimides]]></field>
  <field name="substanceName"><![CDATA[folpet]]></field>
  <field name="substanceName"><![CDATA[Cytochrome P-450 Enzyme System]]></field>
  <field name="substanceName"><![CDATA[benzphetamine N-demethylase]]></field>
  <field name="substanceName"><![CDATA[Oxidoreductases, N-Demethylating]]></field>
  <field name="substanceName"><![CDATA[Aspartate Aminotransferases]]></field>
  <field name="articleDescriptor"><![CDATA[Administration, Oral]]></field>
  <field name="articleDescriptor"><![CDATA[Animals]]></field>
  <field name="articleDescriptor"><![CDATA[Aspartate Aminotransferases]]></field>
  <field name="articleQualifier"><![CDATA[metabolism]]></field>
  <field name="articleDescriptor"><![CDATA[Cytochrome P-450 Enzyme System]]></field>
  <field name="articleQualifier"><![CDATA[metabolism]]></field>
  <field name="articleDescriptor"><![CDATA[Dose-Response Relationship, Drug]]></field>
  <field name="articleDescriptor"><![CDATA[Injections, Intraperitoneal]]></field>
  <field name="articleDescriptor"><![CDATA[Lethal Dose 50]]></field>
  <field name="articleDescriptor"><![CDATA[Male]]></field>
  <field name="articleDescriptor"><![CDATA[Microsomes, Liver]]></field>
  <field name="articleQualifier"><![CDATA[drug effects]]></field>
  <field name="articleQualifier"><![CDATA[enzymology]]></field>
  <field name="articleDescriptor"><![CDATA[Oxidoreductases, N-Demethylating]]></field>
  <field name="articleQualifier"><![CDATA[metabolism]]></field>
  <field name="articleDescriptor"><![CDATA[Phthalimides]]></field>
  <field name="articleQualifier"><![CDATA[administration & dosage]]></field>
  <field name="articleQualifier"><![CDATA[toxicity]]></field>
  <field name="articleDescriptor"><![CDATA[Rats]]></field>
  <field name="articleDescriptor"><![CDATA[Rats, Inbred Strains]]></field>
 </doc>
 <doc>
  <field name="id"><![CDATA[6288971]]></field>
  <field name="articleCreationDate"><![CDATA[1982-12-02T00:00:00Z]]></field>
  <field name="articleYear"><![CDATA[1982]]></field>
  <field name="articleCompletionDate"><![CDATA[1982-12-02T00:00:00Z]]></field>
  <field name="articleRevisionDate"><![CDATA[2003-11-14T00:00:00Z]]></field>
  <field name="articlePubmodel"><![CDATA[Print]]></field>
  <field name="journalTitle"><![CDATA[Journal of toxicology and environmental health]]></field>
  <field name="journalTitleAbrv"><![CDATA[J Toxicol Environ Health]]></field>
  <field name="articleTitle"><![CDATA[Investigation of hyperkeratotic activity of polybrominated biphenyls in Firemaster FF-1.]]></field>
  <field name="articleAbstract"><![CDATA[A polybrominated biphenyl (PBB) mixture was fractionated by normal-phase preparative high-performance liquid chromatography. The hexane fractions were concentrated and applied to rabbit ears. Only the most polar fraction produced hyperkeratosis on the rabbit ears. This active fraction was subfractionated by using the same procedure. Again, the extent of hyperkeratotic activity increased with increasing polarity. The PBBs of the largest concentration levels in the active fraction were purified by preparative gas chromatography and tested on rabbit ears. The major compounds did not demonstrate hyperkeratotic activity.]]></field>
  <field name="author"><![CDATA[Needham L L]]></field>
  <field name="author"><![CDATA[Hill R H]]></field>
  <field name="author"><![CDATA[Orti D L]]></field>
  <field name="author"><![CDATA[Patterson D G]]></field>
  <field name="author"><![CDATA[Kimbrough R D]]></field>
  <field name="author"><![CDATA[Groce D F]]></field>
  <field name="author"><![CDATA[Liddle J A]]></field>
  <field name="articleLang"><![CDATA[eng]]></field>
  <field name="publicationType"><![CDATA[Journal Article]]></field>
  <field name="substanceName"><![CDATA[Biphenyl Compounds]]></field>
  <field name="substanceName"><![CDATA[Polybrominated Biphenyls]]></field>
  <field name="articleDescriptor"><![CDATA[Animals]]></field>
  <field name="articleDescriptor"><![CDATA[Biphenyl Compounds]]></field>
  <field name="articleQualifier"><![CDATA[toxicity]]></field>
  <field name="articleDescriptor"><![CDATA[Chromatography, High Pressure Liquid]]></field>
  <field name="articleDescriptor"><![CDATA[Ear]]></field>
  <field name="articleQualifier"><![CDATA[drug effects]]></field>
  <field name="articleDescriptor"><![CDATA[Female]]></field>
  <field name="articleDescriptor"><![CDATA[Keratosis]]></field>
  <field name="articleQualifier"><![CDATA[chemically induced]]></field>
  <field name="articleDescriptor"><![CDATA[Polybrominated Biphenyls]]></field>
  <field name="articleQualifier"><![CDATA[analysis]]></field>
  <field name="articleQualifier"><![CDATA[toxicity]]></field>
  <field name="articleDescriptor"><![CDATA[Rabbits]]></field>
 </doc>
 <doc>
  <field name="id"><![CDATA[7120515]]></field>
  <field name="articleCreationDate"><![CDATA[1982-12-02T00:00:00Z]]></field>
  <field name="articleYear"><![CDATA[1982]]></field>
  <field name="articleCompletionDate"><![CDATA[1982-12-02T00:00:00Z]]></field>
  <field name="articleRevisionDate"><![CDATA[2012-11-15T00:00:00Z]]></field>
  <field name="articlePubmodel"><![CDATA[Print]]></field>
  <field name="journalTitle"><![CDATA[Journal of toxicology and environmental health]]></field>
  <field name="journalTitleAbrv"><![CDATA[J Toxicol Environ Health]]></field>
  <field name="articleTitle"><![CDATA[Distribution and metabolism of 2,4-dichlorophenol in rats.]]></field>
  <field name="articleAbstract"><![CDATA[The metabolism and distribution of 2,4-dichlorophenol (2,4-DCP) were studied in the rat after intravenous administration of 10 mg/kg. 2,4-DCP was determined by gas chromatography with an electron-capture detector. The highest concentration of 2,4-DCP was found in kidney, followed by liver, fat, and brain. 2,4-DCP is metabolized to glucuronide and other conjugates. The parent compound and its conjugates were rapidly eliminated from the body. The half-lives of 2,4-DCP and its conjugates in plasma, fat, brain, liver, and kidney ranged from 4 to 30 min. The volume of distribution of 2,4-DCP in plasma was 3.7 l/kg. Tissue/plasma ratios indicated that 2,4-DCP has a greater affinity for kidney.]]></field>
  <field name="author"><![CDATA[Somani S M]]></field>
  <field name="author"><![CDATA[Khalique A]]></field>
  <field name="articleLang"><![CDATA[eng]]></field>
  <field name="publicationType"><![CDATA[Journal Article]]></field>
  <field name="substanceName"><![CDATA[Chlorophenols]]></field>
  <field name="substanceName"><![CDATA[2,4-dichlorophenol]]></field>
  <field name="articleDescriptor"><![CDATA[Animals]]></field>
  <field name="articleDescriptor"><![CDATA[Chlorophenols]]></field>
  <field name="articleQualifier"><![CDATA[metabolism]]></field>
  <field name="articleDescriptor"><![CDATA[Chromatography, Gas]]></field>
  <field name="articleDescriptor"><![CDATA[Injections, Intravenous]]></field>
  <field name="articleDescriptor"><![CDATA[Kinetics]]></field>
  <field name="articleDescriptor"><![CDATA[Male]]></field>
  <field name="articleDescriptor"><![CDATA[Rats]]></field>
  <field name="articleDescriptor"><![CDATA[Rats, Inbred Strains]]></field>
  <field name="articleDescriptor"><![CDATA[Tissue Distribution]]></field>
 </doc>
 <doc>
  <field name="id"><![CDATA[7120516]]></field>
  <field name="articleCreationDate"><![CDATA[1982-12-02T00:00:00Z]]></field>
  <field name="articleYear"><![CDATA[1982]]></field>
  <field name="articleCompletionDate"><![CDATA[1982-12-02T00:00:00Z]]></field>
  <field name="articleRevisionDate"><![CDATA[2012-11-15T00:00:00Z]]></field>
  <field name="articlePubmodel"><![CDATA[Print]]></field>
  <field name="journalTitle"><![CDATA[Journal of toxicology and environmental health]]></field>
  <field name="journalTitleAbrv"><![CDATA[J Toxicol Environ Health]]></field>
  <field name="articleTitle"><![CDATA[Subchronic inhalation toxicity of 1,3-dichloropropene/1,2-dichloropropane (D-D) in mice and rats.]]></field>
  <field name="articleAbstract"><![CDATA[Groups of 28 male and 28 female CD-1 mice and Fischer 344 rats were exposed to a mixture of 1,3-Dichloropropene and 1,2-Dichloropropane (D-D) vapors. Exposure concentrations were 0, 5 (4.7), 15 (14.4), or 50 (53.7) ppm, 6 h/d, 5 d/wk for 6 or 12 wk. The following parameters were evaluated: pharmacotoxic signs, body weights, hematology (HGB, HCT, RBC, WBC, and diff. leukocyte count), serum chemistry (BUN, GLU, ALB, GPT, and ALP), urinalysis, gross pathology, histopathology, organ weights, and organ weight/body weight ratios of brain, heart, liver, kidneys, testes or ovaries, and adrenals. The only exposure-related clinical effects observed were increased mean liver/body weight ratios of male rats and mean kidney/body weight ratios of female rats at the 50 ppm exposure level. Slight to moderate diffuse hepatocytic enlargement in 12 of 21 of the 50-ppm male mice after 12 wk exposure was the only compound-related histopathologic change present.]]></field>
  <field name="author"><![CDATA[Parker C M]]></field>
  <field name="author"><![CDATA[Coate W B]]></field>
  <field name="author"><![CDATA[Voelker R W]]></field>
  <field name="articleLang"><![CDATA[eng]]></field>
  <field name="publicationType"><![CDATA[Journal Article]]></field>
  <field name="substanceName"><![CDATA[Allyl Compounds]]></field>
  <field name="substanceName"><![CDATA[1,3-dichloro-1-propene]]></field>
  <field name="substanceName"><![CDATA[Propane]]></field>
  <field name="substanceName"><![CDATA[propylene dichloride]]></field>
  <field name="articleDescriptor"><![CDATA[Allyl Compounds]]></field>
  <field name="articleQualifier"><![CDATA[metabolism]]></field>
  <field name="articleQualifier"><![CDATA[toxicity]]></field>
  <field name="articleDescriptor"><![CDATA[Analysis of Variance]]></field>
  <field name="articleDescriptor"><![CDATA[Animals]]></field>
  <field name="articleDescriptor"><![CDATA[Female]]></field>
  <field name="articleDescriptor"><![CDATA[Male]]></field>
  <field name="articleDescriptor"><![CDATA[Mice]]></field>
  <field name="articleDescriptor"><![CDATA[Organ Size]]></field>
  <field name="articleQualifier"><![CDATA[drug effects]]></field>
  <field name="articleDescriptor"><![CDATA[Propane]]></field>
  <field name="articleQualifier"><![CDATA[analogs & derivatives]]></field>
  <field name="articleQualifier"><![CDATA[metabolism]]></field>
  <field name="articleQualifier"><![CDATA[toxicity]]></field>
  <field name="articleDescriptor"><![CDATA[Rats]]></field>
  <field name="articleDescriptor"><![CDATA[Rats, Inbred F344]]></field>
  <field name="articleDescriptor"><![CDATA[Sex Factors]]></field>
  <field name="articleDescriptor"><![CDATA[Species Specificity]]></field>
 </doc>
 <doc>
  <field name="id"><![CDATA[7120517]]></field>
  <field name="articleCreationDate"><![CDATA[1982-12-02T00:00:00Z]]></field>
  <field name="articleYear"><![CDATA[1982]]></field>
  <field name="articleCompletionDate"><![CDATA[1982-12-02T00:00:00Z]]></field>
  <field name="articleRevisionDate"><![CDATA[2003-11-14T00:00:00Z]]></field>
  <field name="articlePubmodel"><![CDATA[Print]]></field>
  <field name="journalTitle"><![CDATA[Journal of toxicology and environmental health]]></field>
  <field name="journalTitleAbrv"><![CDATA[J Toxicol Environ Health]]></field>
  <field name="articleTitle"><![CDATA[Disposition and excretion of chlorendic acid in Fischer 344 rats.]]></field>
  <field name="articleAbstract"><![CDATA[The absorption, distribution, and excretion of a highly chlorinated dicarboxylic acid, chlorendic acid, was studied in the male Fischer 344 rat. [14C]Chlorendic acid was absorbed after an oral dose of 7.7 mumol per kilogram of body weight. The distribution in various tissues was similar whether the treatment was by the oral or the intravenous route. The major site of [14C]chlorendic acid deposition was the liver, with smaller amounts found in the blood, muscle, skin, and kidneys. Chlorendic acid-derived radioactivity was excreted primarily through the bile and into the feces. The urine contained less than 6% of the total dose. Within 1 d, more than 75% of the total dose was excreted in the feces, primarily as metabolites. Radioactivity in the liver was also primarily metabolites of chlorendic acid. Thus, chlorendic acid was absorbed, metabolized, and excreted primarily in the feces as metabolites. The rapid metabolism and biliary excretion of chlorendic acid contrast with observations for the closely related lipophilic compounds aldrin and dieldrin.]]></field>
  <field name="author"><![CDATA[Decad G M]]></field>
  <field name="author"><![CDATA[Fields M T]]></field>
  <field name="articleLang"><![CDATA[eng]]></field>
  <field name="publicationType"><![CDATA[Journal Article]]></field>
  <field name="substanceName"><![CDATA[Norbornanes]]></field>
  <field name="substanceName"><![CDATA[chlorendic acid]]></field>
  <field name="articleDescriptor"><![CDATA[Administration, Oral]]></field>
  <field name="articleDescriptor"><![CDATA[Animals]]></field>
  <field name="articleDescriptor"><![CDATA[Injections, Intravenous]]></field>
  <field name="articleDescriptor"><![CDATA[Male]]></field>
  <field name="articleDescriptor"><![CDATA[Norbornanes]]></field>
  <field name="articleQualifier"><![CDATA[metabolism]]></field>
  <field name="articleDescriptor"><![CDATA[Rats]]></field>
  <field name="articleDescriptor"><![CDATA[Rats, Inbred F344]]></field>
  <field name="articleDescriptor"><![CDATA[Tissue Distribution]]></field>
 </doc>
 <doc>
  <field name="id"><![CDATA[7120519]]></field>
  <field name="articleCreationDate"><![CDATA[1982-12-02T00:00:00Z]]></field>
  <field name="articleYear"><![CDATA[1982]]></field>
  <field name="articleCompletionDate"><![CDATA[1982-12-02T00:00:00Z]]></field>
  <field name="articleRevisionDate"><![CDATA[2007-11-14T00:00:00Z]]></field>
  <field name="articlePubmodel"><![CDATA[Print]]></field>
  <field name="journalTitle"><![CDATA[Journal of toxicology and environmental health]]></field>
  <field name="journalTitleAbrv"><![CDATA[J Toxicol Environ Health]]></field>
  <field name="articleTitle"><![CDATA[Comparative effects of antioxidants on the toxicity of mixed pyrrolizidine alkaloids from Senecio jacobaea in mice.]]></field>
  <field name="articleAbstract"><![CDATA[The comparative effects of the antioxidants, butylated hydroxyanisole (BHA), ethoxyquin, and cysteine on pyrrolizidine-alkaloid-induced (PA-induced) lethality and acute hepatotoxicity were assessed in female mice. Diets containing 0.75% BHA, 0.25% ethoxyquin, or 1% cysteine were fed to mice for 10 d before the ip administration of mixed PAs from Senecio jacobaea (tansy ragwort), 280 mg/kg. Without the dietary antioxidants, the PAs produced 100% mortality in 24 h. The BHA and ethoxyquin diets were completely and partially protective, respectively, against the PA-induced lethality. The deaths were associated with severe hemorrhagic lesions in liver with or without hepatocytic necrosis. Both BHA and ethoxyquin significantly reduced the incidence of the hemorrhagic lesions but not the necrotic lesions in liver. Cysteine had no significant effect on either mortality or the liver lesions induced by the mixed PAs. These results suggest that dietary antioxidants have differential protective effects against lethality and acute hepatotoxicity induced by mixed PAs from tansy ragwort.]]></field>
  <field name="author"><![CDATA[Miranda C L]]></field>
  <field name="author"><![CDATA[Henderson M C]]></field>
  <field name="author"><![CDATA[Buhler D R]]></field>
  <field name="author"><![CDATA[Schmitz J A]]></field>
  <field name="articleLang"><![CDATA[eng]]></field>
  <field name="publicationType"><![CDATA[Comparative Study]]></field>
  <field name="publicationType"><![CDATA[Journal Article]]></field>
  <field name="publicationType"><![CDATA[Research Support, U.S. Gov't, P.H.S.]]></field>
  <field name="substanceName"><![CDATA[Antioxidants]]></field>
  <field name="substanceName"><![CDATA[Pyrrolizidine Alkaloids]]></field>
  <field name="substanceName"><![CDATA[Butylated Hydroxyanisole]]></field>
  <field name="substanceName"><![CDATA[Cysteine]]></field>
  <field name="substanceName"><![CDATA[Ethoxyquin]]></field>
  <field name="articleDescriptor"><![CDATA[Animals]]></field>
  <field name="articleDescriptor"><![CDATA[Antioxidants]]></field>
  <field name="articleQualifier"><![CDATA[pharmacology]]></field>
  <field name="articleDescriptor"><![CDATA[Butylated Hydroxyanisole]]></field>
  <field name="articleQualifier"><![CDATA[pharmacology]]></field>
  <field name="articleDescriptor"><![CDATA[Cysteine]]></field>
  <field name="articleQualifier"><![CDATA[pharmacology]]></field>
  <field name="articleDescriptor"><![CDATA[Ethoxyquin]]></field>
  <field name="articleQualifier"><![CDATA[pharmacology]]></field>
  <field name="articleDescriptor"><![CDATA[Female]]></field>
  <field name="articleDescriptor"><![CDATA[Liver]]></field>
  <field name="articleQualifier"><![CDATA[pathology]]></field>
  <field name="articleDescriptor"><![CDATA[Mice]]></field>
  <field name="articleDescriptor"><![CDATA[Pyrrolizidine Alkaloids]]></field>
  <field name="articleQualifier"><![CDATA[toxicity]]></field>
 </doc>
 <doc>
  <field name="id"><![CDATA[7120520]]></field>
  <field name="articleCreationDate"><![CDATA[1982-12-02T00:00:00Z]]></field>
  <field name="articleYear"><![CDATA[1982]]></field>
  <field name="articleCompletionDate"><![CDATA[1982-12-02T00:00:00Z]]></field>
  <field name="articleRevisionDate"><![CDATA[2006-11-15T00:00:00Z]]></field>
  <field name="articlePubmodel"><![CDATA[Print]]></field>
  <field name="journalTitle"><![CDATA[Journal of toxicology and environmental health]]></field>
  <field name="journalTitleAbrv"><![CDATA[J Toxicol Environ Health]]></field>
  <field name="articleTitle"><![CDATA[DNA damage induced by auramine O in liver, kidney, and bone marrow of rats and mice, and in a human cell line (alkaline elution assay and SCE induction).]]></field>
  <field name="articleAbstract"><![CDATA[Auramine O has been reported to be carcinogenic in rats and mice. It has been reported as positive in some mutagenicity studies and negative in others. We have found that commercial auramine O is positive in inducing DNA damage in vivo in liver, kidney, and bone marrow cells. DNA damage was also induced after treatment in vitro of a human cell line. Commercial auramine O was also clearly positive for sister chromatid exchange (SCE) induction in vivo in bone marrow cells. Purified auramine was negative in terms of DNA damage and SCE induction. Our commercial auramine O had Michler's ketone as a major contaminant. This compound was capable of inducing both DNA fragmentation and an increase of SCE.]]></field>
  <field name="author"><![CDATA[Parodi S]]></field>
  <field name="author"><![CDATA[Santi L]]></field>
  <field name="author"><![CDATA[Russo P]]></field>
  <field name="author"><![CDATA[Albini A]]></field>
  <field name="author"><![CDATA[Vecchio D]]></field>
  <field name="author"><![CDATA[Pala M]]></field>
  <field name="author"><![CDATA[Ottaggio L]]></field>
  <field name="author"><![CDATA[Carbone A]]></field>
  <field name="articleLang"><![CDATA[eng]]></field>
  <field name="publicationType"><![CDATA[Journal Article]]></field>
  <field name="publicationType"><![CDATA[Research Support, Non-U.S. Gov't]]></field>
  <field name="substanceName"><![CDATA[Aniline Compounds]]></field>
  <field name="substanceName"><![CDATA[Benzophenoneidum]]></field>
  <field name="substanceName"><![CDATA[DNA]]></field>
  <field name="articleDescriptor"><![CDATA[Aniline Compounds]]></field>
  <field name="articleQualifier"><![CDATA[toxicity]]></field>
  <field name="articleDescriptor"><![CDATA[Animals]]></field>
  <field name="articleDescriptor"><![CDATA[Benzophenoneidum]]></field>
  <field name="articleQualifier"><![CDATA[toxicity]]></field>
  <field name="articleDescriptor"><![CDATA[Bone Marrow]]></field>
  <field name="articleQualifier"><![CDATA[drug effects]]></field>
  <field name="articleDescriptor"><![CDATA[Cell Line]]></field>
  <field name="articleQualifier"><![CDATA[drug effects]]></field>
  <field name="articleDescriptor"><![CDATA[DNA]]></field>
  <field name="articleDescriptor"><![CDATA[Kidney]]></field>
  <field name="articleQualifier"><![CDATA[drug effects]]></field>
  <field name="articleDescriptor"><![CDATA[Liver]]></field>
  <field name="articleQualifier"><![CDATA[drug effects]]></field>
  <field name="articleDescriptor"><![CDATA[Male]]></field>
  <field name="articleDescriptor"><![CDATA[Mice]]></field>
  <field name="articleDescriptor"><![CDATA[Rats]]></field>
  <field name="articleDescriptor"><![CDATA[Rats, Inbred Strains]]></field>
  <field name="articleDescriptor"><![CDATA[Sister Chromatid Exchange]]></field>
  <field name="articleQualifier"><![CDATA[drug effects]]></field>
 </doc>
 <doc>
  <field name="id"><![CDATA[7120521]]></field>
  <field name="articleCreationDate"><![CDATA[1982-12-02T00:00:00Z]]></field>
  <field name="articleYear"><![CDATA[1982]]></field>
  <field name="articleCompletionDate"><![CDATA[1982-12-02T00:00:00Z]]></field>
  <field name="articleRevisionDate"><![CDATA[2007-11-15T00:00:00Z]]></field>
  <field name="articlePubmodel"><![CDATA[Print]]></field>
  <field name="journalTitle"><![CDATA[Journal of toxicology and environmental health]]></field>
  <field name="journalTitleAbrv"><![CDATA[J Toxicol Environ Health]]></field>
  <field name="articleTitle"><![CDATA[Influence of dosage, consciousness, and nifedipine on the acute pressor response to intraperitoneally administered cadmium.]]></field>
  <field name="articleAbstract"><![CDATA[The acute pressor effect of intraperitoneally administered cadmium was explored over the dose range 0.015-2 mg/kg in both pentobarbital-anesthetized and conscious rats. The former first respondent at 0.031 mg/kg, and successive doublings of that dosage increased the highest pressures attained in a stepwise fashion until a dosage of 0.25 mg/kg, the maximally effective quantity, was reached. Arterial pressure did not rise in conscious rats until a dose of 1 mg/kg, which gave the maximum response within the range examined. Heart-rate changes with Cd were slight, and rarely significant at a given dosage, but pentobarbital invariably caused tachycardia. Anesthetized rats thus gave a graded response, while conscious animals reacted in an all-or-none fashion. The increased pressor responsiveness of rats under pentobarbital can not be ascribed to its cardiac parasympatholytic effects, since sensitivity was not conferred upon conscious rats when pretreated with atropine at a dose producing even greater tachycardia than that caused by pentobarbital. Nifedipine, which blocks calcium entry into smooth muscle cells, prevented the pressor response to cadmium when given as pretreatment and terminated an ongoing response when give intercurrently. Possible mechanisms to account for the observed behavior are considered.]]></field>
  <field name="author"><![CDATA[Hall C E]]></field>
  <field name="author"><![CDATA[Hungerford S]]></field>
  <field name="articleLang"><![CDATA[eng]]></field>
  <field name="publicationType"><![CDATA[Journal Article]]></field>
  <field name="publicationType"><![CDATA[Research Support, U.S. Gov't, P.H.S.]]></field>
  <field name="substanceName"><![CDATA[Pyridines]]></field>
  <field name="substanceName"><![CDATA[Cadmium Chloride]]></field>
  <field name="substanceName"><![CDATA[Nifedipine]]></field>
  <field name="substanceName"><![CDATA[Cadmium]]></field>
  <field name="substanceName"><![CDATA[Pentobarbital]]></field>
  <field name="articleDescriptor"><![CDATA[Anesthesia]]></field>
  <field name="articleDescriptor"><![CDATA[Animals]]></field>
  <field name="articleDescriptor"><![CDATA[Cadmium]]></field>
  <field name="articleQualifier"><![CDATA[administration & dosage]]></field>
  <field name="articleQualifier"><![CDATA[pharmacology]]></field>
  <field name="articleDescriptor"><![CDATA[Cadmium Chloride]]></field>
  <field name="articleDescriptor"><![CDATA[Drug Interactions]]></field>
  <field name="articleDescriptor"><![CDATA[Female]]></field>
  <field name="articleDescriptor"><![CDATA[Hemodynamics]]></field>
  <field name="articleQualifier"><![CDATA[drug effects]]></field>
  <field name="articleDescriptor"><![CDATA[Hypotension]]></field>
  <field name="articleQualifier"><![CDATA[chemically induced]]></field>
  <field name="articleDescriptor"><![CDATA[Nifedipine]]></field>
  <field name="articleQualifier"><![CDATA[pharmacology]]></field>
  <field name="articleDescriptor"><![CDATA[Pentobarbital]]></field>
  <field name="articleQualifier"><![CDATA[pharmacology]]></field>
  <field name="articleDescriptor"><![CDATA[Pyridines]]></field>
  <field name="articleQualifier"><![CDATA[pharmacology]]></field>
  <field name="articleDescriptor"><![CDATA[Rats]]></field>
  <field name="articleDescriptor"><![CDATA[Rats, Inbred Strains]]></field>
 </doc>
 <doc>
  <field name="id"><![CDATA[6214641]]></field>
  <field name="articleCreationDate"><![CDATA[1982-12-02T00:00:00Z]]></field>
  <field name="articleYear"><![CDATA[1982]]></field>
  <field name="articleCompletionDate"><![CDATA[1982-12-02T00:00:00Z]]></field>
  <field name="articleRevisionDate"><![CDATA[2006-11-15T00:00:00Z]]></field>
  <field name="articlePubmodel"><![CDATA[Print]]></field>
  <field name="journalTitle"><![CDATA[Journal of toxicology and environmental health]]></field>
  <field name="journalTitleAbrv"><![CDATA[J Toxicol Environ Health]]></field>
  <field name="articleTitle"><![CDATA[Teratogenic and antiteratogenic effects of nicotinamide derivatives in chick embryos.]]></field>
  <field name="articleAbstract"><![CDATA[Teratogenic and antiteratogenic effects of nine nicotinamide analogs in chick embryos were investigated. Further, the teratisms of 6-aminonicotinamide (6-AN), nicotinamide analogs, and an organophosphate (diazinon) were compared. White leghorn chick embryos were used. Agents were injected into the yolk of eggs on d 3 of incubation. Morphological observations were made on d 17 of incubation. Chemical names for compounds I to IX are: I, 6-dimethylaminonicotinamide; II, 6-diethylaminonicotinamide; III, 6-methylamino-3-(N-methyl)-nicotinamide; IV, 6-dimethylamino-3-pyrimidine carboximide; V, 6-(dimethylamino)-nicotinic acid; VI, 6-chloro-3-[N-(5-diethylamino)-2-pentyl]-nicotinamide; VII, 6-mercaptonicotinamide; VIII, [N-acetyl-N'-(3-pyridyl)-carbonyl]-hydrazine; IX, nicotinamide 1-N-oxide. The LD50 values in mumol per egg were as follows: 6-AN, 0.073; compound II, 0.23; compound III, 1.11; compound I, 1.32; compound VI, about 3. Compounds IV, V, VII, VIII, and IX showed no toxicity or lethality at the highest doses tested (10 mumol/egg). Among the nine nicotinamide analogs, compounds I, II, and III, which have an amino group at the 6-position of the pyridine ring, were teratogenic. Their teratogenic signs were similar to those caused by 6-AN: they showed growth retardation, anteriorly directed short legs, and coarse, dense feathering. The teratogenic effects of compounds I, II, and III were prevented by pretreatment with nicotinamide, as were the effects of 6-AN and diazinon. Among the nine analogs, only compound VIII had an antiteratogenic effect against the diazinon-induced micromelia (in which the cardinal signs were tibiotarsal angulations and poor feathering). For teratisms produced by 6-aminonicotinamide analogs and organophosphates, nicotinamide was an effective antiteratogenic agent. However, some differences in the malformations induced by both types of agents were found. We suggest that the addition of a 3-acetylpyridine type to the nicotinamide-related teratisms (6-AN type, 3-acetylpyridine type, and organophosphate type) will provide a clearer distinction among the types.]]></field>
  <field name="author"><![CDATA[Uyeki E M]]></field>
  <field name="author"><![CDATA[Doull J]]></field>
  <field name="author"><![CDATA[Cheng C C]]></field>
  <field name="author"><![CDATA[Misawa M]]></field>
  <field name="articleLang"><![CDATA[eng]]></field>
  <field name="publicationType"><![CDATA[Comparative Study]]></field>
  <field name="publicationType"><![CDATA[Journal Article]]></field>
  <field name="substanceName"><![CDATA[Teratogens]]></field>
  <field name="substanceName"><![CDATA[Diazinon]]></field>
  <field name="substanceName"><![CDATA[Niacinamide]]></field>
  <field name="articleDescriptor"><![CDATA[Animals]]></field>
  <field name="articleDescriptor"><![CDATA[Chick Embryo]]></field>
  <field name="articleQualifier"><![CDATA[drug effects]]></field>
  <field name="articleDescriptor"><![CDATA[Diazinon]]></field>
  <field name="articleQualifier"><![CDATA[toxicity]]></field>
  <field name="articleDescriptor"><![CDATA[Lethal Dose 50]]></field>
  <field name="articleDescriptor"><![CDATA[Niacinamide]]></field>
  <field name="articleQualifier"><![CDATA[analogs & derivatives]]></field>
  <field name="articleQualifier"><![CDATA[toxicity]]></field>
  <field name="articleDescriptor"><![CDATA[Structure-Activity Relationship]]></field>
  <field name="articleDescriptor"><![CDATA[Teratogens]]></field>
 </doc>
 <doc>
  <field name="id"><![CDATA[7120522]]></field>
  <field name="articleCreationDate"><![CDATA[1982-12-02T00:00:00Z]]></field>
  <field name="articleYear"><![CDATA[1982]]></field>
  <field name="articleCompletionDate"><![CDATA[1982-12-02T00:00:00Z]]></field>
  <field name="articleRevisionDate"><![CDATA[2006-11-15T00:00:00Z]]></field>
  <field name="articlePubmodel"><![CDATA[Print]]></field>
  <field name="journalTitle"><![CDATA[Journal of toxicology and environmental health]]></field>
  <field name="journalTitleAbrv"><![CDATA[J Toxicol Environ Health]]></field>
  <field name="articleTitle"><![CDATA[Mutagenic and toxic activity of environmental effluents from underground coal gasification experiments.]]></field>
  <field name="articleAbstract"><![CDATA[Using bacterial bioassays, we have screened for the presence of mutagens and toxins in extracts from groundwater, and in tar from product gas, at the sites of two Lawrence Livermore National Laboratory (LLNL) in situ experiments: Hoe Creek II and Hoe Creek III. The sites exhibited different potential biological hazards, suggesting that different gasification processes may represent different human health concerns. We found that mutagens are present in groundwater, persist for at least 2 yr after gasification has been terminated, and show a change in activity with time-possibly in parallel with changes in chemical composition. Preliminary evidence suggests that the mutagens in groundwater are quinoline and aniline derivatives, while the toxins in groundwater may be phenolic compounds. In tar from the product gas, the organic bases and neutrals were found to be genotoxic in both bacterial and mammalian cells; the neutral compounds appear to be the major mutagenic health hazards. Neutral compounds constitute most of the tar (85-97 wt%) and were mutagenic in both the bacterial and mammalian cell assays. Tar in the gas stream may be a problem for the aboveground environment if gas escapes through fractures in the overburden. Because it is mutagenic and induces chromosomal damage to mammalian cells, the tar may represent a disposal problem as well. However, it is difficult to assess tar quantitatively as a health hazard because its mutagenic activity is low, possibly due to contaminants in the neutral fraction that act to suppress mutagenicity.]]></field>
  <field name="author"><![CDATA[Timourian H]]></field>
  <field name="author"><![CDATA[Felton J S]]></field>
  <field name="author"><![CDATA[Stuermer D H]]></field>
  <field name="author"><![CDATA[Healy S]]></field>
  <field name="author"><![CDATA[Berry P]]></field>
  <field name="author"><![CDATA[Tompkins M]]></field>
  <field name="author"><![CDATA[Battaglia G]]></field>
  <field name="author"><![CDATA[Hatch F T]]></field>
  <field name="author"><![CDATA[Thompson L H]]></field>
  <field name="author"><![CDATA[Carrano A V]]></field>
  <field name="author"><![CDATA[Minkler J]]></field>
  <field name="author"><![CDATA[Salazar E]]></field>
  <field name="articleLang"><![CDATA[eng]]></field>
  <field name="publicationType"><![CDATA[Journal Article]]></field>
  <field name="publicationType"><![CDATA[Research Support, U.S. Gov't, Non-P.H.S.]]></field>
  <field name="substanceName"><![CDATA[Fossil Fuels]]></field>
  <field name="substanceName"><![CDATA[Mutagens]]></field>
  <field name="substanceName"><![CDATA[Tars]]></field>
  <field name="substanceName"><![CDATA[Water Pollutants]]></field>
  <field name="substanceName"><![CDATA[Water Pollutants, Chemical]]></field>
  <field name="articleDescriptor"><![CDATA[Animals]]></field>
  <field name="articleDescriptor"><![CDATA[Chromosome Aberrations]]></field>
  <field name="articleDescriptor"><![CDATA[Cricetinae]]></field>
  <field name="articleDescriptor"><![CDATA[Cricetulus]]></field>
  <field name="articleDescriptor"><![CDATA[Fossil Fuels]]></field>
  <field name="articleQualifier"><![CDATA[toxicity]]></field>
  <field name="articleDescriptor"><![CDATA[Mutagenicity Tests]]></field>
  <field name="articleDescriptor"><![CDATA[Mutagens]]></field>
  <field name="articleDescriptor"><![CDATA[Salmonella]]></field>
  <field name="articleQualifier"><![CDATA[drug effects]]></field>
  <field name="articleDescriptor"><![CDATA[Tars]]></field>
  <field name="articleQualifier"><![CDATA[analysis]]></field>
  <field name="articleQualifier"><![CDATA[toxicity]]></field>
  <field name="articleDescriptor"><![CDATA[Water Pollutants]]></field>
  <field name="articleQualifier"><![CDATA[toxicity]]></field>
  <field name="articleDescriptor"><![CDATA[Water Pollutants, Chemical]]></field>
  <field name="articleQualifier"><![CDATA[toxicity]]></field>
 </doc>
 <doc>
  <field name="id"><![CDATA[6981709]]></field>
  <field name="articleCreationDate"><![CDATA[1982-12-02T00:00:00Z]]></field>
  <field name="articleYear"><![CDATA[1982]]></field>
  <field name="articleCompletionDate"><![CDATA[1982-12-02T00:00:00Z]]></field>
  <field name="articleRevisionDate"><![CDATA[2006-11-15T00:00:00Z]]></field>
  <field name="articlePubmodel"><![CDATA[Print]]></field>
  <field name="journalTitle"><![CDATA[Journal of toxicology and environmental health]]></field>
  <field name="journalTitleAbrv"><![CDATA[J Toxicol Environ Health]]></field>
  <field name="articleTitle"><![CDATA[Cytotoxicity of ammonium metavanadate to cultured bovine alveolar macrophages.]]></field>
  <field name="articleAbstract"><![CDATA[Cytotoxicity of ammonium metavanadate to cultured bovine pulmonary alveolar macrophages was measured by cell viability, inhibition of phagocytosis, and reduction of superoxide-dependent chemiluminescence. The degree of toxicity was dependent on the levels of vanadium, the temperature, and the time of exposure. Thus macrophages exposed to vanadium at 0.01 and 0.1 microgram/ml did not exhibit cytotoxic effects even with up to 24 h of exposure, as measured by cell viability and phagocytic index. Vanadium at 0.5 microgram/ml, however, reduced cell viability to 24% and the phagocytic index to 2% of the control within 8 h of exposure. Exposure to NH4 VO3 (up to 1 microgram vanadium/ml) for short periods of time stimulated phagocytic activity. Vanadium toxicity was also demonstrated in suspension culture at 37 degrees C by chemiluminescence assay. This assay seems to be more sensitive than the conventional viability and phagocytic index tests. Thus, the peak light production by macrophages during zymosan phagocytosis was reduced to 93, 59, and 63% by vanadium at 0.1 microgram/ml exposing for 2, 4, and 8 h, respectively, and to 71, 27, and 24% by vanadium at 1.0 microgram/ml for the same time periods. The phagocytic activity of macrophages as measured by chemiluminescence response was not significantly altered by exposure to either 0.1 or 1.0 microgram vanadium/ml measured during the first 24 h of culture at 4 degrees C.]]></field>
  <field name="author"><![CDATA[Wei C]]></field>
  <field name="author"><![CDATA[Misra H P]]></field>
  <field name="articleLang"><![CDATA[eng]]></field>
  <field name="publicationType"><![CDATA[Journal Article]]></field>
  <field name="publicationType"><![CDATA[Research Support, U.S. Gov't, Non-P.H.S.]]></field>
  <field name="substanceName"><![CDATA[Vanadium]]></field>
  <field name="articleDescriptor"><![CDATA[Animals]]></field>
  <field name="articleDescriptor"><![CDATA[Cattle]]></field>
  <field name="articleDescriptor"><![CDATA[Cell Survival]]></field>
  <field name="articleQualifier"><![CDATA[drug effects]]></field>
  <field name="articleDescriptor"><![CDATA[Cells, Cultured]]></field>
  <field name="articleDescriptor"><![CDATA[Luminescent Measurements]]></field>
  <field name="articleDescriptor"><![CDATA[Macrophages]]></field>
  <field name="articleQualifier"><![CDATA[drug effects]]></field>
  <field name="articleDescriptor"><![CDATA[Phagocytosis]]></field>
  <field name="articleQualifier"><![CDATA[drug effects]]></field>
  <field name="articleDescriptor"><![CDATA[Pulmonary Alveoli]]></field>
  <field name="articleQualifier"><![CDATA[drug effects]]></field>
  <field name="articleDescriptor"><![CDATA[Vanadium]]></field>
  <field name="articleQualifier"><![CDATA[toxicity]]></field>
 </doc>
 <doc>
  <field name="id"><![CDATA[7120523]]></field>
  <field name="articleCreationDate"><![CDATA[1982-12-02T00:00:00Z]]></field>
  <field name="articleYear"><![CDATA[1982]]></field>
  <field name="articleCompletionDate"><![CDATA[1982-12-02T00:00:00Z]]></field>
  <field name="articleRevisionDate"><![CDATA[2007-11-14T00:00:00Z]]></field>
  <field name="articlePubmodel"><![CDATA[Print]]></field>
  <field name="journalTitle"><![CDATA[The Journal of trauma]]></field>
  <field name="journalTitleAbrv"><![CDATA[J Trauma]]></field>
  <field name="articleTitle"><![CDATA[Hepatic gluconeogenic capability in sepsis is depressed before changes in oxidative capability.]]></field>
  <field name="articleAbstract"><![CDATA[Since plasma alanine concentrations are markedly elevated in late sepsis and alanine is an important gluconeogenic substrate, we investigated gluconeogenic activity in intra-abdominal sepsis. Sepsis in rats was produced by cecal ligation and puncture. After 17 to 21 hours (late sepsis, LS) livers from these and sham-operated rats were isolated and perfused at constant flow with Krebs buffer in the presence or absence of 10 mM alanine. Various phenylephrine (PE) concentrations were also used to measure gluconeogenic response to alpha-adrenergic stimulation. The results showed that glucose production from alanine by livers from LS rats was depressed in comparison to livers from sham rats (2.6 +/- 0.2 vs. 4.2 +/- 0.4 moles/gm/hr). Moreover, although livers from rats in LS responded to PE stimulation in a dose-dependent manner, the magnitude as well as the threshold of response was decreased in comparison to shams. In contrast to glucose production, VO2 of the sham and LS were not different under any conditions. Previous studies using lactate as a substrate, however, showed that both gluconeogenesis and oxidative responses were decreased in LS. Since hepatic gluconeogenic but not VO2 response was depressed with alanine, these results indicate that the decreased gluconeogenic capability precedes depressed oxidative capability in sepsis.]]></field>
  <field name="author"><![CDATA[Guillem J G]]></field>
  <field name="author"><![CDATA[Clemens M G]]></field>
  <field name="author"><![CDATA[Chaudry I H]]></field>
  <field name="author"><![CDATA[McDermott P H]]></field>
  <field name="author"><![CDATA[Baue A E]]></field>
  <field name="articleLang"><![CDATA[eng]]></field>
  <field name="publicationType"><![CDATA[Journal Article]]></field>
  <field name="publicationType"><![CDATA[Research Support, U.S. Gov't, P.H.S.]]></field>
  <field name="substanceName"><![CDATA[Glucose]]></field>
  <field name="substanceName"><![CDATA[Alanine]]></field>
  <field name="substanceName"><![CDATA[Adenosine Triphosphate]]></field>
  <field name="substanceName"><![CDATA[Phenylephrine]]></field>
  <field name="articleDescriptor"><![CDATA[Adenosine Triphosphate]]></field>
  <field name="articleQualifier"><![CDATA[metabolism]]></field>
  <field name="articleDescriptor"><![CDATA[Alanine]]></field>
  <field name="articleQualifier"><![CDATA[metabolism]]></field>
  <field name="articleDescriptor"><![CDATA[Animals]]></field>
  <field name="articleDescriptor"><![CDATA[Bacterial Infections]]></field>
  <field name="articleQualifier"><![CDATA[metabolism]]></field>
  <field name="articleDescriptor"><![CDATA[Gluconeogenesis]]></field>
  <field name="articleQualifier"><![CDATA[drug effects]]></field>
  <field name="articleDescriptor"><![CDATA[Glucose]]></field>
  <field name="articleQualifier"><![CDATA[metabolism]]></field>
  <field name="articleDescriptor"><![CDATA[Liver]]></field>
  <field name="articleQualifier"><![CDATA[metabolism]]></field>
  <field name="articleDescriptor"><![CDATA[Male]]></field>
  <field name="articleDescriptor"><![CDATA[Oxygen Consumption]]></field>
  <field name="articleQualifier"><![CDATA[drug effects]]></field>
  <field name="articleDescriptor"><![CDATA[Peritonitis]]></field>
  <field name="articleQualifier"><![CDATA[metabolism]]></field>
  <field name="articleDescriptor"><![CDATA[Phenylephrine]]></field>
  <field name="articleQualifier"><![CDATA[pharmacology]]></field>
  <field name="articleDescriptor"><![CDATA[Rats]]></field>
 </doc>
 <doc>
  <field name="id"><![CDATA[7120524]]></field>
  <field name="articleCreationDate"><![CDATA[1982-12-02T00:00:00Z]]></field>
  <field name="articleYear"><![CDATA[1982]]></field>
  <field name="articleCompletionDate"><![CDATA[1982-12-02T00:00:00Z]]></field>
  <field name="articleRevisionDate"><![CDATA[2007-11-14T00:00:00Z]]></field>
  <field name="articlePubmodel"><![CDATA[Print]]></field>
  <field name="journalTitle"><![CDATA[The Journal of trauma]]></field>
  <field name="journalTitleAbrv"><![CDATA[J Trauma]]></field>
  <field name="articleTitle"><![CDATA[Liver adenosine triphosphate (ATP) in hypoxia and hemorrhagic shock.]]></field>
  <field name="articleAbstract"><![CDATA[Reduction of liver ATP in proportion to the severity of shock and hypoxia is well known. We have studied the interrelationships among arterial oxygenation, arterial pH, and liver ATP in experimental hypoxia and in hemorrhagic shock in rats. No significant correlation was found between liver ATP and arterial pH in both hemorrhagic shock and hypoxia and between liver ATP and arterial PO2 in hypoxia. Induction of experimental observations suggest that in this form of hemorrhagic shock, arterial pH may be a sensitive indicator of decreased hepatic perfusion and impaired liver ATP production.]]></field>
  <field name="author"><![CDATA[Pass L J]]></field>
  <field name="author"><![CDATA[Schloerb P R]]></field>
  <field name="author"><![CDATA[Chow F T]]></field>
  <field name="author"><![CDATA[Graham M]]></field>
  <field name="author"><![CDATA[Pearce F J]]></field>
  <field name="author"><![CDATA[Franklin M W]]></field>
  <field name="author"><![CDATA[Drucker W R]]></field>
  <field name="articleLang"><![CDATA[eng]]></field>
  <field name="publicationType"><![CDATA[Journal Article]]></field>
  <field name="publicationType"><![CDATA[Research Support, U.S. Gov't, P.H.S.]]></field>
  <field name="substanceName"><![CDATA[Lactates]]></field>
  <field name="substanceName"><![CDATA[Lactic Acid]]></field>
  <field name="substanceName"><![CDATA[Adenosine Triphosphate]]></field>
  <field name="substanceName"><![CDATA[Oxygen]]></field>
  <field name="articleDescriptor"><![CDATA[Acidosis, Respiratory]]></field>
  <field name="articleQualifier"><![CDATA[blood]]></field>
  <field name="articleQualifier"><![CDATA[metabolism]]></field>
  <field name="articleDescriptor"><![CDATA[Adenosine Triphosphate]]></field>
  <field name="articleQualifier"><![CDATA[metabolism]]></field>
  <field name="articleDescriptor"><![CDATA[Animals]]></field>
  <field name="articleDescriptor"><![CDATA[Anoxia]]></field>
  <field name="articleQualifier"><![CDATA[blood]]></field>
  <field name="articleQualifier"><![CDATA[metabolism]]></field>
  <field name="articleDescriptor"><![CDATA[Arteries]]></field>
  <field name="articleDescriptor"><![CDATA[Hydrogen-Ion Concentration]]></field>
  <field name="articleDescriptor"><![CDATA[Lactates]]></field>
  <field name="articleQualifier"><![CDATA[blood]]></field>
  <field name="articleDescriptor"><![CDATA[Lactic Acid]]></field>
  <field name="articleDescriptor"><![CDATA[Liver]]></field>
  <field name="articleQualifier"><![CDATA[metabolism]]></field>
  <field name="articleDescriptor"><![CDATA[Oxygen]]></field>
  <field name="articleQualifier"><![CDATA[blood]]></field>
  <field name="articleDescriptor"><![CDATA[Rats]]></field>
  <field name="articleDescriptor"><![CDATA[Rats, Inbred Strains]]></field>
  <field name="articleDescriptor"><![CDATA[Shock, Hemorrhagic]]></field>
  <field name="articleQualifier"><![CDATA[blood]]></field>
  <field name="articleQualifier"><![CDATA[metabolism]]></field>
 </doc>
 <doc>
  <field name="id"><![CDATA[7120525]]></field>
  <field name="articleCreationDate"><![CDATA[1982-12-02T00:00:00Z]]></field>
  <field name="articleYear"><![CDATA[1982]]></field>
  <field name="articleCompletionDate"><![CDATA[1982-12-02T00:00:00Z]]></field>
  <field name="articleRevisionDate"><![CDATA[2006-11-15T00:00:00Z]]></field>
  <field name="articlePubmodel"><![CDATA[Print]]></field>
  <field name="journalTitle"><![CDATA[The Journal of trauma]]></field>
  <field name="journalTitleAbrv"><![CDATA[J Trauma]]></field>
  <field name="articleTitle"><![CDATA[Red cell substitutes: hemoglobin solution or fluorocarbon?]]></field>
  <field name="articleAbstract"><![CDATA[Stroma-free hemoglobin (SFH) and Fluosol-DA (FL-DA) are the two acellular oxygen carriers that represent potential red cell substitutes. Although both can support life at zero hematocrit, their effectiveness as O2 carriers at intermediate hematocrits has been unclear. In the presence of red cells, the efficacy of an acellular O2 carrier can be assessed by its contribution to O2 delivery and O2 consumption. This study evaluated the efficacy of SFH and FL-DA in the presence of red cells at hematocrits less than or equal to 10%. The results illustrate that SFH and FL-DA do contribute to O2 delivery and O2 consumption in the presence of red cells. The data indicate that SFH and FL-DA are both effective acellular O2 carriers.]]></field>
  <field name="author"><![CDATA[Gould S A]]></field>
  <field name="author"><![CDATA[Rosen A L]]></field>
  <field name="author"><![CDATA[Sehgal L R]]></field>
  <field name="author"><![CDATA[Sehgal H L]]></field>
  <field name="author"><![CDATA[Rice C L]]></field>
  <field name="author"><![CDATA[Moss G S]]></field>
  <field name="articleLang"><![CDATA[eng]]></field>
  <field name="publicationType"><![CDATA[Journal Article]]></field>
  <field name="publicationType"><![CDATA[Research Support, U.S. Gov't, Non-P.H.S.]]></field>
  <field name="substanceName"><![CDATA[Blood Substitutes]]></field>
  <field name="substanceName"><![CDATA[Drug Combinations]]></field>
  <field name="substanceName"><![CDATA[Fluorocarbons]]></field>
  <field name="substanceName"><![CDATA[Hemoglobins]]></field>
  <field name="substanceName"><![CDATA[hemoglobin, stroma free]]></field>
  <field name="substanceName"><![CDATA[Fluosol-DA]]></field>
  <field name="substanceName"><![CDATA[Oxygen]]></field>
  <field name="articleDescriptor"><![CDATA[Animals]]></field>
  <field name="articleDescriptor"><![CDATA[Blood Substitutes]]></field>
  <field name="articleQualifier"><![CDATA[therapeutic use]]></field>
  <field name="articleDescriptor"><![CDATA[Cardiac Output]]></field>
  <field name="articleDescriptor"><![CDATA[Drug Combinations]]></field>
  <field name="articleQualifier"><![CDATA[therapeutic use]]></field>
  <field name="articleDescriptor"><![CDATA[Exchange Transfusion, Whole Blood]]></field>
  <field name="articleDescriptor"><![CDATA[Fluorocarbons]]></field>
  <field name="articleQualifier"><![CDATA[therapeutic use]]></field>
  <field name="articleDescriptor"><![CDATA[Hematocrit]]></field>
  <field name="articleDescriptor"><![CDATA[Hemoglobins]]></field>
  <field name="articleQualifier"><![CDATA[therapeutic use]]></field>
  <field name="articleDescriptor"><![CDATA[Oxygen]]></field>
  <field name="articleQualifier"><![CDATA[blood]]></field>
  <field name="articleDescriptor"><![CDATA[Oxygen Consumption]]></field>
  <field name="articleDescriptor"><![CDATA[Papio]]></field>
 </doc>
 <doc>
  <field name="id"><![CDATA[7120526]]></field>
  <field name="articleCreationDate"><![CDATA[1982-12-02T00:00:00Z]]></field>
  <field name="articleYear"><![CDATA[1982]]></field>
  <field name="articleCompletionDate"><![CDATA[1982-12-02T00:00:00Z]]></field>
  <field name="articleRevisionDate"><![CDATA[2007-11-14T00:00:00Z]]></field>
  <field name="articlePubmodel"><![CDATA[Print]]></field>
  <field name="journalTitle"><![CDATA[The Journal of trauma]]></field>
  <field name="journalTitleAbrv"><![CDATA[J Trauma]]></field>
  <field name="articleTitle"><![CDATA[Failure of red blood cell transfusion to increase oxygen transport or mixed venous PO2 in injured patients.]]></field>
  <field name="articleAbstract"><![CDATA[Post-trauma patients have an oxygen consumption which is proportional to oxygen delivery, suggesting that tissue oxygen consumption is limited by diffusion. Transfusion of packed red blood cells (RBC), which increases the oxygen-carrying capacity of blood, would be expected to increase mixed venous PO2, thereby improving tissue oxygenation. However, the low P50 of stored blood may increase the affinity of hemoglobin for oxygen and reduce oxygen consumption. To evaluate the net effect of these mechanisms, we studied hemodynamic and oxygen transport parameters before and after RBC transfusion in eight critically ill patients. Mixed venous O2 content was measured directly by fuel cell O2 analyzer, and standard P50 was calculated. Following transfusion of one unit of packed RBC which increased mean hemoglobin from 9.2 +/- 0.3 gm/dl to 10.1 +/- 0.3 gm/dl (p less than 0.01), there were no changes in oxygen delivery (490 +/- 80 ml/min/m2), oxygen consumption (210 +/- 30 ml/min/m2), or mixed venous PO/ (37 +/- 2 Torr). Cardiac index (4.1 +/- 0.71 L/min) decreased by 0.4 L/min/m2 (p less than 0.05). Standard P50 decreased by 4.2 +/- 2.4 Torr following transfusion of two units of RBC (p less than 0.05). Red blood cell transfusion thus failed to increase oxygen consumption in these patients, despite an increase in oxygen content. Thus, RBC transfusion may not improve tissue oxygenation.]]></field>
  <field name="author"><![CDATA[Shah D M]]></field>
  <field name="author"><![CDATA[Gottlieb M E]]></field>
  <field name="author"><![CDATA[Rahm R L]]></field>
  <field name="author"><![CDATA[Stratton H H]]></field>
  <field name="author"><![CDATA[Barie P S]]></field>
  <field name="author"><![CDATA[Paloski W H]]></field>
  <field name="author"><![CDATA[Newell J C]]></field>
  <field name="articleLang"><![CDATA[eng]]></field>
  <field name="publicationType"><![CDATA[Journal Article]]></field>
  <field name="publicationType"><![CDATA[Research Support, U.S. Gov't, P.H.S.]]></field>
  <field name="substanceName"><![CDATA[Hemoglobins]]></field>
  <field name="substanceName"><![CDATA[Oxygen]]></field>
  <field name="articleDescriptor"><![CDATA[Adult]]></field>
  <field name="articleDescriptor"><![CDATA[Aged]]></field>
  <field name="articleDescriptor"><![CDATA[Blood Pressure]]></field>
  <field name="articleDescriptor"><![CDATA[Blood Transfusion]]></field>
  <field name="articleDescriptor"><![CDATA[Cardiac Output]]></field>
  <field name="articleDescriptor"><![CDATA[Erythrocyte Transfusion]]></field>
  <field name="articleDescriptor"><![CDATA[Female]]></field>
  <field name="articleDescriptor"><![CDATA[Hemoglobins]]></field>
  <field name="articleQualifier"><![CDATA[analysis]]></field>
  <field name="articleDescriptor"><![CDATA[Humans]]></field>
  <field name="articleDescriptor"><![CDATA[Male]]></field>
  <field name="articleDescriptor"><![CDATA[Middle Aged]]></field>
  <field name="articleDescriptor"><![CDATA[Oxygen]]></field>
  <field name="articleQualifier"><![CDATA[blood]]></field>
  <field name="articleDescriptor"><![CDATA[Oxygen Consumption]]></field>
  <field name="articleDescriptor"><![CDATA[Veins]]></field>
  <field name="articleDescriptor"><![CDATA[Wounds and Injuries]]></field>
  <field name="articleQualifier"><![CDATA[blood]]></field>
  <field name="articleQualifier"><![CDATA[metabolism]]></field>
  <field name="articleQualifier"><![CDATA[physiopathology]]></field>
  <field name="articleQualifier"><![CDATA[therapy]]></field>
 </doc>
 <doc>
  <field name="id"><![CDATA[7120527]]></field>
  <field name="articleCreationDate"><![CDATA[1982-12-02T00:00:00Z]]></field>
  <field name="articleYear"><![CDATA[1982]]></field>
  <field name="articleCompletionDate"><![CDATA[1982-12-02T00:00:00Z]]></field>
  <field name="articleRevisionDate"><![CDATA[2008-11-21T00:00:00Z]]></field>
  <field name="articlePubmodel"><![CDATA[Print]]></field>
  <field name="journalTitle"><![CDATA[The Journal of trauma]]></field>
  <field name="journalTitleAbrv"><![CDATA[J Trauma]]></field>
  <field name="articleTitle"><![CDATA[Plasma amino acid concentrations during branched-chain amino acid infusions in stressed patients.]]></field>
  <field name="articleAbstract"><![CDATA[To determine the effect of infusing large quantities of BCAA on plasma amino acid concentrations, plasma amino acid profiles were measured in 18 stressed patients before and 48 to 96 hours after initiation of amino acid solutions enriched with or exclusively containing BCAA (15.6+, 50%, 100%). Plasma concentrations of BCAA were elevated in the 100% and 50% BCAA groups, but not in the 15.6% group. Methionine, glycine, and phenylalanine concentrations were increased in the 15.6% BCAA group: methionine and glycine were decreased in the 100% BCAA groups. In the 50% BCAA group, nonbranched-chain amino acids maintained baseline concentrations. The 50% solution best preserved nitrogen balance of the BCAA solutions. The plasma amino acid profiles of patients with maple syrup urine disease (BCAA levels 5 to 10 times normal) were compared to our patients receiving BCAA-enriched solutions. Although plasma BCAA levels were elevated in our patients, allo-isoleucine, alanine, and glutamine concentrations were normal; the amino acid abnormalities of maple syrup urine disease were not observed.]]></field>
  <field name="author"><![CDATA[Desai S P]]></field>
  <field name="author"><![CDATA[Bistrian B R]]></field>
  <field name="author"><![CDATA[Moldawer L L]]></field>
  <field name="author"><![CDATA[Miller M M]]></field>
  <field name="author"><![CDATA[Blackburn G L]]></field>
  <field name="articleLang"><![CDATA[eng]]></field>
  <field name="publicationType"><![CDATA[Journal Article]]></field>
  <field name="publicationType"><![CDATA[Research Support, Non-U.S. Gov't]]></field>
  <field name="publicationType"><![CDATA[Research Support, U.S. Gov't, P.H.S.]]></field>
  <field name="substanceName"><![CDATA[Amino Acids]]></field>
  <field name="substanceName"><![CDATA[Amino Acids, Branched-Chain]]></field>
  <field name="substanceName"><![CDATA[Leucine]]></field>
  <field name="substanceName"><![CDATA[Valine]]></field>
  <field name="substanceName"><![CDATA[Isoleucine]]></field>
  <field name="articleDescriptor"><![CDATA[Abdomen]]></field>
  <field name="articleQualifier"><![CDATA[surgery]]></field>
  <field name="articleDescriptor"><![CDATA[Adult]]></field>
  <field name="articleDescriptor"><![CDATA[Amino Acids]]></field>
  <field name="articleQualifier"><![CDATA[blood]]></field>
  <field name="articleDescriptor"><![CDATA[Amino Acids, Branched-Chain]]></field>
  <field name="articleQualifier"><![CDATA[administration & dosage]]></field>
  <field name="articleQualifier"><![CDATA[blood]]></field>
  <field name="articleDescriptor"><![CDATA[Female]]></field>
  <field name="articleDescriptor"><![CDATA[Humans]]></field>
  <field name="articleDescriptor"><![CDATA[Infusions, Parenteral]]></field>
  <field name="articleDescriptor"><![CDATA[Isoleucine]]></field>
  <field name="articleQualifier"><![CDATA[blood]]></field>
  <field name="articleDescriptor"><![CDATA[Leucine]]></field>
  <field name="articleQualifier"><![CDATA[blood]]></field>
  <field name="articleDescriptor"><![CDATA[Male]]></field>
  <field name="articleDescriptor"><![CDATA[Middle Aged]]></field>
  <field name="articleDescriptor"><![CDATA[Postoperative Care]]></field>
  <field name="articleDescriptor"><![CDATA[Stress, Physiological]]></field>
  <field name="articleQualifier"><![CDATA[blood]]></field>
  <field name="articleQualifier"><![CDATA[etiology]]></field>
  <field name="articleQualifier"><![CDATA[therapy]]></field>
  <field name="articleDescriptor"><![CDATA[Valine]]></field>
  <field name="articleQualifier"><![CDATA[blood]]></field>
 </doc>
 <doc>
  <field name="id"><![CDATA[7120528]]></field>
  <field name="articleCreationDate"><![CDATA[1982-12-02T00:00:00Z]]></field>
  <field name="articleYear"><![CDATA[1982]]></field>
  <field name="articleCompletionDate"><![CDATA[1982-12-02T00:00:00Z]]></field>
  <field name="articleRevisionDate"><![CDATA[2006-11-15T00:00:00Z]]></field>
  <field name="articlePubmodel"><![CDATA[Print]]></field>
  <field name="journalTitle"><![CDATA[The Journal of trauma]]></field>
  <field name="journalTitleAbrv"><![CDATA[J Trauma]]></field>
  <field name="articleTitle"><![CDATA[Liver blood flow rate and glucose metabolism in hemorrhagic hypotension and shock.]]></field>
  <field name="articleAbstract"><![CDATA[Liver blood flow was measured in dogs using 133Xe clearance technique under control conditions and during various stages of hypotension and of hemorrhagic shock. Initial liver mean blood flow rate in all dogs combined are 101.9 +/- 11.5 ml/100 gm liver/min and was not significantly altered in the control group. Liver blood flow rate was reduced in the experimental group during hemorrhagic hypotension and shock and was correlated with the severity of the disease. Peripheral vasodilatation was observed in one subgroup of experimental animals while severe vasoconstriction was found in another subgroup. Glucose concentrations in the hepatic vein were significantly above that of arterial and portal venous blood; all experimental animals were hyperglycemic. The outflow of glucose from the liver was increased during shock in ten animals. It was, however, reduced in 17 animals.]]></field>
  <field name="author"><![CDATA[Bor N M]]></field>
  <field name="author"><![CDATA[Alvur M]]></field>
  <field name="author"><![CDATA[Ercan M T]]></field>
  <field name="author"><![CDATA[Bekdik C F]]></field>
  <field name="articleLang"><![CDATA[eng]]></field>
  <field name="publicationType"><![CDATA[Journal Article]]></field>
  <field name="publicationType"><![CDATA[Research Support, Non-U.S. Gov't]]></field>
  <field name="substanceName"><![CDATA[Glucose]]></field>
  <field name="articleDescriptor"><![CDATA[Animals]]></field>
  <field name="articleDescriptor"><![CDATA[Blood Flow Velocity]]></field>
  <field name="articleDescriptor"><![CDATA[Blood Pressure]]></field>
  <field name="articleDescriptor"><![CDATA[Dogs]]></field>
  <field name="articleDescriptor"><![CDATA[Female]]></field>
  <field name="articleDescriptor"><![CDATA[Glucose]]></field>
  <field name="articleQualifier"><![CDATA[metabolism]]></field>
  <field name="articleDescriptor"><![CDATA[Hypotension]]></field>
  <field name="articleQualifier"><![CDATA[etiology]]></field>
  <field name="articleQualifier"><![CDATA[metabolism]]></field>
  <field name="articleQualifier"><![CDATA[physiopathology]]></field>
  <field name="articleDescriptor"><![CDATA[Liver]]></field>
  <field name="articleQualifier"><![CDATA[metabolism]]></field>
  <field name="articleDescriptor"><![CDATA[Liver Circulation]]></field>
  <field name="articleDescriptor"><![CDATA[Male]]></field>
  <field name="articleDescriptor"><![CDATA[Shock, Hemorrhagic]]></field>
  <field name="articleQualifier"><![CDATA[complications]]></field>
  <field name="articleQualifier"><![CDATA[metabolism]]></field>
  <field name="articleQualifier"><![CDATA[physiopathology]]></field>
  <field name="articleDescriptor"><![CDATA[Vascular Resistance]]></field>
 </doc>
 <doc>
  <field name="id"><![CDATA[7120529]]></field>
  <field name="articleCreationDate"><![CDATA[1982-12-02T00:00:00Z]]></field>
  <field name="articleYear"><![CDATA[1982]]></field>
  <field name="articleCompletionDate"><![CDATA[1982-12-02T00:00:00Z]]></field>
  <field name="articleRevisionDate"><![CDATA[2004-11-17T00:00:00Z]]></field>
  <field name="articlePubmodel"><![CDATA[Print]]></field>
  <field name="journalTitle"><![CDATA[The Journal of trauma]]></field>
  <field name="journalTitleAbrv"><![CDATA[J Trauma]]></field>
  <field name="articleTitle"><![CDATA[Trauma operating room in conjunction with an air ambulance system: indications, interventions, and outcomes.]]></field>
  <field name="articleAbstract"><![CDATA[We report a retrospective study of 198 trauma patients brought directly to a trauma operating room by an air ambulance system. Despite rapid transport, expert prehospital resuscitation, and the capability of early surgical intervention, the overall mortality was high (57%). There was no significant salvage of patients arriving without pulse, blood pressure or cardiac activity. Optimal trauma care failed to show encouraging results in this preselected group of patients with predominantly blunt and multisystem injury. The justification and cost effectiveness of this system of trauma care is discussed.]]></field>
  <field name="author"><![CDATA[Law D K]]></field>
  <field name="author"><![CDATA[Law J K]]></field>
  <field name="author"><![CDATA[Brennan R]]></field>
  <field name="author"><![CDATA[Cleveland H C]]></field>
  <field name="articleLang"><![CDATA[eng]]></field>
  <field name="publicationType"><![CDATA[Journal Article]]></field>
  <field name="articleDescriptor"><![CDATA[Adolescent]]></field>
  <field name="articleDescriptor"><![CDATA[Adult]]></field>
  <field name="articleDescriptor"><![CDATA[Aircraft]]></field>
  <field name="articleDescriptor"><![CDATA[Ambulances]]></field>
  <field name="articleDescriptor"><![CDATA[Child]]></field>
  <field name="articleDescriptor"><![CDATA[Child, Preschool]]></field>
  <field name="articleDescriptor"><![CDATA[Costs and Cost Analysis]]></field>
  <field name="articleDescriptor"><![CDATA[Emergency Medical Services]]></field>
  <field name="articleQualifier"><![CDATA[economics]]></field>
  <field name="articleDescriptor"><![CDATA[Female]]></field>
  <field name="articleDescriptor"><![CDATA[Humans]]></field>
  <field name="articleDescriptor"><![CDATA[Infant]]></field>
  <field name="articleDescriptor"><![CDATA[Male]]></field>
  <field name="articleDescriptor"><![CDATA[Middle Aged]]></field>
  <field name="articleDescriptor"><![CDATA[Operating Rooms]]></field>
  <field name="articleDescriptor"><![CDATA[Outcome and Process Assessment (Health Care)]]></field>
  <field name="articleDescriptor"><![CDATA[Retrospective Studies]]></field>
  <field name="articleDescriptor"><![CDATA[Transportation of Patients]]></field>
  <field name="articleDescriptor"><![CDATA[Wounds and Injuries]]></field>
  <field name="articleQualifier"><![CDATA[diagnosis]]></field>
  <field name="articleQualifier"><![CDATA[mortality]]></field>
  <field name="articleQualifier"><![CDATA[surgery]]></field>
 </doc>
 <doc>
  <field name="id"><![CDATA[7120530]]></field>
  <field name="articleCreationDate"><![CDATA[1982-12-02T00:00:00Z]]></field>
  <field name="articleYear"><![CDATA[1982]]></field>
  <field name="articleCompletionDate"><![CDATA[1982-12-02T00:00:00Z]]></field>
  <field name="articleRevisionDate"><![CDATA[2006-11-15T00:00:00Z]]></field>
  <field name="articlePubmodel"><![CDATA[Print]]></field>
  <field name="journalTitle"><![CDATA[The Journal of trauma]]></field>
  <field name="journalTitleAbrv"><![CDATA[J Trauma]]></field>
  <field name="articleTitle"><![CDATA[Traumatic head injury and pulmonary damage.]]></field>
  <field name="articleAbstract"><![CDATA[Head-injury victims may develop pulmonary complications such as hemorrhagic edema, congestion, and hyperemia. In the present experiments we examined changes in lung surface tension, cholesterol, and phospholipids of alveolar lavage recovered from cats experimentally exposed to a sudden lethal blow to the occiput by captive bolt. Minimum surface tension and cholesterol from traumatized cats which developed convulsive seizures immediately after the blow were more than doubled while no change was seen in traumatized cats without seizures. Total phospholipids and disaturated phosphatidyl choline in either group were not increased over control levels. However, the ratio of cholesterol to total phospholipids increased significantly in traumatized cats with seizures, but did not increase in the cats without seizures. Lung wash protein was higher than in controls in both groups of traumatized cats. This work suggests that at least part of the pulmonary changes following this mechanical head injury may be mediated through a change in the alveolar surface lining.]]></field>
  <field name="author"><![CDATA[Crittenden D J]]></field>
  <field name="author"><![CDATA[Beckman D L]]></field>
  <field name="articleLang"><![CDATA[eng]]></field>
  <field name="publicationType"><![CDATA[Journal Article]]></field>
  <field name="publicationType"><![CDATA[Research Support, Non-U.S. Gov't]]></field>
  <field name="substanceName"><![CDATA[Phospholipids]]></field>
  <field name="substanceName"><![CDATA[Proteins]]></field>
  <field name="substanceName"><![CDATA[Cholesterol]]></field>
  <field name="articleDescriptor"><![CDATA[Animals]]></field>
  <field name="articleDescriptor"><![CDATA[Brain Injuries]]></field>
  <field name="articleQualifier"><![CDATA[complications]]></field>
  <field name="articleQualifier"><![CDATA[metabolism]]></field>
  <field name="articleQualifier"><![CDATA[pathology]]></field>
  <field name="articleDescriptor"><![CDATA[Cats]]></field>
  <field name="articleDescriptor"><![CDATA[Cholesterol]]></field>
  <field name="articleQualifier"><![CDATA[metabolism]]></field>
  <field name="articleDescriptor"><![CDATA[Lung]]></field>
  <field name="articleQualifier"><![CDATA[metabolism]]></field>
  <field name="articleQualifier"><![CDATA[pathology]]></field>
  <field name="articleDescriptor"><![CDATA[Phospholipids]]></field>
  <field name="articleQualifier"><![CDATA[metabolism]]></field>
  <field name="articleDescriptor"><![CDATA[Proteins]]></field>
  <field name="articleQualifier"><![CDATA[metabolism]]></field>
  <field name="articleDescriptor"><![CDATA[Seizures]]></field>
  <field name="articleQualifier"><![CDATA[etiology]]></field>
  <field name="articleQualifier"><![CDATA[metabolism]]></field>
  <field name="articleDescriptor"><![CDATA[Surface Tension]]></field>
 </doc>
 <doc>
  <field name="id"><![CDATA[6214642]]></field>
  <field name="articleCreationDate"><![CDATA[1982-12-02T00:00:00Z]]></field>
  <field name="articleYear"><![CDATA[1982]]></field>
  <field name="articleCompletionDate"><![CDATA[1982-12-02T00:00:00Z]]></field>
  <field name="articleRevisionDate"><![CDATA[2005-11-17T00:00:00Z]]></field>
  <field name="articlePubmodel"><![CDATA[Print]]></field>
  <field name="journalTitle"><![CDATA[The Journal of trauma]]></field>
  <field name="journalTitleAbrv"><![CDATA[J Trauma]]></field>
  <field name="articleTitle"><![CDATA[Suppressor cell activity after major injury: indirect and direct functional assays.]]></field>
  <field name="articleAbstract"><![CDATA[In vitro responses to streptokinase-streptodornase (SKSD), mumps, and mixed lymphocyte culture (MLC) in 19 burned and 13 multitrauma patients were studied sequentially by lymphocyte tritiated thymidine incorporation and compared to responses of 28 normals. Mean responses to SKSD remained significantly depressed from normal for up to 14 to 28 days following injury: MLC responses, significantly depressed at 48 hours, recovered promptly to normal levels. Because of evidence that the proliferative capacity of the T-cell population to soluble antigens is contained within the inducer subpopulation while both inducer and suppressor subpopulations respond in MLC, the observed increase in MLC responses, coupled with a sustained depression of SKSD and mumps responses, suggests activation of a population of suppressor cells. In a direct assay of suppressor cell function, lymphocytes from three or four multitrauma patients incubated in a two-way MLC with normal lymphocytes significantly suppressed PHA responsiveness, confirming the findings of the direct assay.]]></field>
  <field name="author"><![CDATA[Keane R M]]></field>
  <field name="author"><![CDATA[Munster A M]]></field>
  <field name="author"><![CDATA[Birmingham W]]></field>
  <field name="author"><![CDATA[Shatney C]]></field>
  <field name="author"><![CDATA[Winchurch R A]]></field>
  <field name="articleLang"><![CDATA[eng]]></field>
  <field name="publicationType"><![CDATA[Journal Article]]></field>
  <field name="substanceName"><![CDATA[Antigens, Viral]]></field>
  <field name="substanceName"><![CDATA[Phytohemagglutinins]]></field>
  <field name="substanceName"><![CDATA[Streptodornase and Streptokinase]]></field>
  <field name="articleDescriptor"><![CDATA[Adolescent]]></field>
  <field name="articleDescriptor"><![CDATA[Adult]]></field>
  <field name="articleDescriptor"><![CDATA[Aged]]></field>
  <field name="articleDescriptor"><![CDATA[Antigens, Viral]]></field>
  <field name="articleQualifier"><![CDATA[immunology]]></field>
  <field name="articleDescriptor"><![CDATA[Burns]]></field>
  <field name="articleQualifier"><![CDATA[immunology]]></field>
  <field name="articleDescriptor"><![CDATA[Humans]]></field>
  <field name="articleDescriptor"><![CDATA[Lymphocyte Culture Test, Mixed]]></field>
  <field name="articleDescriptor"><![CDATA[Middle Aged]]></field>
  <field name="articleDescriptor"><![CDATA[Mumps virus]]></field>
  <field name="articleQualifier"><![CDATA[immunology]]></field>
  <field name="articleDescriptor"><![CDATA[Phytohemagglutinins]]></field>
  <field name="articleQualifier"><![CDATA[pharmacology]]></field>
  <field name="articleDescriptor"><![CDATA[Streptodornase and Streptokinase]]></field>
  <field name="articleQualifier"><![CDATA[immunology]]></field>
  <field name="articleDescriptor"><![CDATA[T-Lymphocytes, Regulatory]]></field>
  <field name="articleQualifier"><![CDATA[immunology]]></field>
  <field name="articleDescriptor"><![CDATA[Wounds and Injuries]]></field>
  <field name="articleQualifier"><![CDATA[immunology]]></field>
 </doc>
</add>